Dynamic regulation of GATA transcription factors in hematopoiesis by Costa Gonçalves Ferreira, R.L. (Rita) da
 Dynamic regulation of GATA transcription factors 
in hematopoiesis 
Dynamische regulatie van GATA transcriptie factoren in 
hematopoïese 
Proefschrift
ter verkrijging van de graad van doctor aan de 
Erasmus Universiteit Rotterdam 
op gezag van de 
Rector Magnificus
Prof.dr. S.W.J. Lamberts 
en volgens besluit van het College voor Promoties. 
De openbare verdediging zal plaatsvinden op
woensdag 27 oktober 2004 om 15.45 uur 
door
 
Rita Luisa da Costa Gonçalves Ferreira 
geboren te Coimbra (Portugal)
Promotiecommissie
Promotor:  Prof.dr. F.G. Grosveld 
Overige leden: Dr.ir. D. N. Meijer 
      Dr. R. Delwel
      Dr.ir. N. Galjart
Copromotor:  Dr. J.N.J. Philipsen
Cover: GATA (which means“female cat” in Portuguese and other languages) chasing a 
laboratory mouse on a DNA strand.
Cover design: Lucas Spensberger.
The work presented in this thesis was performed at the Department of Cell 
Biology at the Erasmus University Medical Center Rotterdam. This department 
is part of the  Medisch Genetich Centrum Zuid-West Nederland.
The research was partially supported by the Nederland Organisatie voor 
Weterschappelijk Onderzoek (NWO) and the Nederlandse Kankerbestrijding 
Koningin Wilhermina Fonds (KWF).
Ao meu pai.
4Contents
Scope of this thesis        7
Chapter1         9
Introduction
 1. Hematopoiesis       10
  1.1 Erythropoiesis      13
  1.2 T-cell differentiation     16
   1.2.1 Thymic T-cell differentiation  17
   1.2.2 Peripheral T-cell differentiation  19
 2. Transcriptional control of hematopoiesis   21
  2.1 Transcriptional control of gene expression  21
  2.2 Hematopoietic transcription factors   23
 3. The GATA family of transcription factors   25
  3.1 GATA1       25
   3.1.1 Regulation of GATA1 activity  28
   3.1.2 Protein-protein interactions   30
   3.1.3 GATA1 target genes    34
  3.2 GATA2       37
   3.2.1 Regulation of GATA2 activity  38
  3.3 GATA3       39
   3.3.1 Regulation of GATA3 activity  40
   3.3.2 Protein-protein interactions   41
   3.3.3 GATA3 target genes    41
5Chapter 2         53
An intrinsic but cell-nonautonomous defect in GATA-1-overexpressing 
mouse erythroid cells.
Chapter 3         65
Expression profiling of GATA1-overexpressing erythroid cells.
Chapter 4         83
Rescue of GATA1 null mice by GATA transgenes requires the correct 
spatio-temporal expression pattern
Chapter 5         101
Enforced expression of GATA-3 during T cell development inhibits 
maturation of CD8 single-positive cells and induces thymic lymphoma 
in transgenic mice
Chapter 6         121
Enforced expression of GATA-3 in transgenic mice inhibits Th1 
differentiation and induces de formation of a T1/ST2 expressing Th2-
committed T cell compartment in vivo.
Chapter 7         139
Discussion
Summary         147
Samenvatting        149
Sumário         151
List of abbreviations       153
Curriculum Vitae        154
Acknowledgments        155

7Scope of this thesis
 Hematopoiesis, the process of generation of all mature blood lineages from a single 
hematopoietic stem cell, occurs by a succession of lineage-commitment steps.  Each lineage-
commitment step involves a restriction of differentiation potential and the establishment 
of lineage-specific expression profiles. These expression profiles rely on lineage-specific 
transcription factors to modulate the expression of their target genes. Therefore, hematopoiesis 
is an excellent model system to investigate how particular transcription factors influence the 
establishment of lineage-specific expression profiles and how their activity is regulated. 
 This thesis is focused on the study of transcription factors GATA1, GATA2 and GATA3, 
which are very similar to each other but have distinct expression profiles during hematopoiesis. 
Making use of transgenic mouse models where the expression of these genes was altered, the 
studies presented in this thesis were aimed to understand the importance of the correct spatio-
temporal regulation of these genes for the differentiation of different hematopoietic lineages.
 Chapter 1 gives an overview of the current knowledge about the general transcriptional 
control of hematopoiesis and what is known about the regulation and function of the transcription 
factors GATA1, GATA2 and GATA3.
 In Chapter 2, evidence is shown that GATA1 expression has to be downregulated in 
the final stages of erythroid development for terminal differentiation to occur. When that fails to 
occur, erythropoiesis is impaired. Consequently, overexpression of GATA1 in transgenic mice 
leads to severe anemia resulting in embryonic lethality.
In Chapter 3 cDNA microarray technology was employed to analyse the expression 
profile of the GATA1 overexpressing mice (described in Chapter 2) in order to identify putative 
GATA1 target genes.
Hematopoietic GATA proteins are very similar and have partially overlapping expression 
patterns, suggesting that they may have redundant functions. In Chapter 4 we have used the 
rescue of a Gata1 null mutation by GATA1, GATA2 and GATA3 transgenes under the control 
of different promoters to demonstrate the importance of timing of GATA factor expression 
during erythroid development. GATA1, GATA2 and GATA3 expressed under the control of 
GATA1 regulatory sequences are able to rescue the Gata1 null phenotype but fail to do so when 
expressed under the control of the β-globin regulatory sequences.
Chapters 5 and 6 show the consequences of forced expression of GATA3 throughout T-
cell differentiation. GATA3 overexpression in transgenic mice is shown to inhibit the maturation 
of CD8 single-positive cells and Th1 differentiation as well as induce thymic lymphomas.
In the last Chapter, the results presented in this thesis are briefly discussed, as well 
as the future prospect of the research on the regulation of GATA transcription factors in 
hematopoiesis.

Chapter 1
Introduction
Parts of this chapter have been submitted for 
publication
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1. Hematopoiesis
The blood is one of the most fascinating tissues not only by its unique structure but 
also by its variety of cells. Each cell type has a distinct appearance and performs specific and 
essential biological functions6,24,99.
 The most abundant cells in the blood are the erythrocytes, occupying about 45% of 
its volume. Erythrocytes are enucleated biconcave discoid cells, filled with hemoglobin, 
responsible for the transport of oxygen and carbon dioxide throughout the body. The other 
hematopoietic cell types are less abundant, occupying about 1% of the blood volume, but 
performing equally important biological functions. Platelets are rod-shaped cell fragments, 
derived from large cells denominated megakaryocytes, with an essential role in coagulation. 
Lymphocytes, subdivided in B- and T-lymphocytes, play a crucial role in the specific immune 
response against microorganisms and foreign macromolecules. T-lymphocytes (or T-cells) act 
as direct killers of infected cells (cytotoxic T-cells) or by activating other cells to eliminate 
infected cells (T-helper cells). B-lymphocytes (or B-cells) produce soluble antibodies that can 
neutralise and promote the destruction of microorganisms or toxins. Granulocytes, subdivided 
in neutrophils, eosinophils and basophils are part of the innate immune system and involved 
in the inflammatory response and phagocytosis. Despite their hematopoietic origin, other cells 
such as macrophages and mast cells, which are also involved in the inflammatory response 
and phagocytosis, are not found in the circulation but within tissues. Macrophages arise from 
precursors denominated monocytes, which are circulating in the blood before they migrate to 
the tissues where they terminally differentiate.  Mast cells originate from as yet unidentified 
progenitors in the bone marrow that migrate through the blood into mucosal tissues where they 
differentiate into mature mast cells. 
Remarkably, all these different cells originate from a common cell type, the hematopoietic 
stem cell (HSC), by a highly complex process termed hematopoiesis (Fig. 1).
 
 HSCs are characterised by the ability to duplicate themselves (self-renewal) and to 
give rise to all the different hematopoietic cell types (pluripotency)124. These cells are extremely 
rare, with an incidence of 1 to 10 HSCs per 100.000 cells in the murine bone marrow3.  This 
small pool of HSCs is maintained because these cells can self-renew. In contrast, most of the 
descendant cells will lose this ability and commit to differentiation, becoming multilineage 
precursors (MLP). 
 The differentiation process occurs through a series of commitment steps, each leading 
to further restriction to a certain hematopoietic cell lineage. The nature of the first lineage 
commitment step remains a controversial issue since currently two models are proposed106,195. 
The most wildly accepted model claims that the first commitment step separates lymphoid 
from myeloid potential and is supported by the identification of common lymphoid progenitors 
(CLPs) and common myeloid precursor (CMPs). CLPs are restricted to the lymphoid lineage 
and can give rise exclusively to B, T-cells and natural killer (NK) cells110 while CMP can 
give rise to granulocytes, erythrocytes, megakaryocytes and macrophages in in vitro colony 
assays4,102. These CMPs will undergo further lineage restriction when the granulocyte/monocyte 
potential is separated from the erythroid/megakaryocyte potential4. The existence of CLP is 
contested by the identification of myeloid/T-cell (MTP) and Myeloid/B-cell (MBP) bipotent 
precursors by Kawamoto and colleagues107. These suggested an alternative model in which 
myeloid (granulocyte/macrophage) potential is maintained in the early commitment stages of 
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all hematopoietic lineages. According to this model MLPs can give rise to CMPs or to common 
myeloid lymphoid precursors (CMLPs). CMLPs further commit into either MBPs or MTPs. 
Later on the myeloid potential is separated from the megakaryocytic/erythroid and the B-cell 
and T-cell potential (reviewed by Katsura106).
Figure 1 - Schematic representation of the main lineage commitment steps in hematopoiesis.  The hematopoietic 
stem cell (HSC) is the basis of the hematopoietic hierarchy and give rise to multilineage progenitors (MLP), which can 
differentiate into all the hematopoietic lineages. MLP become lineage restricted to the lymphoid and myeloid lineage 
in the common lymphoid progenitor (CLP) and common myeloid progenitor (CMP) respectively.  Common lymphoid 
progenitor can give rise exclusively to B and T-cells while CMP can give rise to megakaryocytes/erythroid progenitors 
(EMP) and granulocyte/monocyte progenitors (GMP). Alternatively, it is also believed that the first lineage-commitment 
separates myeloid and erythroid potential, in the CMP, from myeloid lymphoid potential, in common myeloid lymphoid 
progenitor (CMLP). CMLP can that further differentiate in B-cells, T-cells and GMP (dashed line). MEP can differentiate 
into erythrocytes and platelets while GMP can differentiate into granulocytes and macrophages. Hematopoietic 
transcription factors relevant for the development of particular hematopoietic lineages are indicated.
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CMPs can further commit into either granulocyte/macrophage lineage-restricted 
progenitors (GMPs), also denominated CFU-GM, that give rise exclusively to granulocytes and 
macrophages or megakaryocyte/erythrocyte lineage-restricted progenitors (MEPs), also named 
CFU-MeE, which are restricted to the production of megakaryocytes and erythrocytes4. Each of 
these steps also contributes to the amplification of cell numbers since cell proliferation occurs 
at each stage of commitment24. In this way, a single HSC can be the source of a large number of 
mature hematopoietic cells.
During the last few years, however, the idea of this rigid hierarchy between the HSC and 
the different hematopoietic cells has been questioned. An increasing number of reports suggests 
the occurrence of transdifferentiation between different hematopoietic precursors (reviewed by 
Graf66).
How the decision to commit to a particular cell lineage is achieved is still a matter 
of speculation. Two contrasting models have been put forward to explain why and how 
a commitment step occurs at a given time. The instructive model states that a specific or 
combination of specific exogenous signals determines a commitment step. These signals are 
most likely ligands that interact with specific receptors in the cell, activating pathways that lead 
to the expression of genes specific for the subsequent commitment stage. This model reinforces 
the importance of the stroma in differentiation. The probabilistic model proposes that the critical 
gene expression changes leading to differentiation occur in a stochastic manner and the role of 
the stroma is only to provide a selective environment for the growth of the committed progenitor 
cells39,52. 
Recent reports favour the second model. In one report5, oligonucleotide microarray 
technology was employed for gene expression profiling of HSCs, multipotent percursors and 
the more restricted CLPs and CMPs. This study revealed that both non-hematopoietic and 
hematopoietic lineage-restricted genes are expressed in HSCs but their numbers decrease 
throughout lineage commitment since CMPs and CLPs selectively express myeloid and 
lymphoid-specific genes, respectively. Another report43 shows evidence for a stochastic 
activation of both α and β globin clusters. Upon stochastic activation the expression patterns 
are fixed and clonally maintained in differentiated cells. 
Several different tissues are responsible for the production of hematopoietic cells during 
embryonic development  (reviewed by Dzierzak and colleagues49). 
The yolk sac is the first hematopoietic tissue in mammalian ontogeny and it is 
responsible for what is known as primitive hematopoiesis. This first wave of hematopoiesis 
consists mainly, but not exclusively, of the production of large, nucleated, primitive erythrocytes 
that synthesize embryonic globins. Primitive hematopoiesis starts between embryonic day 7.0 
(E7.0) and E7.5 in mice, or day 15 and 18 in humans, in the blood islands that emerge from the 
mesoderm in the visceral yolk sac. Blood islands are masses of cells that gradually differentiate 
into primitive erythroblasts surrounded by visceral endoderm and mesoderm cells. These 
primitive erythroblasts enter the vascular system of the embryo proper where they continue to 
divide for several days, eventually reaching terminal differentiation characterised by G1 arrest. 
Hematopoiesis in the yolk sac continues until approximately E13 but primitive erythrocytes can 
be observed in the blood stream up to E16 (reviewed by and colleagues182).
Definitive hematopoiesis relies on the definitive HSC and is responsible for the 
production of all hematopoietic lineages present in the adult organism including the definitive 
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erythrocytes, characterised by the absence of nucleus and expression of adult globins. The 
embryonic origin of definitive hematopoiesis is a controversial issue since currently two very 
distinct models are proposed.
  The first model proposes that definitive hematopoiesis is established by HSCs that have 
migrated from the yolk sac and colonise the Aorta-Gonads-Mesonephros (AGM) region and the 
fetal liver153,181 (reviewed by and colleagues182). The second and more recent model proposes 
that definitive hematopoiesis relies on HSCs originated within the AGM region of the embryo, 
around E9.0, that later colonise the fetal liver 141,142,157 (Palis and Yoder50). In the past, studies 
using avian46 and amphibian232 embryos have identified an intra-embryonic source of definitive 
HSCs. This intra-embryonic hematopoietic source was mapped to the region containing the 
dorsal aorta but it was considered to be a feature of lower vertebrates, lost in mammals. Only 
years later the same intra-embryonic source of definitive HSCs was identified in the AGM 
region of the murine embryo142.  
Regardless of the controversy around its origins, it is generally accepted that definitive 
HSCs colonise the fetal liver which, by E11.5, becomes the principal hematopoietic tissue 
of the embryo51,157. Later in gestation the thymus and spleen are formed and colonised by 
hematopoietic progenitors involved in the production of differentiated lymphoid cells in fetal 
and adult stages.  A recent report10 suggests that the placenta is another major hematopoietic 
organ during embryonic development. Around birth, the HSCs migrate from the fetal liver to 
the bone marrow, which becomes the principal hematopoietic tissue throughout adult life. In 
humans, the bone marrow is the exclusive site of postnatal hematopoiesis, whereas in mice 
hematopoiesis also occurs in the spleen24.
1.1 Erythropoiesis
The generation of mature erythrocytes is an important, and therefore tightly controlled 
process, since the amount of these cells in the body must remain fairly constant (approximately 
45% of the blood volume) to guarantee the supply of oxygen to the body tissues. The average 
lifespan of an erythrocyte is 60 days in mice and 120 days in humans, which implies that new 
cells must be constantly produced. 
 Like all other cells in the hematopoietic system, erythrocytes descend from the HSC. 
This process, denominated erythropoiesis, involves a great variety of cells at different stages of 
differentiation between the HSC and the mature erythrocyte (Fig. 2). 
Figure 2 - Schematic representation of the different stages in erythroid differentiation. Erythroid/megakaryocyte 
progenitors (MEP) can give rise to both erythrocytes and megakaryocytes. Burst forming units- erythroid (BFU-e) and 
colony forming units-erythroid (CFU-e) are erythroid restricted progenitors that can only be identified via functional 
assays. Terminal erythroid differentiation starts with the proerythroblast, the first morphologically identifiable progenitor, 
and terminates upon enucleation.
  Proerythroblast  CFU-e Basophilic
Erythroblast
Polychromatic
Erythroblast
Orthochromatic
Erythroblast
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 As mentioned above, commitment to the erythroid lineage involves several steps. The 
first step consists of the differentiation of the HSC into a MLP, also called CFU-S, which is 
a pluripotent cell but without the capacity to self-renew. CMPs are derived from this MLP 
and can give rise to MEPs, which are fully restricted to the megakaryocytic and erythroid 
lineages. The Burst Forming Unit-Erythroid (BFU-E) is the most primitive erythroid-restricted 
progenitor, identifiable exclusively by functional assays256. In the presence of erythropoietin 
(Epo), interleukin 3 (IL3), granulocyte-macrophage colony-stimulating factor (GM-CSF), 
thrombopoietin and stem cell factor (SCF), this cell can give rise to large colonies containing 
more than 500 hemoglobinized erythroblasts after 5 to 7 or 14 to 16 days of culture of murine 
and human cells respectively. The BFU-E further differentiates into the Colony Forming Unit-
Erythroid (CFU-E), a more mature erythroid progenitor closely related to the proerythroblast. In 
the presence of low concentrations of Epo, CFU-Es give rise to small colonies, containing 8 to 
64 hemoglobinized erythroblasts215,256 after 2 to 4 or 5 to 8 days of culture of murine and human 
cells, respectively. 
 The proerythroblast, derived from the CFU-E, is the earliest morphologically identifiable 
erythroid progenitor. The proerythroblast is a large cell (14-19µm and 11-13µm in diameter in 
human and mice respectively) characterised by a large nucleus (occupying about 80% of the 
cell), with visible nucleoli, surrounded by a basophilic cytoplasm. Basophilic erythroblasts are 
slightly smaller cells (12-17µm and 10-11µm in diameter, in human and mice respectively) 
where condensation of chromatin begins to occur, giving the nucleus a granular appearance. The 
cytoplasm is very basophilic due to the presence of large numbers of ribosomes. Hemoglobin 
can be detected for the first time by cytological staining methods at the polychromatophilic 
erythroblast stage. These cells are smaller (12-15µm and 9-10µm in diameter, in human and 
mice respectively) as are their nuclei. Full hemoglobinization occurs at the orthochromatic 
erythroblast stage. These cells are the smallest nucleated erythrocyte precursors (8-12µm 
and 7-8µm in diameter in humans and mice respectively) and their nuclei undergo pycnotic 
degeneration, that is, the chromatin becomes very condensed and the nuclei shrink. Finally 
the nucleus is extruded from the cell that is now denominated reticulocyte. Reticulocytes are 
larger than fully mature erythrocytes (7-8 μm and 3.5-4.5µm in diameter, in human and mice 
respectively) have irregular shapes but still contain certain cytoplasmic organelles7,24.
 Terminal erythroid differentiation, from the proerythroblast to reticulocyte, takes 48 to 
72 hours. Reticulocyte maturation continues for another 48 hours until all unnecessary organelles 
are eliminated and the cell acquires the discoid shape of the fully mature erythrocyte20. 
Terminal erythroid differentiation occurs in an identifiable anatomic unit both in vivo105 
and in liquid culture7, that provides a unique environment for maturing erythroid precursors: the 
erythroblastic island (Fig. 3).  This is a sponge-like structure, consisting of a central macrophage 
surrounded by erythroid precursors at different stages of maturation. The more immature 
precursors are located closer to the centre but as they mature they move away from the body of 
the macrophage. Erythroid precursors keep in contact with the cytoplasmatic extensions of the 
macrophage during all stages of maturation until occurrence of enucleation20. Upon enucleation 
the reticulocyte detaches from the macrophage leaving its nucleus behind to be phagocytosed 
by the macrophage7,8.
One obvious function of the macrophage, within the erythroblastic island, is phagocytosis 
but it is unlikely to be its only function. It is known that the presence of the macrophage is not 
essential for the amplification or maturation of the erythoblasts in different culture systems but 
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these do not represent the in vivo environment. It is probable that the macrophage influences the 
local concentration of nutrients and/or growth factors, especially considering the proximity of the 
erythroblasts and the presence of structures resembling gap junctions between the macrophage 
and the erythroblasts7. Furthermore, the macrophage is responsible for the destruction of the 
nucleus expelled by the erythroid precursors during differentiation.
A recent report108 demonstrated that macrophages are indispensable for definitive 
erythropoiesis. Macrophages from Dnase II knockout mice are unable to degrade the DNA from 
the nucleus expelled by the erythroid precursors. The DNA from the engulfed nucleus therefore 
remains in cytoplasmatic inclusions and these macrophages are no longer able to perform 
their supportive functions.  This leads to defective erythropoiesis and consequent embryonic 
lethality.
Amplification of the erythroid precursors also occurs during terminal differentiation. 
In the 48 to 72 hours that the erythoblast remains associated with the macrophage in the 
erythroblastic island, 4 to 5 cell divisions take place8,20. Extra evidence for this was obtained 
from the observation of the erythroblastic islands formed in bone-marrow liquid cultures7. 
Proerythroblasts occur singly while basophilic and polychromatophilic erythroblasts form 
groups of 4, 8 or 16 and orthochromatic erythroblast and reticulocytes are found in groups of 
up to 32 cells. These numbers correlate well with the notion that 4 to 5 divisions occur during 
erythroid terminal differentiation.
Figure 3 - Simplified model of the erythroblastic island. The central macrophage (in grey) is surrounded by erythroid 
precursors at different stages of maturation, the more immature cells located closer to the centre and the more mature 
cells further away from the body of the macrophage. Adapted from reference 252.
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Polychromatic Erythroblast
Basophilic Erythroblast
 Proerythroblast
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1.2 T-cell differentiation 
  
The immune system is responsible for the defence of an organism against infection. 
Granulocytes and macrophages constitute the first line of defence by directly recognising and 
killing pathogens. Lymphocytes are responsible for a more sophisticated type of immunity, 
called adaptive immunity, since they can specifically recognise and eliminate extracellular and 
intracellular pathogens, and generate memory lymphocytes that can rapidly and effectively 
respond to re-infection. B-lymphocytes eliminate pathogens by producing specific antibodies 
that circulate in the plasma and can recognise pathogens, thus triggering phagocytosis by 
macrophages. T-lymphocytes eliminate pathogens either by direct interaction with infected cells 
(cytotoxic T-cells) or by activating other cells that will eliminate the infected cells (T-helper 
cells). 
The remainder of this chapter will be focussed on T-lymphocytes, in particular on their 
development in the thymus and lineage commitment into the different subsets of mature T-
cells.
T-lymphocytes recognise infected cells via the T-cell receptor (TCR) complex99. The 
TCR complex is composed of the TCR, a heterodimer composed of two transmembrane 
glycoproteins (usually TCRα and TCRβ)18,60, and four other proteins, collectively called CD3133. 
Diversity of T-cell receptors, essential for the recognition of the different antigens, is achieved 
by the recombination of the genes encoding for the receptor α and β chains. During recognition 
of the antigen, CD4 or CD8 co-receptors, associated with the T-cell receptor complex, aggregate 
in the membrane bringing several TCRs in close proximity, which triggers the signalling cascade 
via the TCR100.
Recognition of the infected cells occurs because these cells present specific peptides 
from the pathogen at their surface that can be recognised by the TCR complex. These antigens 
are displayed by specific membrane glycoproteins, the major histocompatibility complex 
(MHC) proteins (reviewed by Germain62). There are two classes of MHC molecules. MHC class 
I molecules display peptides from proteins synthesised in the cytoplasm, mainly viral antigens. 
MHC class II molecules display peptides from proteins in intracellular vesicles, derived from 
pathogens such as bacteria and eukaryotic parasites, internalised by macrophages. MHC class 
I molecules are expressed in the majority of nucleated cells while MHC class II expression 
is restricted to particular types of cells, such as dendritic cells, macrophages and B-cells, 
collectively denominated antigen presenting cells (APCs)99. 
Three distinct lineages of mature T-lymphocytes are identifiable based on the way they 
recognise the antigens and eliminate the infected cells. Cytotoxic T-cells recognise antigens 
presented by MHC class II molecules and directly kill the infected cell. These cells are 
characterised by the expression of the MHC class II co-receptor CD8.  CD4 T-cells recognise 
antigens presented by MHC class I molecules and are characterised by the expression of the 
MHC class I co-receptor CD4. Depending in their way of elimination of the infected cells 
CD4 T-cells can be further classified into T-helper cell type 1 (Th1) or Th2. Th1 cells activate 
the infected macrophage to destroy the pathogen while Th2 cells induce B-cells to produce 
antibodies (reviewed by Abbas and colleagues1).
 However, there are other types of T-cells that act in an antigen unspecific manner and 
are important for the regulation of T-cell activation (reviewed by Suciu-Focaand colleagues217). 
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Such T-cells, also produced in the thymus, possess suppressor/regulatory function over mature 
CD8 and CD4 T-cells mediated by cytokines, T-cell-T-cell or T-cell-APC interactions.   CD4 
regulatory T-cells (T
R
) express high levels of CD25 (IL2 receptor α-chain) while CD8 suppressor 
T-cells (T
S
) are characterized by the absence of CD28 expression.
 Another type of T-cell has been named natural killer T-cell (NKT-cell) (reviewed 
by Godfrey and colleagues65). Such cells share some characteristics with NK cells like the 
expression of NK1.1 and the production of high levels of IL4 and interferon γ (INF-γ). CD4-
CD8- double negative (DN), CD4+ and CD8+ subsets of NKT-cells have been identified but their 
specific functions remain unclear despite suggestion that they may participate in Th2 induction 
and Th1 inhibition.
1.2.1 Thymic T-cell differentiation 
T-lymphocytes, like all hematopoietic cells, derive from the HSCs. In adults, the HSCs 
are confined to the bone marrow but T-cell progenitors require specific microenvironments 
to mature so they leave the bone marrow to colonise the thymus (thymus-dependent (T)-
lymphocytes).
 The thymus is a lymphoid organ composed of numerous lobules, each comprising two 
distinct regions: the cortex and the medulla. The cortex contains the T-cell precursors embedded 
in the thymic stroma, which provides the unique microenvironment necessary for maturation236. 
The more mature T-cells, together with dendritic cells and macrophages, are found in the medulla. 
The thymus rudiment starts to arise early in embryonic development (E9.0) and when it is fully 
formed (E11.5) it attracts bone marrow-derived progenitors that will become committed to the 
T-cell and dendritic cell lineages. Later on the thymus is also colonised by macrophages119.
The identification of the bone marrow-derived lymphoid progenitor that migrates to 
the thymus and gives rise to the lymphoid lineage is still a matter of debate. Such progenitors 
are present in the thymus in very low numbers making their identification extremely difficult. 
Consequently, several research groups have identified distinct cells as the earliest T-cell 
progenitor in the thymus. They are generally characterised by the absence of both CD4 and CD8 
co-receptors expression and therefore are generally called double negative (DN) thymocytes. 
Based on the expression of phagocyte glycoprotein-1 (CD44) and CD25, the DN T-cells can 
be subdivided into four different populations, reflecting differentiation stages64. The earliest T-
cell progenitors in the thymus are characterized by a CD44+CD25- phenotype (DN1). However, 
this classification is not very precise since cells other than T-cells express CD44 and do not 
express CD25. More detailed analysis of the DN1 cell population in the thymus revealed the 
existence of different cell types. Allman and colleagues9 identified as an early T-cell progenitor 
the population of DN1 cells expressing CD117 (c-kit) but not CD127 (IL7Rα). This finding 
contradicts the idea that both B and T-cells originate from a CLP characterized by the expression 
of CD127 but not CD117 and suggests the existence of another bone-marrow progenitor for 
the T-cell lineage. However, Martin and colleagues136 identified a B220+CD19-CD117+ bone 
marrow cell type capable of generating mature T-cells, and suggest that these cells derive from 
the CLP and represent the most differentiated population of cell before commitment to the B-cell 
lineage, still possessing T-cell potential. Using a variety of cell markers Porritt and colleagues194 
identified five independent cell types within the DN1 population (DN1a-e) showing that the DN 
population may be composed by several distinct T-cell progenitors. DN1a and DN1b appear to be 
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classical T-cell progenitors since they have proliferation potential and exhibit characteristics of a 
differentiation intermediate between bone-marrow progenitors and committed T-cell precursors. 
Furthermore, DN1a seems to give rise to DN1b in culture suggesting that DN1a is the earliest 
intrathymic progenitor. DN1c, DN1d and DN1e are not conventional T-cell progenitors since 
they do not have proliferation potential but they do give rise to mature T-cells. DN1c can also 
give rise to B-cells, in agreement with the progenitors described by Martin and colleagues136.
 Commitment to the T-cell lineage, at the pro-T-cell or DN2 stage, is achieved by the 
induction of CD25 expression. At this stage cell proliferation is dependent on the presence of 
interleukin-7 (IL-7) and rearrangements of the T-cell receptor γ (TCRγ) locus are detected 31. Loss 
of CD44 expression and proliferation capacity indicates the transition to the next developmental 
stage, the early pre-T-cell or DN3 stage, where the T-cell receptor β chain (TCRβ) locus starts 
to be rearranged. When the rearrangement is complete the TCRβ is presented at the surface of 
the cell in a complex with pre TCRα chain.  Those cells that produce a functional TCRβ will 
proceed through the next step of differentiation, late pre-T-cell, by downregulation of CD25 
expression after which they can proliferate (reviewed by Fehling and von Boehmer54).
Cells that have successfully undergone β-selection are ready to start expressing the CD4 
and CD8 antigens and therefore enter the double positive (DP) stage of differentiation. At this 
stage, the TCRα locus is rearranged followed by selection of the TCRαβ molecules presented 
at the cell surface. T-cells are positively selected based on their capacity to recognise MHC 
molecules (reviewed by von Boehmer238). Negative selection consists on the removal of all the 
cells that can recognise self peptide bound to MHC molecules (reviewed by Nossal168). 
T-cells expressing TCRαβ are able to recognise exclusively foreign peptides presented 
by MHC molecules and can differentiate further into either CD4+ or CD8+ single positive T-cells 
(Fig. 4).
Figure 4 - Schematic representation of the different stages of T-cell differentiation in the thymus. The thymus is 
colonized by bone marrow-derived progenitors that constitute the CD4 CD8 double negative (DN) 1 stage; their identity 
is still a matter of debate. Precursors become restricted to the T-cell lineage at the DN2 stage. By the DN3 stage, the T-cell 
receptor β chain (TCRβ) locus starts to be rearranged. Cells that have successfully undergone β-selection start expressing 
the CD4 and CD8 antigens, thus entering the double positive (DP) stage. At this stage, the TCRα locus is rearranged 
followed by positive and negative selection of TCRαβ presented at the cell surface. Selected cells differentiate further 
into either CD4+ or CD8+ single positive T-cells.
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1.2.2 Peripheral T-cell differentiation
 Once they have completed their development in the thymus, CD8+ and CD4+ T-cells 
leave this organ and migrate through the blood into the peripheral lymphoid organs (lymph 
nodes and spleen). These cells are called naive T-cells because they never encountered their 
specific antigen and they will remain in circulation in the blood and peripheral lymphoid organs 
until such encounter takes place. Naive T-cells are arrested at the G0 stage of the cell cycle 
and can circulate many years without dividing. They have condensed chromatin and therefore 
synthesise little RNA and protein.
 When these naive T-cells recognise their specific antigen, presented by MHC molecules 
on the surface of APCs, they stop to circulate, proliferate and finally differentiate into effector T-
cells. Recognition of the antigen alone is not sufficient to activate a naive T-cell. In the absence 
of co-stimulatory signals from the APCs, T-cells express an IL2 receptor composed of β- and 
γ- chains with low affinity for IL2. In the presence of co-stimulatory signals from the APCs T-
cells start to express the IL2 receptor α- chain, that confers higher affinity of the receptor for 
IL2, and IL2 itself. Binding of IL2 to the high affinity IL2 receptor triggers the cells to enter the 
G1 phase of the cell cycle, thus allowing proliferation.
After 4 to 5 days of proliferation, the naive T-cells differentiate into effector T-cells. 
Naive CD8+ T-cells differentiate only into cytotoxic CD8+ T-cells while naive CD4+ T-cells can 
differentiate into either Th1 or Th2 cells (reviewed by Abbas and colleagues1; Fig. 5). Th1 cells 
are characterised by the expression of INF-γ, tumor necrosis factor-β (TNF-β) and IL2 and act 
by activating infected macrophages to destroy the pathogen154. In contrast, Th2 cells activate B-
cells that produce antibodies against those pathogens and are characterised by the production of 
IL4, IL5, IL6 IL10 and IL13154 (Fig. 5).
Figure 5 - Schematic representation of the stages of T-cell differentiation in the periphery. Upon antigen stimulation 
, naive CD8+ T-cells, differentiate into cytotoxic T-cell. Naive CD4+  T-cells differentiate into T-helper cells type 1 (Th1) 
or Th2 depending, at least partially, on the cytokines produced by the antigen presenting cell (APC). In the presence 
of IL12, cells become Th1 and start producing IL2, INFγ and IL10. In the presence of IL4, the cells become Th2 
characterised by the production of IL4, IL5, IL10 and IL13. Adapted from reference 170.
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The mechanism by which naive CD4+ T-cells differentiate into either Th1 or Th2 is 
poorly understood (reviewed by O’Garra and Arai170). It appears to involve several steps, 
passing through an intermediate stage, Th0, at which both Th1 and Th2-specific cytokines are 
expressed followed by a restriction to expression of either Th1 or Th2-specific cytokines2,104,161. 
The choice of differentiation pathway appears to depend on environmental cues. The presence 
of IL12 and IL4 is known to influence Th1 or Th2 differentiation, respectively111,206,207. IL12 
signalling, through the IL2 receptor, activates the transcription factor STAT4, which leads to 
the upregulation of INFγ14,98. IL18 was shown to synergize with IL12 in the upregulation of 
INFγ. The INFγ gene can also be transactivated by the Th1-restricted transcription factor T-
bet. Ectopic expression of T-bet can initiate the Th1 genetic programme and repress the Th2 
programme. IL4 directs differentiation into Th2 cells by similar mechanisms. IL4 signalling, 
through the IL4 receptor, activates Stat6 leading to the upregulation of IL4, IL5 and IL10 and 
repression of INFγ121. Stat6 is also responsible for the expression of Th2-specific transcription 
factors c-maf and GATA3, but GATA3 can also be regulated in a STAT6-independent way178. 
Both c-maf and GATA3 are involved in the transactivation of Th2-specific cytokines88. GATA3, 
like T-bet in Th1 differentiation, is crucial for Th2 differentiation since its ectopic expression 
can initiate the Th2 genetic programme and repress the Th1 programme (reviewed later in this 
thesis). A recent report11 shows that Notch signalling is also involved in the regulation of CD4+ 
T-cells differentiation into either Th1 or Th2. Different Notch ligands, expressed by the APCs, 
trigger different responses by the naive CD4+ T-cells. While expression of Delta ligands promote 
Th1 differentiation, Jagged expression leads to Th2 differentiation by inducing IL4 expression 
and promoting GATA3 induction and T-bet repression. These may explain the observed STAT6-
independent expression of GATA3 in Th2 cells.
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2. Transcriptional control of hematopoiesis
 The development of mature blood cells of distinct lineages, from the HSCs, involves a 
progressive restriction of differentiation potential and the establishment of lineage-specific gene 
expression profiles. The establishment of these expression profiles relies on lineage-specific 
transcription factors to modulate the expression of their target genes. In this Chapter a general 
introduction of transcription control of gene expression will be given followed by an overview 
of lineage-specific transcription factors involved in hematopoiesis.
2.1 Transcriptional control of gene expression
 The synthesis of a functional protein involves several steps starting with transcription, 
proceeding through RNA processing, transport and translation and finally activation of protein 
activity. Consequently, gene expression control can, in principle, be exerted at each and every 
one of these steps. 
  The first and foremost important level of gene expression control is at the step of 
transcription. Transcription is the process through which an RNA copy of the DNA sequences 
encoding a gene is made. This RNA copy is processed and usually used as a template for the 
translation into protein. Controlling gene expression at this level presents the most benefits to 
the cell by preventing the synthesis of mRNA. 
 Transcription involves three independent stages: initiation, elongation and termination. 
During transcription initiation RNA polymerase, the enzyme responsible for RNA synthesis, 
binds to target DNA sequences allowing transcription to start. Eukaryotes posses three RNA 
polymerases responsible for the transcription of different types of genes: RNA polymerase I 
and III transcribe genes encoding transfer RNA, ribosomal RNA and several small RNAs while 
RNA polymerase II transcribes the vast majority of protein-encoding genes. RNA polymerase 
II can only initiate transcription with the help of several general transcription factors (TFIIA, 
TFIIB, TFIID, TFIIE, TFIIF and TFIIH). Through the elongation stage, the RNA polymerase, 
with the assistance of elongation factors, can then move along the DNA template making the 
RNA copy. A process involving the dissociation of the RNA polymerase from the DNA finally 
terminates transcription.  Transcription is mainly regulated at the initiation stage, which will be 
the focus of this Chapter.
Chromatin
 The first level of transcriptional control is chromatin structure. In order to fit in the 
nucleus DNA is compacted into chromatin, in which most of the DNA sequences are relatively 
inaccessible. The structural unit of chromatin is the nucleosome that consists of 146bp DNA 
stretches wrapped twice around an octameric core of histone proteins, containing two molecules 
each of histones H2A, H2B, H3 and H4. A region of linker DNA, of variable length, separates 
each nucleosome from the next giving rise to a structure resembling “beads on a string”, the 
10nm fibre (reviewed by Kornberg and Lorch112). A second level of compaction, the 30nm fibre, 
is obtained by the binding of histone H1 to the linker DNA221. This level of compaction is still 
not sufficient to fit the DNA in the nucleus. A third level of compaction is therefore characterised 
by folding of the 30nm fibre into chromatin loops, reaching maximum compaction in mitotic 
chromosomes (reviewed by Belmont and colleagues17). 
Two types of chromatin can be distinguished in the interphase nucleus: heterochromatin, 
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a more condensed form usually located in the periphery of the nucleus and euchromatin, less 
dense and spread throughout the nucleus. Heterochromatin is generally considered to be 
transcriptionally inactive while euchromatin is transcriptionally active. In fact, only about 10% 
of euchromatin is transcriptionally active at a given time. The remaining 90% of transcriptionally 
inactive euchromatin is in a reversibly closed chromatin configuration not allowing transcription 
(reviewed by Dillon and Festenstein47). 
For transcription to occur, closed chromatin must be remodelled into a more relaxed 
form, which allows access of the transcription machinery to DNA. Modification of key amino 
acids at the N-terminal tails of histones is the best-studied mechanism of chromatin remodelling 
(reviewed by Berger19). For example, acetylation of particular lysine residues at the histone 
tails is associated with transcription activity since the presence of an acetyl group neutralises 
the positive charge of the lysine, therefore decreasing the affinity of the nucleosome for the 
DNA. Histone acetytransferases (HATs), several of which have been identified and extensively 
studied, mediate histone acetylation. The acetylated status is reversible and different histone 
deacetylases (HDACs) have also been identified (reviewed by Struhl216). Methylation of lysine 
and arginine residues can be associated with either transcriptional silencing or activation 
(reviewed by Kouzarides113). It is now believed that the combination of several modifications, 
rather than one single modification, dictates the transcriptional status of chromatin (reviewed by 
Iizuka and Smith91 and Jenuwein and Allis101).
The enzymes involved in chromatin remodelling are often components of large protein 
complexes denominated chromatin-remodelling complexes. Several complexes have been 
identified, first in yeast and later in mammals (reviewed in Feng and Zhang55, Kornberg and 
Lorch112 and Martens and Winston135).
After access to the DNA is obtained, general transcription factors and RNA polymerase 
can, in principle, bind the promoter of the target gene. Promoters are specific regulatory 
sequences located immediately upstream of the RNA transcription initiation site. Eukaryotic 
promoters are constituted of about 100bp of sequence containing several conserved DNA motifs 
necessary for the recognition by general transcription factors and RNA polymerase.  Several of 
these DNA motifs, such as the TATA box and upstream promoter elements such as CCAAT and 
CACC boxes, are well characterised. Promoters contain all the elements necessary for initiation 
of transcription but other cis-regulatory elements, including enhancers and locus control regions 
(LCRs), interact with the promoter in order to ensure the correct spatio-temporal levels of 
expression.  Enhancers were originally identified15 as cis-acting DNA sequences that increase 
transcription in a manner that is independent of their orientation and distance relative the RNA 
start site (reviewed by Blackwood and Kodanaga22). These regulatory elements have variable 
length and are composed of arrays of DNA motifs that can be specifically bound by transcription 
factors and can activate transcription independently of their orientation.
LCRs share many of the properties of enhancers but in addition posses the ability to open 
chromatin and prevent heterochromatinisation (reviewed by Grosveld72). The first LCR was 
identified in the human β-globin locus but several others have been identified since suggesting 
an important role in the regulation of transcription. LCRs are generally defined by their ability 
to drive high-level expression of linked genes in a tissue-specific, copy number-dependent and 
position-independent manner71 .
 Transcription factors
Despite the fact that all cells in an organism have identical genetic information, each 
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cell type expresses a restricted number of genes. The establishment of these expression profiles 
is orchestrated by specific transcription factors.  These proteins, in response to environmental or 
physiological cues, can recognise specific target sequences located at the promoter, enhancer or 
LCR of a specific gene and activate or repress its transcription. 
Transcription factors recognise their target sequences through specific DNA-binding 
domains, comprised of 60 to 100 amino acids (reviewed by Mitchell and Tjian151). Different 
types of DNA-binding domains can be found in transcription factors, including helix-turn-
helix motifs, zinc-fingers, leucine zippers and helix-loop-helix motifs (reviewed by Harrison80). 
Amino acids at the surface of these domains recognise and bind the DNA target sequence, 
implying that even small differences in the amino acid sequence in this region can alter the 
recognised DNA sequence. Transcription factors are classified into families based on their 
DNA-binding specificity.
Binding of the transcription factor to DNA is necessary but not sufficient for transcription 
activation. Transcription factors interact with other proteins that influence the outcome of DNA 
binding by the transcription factor, i.e., transcription activation or repression. Therefore, other 
types of domains can be identified in transcription factors such as transcription activation/
repression domains and protein-binding domains. These domains, commonly regions of 30 to 
100 amino acids, are usually separated from the DNA binding domain. Through these domains 
transcription factors can interact with the basic transcription machinery and recruit co-factors, 
transcriptional activator/repressor complexes or chromatin remodelling complexes (reviewed 
by Roberts200).
 Transcription factors, like any protein, can also be subject to post-translational 
modifications. Post-translational modifications involve either the covalent binding of small 
molecules to specific amino acids or cleavage of parts of the protein after translation, which 
makes the final protein different from precursor. These alterations in proteins have consequences 
for their activity and therefore are extremely important for their biological function. Many types 
of post-translational modifications have been described including acetylation, phosphorylation, 
glycosylation, and ubiquitilation (reviewed by Han and Martinage75).  Recently an increasing 
number of post-translational modifications in transcription factors have been reported. Despite 
the fact that in most of the cases the functional significance of such modification is not clear, 
in some cases it has been shown that modifications such as acetylation16,94, phosphorylation250, 
ubiquitilation45 and sumoylation63 are of the utmost importance for the normal function of 
transcription factors. A good example of the importance of post-transcriptional modification in 
the function of transcription factors is the tumour supressor gene p53 (reviewed by Xu258). 
2.2 Hematopoietic transcription factors
 Hematopoiesis is not only essential for the formation of blood, and therefore for 
the life of an organism, but it also provides a very interesting model system for the study of 
cell differentiation.  Understanding how a pluripotent stem cell undergoes successive lineage 
restrictions and finally differentiates into a mature blood cell has been a challenge to many 
scientists over the years. Restriction to a particular cell lineage is associated with a lineage-
specific expression profile, established by lineage-specific transcription factors. Therefore, 
understanding how these transcription factors function is essential to comprehend cell 
differentiation.
 In the last two decades a wide variety of transcription factors were found to be involved 
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in the establishment of hematopoietic cell lineages (reviewed by Cantor and Orkin29,30, Perry and 
Soreq186 and Shivdasani and Orkin211) (Fig. 1). These findings relied on the study of genetically 
modified mice, either knockouts, where the gene is functionally deleted, or transgenics, where 
the gene is ectopically expressed. In this section the functions of lineage-specific transcription 
factors involved in hematopoiesis will be discussed. Since the number of transcription factors 
with identifiable functions during hematopoiesis is too vast to allow a thorough discussion 
of every one of them, the discussion will be focussed on those that appear to play the most 
important roles in particular stages of hematopoiesis. This does not mean that other transcription 
factors do not play equally important roles during hematopoiesis but only that they show more 
subtle phenotypes in studies using genetically modified mice and therefore their function is 
more difficult to be identified. 
 Several transcription factors were shown to be essential at very early stages of 
hematopoiesis, for the differentiation of MLPs from the HSCs (reviewed by Shivdasani and 
Orkin211 and Zhu and Emerson270). TAL1, a basic helix-loop-helix transcription factor, and 
LMO2, a LIM-domain transcription factor, are critical for the onset of hematopoiesis since null 
embryos show complete absence of primitive and definitive hematopoiesis193,199,210,244. The zinc-
finger transcription factor GATA2 is also essential for the early stages of hematopoiesis. Both 
primitive and definitive hematopoiesis are abrogated when the GATA2 gene is deleted, but it 
appears to play a role in the proliferation of the early precursors rather than in their differentiation 
(reviewed later in this thesis).  AML1 is crucial for the early stages of definitive hematopoiesis. 
In AML1 null embryos yolk sac hematopoiesis is normal but fetal liver hematopoiesis is 
absent171. HOXB4, a member of the large HOX family of transcription factors, was shown to 
be important for the proliferation of HSCs. Overexpression of Hoxb4 in murine bone marrow204 
and embryonic stem (ES) cells83 enhanced the proliferation capacity of the HSCs and definitive 
erythroid progenitors, respectively, without perturbing the differentiation into the different 
hematopoietic lineages. In agreement, mice deficient in both HOXB3 and HOXB421 or HOXB4 
alone27 show reduced numbers of hematopoietic progenitors and diminished cellularity of the 
hematopoietic organs but lineage commitment is not perturbed.
Once MLPs arise from the HSC and proliferate, the process of lineage restriction 
starts. A number of transcription factors that are preferentially expressed in cells destined to a 
particular lineage have been identified but few have been extensively studied. PU.1, a member 
of the ets family of transcription factors, is the best-studied transcription factor known to be 
involved in early lineage restriction. PU.1’s effect on lineage commitment is dependent on its 
expression level: a high level of expression leads to commitment to the myeloid lineage while 
lower levels of expression lead to commitment to the lymphoid lineage. This is supported by 
two observations. First, PU.1 null mice die around birth and show absence of B-lymphocytes, 
granulocytes and monocytes205. Secondly, overexpression of PU.1 leads to commitment to the 
myeloid lineage, more specifically, to the granulocytic/monocytic lineage165. These findings are 
in agreement with the lineage commitment model in which a CMLP gives rise to MBPs and 
MTPs (reviewed By Katsura106).
 More is known about transcription factors involved in specific hematopoietic lineages. 
Some examples of such transcription factors are GATA1, FOG1 and GATA3. The zinc-finger 
transcription factor GATA1 is essential for the development of the erythroid, megakaryocytic and 
eosinophilic lineages. FOG1, another zinc-finger transcription factor and co-factor of GATA1, 
is also crucial for the erythroid and megakaryocytic lineages. GATA3 plays an essential role in 
T-cell development. The functions of these factors will be discussed  later in this thesis.
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3. The GATA family of transcription factors
The GATA family consists of six transcription factors, GATA1 to GATA-6. These 
transcription factors are categorised as a family due to the fact that they all bind to the DNA 
consensus sequence (A/T)GATA(A/G) by two characteristic C
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zinc-finger motifs109,137,143,253,260, commonly designated by GATA fingers.
 The zinc-finger motifs are the regions with highest homology between the GATA 
family members. Outside these regions, the conservation between GATA factors is low174,260. 
Furthermore, the overall homology of an individual member is higher between species than 
between different members of the same species260,272.
 The GATA family is subdivided into two subfamilies based on the expression profiles 
of the individual transcription factors. GATA1, GATA2 and GATA3 belong to the hematopoietic 
subfamily since they are expressed mainly in the hematopoietic system248 (Fig. 6). The non-
hematopoietic subfamily is composed by GATA4, GATA5, and GATA6, which are expressed in 
several tissues including intestine, lung and heart but not in the hematopoietic system152.
Figure 6 - Schematic representation of the murine hematopoietic GATA proteins. The zinc-finger 
domains (in black), N-terminus domain (dark grey) and the know sites modified by acetylation 
(A), phosphorylation (P) and SUMOylation (S) are shown; the numbers indicate the modified 
amino acid.
3.1 GATA1
GATA1, also known as NF-E1, NF-1, Ery-1 and GF-1, is the founder member of the 
GATA family of transcription factors. It was first identified as a protein with binding specificity 
to the β-globin 3’ enhancer53,243 and cloned from a murine erythroleukemia (MEL) cell line 
cDNA library228. The human homologue was soon after cloned and its localization assigned to 
the X-chromosome at position Xp21-11271. The murine GATA1 gene is also located on the X 
chromosome271.  
GATA1 is expressed in primitive and definitive erythrocytes59,125, megakaryocytes138,202, 
eosinophils274, mast cells138, and in the Sertoli cells of the testis 95,262. Several gene targeting 
studies were performed to attempt to elucidate the importance of GATA1 function in these 
cells.
These studies have shown that GATA1 is essential for normal erythropoiesis. GATA1-
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deficient embryonic stem (ES) cells are able to contribute to all different tissues in chimeric 
mice, with the exception of the mature red blood cells188. More detailed analysis of erythropoiesis 
in these chimeric mice revealed that GATA1 null erythroid cells fail to mature beyond the 
proerythroblast stage189. In vitro differentiation of GATA1-deficient ES cells confirmed this 
arrest of both primitive and definitive erythropoiesis at the proerythroblast stage246 and showed 
that the arrested precursors die by apoptosis247. Not surprisingly, GATA1 null murine embryos 
die from severe anaemia between E10.5 and E11.559. GATA1 knock-down embryos (GATA1.05), 
which express only approximately 5% of the wild-type GATA1 levels, also show an arrest of the 
primitive erythropoiesis and die between E11.5 and E12.5219. Other GATA1 knock-down mice 
(GATA1 low)140, which express about 20% of the wild-type GATA1 levels, show a somewhat 
milder phenotype. Despite the fact that the majority of GATA1 low mice die between E13.5 and 
E14.5, due to ineffective primitive and definitive erythroid differentiation, some are born alive 
(2% of the expected 25%) and a small number survive to adulthood. These mice are anaemic at 
birth but they recover from the anaemia and show a normal life span. From the analysis of these 
different mouse models a direct relationship between the expression levels of GATA1 and the 
severity of the phenotype is evident.
The analysis of a megakaryocyte-specific knockout of GATA1 has revealed a critical 
role for this factor in megakaryocytic development212. Absence of GATA1 in megakaryocytes 
leads to an increased proliferation and deficient maturation of megakaryocytic progenitors as 
well as reduced number of circulating platelets. The platelets produced are not fully functional 
and show an abnormal morphology239.
GATA1 also plays an essential role in eosinophil development. The first evidence for 
a role of GATA1 in eosinophil development comes from the observation that forced GATA1 
expression in Myb-Ets-transformed chicken myeloblasts induced a reprogramming of these 
myeloblasts into cells resembling either transformed eosinophils or thromboblasts114. In a later 
report, forced expression of both GATA1 and GATA2 was also shown to instruct CD34-positive 
bone marrow cells to develop into eosinophils86. In the same report, it was also shown that 
GATA1 deficient fetal liver precursor cells are unable to generate eosinophilic colonies in 
culture86. Furthermore, the deletion of a double GATA site present in the GATA1 promoter was 
found to cause the selective loss of the eosinophilic lineage263.
Mast cells are somewhat different from the majority of the hematopoietic cells. They 
originate from the HSC in the bone marrow but the precursor cells migrate, through the blood, 
to connective or mucosal tissues, where they proliferate and differentiate into mature mast cells. 
GATA1 is abundant in the more mature mast cells but it is almost undetectable in the bone 
marrow progenitors suggesting a possible role in the terminal differentiation of mast cells79. 
Also, it was noticed that GATA1.05 heterozygous female mice, expressing 5% of the wild-type 
GATA1 levels in approximately 50% of the cells owing to the process of X-inactivation, certain 
mast cells show a defective maturation79. Final proof of the importance of GATA1 in mast cell 
maturation arose from the analysis of GATA1 low mice146. These mice express about 20% of the 
wild-type GATA1 levels but in contrast to the GATA1.05 mice, some reach adulthood allowing 
a more detailed analysis of the mast cell phenotype. Indeed, connective tissues from GATA1 
low mice contain large numbers of mast cell precursors but normal numbers of mature mast 
cells, with abnormal morphology. Many of these precursors die by apoptosis, which explains 
the normal numbers of mature cells. The defect observed is GATA1-specific, since forced 
expression of GATA1 rescues the maturation potential of these cells.
Although GATA1 is expressed in the Sertoli cells of the testis at critical stages of 
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spermatogenesis, testis-specific deletion of GATA1 does not result in an apparent phenotype127.
Despite all the knowledge about the consequences of GATA1 absence in different 
hematopoietic lineages we are far from knowing the specific functions performed by this 
transcription factor in those cells. 
Based on the observation that GATA1 null erythroid cells undergo apoptosis, it as been 
suggested that GATA1 is directly involved in cell survival. Several lines of evidence support this 
theory: GATA1 activates transcription of the Epo receptor (EpoR)34 and Epo signalling is known 
to be important for erythroid progenitor survival115. Furthermore, one of the known target genes 
of GATA1 is Bcl-
XL
, a gene encoding an anti-apoptotic protein70. 
Another possible GATA1 function is the regulation of G1/S cell cycle progression. Cell 
cycle control is of the utmost importance in hematopoietic differentiation since progenitors 
must be able to proliferate in order to proceed through hematopoietic development, but for 
terminal differentiation to occur cells must exit the cell cycle254. This idea is reinforced by 
the identification of a variety of GATA1 target genes involved in cell cycle regulation or with 
known functions in proliferation of differentiation processes203.
 GATA1 has also been implicated in the reprogramming of hematopoietic precursors. 
Forced expression of GATA1 was shown to reprogram myeloblasts and CD34+ bone marrow 
cells to develop into eosinophils86,114. Furthermore, forced expression of GATA1 was also shown 
to reprogram GMPs to give rise to erythroid, eosinophilic and basophilic-like cells85. By clone 
tracking the authors demonstrated that the GATA1 effect is at the cell commitment level and not 
due to effects on clone selection. Another recent report96 shows that ectopic GATA1 expression 
guides hematopoietic precursors to commitment to the erythrocyte-megakaryocytic lineage. It is 
not clear from these reports if the GATA1-induced lineage reprogramming is a GATA1–specific 
characteristic, or whether it is a general effect of the ectopic expression of lineage-specific 
transcription factors. In Chapter 4 of this thesis, the importance of spatial-temporal expression 
of the GATA transcription factors during erythroid development will be addressed.
At least three functional domains have been identified within the GATA1 protein: An N-
terminal activation domain, the N-terminal zinc finger (N-finger) and the C-terminal zinc finger 
(C-finger). The C-finger is essential for GATA1 function since it is responsible for the recognition 
of the GATA consensus sequence and consequent binding to DNA137,261. The importance of the 
N-finger to GATA1 function has been more difficult to define. Although early studies, in non-
erythroid cells, indicated that the N-finger was not essential for GATA1-mediated transcriptional 
activation137, it was later shown that this zinc finger plays a crucial role in GATA1’s ability to 
induce terminal erythroid differentiation249. The N-finger contributes to the stabilisation and 
specificity of DNA binding137,253. More recently, it was shown that this finger mediates the 
formation of complexes with cofactors. These interactions can involve only the N-finger, as is 
the case with FOG157, or as a collaboration between N and C-finger, for example with Sp1 and 
EKLF69,144, and GATA1 itself132. Early studies, using reporter assays in non-erythroid cells, show 
that the most N-terminal 80 aminoacids of the GATA1 protein are essential for its transcriptional 
activation activity137. Surprisingly, in another report249 this transactivation domain was shown to 
be dispensable for GATA1-mediated terminal erythroid differentiation. This discrepancy may 
be related with the expression levels of the GATA1 mutants (see below).
 To examine the function of each of the three GATA1 domains in a more reliable way, 
Shimizu and colleagues208 made use of transgenic rescue of GATA1.05 knock down mice. By 
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analysing the offspring resulting from the crossing between GATA1.05 mice and transgenic mice 
expressing different GATA1 mutants, the requirements for the different functional domains were 
unravelled.  In agreement with the previous reports, the C-finger was shown to be indispensable 
for GATA1 function in both primitive and definitive erythropoiesis but the N-finger was shown 
to be necessary only for definitive erythropoiesis. Like the N-finger, the transactivation domain 
appeared to have different functions in primitive and definitive erythropoiesis. When expressed 
at levels higher than the endogenous GATA1, the transactivation domain mutant can sustain 
both primitive and definitive erythropoiesis but when expressed at lower levels, definitive 
erythropoiesis is impaired. From these data it can be concluded that all the GATA1 domains 
are required for definitive erythropoiesis while only the C-finger is absolutely essential for 
primitive erythropoiesis. This demonstrates that the primitive and definitive erythroid lineages 
have different requirements for GATA1.
3.1.1 Regulation of GATA1 activity
 GATA1 activity in vivo is tightly regulated. Increasing GATA1 activity can lead to 
phenotypes as strong as embryonic lethality251 (Chapter 2 of this thesis). The activity of proteins 
can be regulated by different mechanisms. The mechanisms thought to be involved in the 
regulation of GATA1 activity will be reviewed in this section. 
Transcriptional regulation 
 The GATA1 transcription unit is composed of two alternative non-coding first exons, 
IT and IE95, and five coding exons, II to VI229. Exon IT is primarily used in Sertoli cells of the 
testis while exon IE is used in hematopoietic cells95. The proteins expressed in hematopoietic 
and Sertoli cells are identical since exon II harbours the translation start site. The two zinc finger 
motifs are encoded separately in exon IV and V. 
 The testis promoter and exon IT are located 8kb upstream of exon IE. Disruption 
of the erythoid promoter leads to an arrest in primitive erythropoiesis without affecting the 
expression from the testis promoter219. Both testis- and erythroid-specific promoters contain 
GATA sites that are required for the proper functioning of the promoter95,173,240, suggesting a 
positive feedback loop229. Interestingly, both GATA1 promoters lack a TATA box76,229. 
DNase I hypersensitivity analysis of the GATA1 locus, in erythoid cells, identified three 
main hypersensitive (HS) regions. HSI is located between 3.9 and 2.6kb upstream of IE, HSII 
corresponds to the region surrounding the IE promoter and HS III corresponds to intron I139. 
 Transcription of the GATA1 gene in different hematopoietic lineages has different 
regulatory sequence requirements. HSI, also called GATA1 upstream activating element, can 
drive reporter gene transcription exclusively in primitive erythrocytes while together with 
intron I this element can drive expression of the reporter gene in both primitive and definitive 
erythroid cells172. Furthermore, GATA1 transcription in erythroid and megakaryocytic cells has 
different sequence requirements within HSI212,240. Expression in both lineages is dependent of 
the presence of an intact GATA site, but megakaryocytic expression requires the 3’ end of HSI, 
which is dispensable for erythroid expression.
 Translational regulation
GATA1 possesses an alternative translation initiation site located at methionine 8428. 
Translation from this alternative initiation site gives rise to a 40kD protein, GATA1s, which 
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lacks 83 amino acids at the N-terminal region, i.e. the N-terminal transactivation domain. 
GATA1s can be detected in MEL and K562 cells as well as in mouse tissues but its expression 
level is much lower that the full length GATA1 forms. This protein shows normal DNA binding 
activity but a reduced transactivation potential which is in agreement with the reported role of 
the N-terminus as a transactivation domain137.
Exclusive translation of GATA1s has been implicated in myeloid leukemogenesis 
(reviewed by Gurbuxani and colleagues73) . Mutations in exon II of the GATA1 gene, introducing 
premature stop codons in the region encoding the N-terminal transactivation domain, have 
been identified in Down syndrome patients suffering from acute megakaryoblastic leukemia 
(AMKL)245 and transient myeloproliferative disorder (TMD)87,159. The mechanism by which 
GATA1 contributes to the leukemogenic process is not known but it most likely involves the 
blockage of megakaryocytic differentiation since it is known that reduced levels of GATA1 
lead to excessive proliferation and impaired differentiation of megakaryocytes. Despite the fact 
that GATA1 mutants lacking the N-termimal transactivating domain can rescue the GATA1.05 
knock-down phenotype208, when expressed at high levels, it can be hypothesized that GATA1s is 
not fully functional and therefore unable to drive terminal megakaryocytic differentiation.
 Post-translational regulation
Acetylation
 GATA1 can be acetylated both in vitro and in vivo by the ubiquitously expressed 
acetyltransferases P300 25 and CREB-Binding Protein (CBP)90. Murine GATA1 is acetylated 
at two conserved lysine-rich motifs (aa245-252 and aa308-316) localised just C-terminal from 
each zinc finger. These motifs are conserved among members of the GATA-family and between 
different species.
 The functional importance of GATA1 acetylation is not clear. The interaction between 
GATA1 and P300/CBP, and consequent acetylation of the transcription factor, seems to stimulate 
its transcription activity23,25.  Boyes et al. also reported that in chicken GATA1 acetylation 
increased DNA-binding activity, but Hung and colleagues25 did not see this effect with murine 
GATA1. It has also been suggested that acetylation plays an important role in targeting GATA1 
for degradation by ubiquitination (J. Boyes, personal communication). Acetylation of GATA1 
appears to be required for the in vitro differentiation of the GATA1 null cell line G1E23.
Phosphorylation 
GATA1 can be phosphorylated at seven serine residues40 (Fig. 6). Six of these 
residues (S26, S49, S72, S142, S178 and S187), situated at the N-terminus of the protein, are 
phosphorylated in uninduced MEL cells. The seventh serine (S310), which is located near 
the DNA-binding domain, only becomes phosphorylated upon DMSO induction of the MEL 
cells. This suggests a possible role forphosphorylation in both DNA binding and transcriptional 
activity of the protein. Surprisingly, substitution of the serines for alanines did not have any 
consequence in GATA1 DNA binding or transcriptional activity40.
Another somewhat contradictory report shows that the phosphorylation of GATA1, in 
induced K562 cells, increases DNA binding184. The same report confirms that such increase 
in DNA binding does not occur in induced MEL cells and suggests that GATA1 is already 
phosphorylated in uninduced MEL cells while in K562 cells GATA1 becomes phosphorylated 
upon induction, which leads to an increased DNA binding of the protein. A recent report225 
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shows that GATA1 phosphorylation at S26 and S178 is dependent of cytokine signalling via 
the MAPK pathway. A mutation of these serine residues interferes with the ability of GATA1 to 
interact with LMO2, a known interaction partner of GATA1 (reviewed later in this thesis).
SUMOylation
 It was recently reported that GATA1 is modified by covalenty binding of SUMO1, 
both in vitro and in vivo37. Although SUMOylation is commonly assocated with transcriptional 
repression, no apparent effect on GATA1 transcriptional activity was observed by the authors in 
a number of assays. GATA1 SUMOylation also does not interfere with the cellular localization 
of the transcription factor therefore the specific function of GATA1 SUMOylation remains 
unknown.
Protein degradation
 Another possible regulatory mechanism for protein activity in general is degradation. 
Our current hypothesis is that GATA1 activity must be high at early stages of erythroid 
differentiation, but must be downregulated for terminal erythroid differentiation to occur (see 
Chapter 2 and 4 of this thesis). This implies protein degradation as a potentially important 
regulatory mechanism for GATA1 function.
 GATA1 degradation via caspase-mediate cleavage has been reported44.  This report 
shows that activation of caspases, via death receptors, leads to an arrest in terminal erythroid 
differentiation. The authors attributed the differentiation arrest to a decrease of GATA1 protein 
levels due to caspase-mediated cleavage, since expression of a caspase-resistant GATA1 mutant, 
but not a wild-type GATA1, restored terminal erythroid differentiation.
From the observation that the Fas death receptor is expressed throughout erythroid 
differentiation but its ligand, FasL, is only expressed in the more mature erythroblasts a model 
emerges in which mature erythroblasts participate in a negative-feedback loop to attenuate 
differentiation of earlier erythroid progenitors.
 In contrast, our group has shown that overexpression of GATA1 in erythroid cells, 
both in vitro254 and in vivo251, inhibits erythroid differentiation. Based on this fact a somewhat 
contrasting model can be envisaged: GATA1 degradation by caspases leads to a reduction of 
GATA1 levels at late stages of erythroid differentiation thereby allowing terminal differentiation. 
In the presence of high levels of GATA1 erythroid cells fail to differentiate but surprisingly 
if wild-type erythroid cells are present, the overexpressing cells can differentiate normally251. 
Further analysis74 showed that differentiating erythroid cells can signal to GATA1 overexpressing 
erythroid cells, which are normally blocked in differentiation, to terminally differentiate. This 
might involve activation of death receptors present in erythroid precursors by ligands produced 
by differentiated erythroid cells, promoting caspase-mediated cleavage of GATA1. 
3.1.2 Protein-protein interactions
  GATA1 is now known to interact with a variety of proteins, either co-factors or 
transcription factors. These interactions play important roles in hematopoiesis since they lead to 
transcription activation or repression of GATA1 target genes. The most important interactions 
between GATA1 and other proteins known to date will be reviewed in this section.
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GATA1
 It has been shown that GATA1 can self-associate in vitro42, both in solution and when 
bound to DNA. Both the C-finger and the N-finger can independently associate with full-length 
GATA1 protein since the interaction is mediated by N-finger-C-finger contacts132. GATA1 
dimerization may play an important role in the regulation of promoters containing multiple 
GATA sites since mutation of particular residues in the finger regions reduces the GATA1 
transactivation potential in reporter assays132. Furthermore, GATA1 dimerization was shown to 
be important for the positive regulation of the GATA1 promoter in zebrafish167.
Other potential functions for GATA1 dimerization may be to establish contact between 
promoters and enhancers, and to recruit chromatin-remodelling complexes.
FOG1
 Friend of GATA1 (FOG1), a protein containing nine widely-spaced zinc fingers, was 
identified in a yeast two-hybrid screen as a GATA1 co-factor230. It binds to the N-terminal zinc 
finger of GATA1 mainly via its zinc finger 657 although fingers 1, 5 and 9 also contribute to the 
binding58. FOG1 is co-expressed with GATA1 in the erythroid and megakaryocytic lineages and 
co-operates with GATA1 during erythroid and megakaryocytic differentiation230.
The phenotype of FOG1 null mice closely resembles the GATA1 null phenotype. Both 
mutant mice die during midgestation from severe anemia caused by a defect in primitive and 
definitive erythropoiesis, suggesting that FOG1 is essential for GATA1 function. In contrast to 
GATA1 deficiency, however, loss of FOG1 leads to a complete ablation of the megakaryocytic 
lineage, revealing a GATA1-independent role of FOG1 in megakaryopoiesis231. Definitive 
proof that the FOG1/GATA1 interaction is essential for GATA1 function during erythroid 
differentiation was obtained by the analysis of GATA1 mutants defective in FOG1 binding 
and subsequent identification of compensatory mutations in the FOG138. Erythroid precursors 
expressing GATA1 mutants unable to bind FOG1 fail to differentiate but this phenotype is 
rescued by the expression of the FOG1 mutants that can bind these GATA1 mutant proteins.
Although it has no apparent DNA-binding activity, FOG1 is known to differently 
modulate GATA1 activity depending on the promoter context. It synergizes with GATA1 in 
the activation of certain promoters230 while repressing GATA1-mediated activation of other 
promoters58. 
One can speculate about possible mechanisms of action for FOG1. FOG1 may be a 
bridging factor coupling DNA-bound GATA1 to the general transcription machinery and 
repressor/activator complexes.  Recent work in our laboratory shows that FOG1 links GATA1 
to the MeCP1 transcriptional repressor complex201.
RB
The tumor suppressor protein retinoblastoma (RB) plays important roles in many stages 
of the differentiation process, including regulation of progenitor proliferation, terminal cell 
cycle exit, induction of tissue-specific gene expression and protection from apoptosis129. The 
phosphorylation state of RB determines the progression of cell cycle from G1 to S-phase.  In 
G1, RB exists in an active, hypophosphorylated, state and is in complex with E2F. The E2F 
family of transcription factors is the best characterized target of RB, regulating the timing and 
expression levels of many genes involved in cell cycle progression77. RB-E2F complexes stop 
cell cycle progression by preventing transcription of E2F target genes, either by sequestering E2F 
or by recruiting repression complexes such as SWI/SNF and histone deacetylases to promoters. 
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At the G1-S transition, CyclinD-cdk4/6 and CyclinE-cdk2 complexes phosphorylate RB. 
Hyperphosphorylation of RB results in the dissociation of transcription repression complexes 
and the release of E2F. Free E2F is now able to activate transcription of genes necessary for 
entrance S-phase and cell cycle progression78.
 Mice deficient for RB are embryonic lethal and show neuronal and hematopoietic 
defects97,122. Recently, the cause of death was attributed to placental malformation257. RB 
null embryos supplied with a wild-type placenta are viable, showing no signs of neuronal 
abnormalities. A mild defect in erythroid differentiation is still observed indicating that this 
defect is a direct consequence of RB insufficiency. However, RB null ES cells contribute to all 
tissues in chimaeric mice and these mice show no apparent defect in the erythroid lineage131,255. 
RB null fetal liver cells are also able to repopulate blood lineages of lethally irradiated recipient 
mice but, surprisingly, erythropoiesis is impaired89. RB null erythroid precursors show increased 
proliferation and a blockage of late stages of terminal differentiation leading to the presence of 
nucleated erythrocytes in the peripheral blood and anemia. This indicates that RB function is 
cell non-autonomous, that is, in the presence of wild-type cells RB null cells show a normal 
phenotype, suggesting that the RB requirement of an erythroid cell can be bypassed by signals 
supplied by another erythroid cell252. This is remarkably similar to the phenotype of the GATA1 
overexpressing mice251 (see Chapter 2 of this thesis), which is also cell non-autonomous.
Furthermore, GATA1 has been shown to bind RB in erythroid cells and erythroid-
specific GATA1 overexpression leads to RB hyperphosphorylation via an as yet unknown 
mechanism254.
Krüppel-like factors
 GATA1 has been shown to physically interact and functionally synergize with Sp1 and 
erythroid Krüppel-like factor (EKLF or KLF1)69,144, two transcription factors belonging to the 
wide Sp/XKLF family of transcription factors (reviewed by Philipsen and Suske191).
 Sp1 is a ubiquitously expressed transcription factor essential for early embryonic 
development. Sp1 null embryos die around E9.5 and show a broad range of abnormalities, 
but transcription of embryonic globin genes is activated134. In contrast, EKLF is an erythroid-
specific transcription factor147. EKLF null mice are embryonic lethal due to a defect in definitive 
erythropoiesis169,185. These embryos succumb to fatal anemia due to a defect in hemoglobin 
accumulation, explained by the EKLF requirement for β-globin expression169,185.
 The fact that Sp1 and EKLF can recognize GC and/or CACC motifs, which are found 
in close proximity of GATA motifs in several promoters, enhancers and LCRs, suggested a 
functional cooperation between these proteins. GATA1 was shown to bind the zinc-finger 
domain of Sp1 and EKLF mainly via its C-finger and reporter assays demonstrated that GATA1 
transcriptional activity can be synergistically increased by these interactions69,144. The interaction 
between GATA1 and either Sp1 or EKLF was shown to be dependent on the promoter69, 
suggesting discrete roles for these two factors in the regulation of erythroid-specific genes. 
Interaction between GATA1 and Sp1 or EKLF may play a crucial role in, for example, 
bringing regulatory elements such as enhancers and LCRs in close proximity of promoters by 
promoting the formation of DNA loops. Recently, the formation of a complex containing the β-
globin LCR and the promoters of the actively transcribing β-globin gene, the Active Chromatin 
Hub (ACH), has been demonstrated32,223. Furthermore, the presence of the transcription factor 
EKLF was shown to be crucial for the formation of the ACH48.
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LMO2
GATA1 had been reported to be in a complex together with LMO2, LDB1, TAL1 and 
E2A that can activate transcription from promoters containing an E-box (CANNTG consensus 
sequence) and a GATA binding site separated by 9 nucleotides242. The GATA-E-box motif has 
been reported in promoters of several genes12,36,240 suggesting an important role for this motif. 
GATA1 interacts directly with LMO2, but not with TAL1, in erythroid cells176,177.  These 
authors also showed that GATA1 and TAL1, in the presence of LMO2, synergistically activate 
transcription of reporter genes177. From these data, a model was proposed in which GATA1 
and the TAL1-E2A complex233,241 bind DNA and LMO2, together with its partner LDB1. 
LMO2 makes the bridge between the transcription factors, either as single a molecule or by 
homodimerization. 
The role of such a complex in hematopoiesis is not known but considering the important 
functions of the intervening proteins (reviewed elsewhere in this thesis) it is likely that this 
complex is of extreme importance.  This complex was found to bind the GATA-E-box motif 
in the upstream regulatory sequence (HSI) of the GATA1 gene, and the integrity of the GATA 
binding site is crucial for binding. However, its functional importance remains unknown240. 
Furthermore, disruption of the GATA-E-box-GATA motif present in the EKLF promoter 
abrogates the expression of the gene. This suggests that the formation of GATA1/LMO2/TAL1 
complex is required for transcription activation12,36.
 
PU.1
 PU.1 is a member of the ets family of transcription factor required for the development 
of the lymphoid and granulocytic/monocytic lineages (reviewed elsewhere in this thesis). 
Expression of PU.1 and GATA1 seems to be mutually exclusive suggesting an antagonistic 
effect of these two transcription factors. 
Several lines of evidence indicate that GATA1 and PU.1 functionally antagonise each 
other via direct physical interaction166,197,266. PU.1 and GATA1 interaction takes place via the 
DNA-binding domains of both proteins197,266 but the mechanisms by which these transcription 
factors antagonise each other are quite distinct. GATA1 inhibits PU.1 by preventing it to interact 
with its cofactor c-Jun266 while PU.1 inhibits GATA1 by preventing its binding to DNA267. 
P300/CBP
P300 and CBP are ubiquitously expressed proteins with histone acetyltransferase (HAT) 
properties, known to interact with a large number of transcription factors. The mechanism by 
which P300 and CBP intervene in transcription regulation is not clear and several models have 
been proposed. Binding of P300/CBP to transcription factors can be a way to recruit histone 
acetyltransferase to the vicinity of nucleosomes and induce an open chromatin configuration, 
thus stimulating transcription. CBP and P300 can also serve as a bridging molecule between 
components of the general transcription machinery and enhanceosome complexes. Furthermore, 
P300 and CBP are known to be responsible for the acetylation of transcription factors which 
seems to have a direct effect on their function (reviewed by Vo and Goodman237).
 GATA1 has been shown to bind P30025 and CBP90 both in vitro and in vivo.  As mentioned 
before, P300 and CBP acetylate GATA125,90 but it is unlikely that this is the only function of 
these proteins. The involvement of P300/CBP in the recruitment of other transcription factors, 
co-factors or chromatin-remodelling complexes to regulatory sequences bound by GATA1 may 
be envisaged.
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PIASy
 It has been recently reported that GATA1 can be SUMOylated and such modification 
is promoted by the SUMO ligase PIASy37. Interestingly, SUMOylation does not seem to 
be required for GATA1 transcriptional activity but the interaction of GATA1 with PIASy, 
independent of SUMOylation, results in a repression of the GATA1 transactivation potential. 
PYASy is a member of the PIAS (Protein Inhibitor of Activated STAT) protein family original 
identified has negative regulators of STAT transcription factors but later on classified as E3-like 
SUMO ligases. E3-like PIAS proteins concentrate in nuclear foci that partially localize with 
PML bodies, nuclear bodies of as yet undefined biological function but that contain numerous 
transcription factors and transcription coregulators, most of them known to be SUMOylated 
(reviewed by Muller and colleagues158). This suggests an important role in the regulation of 
transcription factors.
 
3.1.3 GATA1 target genes
 GATA sequences are quite abundant in the genome and GATA consensus sequences can 
be found in the promoters of many genes by searching the appropriate databases. An increasing 
number of GATA1 target genes are being identified using functional assays and more recently 
using high-throughput gene expression analysis afforded by DNA microarrays.
 In this Chapter, a short overview of the most relevant of the growing number of 
known GATA1 target genes will be given. In Chapter 3 of this thesis data is presented from the 
gene expression analysis, using the cDNA microarray technology, of both in vivo and in vitro 
erythroid-specific GATA1 overexpression model systems.
α and β-globins
 GATA1 was first identified by its interaction with the β-globin gene enhancer and was 
soon shown to bind to multiple regulatory regions in both the α- and β-globin locus243,53,137. 
Despite the absence of GATA1, GATA1 null erythroid cells are still able to produce hemoglobin 
suggesting that GATA1 may not play a critical role in the transcription of the globin genes246. 
Another possibility is that GATA1 is replaced by GATA2, which is known to be upregulated 
in GATA1 null cells, since GATA binding sites are essential for expression of β-LCR driven 
transgenes190.
Heme biosynthesis enzymes
 Hemoglobin, present in large quantities in erythrocytes, is the protein responsible for 
the transport of oxygen and carbon dioxide throughout the body. Hemoglobin is a tetrameric 
protein composed of two α-like and two β-like globin chains. Each globin chain carries a heme 
group, a ring shaped molecule containing a central iron atom, which can reversibly bind oxygen. 
Heme is synthesised from glycin and succinyl CoA via a series of steps involving the action of 
8 enzymes (reviewed by Ponka192).  Several of the genes encoding for enzymes involved in the 
heme biosynthesis (ALAS2, ALAD, HMBS) are known GATA1 target genes174,203 emphasising 
once more the important and broad function of GATA1 in erythroid cells.
ABCme
ABCme (ABC mitochondrial erythroid) was identified as a GATA1 target gene209 upon 
analysis of  genes induced during GATA1-dependent differentiation of the G1E GATA1 null 
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erythroid progenitors209.  ABCme belongs to the ABC (ATP-binding cassette) protein family, 
which members are involved in the transport of compounds through cellular membranes. 
ABCme is a mitochondrial inner membrane protein transporter, expressed in several tissues but 
predominantly in erythroid cells. ABCme overexpression in MEL cells enhances hemoglobin 
production suggesting a possible role in heme biosynthesis.
Erythropoietin (Epo) and Epo receptor (EpoR) 
Erythropoietin (Epo) is the major growth factor for erythroid cells.  Epo interacts with 
the Epo receptor (EpoR), a cell surface receptor expressed in erythroid, megakaryocytic and 
mast cells, triggering signalling cascades leading to the proliferation, differentiation and survival 
of erythroid progenitors (reviewed by Lacombe and Mayeux115 ). 
GATA1 was first reported to be involved in the regulation of the EpoR by Zon and 
colleagues273. These authors showed that GATA1 could specifically bind and transactivate the 
EpoR promoter. A second report34 also shows that GATA1 is expressed prior to the EpoR but its 
expression is strongly enhanced by EpoR-mediated signals. Surprisingly, Weiss and collegues246 
showed that EpoR is normally transcribed in GATA1 null erythroblasts, strongly suggesting a 
role for GATA2 in EpoR expression in early erythroid precursors.
In contrast to their function as Epo receptor activators, GATA proteins were shown to 
negatively regulate apoxia-induced Epo expression by binding to GATA sites in its promoter92,93. 
The reason for the contrasting functions of GATA proteins in the regulation of the EpoR and Epo 
genes remains unclear. 
Bcl-XL
 It has been hypothesized that GATA1, in collaboration with Epo, can act as a survival 
factor during erythroid differentiation.  The mechanism by which that is accomplished is not 
known but Bcl-X, a member of the Bcl2 gene family, is a good candidate to mediate survival 
during erythroid development. Due to alternative splicing the Bcl-X gene can originate two 
distinct mRNAs: Bcl-
XL
, a larger mRNA that codes for a protein with anti-apoptotic properties 
and Bcl-XS, a smaller mRNA that, surprisingly, encodes for a pro-apoptotic protein. Bcl-XL 
expression increases in late stages of erythroid differentiation and appears to be dependent on 
Epo155,213,68. 
  Based on these observations, Gregory and colleagues70 analyzed the expression of 
Bcl-XL during erythroid differentiation in G1E GATA1 null erythroid progenitors rescued by 
the expression of GATA1. These data show that Bcl-XL, is upregulated in a GATA1-dependent 
manner during erythroid differentiation. This suggests that GATA1, together with Epo, prevents 
apoptosis in differentiating erythroid cells by promoting the expression of anti-apoptotic proteins 
such as Bcl-
XL
. A direct interaction between GATA1 and the BCL-XL promoter has yet to be 
demonstrated.
GATA2
 GATA2 is an important regulator of hematopoiesis, its downregulation being crucial 
for hematopoietic differentiation (reviewed later in this thesis).
 The first clue about a possible regulation of the GATA2 gene by GATA1 was the 
observation that GATA2 is upregulated in the absence of GATA1246. Further analysis of GATA1-
regulated genes consistently identified GATA2 as being repressed by GATA1203,209 through a 
mechanism  involving a GATA1/FOG1/MeCP1 complex201.
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 In a recent report67, GATA1 was reported to bind to a region 2.4kb upstream of the 
GATA2 1G promoter. The same report also showed that GATA2, together with CBP, can bind 
to the same regions, as GATA1 in its absence and that displacement of GATA2 by GATA1 is 
the cause of repression. This data suggests a mechanism by which GATA1 directly represses 
GATA2: GATA2, when bound to the –2.8kb site of its own locus, recruits CBP to this region 
leading to histone acetylation and consequently activation of transcription. GATA2 displacement 
by GATA1 leads to a loss of CBP and the establishment of a closed chromatin configuration 
through the histone deacytylase activity of MeCP1201.  
EKLF
EKLF can bind to and synergistically function with GATA169,144 but it is also a GATA1 
target gene. Three GATA binding sites, capable of binding GATA1, were identified in the EKLF 
promoter and one of them was shown to be crucial for initiation of transcription41. Moreover, 
forced expression of GATA1 can activate the EKLF promoter in non-erythroid cells and EKLF 
expression is downregulated in the absence of GATA1246 but it is restored upon its reintroduction203. 
GATA1 appears to induce EKLF expression as a GATA1/LDB1/TAL1 complex201.
TAL1
In the hematopoietic system TAL1 expression, driven by promoter Ia, is restricted to 
erythroid, megakaryocytic and mast cell lineages156. The similarities between TAL1 and GATA1 
expression patterns and the presence of GATA consensus sequences in the TAL1 Ia promoter 
suggested regulation of TAL1 expression by GATA1. More detailed analysis of the promoter 
requirements for TAL1 expression confirmed that GATA1 could bind the GATA consensus 
sequences in the TAL1 promoter Ia and transactivate its transcription120.
Cell cycle core components and proliferation-related genes
A function in G1/S cell cycle progression has been assigned to GATA1 during erythroid 
differentiation (reviewed elsewhere in this thesis). Recently, Rylski and collegues203 have 
reported the identification of core cell cycle components as target genes of GATA1. Making 
use of a model system in which a proliferating GATA1 null cell line (G1E) can be induced to 
differentiate by reintroduction of GATA1249, the authors analysed the influence of GATA1 in the 
transcription of genes involved in activation and inhibition of cell cycle progression. GATA1 
appeared to be able to repress expression of core cell cycle protein such as Cyclin D2 and 
Cdk6, involved in cell cycle progression, and activate transcription of cell cycle progression 
inhibitors such as p18INK4c and p27Kip1. Furthermore, it seemed to induce expression of growth 
inhibitors, including Btg2, Hipk2, JunB and Creg, and downregulate the expression of genes 
with mitogenic properties such as Myc, Myb and Nab2.  
Unfortunately, the experiment described above was not able to distinguish between 
direct GATA1 target gene and differentially expressed genes due to secondary effects. In an 
attempt to clarify this issue, the authors performed a more detailed analysis of the interaction 
between Myc and GATA1 and showed that GATA1 represses transcription of the Myc gene by 
direct binding to its promoter. GATA1 binds the Myc promoter as a GATA/Gfi-1b complex201. 
Surprisingly, forced expression of Myc was shown to inhibit GATA1-induced cell cycle arrest 
but not erythroid maturation. This suggests that Myc may be responsible for the transcriptional 
control of cell cycle genes such as Cyclin D2 and p18INK4c and p27Kip1 but does not interfere in 
the control of genes involved in erythroid differentiation.
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3.2 GATA2
 Yamamoto and colleges identified GATA2, the second member of the GATA family, in 
chicken, by homology to GATA1260.  
 The expression pattern of GATA2 in the hematopoietic lineages substantially overlaps 
that of GATA1. It is expressed in CD34 positive multilineage progenitors, early erythroid 
progenitors, megakaryocytes and mast cells160. GATA2 expression is particularly high in 
multipotential progenitors but its expression is downregulated upon differentiation into more 
committed progenitors125,175. Furthermore, GATA2 expression was detected in the para-aortic 
splanchnopleura at E9.5 in the AGM region at E10.5, fetal liver and bone marrow149. 
GATA2 plays an important role in the regulation of proliferation and differentiation of 
stem cell/multipotential precursors. GATA2 null mice die between E10 and E11 due to severe 
anemia226. The primitive erythroid cells in these embryos are apparently normal, but the total 
number of cells is very low, causing the lethal anemia. The analysis of GATA2 null chimaeric 
mice showed the inability of GATA2 null ES cells to contribute to all definitive hematopoietic 
lineages226. In vitro differentiation of GATA2 null ES cells suggests an involvement in 
proliferation and survival of hematopoietic precursors, and possibly in the determination of 
their life span227. 
GATA2 overexpression studies reinforced this hypothesis. Enforced expression of 
GATA2 in adult bone marrow cells blocked normal hematopoiesis by inhibiting proliferation 
and differentiation of hematopoietic stem cells187. Erythroid differentiation is also blocked by 
erythroid-specific overexpression of GATA226 (see Chapter 4 of this thesis).
A recent report150 suggests a role for GATA2 in the formation of HSCs. Using transgenic 
mice in which GFP expression is driven by the GATA2 promoter, the authors showed that 
GATA2 is highly expressed in endothelial cells, the potential candidates for HSCs precursors. 
Its expression decreases upon the start of differentiation, and is upregulated again after the 
cells have acquired HSC characteristics. A model is proposed in which GATA2 is expressed 
in hematogenic cells, inhibiting their differentiation and thereby preventing the unregulated 
differentiation of the precursor cells and preserving the pool of immature cells.  The later 
upregulation of GATA2 in HSCs is in agreement with the previous described function of GATA2 
in the expansion of HSCs. Furthermore, recent data shows a GATA2 dose dependent effect in 
the production and expansion of HSCs in the AGM region and in their proliferation in adult 
bone marrow128.
Since GATA2 null mutants are embryonic lethal and hematopoiesis is severely impaired, 
it becomes very difficult to evaluate the importance of this transcription factor in particular 
hematopoietic lineages. In spite of that, there are some indications that GATA2 plays a crucial 
role in mast cell formation. GATA2 is abundantly expressed in mast cell precursors but is almost 
undetectable in more mature mast cells79 and in in vitro cultures of GATA2 null yolk sac cells, 
formation of mast cells is completely ablated227
Outside the hematopoietic system GATA2 is expressed in placenta130,162 , in the central 
nervous system, kidney and other tissues where, once more, it performs important functions. 
GATA2, together with GATA3, was shown to regulate the synthesis of placental hormones 130 
and GATA2 null embryos display neurological defects consistent with impaired proliferation 
and/or survival of early ventral neuronal precursors162. 
Unexpectedly, when the hematopoietic phenotype of the GATA2 null mice was rescued 
by the presence of a YAC containing the GATA2 gene, an important role for GATA2 in urogenital 
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development was revealed269. Rescued GATA2 null mice were viable but died soon after birth 
due to hydroureternephrosis. Numerous other urogenital abnormalities were identified upon a 
more detailed analysis of the embryonic urogenital development.
3.2.1 Regulation of GATA2 activity
Transcriptional regulation 
The GATA2 transcription unit, like GATA1, is composed of two alternative non-coding 
first exons, IS and IG, and five coding exons, II to V148. The common second exon contains 
the translation initiation site and the zinc fingers are coded separately in exons IV and V, 
respectively. Exon VI codes for the basic amino acid tail region, the 3’ untranslated region 
and two polyadenylation signals, responsible for the expression of two mRNAs with different 
size160.
The IS promoter is specific for hematopoietic progenitors while the IG promoter is 
generally used in the tissues and cell lines that express GATA2, including hematopoietic cells. 
Further analysis of the IS promoter using transgenic mice revealed that it can independently 
drive GATA2 expression in definitive HSCs and/or early hematopoietic precursors in the AGM 
and adult bone marrow149. Both GATA2 promoters contain putative DNA binding sites for a 
variety of transcription factors, including GATA binding sites.
Post-translational regulation
Acetylation
 It has been reported recently that GATA2 exists as an acetylated protein in immature 
precursor cells82. GATA2 can be acetylated by P300 and GCN5 and its acetylation was shown to 
increase DNA-binding activity. Like GATA1, GATA2 displayed a transcriptional synergism with 
p300 that was impaired by mutation of acetylation sites. Acetylation appears to be important 
for the normal function of GATA2 since mutations in the acetylation sites abolished its growth 
inhibitory effect.
Phosphorylation
 GATA2 was shown to exist in hematopoietic progenitors in a phosphorylated form224. 
Stimulation of hematopoietic precursors with IL-3 results in an increased phosphorylation of 
the GATA2 protein, possibly mediated by mitogen-activated protein kinases. The function 
of phosphorylated GATA2 is not clear, it does not influence its transactivation potencial but 
it is conceivable that it is involved in the GATA2-dependent proliferation of hematopoietic 
precursors.
SUMOylation
 It has also been demonstrated that GATA2 can by modified by SUMO in endothelial 
cells35. SUMO modification of transcription factors is often associated with reduced transcriptional 
activity. However, the effect of SUMOylation in GATA2 function is not known.
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3.3 GATA3
 GATA3 was identified, together with GATA2, based on its homology to GATA1260. 
In mice, GATA3 starts to be expressed around E8 in the ectodermal cone and trophoblastic 
cells surrounding the embryonic cavity. At E10 its expression is detected within the central 
and peripheral nervous systems. The expression within the CNS and PNS remains throughout 
development but becomes more and more restricted to certain structures.  By E14.5, GATA3 
expression is also detected in the thymic rudiment, kidney and adrenal medulla61.
 The importance of GATA3 expression in the central and peripheral nervous systems 
was confirmed upon analysis of GATA3 null mice. Homozygous mice for the GATA3 null 
mutation die between E11 and E12 and display marked growth retardation and varying 
degrees of abnormalities in the brain and spinal cord183. The cause of death was later attributed 
to a noradrenaline deficiency126 since feeding of pregnant mutant females with a synthetic 
catecholamine intermediate allowed survival of GATA3 null embryos up to E16.5.
 GATA3 haplo-insufficiency in humans is associated with the hypoparathyroidism, 
deafness and renal anomaly (HDR) syndrome235. Mice heterozygous for GATA3 do not show any 
obvious renal abnormalities or parathyroidism, however, heterozygous GATA3 ko mice suffer 
from hearing loss234. GATA3 expression is detected in kidney during development, indicating a 
possible function for GATA3 in this organ. GATA3 is also know to be involved, together with 
GATA2, in the regulation of expression of placental hormones130.
Within the hematopoietic system, the GATA3 expression pattern differs from the 
other hematopoietic GATA factors since it is expressed exclusively in T-lymphocytes260. The 
expression of GATA3 in early thymic rudiment and in CD4- CD8- double negative (DN) T-cells61 
suggested an important role in T-cell development. This was confirmed by analysis of GATA3 
KO chimeric mice, in which GATA3 ES cells contributed to all the hematopoietic lineages with 
the exception of thymocytes222,84. 
 A detailed analysis of GATA3 expression in T cells84 demonstrated that GATA3 is 
expressed throughout  T-cell differentiation in the thymus. Making use of a lacZ reporter insertion 
in the GATA3 locus, the authors showed that GATA3 is expressed at low levels during the DN 
stage of T-cell progenitors. Surprisingly, the lowest level of expression is observed during TCR 
rearrangement when the cells are in cell cycle arrest in G1. In cells where TCRβ rearrangement 
occurred successfully GATA3 expression is upregulated. GATA3 expression is maintained in 
CD4+ SP T-cells but its expression is gradually downregulated in CD8+ SP T-cells.
Several lines of evidence indicate that GATA3 is essential for the earlier stages of T-
cell development in the thymus, in particular for the expansion of the T-cell progenitors. The 
first evidence for the requirement of GATA3 at the earliest stage of T-cell differentiation came 
from the observation that antisense GATA3 oligonucleotides inhibit T-cell differentiation of 
fetal liver lymphoid precursors but not of more committed fetal thymic precursors81. This was 
confirmed by RAG-2 KO complementation experiments showing that differentiation of GATA3 
null T-cells is blocked at the CD4-CD8- DN stage222. Another report also shows that GATA-3 
null ES cells do not contribute to the earliest T cell precursors (DN1) in the thymus of chimeric 
mice84. A more detailed analysis of the precise function of GATA3 during the DN stage179, using 
conditionally deficient mice, revealed its importance not only in regulating the expression of the 
TCRβ but also during β selection.  
The observation that GATA3 is differentially expressed in CD8+ and CD4+ SP T-cells84 
suggests a functional role for GATA3 in these lineages. In Chapter 5 of this thesis164 it is shown 
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that GATA3 indeed plays a role in the commitment to CD4+ SP lineage, since forced expression 
of GATA3 during T-cell development in the thymus inhibits the maturation of CD8+ SP T-cells 
and induces thymic lymphomas. Analysis of GATA3 conditional knockout mice179 confirmed 
that GATA3 is necessary for the generation of CD4+ thymocytes.
In activated CD4+ T-cells, GATA3 is selectively expressed in the Th2 subset264,268. Two 
independent reports264,268 showed that GATA3 is expressed in peripheral naive CD4+ T-cells. 
This expression is maintained or even increased in cells induced to differentiate to the Th2 
subset, but it is drastically downregulated in the Th1 subset. Differentiation of naive CD4+ T-
cells into either Th1 or Th2 T-cells is largely dependent on signals from the APC. IL12 promotes 
Th1 development by activation of the INFγ via a STAT4 mediated signalling pathway while IL4 
promotes Th2 development by upregulation of IL4 production mediated by a STAT6 signalling 
pathway. Cytokines induction of Th1 and Th2 differentiation is also related with differential 
expression of the transcription factor T-bet (T-box expressed in T-cells) in Th1 and GATA3 Th2 
cells (reviewed by O’Garra and Arai170,198 and Rengarajan and colleagues170,198). T-bet expression 
is sufficient to convert Th2 cells into Th1 cells by inducing the expression of INFγ and repression 
of IL4 and IL5218. GATA3 also seems to control Th1/Th2 priming by controlling the expression 
of specific Th1 and Th2 cytokines. GATA3 influence the upregulation of IL4 in Th2 cells and 
represses Th12 mediated signalling by repressing the IL12 receptor β2-chain expression178,196.
In Chapter 6 of this thesis163, we show that forced expression of GATA3 during T-
cell development inhibits the differentiation of CD4+ naive T-cells into the Th1 lineage. 
This supports the hypothesis of the necessity for GATA3 in Th2 cells, but until recently the 
requirement for endogenous GATA3 in Th2 cells was not proven. Using a conditional-knock 
out approach, Pai and colleagues180 have now demonstrated that endogenous GATA3 is essential 
for the maintenance of the Th2 phenotype. GATA3-deficient Th2 cells from GATA3 conditional 
knockout animals showed reduced IL4, IL5, IL-13 and IL-10 production and, conversely, IFN-γ 
production was increased.
The presence of GATA binding sites in the promoter regions of all Th2 cytokines 
suggests an important role in the establishment of the Th2 cytokine profile. GATA3 was shown 
to directly interact with the IL5 promoter123,268 and indirectly with the IL4 promoter196. GATA3 
is involved in chromatin remodelling of the IL4/IL13 locus in Th1-committed cells, thereby 
indirectly allowing its expression123,220. Furthermore, GATA3 plays a role in the downregulation 
of the Th1-specific cytokines, since forced expression of GATA3 in Th1-commited cells leads 
to a downregulation of INF-γ56,178.
3.3.1 Regulation of GATA3 activity
Transcriptional regulation
The GATA3 transcription unit is composed of six exons. The first exon consists entirely 
of 5’ untranslated sequence since the translation start site is present in exon II. The two zinc 
finger motifs are coded separately in exon IV and V and the polyadenylation signal and 3’ 
untranslated region are located in exon VI. GATA3 transcription initiation site was mapped 
to 189 nucleotides upstream intron I and cis-regulatory elements present in a segment of the 
GATA3 locus from –2052 to +1004 were shown to be necessary but not sufficient to fully 
recapitulate GATA3 expression during embryonic development61.
Extensive analysis of the GATA3 locus identified specific regulatory elements required 
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for the correct expression in CNS, urogenital and endocardial tissues116,117.
Asnagli and colleagues13 recently identified an alternative promoter for GATA3 (Ia) 
located approximately 10Kb upstream of the previously known promoter (Ib). Analysis of the 
promoter usage in different tissues and cell lines revealed that promoter Ib is preferentially used 
in T-cells while promoter Ia is used in the CNS and in later stages of Th2 development.
Post-translational regulation
Acetylation
Aiming to obtain a GATA3 dominant negative protein, Smith and colleagues214 performed 
site-directed mutagenesis in the putative transactivation domain of GATA3 present between the 
two zinc-fingers. A mutant, where amino acids 305 to 307 (KRR) were mutated to alanine 
(AAA), was identified that behaved like a dominant negative when co-transfected with wild-
type GATA3 and GATA1. This mutant was shown to bind DNA similarly to wild type but fail to 
activate transcription. This mutant was later shown to be hypoacetylated259 due to the mutation 
in the KRR motif. The same report shows that the GATA3 acetylation level directly correlates 
with transcription activation. An increase in transcription activity by wild-type GATA3, but 
not by the KRR-mutant, is observed in the presence of P300 suggesting that GATA3 can be 
acetylated by P300.
Phosphorylation
GATA3 was shown to be phosphorylated in Th2 cells by mitogen-activated protein 
kinase p3833. The p38-kinase-induced phosphorylation of GATA3 seems to be important for 
the IL5 promoter activation but the exact function of acetylated GATA3 is unknown. It may be 
important for the interaction with other regulatory proteins or may be directly influence GATA3 
activity.
3.3.2 Protein-protein interactions
ROG
Repressor of GATA (ROG) has been identified as a GATA3 interacting protein via an 
yeast two-hybrid screen of a Th2 cDNA library145. ROG is a member of the PDZ protein family, 
since it contain a BTB and three zinc finger domains. The interaction between ROG and GATA3 
takes place via the zinc-fingers of both proteins, being the C-finger of GATA3 crucial for the 
interaction.  ROG is specifically expressed in lymphoid cells and its expression is upregulated 
upon T-cells stimulation. ROG is a potent repressor of GATA3 induced transactivation of Th2 
cytokines by preventing its binding to DNA. Surprisingly, ROG can also regulate the expression 
of Th1 cytokines most likely by a GATA3 independent mechanism.
3.3.3 GATA3 target genes
TCR 
 T-cell receptor δ chain was the first target gene of GATA3 to be identified. In fact, a 
fragment of the human TCR δ enhancer, containing two GATA consensus sequences, was used 
to identify and clone the human GATA3 gene103. GATA binding sites can also be found in the 
TCRα and TCRβ enhancers suggesting that these genes are also GATA3 target genes.
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Th2 cytokines
 As mentioned above GATA3 is differentially expressed in Th1 and Th2 subsets of 
activated CD4+ T-cells. It is therefore probable that GATA3 is involved in the regulation of Th2-
specific cytokines.
A direct effect of GATA3 in the expression of IL5 has been shown and forced expression 
of this transcription factor in Th1 committed cells promotes IL5 expression123,268. Interestingly, 
a direct role for GATA3 in IL4 promoter activation has not been shown265 but GATA3 appears 
to play a permissive role in enhancing IL4 expression. This suggests that other factor may be 
required, together with GATA3, for the activation of this promoter196. Finally, Lavenu-Bombled 
and colleagues118 reported a direct effect of GATA3 in the regulation of IL-13 expression.
Introduction
43
References
1. Abbas, AK, Murphy, KM and Sher, A. (1996) Functional diversity of helper T lymphocytes. Nature,  383, 787-
793.
2. Abehsira-Amar, O, Gibert, M, Joliy, M, Theze, J and Jankovic, DL. (1992) IL-4 plays a dominant role in the 
differential development of Tho into Th1 and Th2 cells. J Immunol,  148, 3820-3829.
3. Abkowitz, JL, Golinelli, D, Harrison, DE and Guttorp, P. (2000) In vivo kinetics of murine hemopoietic stem 
cells. Blood,  96, 3399-3405.
4. Akashi, K, Traver, D, Miyamoto, T and Weissman, IL. (2000) A clonogenic common myeloid progenitor that 
gives rise to all myeloid lineages. Nature,  404, 193-197.
5. Akashi, K, He, X, Chen, J, Iwasaki, H, Niu, C, Steenhard, B, Zhang, J, Haug, J and Li, L. (2003) Transcriptional 
accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early 
hematopoiesis. Blood,  101, 383-389.
6 .Alberts, B, Johnson, A, Lewis, J, Raff, M, Roberts, K and Walter, P. (2002) Molecular Biology of The Cell. 
Garland Science, New York.
7. Allen, TD and Dexter, TM. (1982) Ultrastructural aspects of erythropoietic differentiation in long-term bone 
marrow culture. Differentiation,  21, 86-94.
8. Allen, TD and Testa, NG. (1991) Cellular interactions in erythroblastic islands in long-term bone marrow cultures, 
as studied by time-lapse video. Blood Cells,  17, 29-38; discussion 39-43.
9 .Allman, D, Sambandam, A, Kim, S, Miller, JP, Pagan, A, Well, D, Meraz, A and Bhandoola, A. (2003) 
Thymopoiesis independent of common lymphoid progenitors. Nat Immunol,  4, 168-174.
10. Alvarez-Silva, M, Belo-Diabangouaya, P, Salaun, J and Dieterlen-Lievre, F. (2003) Mouse placenta is a major 
hematopoietic organ. Development,  130, 5437-5444.
11. Amsen, D, Blander, JM, Lee, GR, Tanigaki, K, Honjo, T and Flavell, RA. (2004) Instruction of distinct CD4 T 
helper cell fates by different notch ligands on antigen-presenting cells. Cell,  117, 515-526.
12. Anderson, KP, Crable, SC and Lingrel, JB. (1998) Multiple proteins binding to a GATA-E box-GATA motif 
regulate the erythroid Kruppel-like factor (EKLF) gene. J Biol Chem,  273, 14347-14354.
13. Asnagli, H, Afkarian, M and Murphy, KM. (2002) Cutting edge: Identification of an alternative GATA-3 promoter 
directing tissue-specific gene expression in mouse and human. J Immunol,  168, 4268-4271.
14. Bacon, CM, Petricoin, EF, 3rd, Ortaldo, JR, Rees, RC, Larner, AC, Johnston, JA and O’Shea, JJ. (1995) Interleukin 
12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci U S A, 
92, 7307-7311.
15. Banerji, J, Rusconi, S and Schaffner, W. (1981) Expression of a beta-globin gene is enhanced by remote SV40 
DNA sequences. Cell,  27, 299-308.
16. Bannister, AJ and Miska, EA. (2000) Regulation of gene expression by transcription factor acetylation. Cell Mol 
Life Sci,  57, 1184-1192.
17. Belmont, AS, Dietzel, S, Nye, AC, Strukov, YG and Tumbar, T. (1999) Large-scale chromatin structure and 
function. Curr Opin Cell Biol,  11, 307-311.
18. Bentley, GA and Mariuzza, RA. (1996) The structure of the T cell antigen receptor. Annu Rev Immunol,  14, 563-
590.
19. Berger, SL. (2002) Histone modifications in transcriptional regulation. Curr Opin Genet Dev,  12, 142-148.
20. Bessis, M, Lessin, LS and Beutler, E. (1983) Morphology of the erythron. In Williams, WJ, Beutler, E, Erslev, AJ 
and Lichtman, MA (eds.), Hematology 3rd Edition. McGraw-Hill Book Company, Vol. 1, pp. 257-279.
21. Bjornsson, JM, Larsson, N, Brun, AC, Magnusson, M, Andersson, E, Lundstrom, P, Larsson, J, Repetowska, E, 
Ehinger, M, Humphries, RK and Karlsson, S. (2003) Reduced proliferative capacity of hematopoietic stem cells 
deficient in Hoxb3 and Hoxb4. Mol Cell Biol,  23, 3872-3883.
22. Blackwood, EM and Kadonaga, JT. (1998) Going the distance: a current view of enhancer action. Science,  281, 
61-63.
23. Blobel, GA, Nakajima, T, Eckner, R, Montminy, M and Orkin, SH. (1998) CREB-binding protein cooperates with 
transcription factor GATA-1 and is required for erythroid differentiation. Proc Natl Acad Sci U S A,  95, 2061-
2066.
24. Bondurant, MC and Koury, MJ. (1998) Origin and development of blood cells. In Lee, GR, Lukens, J, Rodgers, 
GM, Greer, JP and Paraskevas, f (eds.), Wintrobe’s Clinical Hematology. Williams and Wilkins, Vol. 1, pp. 152-
155.
25. Boyes, J, Byfield, P, Nakatani, Y and Ogryzko, V. (1998) Regulation of activity of the transcription factor GATA-1 
by acetylation. Nature,  396, 594-598.
26. Briegel, K, Lim, KC, Plank, C, Beug, H, Engel, JD and Zenke, M. (1993) Ectopic expression of a conditional 
GATA-2/estrogen receptor chimera arrests erythroid differentiation in a hormone-dependent manner. Genes Dev, 
7, 1097-1109.
27. Brun, AC, Bjornsson, JM, Magnusson, M, Larsson, N, Leveen, P, Ehinger, M, Nilsson, E and Karlsson, S. 
Chapter 1 
44
(2004) Hoxb4 deficient mice have normal hematopoietic development but exhibit a mild proliferation defect in 
hematopoietic stem cells. Blood.
28. Calligaris, R, Bottardi, S, Cogoi, S, Apezteguia, I and Santoro, C. (1995) Alternative translation initiation site 
usage results in two functionally distinct forms of the GATA-1 transcription factor. Proc Natl Acad Sci U S A,  92, 
11598-11602.
29. Cantor, AB and Orkin, SH. (2001) Hematopoietic development: a balancing act. Curr Opin Genet Dev,  11, 513-
519.
30. Cantor, AB and Orkin, SH. (2002) Transcriptional regulation of erythropoiesis: an affair involving multiple 
partners. Oncogene,  21, 3368-3376.
31. Capone, M, Hockett, RD, Jr. and Zlotnik, A. (1998) Kinetics of T cell receptor beta, gamma, and delta 
rearrangements during adult thymic development: T cell receptor rearrangements are present in CD44(+)CD25(+) 
Pro-T thymocytes. Proc Natl Acad Sci U S A,  95, 12522-12527.
32 .Carter, D, Chakalova, L, Osborne, CS, Dai, YF and Fraser, P. (2002) Long-range chromatin regulatory interactions 
in vivo. Nat Genet,  32, 623-626.
33. Chen, CH, Zhang, DH, LaPorte, JM and Ray, A. (2000) Cyclic AMP activates p38 mitogen-activated protein 
kinase in Th2 cells: phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression. J Immunol, 
165, 5597-5605.
34. Chiba, T, Nagata, Y, Kishi, A, Sakamaki, K, Miyajima, A, Yamamoto, M, Engel, JD and Todokoro, K. (1993) 
Induction of erythroid-specific gene expression in lymphoid cells. Proc Natl Acad Sci U S A,  90, 11593-11597.
35. Chun, TH, Itoh, H, Subramanian, L, Iniguez-Lluhi, JA and Nakao, K. (2003) Modification of GATA-2 
transcriptional activity in endothelial cells by the SUMO E3 ligase PIASy. Circ Res,  92, 1201-1208.
36. Cohen-Kaminsky, S, Maouche-Chretien, L, Vitelli, L, Vinit, MA, Blanchard, I, Yamamoto, M, Peschle, C and 
Romeo, PH. (1998) Chromatin immunoselection defines a TAL-1 target gene. Embo J,  17, 5151-5160.
37. Collavin, L, Gostissa, M, Avolio, F, Secco, P, Ronchi, A, Santoro, C and Del Sal, G. (2004) Modification of the 
erythroid transcription factor GATA-1 by SUMO-1. Proc Natl Acad Sci U S A,  101, 8870-8875.
38. Crispino, JD, Lodish, MB, MacKay, JP and Orkin, SH. (1999) Use of altered specificity mutants to probe a 
specific protein-protein interaction in differentiation: the GATA-1:FOG complex. Mol Cell,  3, 219-228.
39. Cross, MA and Enver, T. (1997) The lineage commitment of haemopoietic progenitor cells. Curr Opin Genet Dev, 
7, 609-613.
40. Crossley, M and Orkin, SH. (1994) Phosphorylation of the erythroid transcription factor GATA-1. J Biol Chem, 
269, 16589-16596.
41. Crossley, M, Tsang, AP, Bieker, JJ and Orkin, SH. (1994) Regulation of the erythroid Kruppel-like factor (EKLF) 
gene promoter by the erythroid transcription factor GATA-1. J Biol Chem,  269, 15440-15444.
42. Crossley, M, Merika, M and Orkin, SH. (1995) Self-association of the erythroid transcription factor GATA-1 
mediated by its zinc finger domains. Mol Cell Biol,  15, 2448-2456.
43. de Krom, M, van de Corput, M, von Lindern, M, Grosveld, F and Strouboulis, J. (2002) Stochastic patterns in 
globin gene expression are established prior to transcriptional activation and are clonally inherited. Mol Cell,  9, 
1319-1326.
44. De Maria, R, Zeuner, A, Eramo, A, Domenichelli, C, Bonci, D, Grignani, F, Srinivasula, SM, Alnemri, ES, Testa, 
U and Peschle, C. (1999) Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature, 
401, 489-493.
45. Desterro, JM, Rodriguez, MS and Hay, RT. (2000) Regulation of transcription factors by protein degradation. Cell 
Mol Life Sci,  57, 1207-1219.
46. Dieterlen-Lievre, F. (1975) On the origin of haemopoietic stem cells in the avian embryo: an experimental 
approach. J Embryol Exp Morphol,  33, 607-619.
47. Dillon, N and Festenstein, R. (2002) Unravelling heterochromatin: competition between positive and negative 
factors regulates accessibility. Trends Genet,  18, 252-258.
48. Drissen, R, Palstra, RJ, Gillemans, N, Splinter, E, Grosveld, F, Philipsen, S and de Laat, W. (accepted for 
publication) The active spatial organisation of the b-globin locus requires the transcription factor EKLF. Genes 
and Development.
49. Dzierzak, E, Medvinsky, A and de Bruijn, M. (1998) Qualitative and quantitative aspects of haematopoietic cell 
development in the mammalian embryo. Immunol Today,  19, 228-236.
50. Dzierzak, E. (1999) Embryonic beginnings of definitive hematopoietic stem cells. Ann N Y Acad Sci,  872, 256-
262; discussion 262-254.
51. Ema, H and Nakauchi, H. (2000) Expansion of hematopoietic stem cells in the developing liver of a mouse 
embryo. Blood,  95, 2284-2288.
52. Enver, T and Greaves, M. (1998) Loops, lineage, and leukemia. Cell,  94, 9-12.
53 .Evans, T, Reitman, M and Felsenfeld, G. (1988) An erythrocyte-specific DNA-binding factor recognizes a 
regulatory sequence common to all chicken globin genes. Proc Natl Acad Sci U S A,  85, 5976-5980.
54. Fehling, HJ and von Boehmer, H. (1997) Early alpha beta T cell development in the thymus of normal and 
genetically altered mice. Curr Opin Immunol,  9, 263-275.
Introduction
45
55. Feng, Q and Zhang, Y. (2003) The NuRD complex: linking histone modification to nucleosome remodeling. Curr 
Top Microbiol Immunol,  274, 269-290.
56. Ferber, IA, Lee, HJ, Zonin, F, Heath, V, Mui, A, Arai, N and O’Garra, A. (1999) GATA-3 significantly downregulates 
IFN-gamma production from developing Th1 cells in addition to inducing IL-4 and IL-5 levels. Clin Immunol, 
91, 134-144.
57. Fox, AH, Kowalski, K, King, GF, Mackay, JP and Crossley, M. (1998) Key residues characteristic of GATA N-
fingers are recognized by FOG. J Biol Chem,  273, 33595-33603.
58. Fox, AH, Liew, C, Holmes, M, Kowalski, K, Mackay, J and Crossley, M. (1999) Transcriptional cofactors of the 
FOG family interact with GATA proteins by means of multiple zinc fingers. Embo J,  18, 2812-2822.
59. Fujiwara, Y, Browne, CP, Cunniff, K, Goff, SC and Orkin, SH. (1996) Arrested development of embryonic red cell 
precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci U S A,  93, 12355-12358.
60. Garcia, KC, Degano, M, Stanfield, RL, Brunmark, A, Jackson, MR, Peterson, PA, Teyton, L and Wilson, IA. 
(1996) An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science,  274, 
209-219.
61. George, KM, Leonard, MW, Roth, ME, Lieuw, KH, Kioussis, D, Grosveld, F and Engel, JD. (1994) Embryonic 
expression and cloning of the murine GATA-3 gene. Development,  120, 2673-2686.
62. Germain, RN. (1994) MHC-dependent antigen processing and peptide presentation: providing ligands for T 
lymphocyte activation. Cell,  76, 287-299.
63. Gill, G. (2003) Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on 
transcription factor activity. Curr Opin Genet Dev,  13, 108-113.
64. Godfrey, DI, Kennedy, J, Suda, T and Zlotnik, A. (1993) A developmental pathway involving four phenotypically 
and functionally distinct subsets of CD3-CD4-CD8- triple-negative adult mouse thymocytes defined by CD44 and 
CD25 expression. J Immunol,  150, 4244-4252.
65. Godfrey, DI, Hammond, KJ, Poulton, LD, Smyth, MJ and Baxter, AG. (2000) NKT cells: facts, functions and 
fallacies. Immunol Today,  21, 573-583.
66. Graf, T. (2002) Differentiation plasticity of hematopoietic cells. Blood,  99, 3089-3101.
67. Grass, JA, Boyer, ME, Pal, S, Wu, J, Weiss, MJ and Bresnick, EH. (2003) GATA-1-dependent transcriptional 
repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. Proc 
Natl Acad Sci U S A,  100, 8811-8816.
68. Gregoli, PA and Bondurant, MC. (1997) The roles of Bcl-X(L) and apopain in the control of erythropoiesis by 
erythropoietin. Blood,  90, 630-640.
69. Gregory, RC, Taxman, DJ, Seshasayee, D, Kensinger, MH, Bieker, JJ and Wojchowski, DM. (1996) Functional 
interaction of GATA1 with erythroid Kruppel-like factor and Sp1 at defined erythroid promoters. Blood,  87, 
1793-1801.
70. Gregory, T, Yu, C, Ma, A, Orkin, SH, Blobel, GA and Weiss, MJ. (1999) GATA-1 and erythropoietin cooperate to 
promote erythroid cell survival by regulating bcl-xL expression. Blood,  94, 87-96.
71. Grosveld, F, van Assendelft, GB, Greaves, DR and Kollias, G. (1987) Position-independent, high-level expression 
of the human beta-globin gene in transgenic mice. Cell,  51, 975-985.
72. Grosveld, F. (1999) Activation by locus control regions? Curr Opin Genet Dev,  9, 152-157.
73. Gurbuxani, S, Vyas, P and Crispino, JD. (2003) Recent insights into the mechanisms of myeloid leukemogenesis 
in Down syndrome. Blood.
74. Gutierrez, L, Lindeboom, F, Langeveld, A, Grosveld, F, Philipsen, S and Whyatt, D. (2004) Homotypic signalling 
regulates Gata1 activity in the erythroblastic island. Development,  131, 3183-3193.
75. Han, KK and Martinage, A. (1992) Post-translational chemical modification(s) of proteins. Int J Biochem,  24, 
19-28.
76. Hannon, R, Evans, T, Felsenfeld, G and Gould, H. (1991) Structure and promoter activity of the gene for the 
erythroid transcription factor GATA-1. Proc Natl Acad Sci U S A,  88, 3004-3008.
77. Harbour, JW and Dean, DC. (2000) The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev, 
14, 2393-2409.
78. Harbour, JW and Dean, DC. (2000) Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol,  2, E65-
67.
79. Harigae, H, Takahashi, S, Suwabe, N, Ohtsu, H, Gu, L, Yang, Z, Tsai, FY, Kitamura, Y, Engel, JD and Yamamoto, 
M. (1998) Differential roles of GATA-1 and GATA-2 in growth and differentiation of mast cells. Genes Cells,  3, 
39-50.
80. Harrison, SC. (1991) A structural taxonomy of DNA-binding domains. Nature,  353, 715-719.
81. Hattori, N, Kawamoto, H, Fujimoto, S, Kuno, K and Katsura, Y. (1996) Involvement of transcription factors 
TCF-1 and GATA-3 in the initiation of the earliest step of T cell development in the thymus. J Exp Med,  184, 
1137-1147.
82. Hayakawa, F, Towatari, M, Ozawa, Y, Tomita, A, Privalsky, ML and Saito, H. (2004) Functional regulation of 
GATA-2 by acetylation. J Leukoc Biol,  75, 529-540.
83. Helgason, CD, Sauvageau, G, Lawrence, HJ, Largman, C and Humphries, RK. (1996) Overexpression of HOXB4 
Chapter 1 
46
enhances the hematopoietic potential of embryonic stem cells differentiated in vitro. Blood,  87, 2740-2749.
84. Hendriks, RW, Nawijn, MC, Engel, JD, van Doorninck, H, Grosveld, F and Karis, A. (1999) Expression of the 
transcription factor GATA-3 is required for the development of the earliest T cell progenitors and correlates with 
stages of cellular proliferation in the thymus. Eur J Immunol,  29, 1912-1918.
85. Heyworth, C, Pearson, S, May, G and Enver, T. (2002) Transcription factor-mediated lineage switching reveals 
plasticity in primary committed progenitor cells. Embo J,  21, 3770-3781.
86. Hirasawa, R, Shimizu, R, Takahashi, S, Osawa, M, Takayanagi, S, Kato, Y, Onodera, M, Minegishi, N, Yamamoto, 
M, Fukao, K, Taniguchi, H, Nakauchi, H and Iwama, A. (2002) Essential and instructive roles of GATA factors in 
eosinophil development. J Exp Med,  195, 1379-1386.
87. Hitzler, JK, Cheung, J, Li, Y, Scherer, SW and Zipursky, A. (2003) GATA1 mutations in transient leukemia and 
acute megakaryoblastic leukemia of Down syndrome. Blood.
88. Ho, IC, Hodge, MR, Rooney, JW and Glimcher, LH. (1996) The proto-oncogene c-maf is responsible for tissue-
specific expression of interleukin-4. Cell,  85, 973-983.
89. Hu, N, Gulley, ML, Kung, JT and Lee, EY. (1997) Retinoblastoma gene deficiency has mitogenic but not 
tumorigenic effects on erythropoiesis. Cancer Res,  57, 4123-4129.
90. Hung, HL, Lau, J, Kim, AY, Weiss, MJ and Blobel, GA. (1999) CREB-Binding protein acetylates hematopoietic 
transcription factor GATA-1 at functionally important sites. Mol Cell Biol,  19, 3496-3505.
91. Iizuka, M and Smith, MM. (2003) Functional consequences of histone modifications. Curr Opin Genet Dev,  13, 
154-160.
92. Imagawa, S, Yamamoto, M and Miura, Y. (1997) Negative regulation of the erythropoietin gene expression by the 
GATA transcription factors. Blood,  89, 1430-1439.
93. magawa, S, Suzuki, N, Ohmine, K, Obara, N, Mukai, HY, Ozawa, K, Yamamoto, M and Nagasawa, T. (2002) 
GATA suppresses erythropoietin gene expression through GATA site in mouse erythropoietin gene promoter. Int 
J Hematol,  75, 376-381.
94. Imhof, A, Yang, XJ, Ogryzko, VV, Nakatani, Y, Wolffe, AP and Ge, H. (1997) Acetylation of general transcription 
factors by histone acetyltransferases. Curr Biol,  7, 689-692.
95. Ito, E, Toki, T, Ishihara, H, Ohtani, H, Gu, L, Yokoyama, M, Engel, JD and Yamamoto, M. (1993) Erythroid 
transcription factor GATA-1 is abundantly transcribed in mouse testis. Nature,  362, 466-468.
96. Iwasaki, H, Mizuno, S, Wells, RA, Cantor, AB, Watanabe, S and Akashi, K. (2003) GATA-1 converts lymphoid 
and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages. Immunity,  19, 451-462.
97. Jacks, T, Fazeli, A, Schmitt, EM, Bronson, RT, Goodell, MA and Weinberg, RA. (1992) Effects of an Rb mutation 
in the mouse. Nature,  359, 295-300.
98. Jacobson, NG, Szabo, SJ, Weber-Nordt, RM, Zhong, Z, Schreiber, RD, Darnell, JE, Jr. and Murphy, KM. (1995) 
Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and 
activator of transcription (Stat)3 and Stat4. J Exp Med,  181, 1755-1762.
99. Janeway, CA and Travers, P. (1997) Immunobiology: The Immune System in Health and Disease. Current Biology 
Ltd /Garland Publishing Inc., London/ New York.
100. Janeway, CA, Jr. (1992) The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and 
CD45 in T cell activation. Annu Rev Immunol,  10, 645-674.
101. Jenuwein, T and Allis, CD. (2001) Translating the histone code. Science,  293, 1074-1080.
102. Johnson, GR and Metcalf, D. (1977) Pure and mixed erythroid colony formation in vitro stimulated by spleen 
conditioned medium with no detectable erythropoietin. Proc Natl Acad Sci U S A,  74, 3879-3882.
103. Joulin, V, Bories, D, Eleouet, JF, Labastie, MC, Chretien, S, Mattei, MG and Romeo, PH. (1991) A T-cell specific 
TCR delta DNA binding protein is a member of the human GATA family. Embo J,  10, 1809-1816.
104. Kamogawa, Y, Minasi, LA, Carding, SR, Bottomly, K and Flavell, RA. (1993) The relationship of IL-4- and IFN 
gamma-producing T cells studied by lineage ablation of IL-4-producing cells. Cell,  75, 985-995.
105. Kashimura, M. (1982) Scanning electron microscopy studies of bone marrow. Scan Electron Microsc, 445-453.
106. Katsura, Y. (2002) Redefinition of lymphoid progenitors. Nat Rev Immunol,  2, 127-132.
107. Kawamoto, H, Ohmura, K and Katsura, Y. (1997) Direct evidence for the commitment of hematopoietic stem cells 
to T, B and myeloid lineages in murine fetal liver. Int Immunol,  9, 1011-1019.
108. Kawane, K, Fukuyama, H, Kondoh, G, Takeda, J, Ohsawa, Y, Uchiyama, Y and Nagata, S. (2001) Requirement 
of DNase II for definitive erythropoiesis in the mouse fetal liver. Science,  292, 1546-1549.
109. Ko, LJ and Engel, JD. (1993) DNA-binding specificities of the GATA transcription factor family. Mol Cell Biol, 
13, 4011-4022.
110. Kondo, M, Weissman, IL and Akashi, K. (1997) Identification of clonogenic common lymphoid progenitors in 
mouse bone marrow. Cell,  91, 661-672.
111. Kopf, M, Le Gros, G, Bachmann, M, Lamers, MC, Bluethmann, H and Kohler, G. (1993) Disruption of the murine 
IL-4 gene blocks Th2 cytokine responses. Nature,  362, 245-248.
112. Kornberg, RD and Lorch, Y. (1999) Twenty-five years of the nucleosome, fundamental particle of the eukaryote 
chromosome. Cell,  98, 285-294.
113. Kouzarides, T. (1999) Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev,  9, 40-48.
Introduction
47
114. Kulessa, H, Frampton, J and Graf, T. (1995) GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, 
thromboblasts, and erythroblasts. Genes Dev,  9, 1250-1262.
115. Lacombe, C and Mayeux, P. (1999) The molecular biology of erythropoietin. Nephrol Dial Transplant,  14 Suppl 
2, 22-28.
116. Lakshmanan, G, Lieuw, KH, Grosveld, F and Engel, JD. (1998) Partial rescue of GATA-3 by yeast artificial 
chromosome transgenes. Dev Biol,  204, 451-463.
117. Lakshmanan, G, Lieuw, KH, Lim, KC, Gu, Y, Grosveld, F, Engel, JD and Karis, A. (1999) Localization of distant 
urogenital system-, central nervous system-, and endocardium-specific transcriptional regulatory elements in the 
GATA-3 locus. Mol Cell Biol,  19, 1558-1568.
118. Lavenu-Bombled, C, Trainor, CD, Makeh, I, Romeo, PH and Max-Audit, I. (2002) Interleukin-13 gene expression 
is regulated by GATA-3 in T cells: role of a critical association of a GATA and two GATG motifs. J Biol Chem, 
277, 18313-18321.
119. Leclercq, G and Plum, J. (1996) Thymic and extrathymic T cell development. Leukemia,  10, 1853-1859.
120. Lecointe, N, Bernard, O, Naert, K, Joulin, V, Larsen, CJ, Romeo, PH and Mathieu-Mahul, D. (1994) GATA-and 
SP1-binding sites are required for the full activity of the tissue-specific promoter of the tal-1 gene. Oncogene,  9, 
2623-2632.
121. Lederer, JA, Perez, VL, DesRoches, L, Kim, SM, Abbas, AK and Lichtman, AH. (1996) Cytokine transcriptional 
events during helper T cell subset differentiation. J Exp Med,  184, 397-406.
122. Lee, EY, Chang, CY, Hu, N, Wang, YC, Lai, CC, Herrup, K, Lee, WH and Bradley, A. (1992) Mice deficient for 
Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature,  359, 288-294.
123. Lee, HJ, Takemoto, N, Kurata, H, Kamogawa, Y, Miyatake, S, O’Garra, A and Arai, N. (2000) GATA-3 induces T 
helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells. J Exp Med,  192, 
105-115.
124. Lemischka, IR, Raulet, DH and Mulligan, RC. (1986) Developmental potential and dynamic behavior of 
hematopoietic stem cells. Cell,  45, 917-927.
125. Leonard, M, Brice, M, Engel, JD and Papayannopoulou, T. (1993) Dynamics of GATA transcription factor 
expression during erythroid differentiation. Blood,  82, 1071-1079.
126. Lim, KC, Lakshmanan, G, Crawford, SE, Gu, Y, Grosveld, F and Engel, JD. (2000) Gata3 loss leads to embryonic 
lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat Genet,  25, 209-212.
127. Lindeboom, F, Gillemans, N, Karis, A, Jaegle, M, Meijer, D, Grosveld, F and Philipsen, S. (2003) A tissue-specific 
knockout reveals that Gata1 is not essential for Sertoli cell function in the mouse. Nucleic Acids Res,  31, 5405-
5412.
128. Ling, K, Ottersbach, K, van Hamburg, J, Oziemlak, A, Tsai, F, Orkin, SH, Ploemacher, R, Hendriks, R and 
Dzierzak, E. (manuscript submitted for publication).
129. Lipinski, MM and Jacks, T. (1999) The retinoblastoma gene family in differentiation and development. Oncogene, 
18, 7873-7882.
130. Ma, GT, Roth, ME, Groskopf, JC, Tsai, FY, Orkin, SH, Grosveld, F, Engel, JD and Linzer, DI. (1997) GATA-2 
and GATA-3 regulate trophoblast-specific gene expression in vivo. Development,  124, 907-914.
131. Maandag, EC, van der Valk, M, Vlaar, M, Feltkamp, C, O’Brien, J, van Roon, M, van der Lugt, N, Berns, A and 
te Riele, H. (1994) Developmental rescue of an embryonic-lethal mutation in the retinoblastoma gene in chimeric 
mice. Embo J,  13, 4260-4268.
132. Mackay, JP, Kowalski, K, Fox, AH, Czolij, R, King, GF and Crossley, M. (1998) Involvement of the N-finger in 
the self-association of GATA-1. J Biol Chem,  273, 30560-30567.
133. Malissen, B and Malissen, M. (1996) Functions of TCR and pre-TCR subunits: lessons from gene ablation. Curr 
Opin Immunol,  8, 383-393.
134. Marin, M, Karis, A, Visser, P, Grosveld, F and Philipsen, S. (1997) Transcription factor Sp1 is essential for early 
embryonic development but dispensable for cell growth and differentiation. Cell,  89, 619-628.
135. Martens, JA and Winston, F. (2003) Recent advances in understanding chromatin remodeling by Swi/Snf 
complexes. Curr Opin Genet Dev,  13, 136-142.
136. Martin, CH, Aifantis, I, Scimone, ML, von Andrian, UH, Reizis, B, von Boehmer, H and Gounari, F. (2003) 
Efficient thymic immigration of B220+ lymphoid-restricted bone marrow cells with T precursor potential. Nat 
Immunol,  4, 866-873.
137. Martin, DI and Orkin, SH. (1990) Transcriptional activation and DNA binding by the erythroid factor GF-1/NF-
E1/Eryf 1. Genes Dev,  4, 1886-1898.
138. Martin, DI, Zon, LI, Mutter, G and Orkin, SH. (1990) Expression of an erythroid transcription factor in 
megakaryocytic and mast cell lineages. Nature,  344, 444-447.
139. McDevitt, MA, Fujiwara, Y, Shivdasani, RA and Orkin, SH. (1997) An upstream, DNase I hypersensitive region 
of the hematopoietic-expressed transcription factor GATA-1 gene confers developmental specificity in transgenic 
mice. Proc Natl Acad Sci U S A,  94, 7976-7981.
140. McDevitt, MA, Shivdasani, RA, Fujiwara, Y, Yang, H and Orkin, SH. (1997) A “knockdown” mutation created by 
cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor 
Chapter 1 
48
GATA-1. Proc Natl Acad Sci U S A,  94, 6781-6785.
141. Medvinsky, A and Dzierzak, E. (1996) Definitive hematopoiesis is autonomously initiated by the AGM region. 
Cell,  86, 897-906.
142. Medvinsky, AL, Samoylina, NL, Muller, AM and Dzierzak, EA. (1993) An early pre-liver intraembryonic source 
of CFU-S in the developing mouse. Nature,  364, 64-67.
143. Merika, M and Orkin, SH. (1993) DNA-binding specificity of GATA family transcription factors. Mol Cell Biol, 
13, 3999-4010.
144. Merika, M and Orkin, SH. (1995) Functional synergy and physical interactions of the erythroid transcription 
factor GATA-1 with the Kruppel family proteins Sp1 and EKLF. Mol Cell Biol,  15, 2437-2447.
145. Miaw, SC, Choi, A, Yu, E, Kishikawa, H and Ho, IC. (2000) ROG, repressor of GATA, regulates the expression 
of cytokine genes. Immunity,  12, 323-333.
146. Migliaccio, AR, Rana, RA, Sanchez, M, Lorenzini, R, Centurione, L, Bianchi, L, Vannucchi, AM, Migliaccio, G 
and Orkin, SH. (2003) GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-
1low mouse mutant. J Exp Med,  197, 281-296.
147. Miller, IJ and Bieker, JJ. (1993) A novel, erythroid cell-specific murine transcription factor that binds to the 
CACCC element and is related to the Kruppel family of nuclear proteins. Mol Cell Biol,  13, 2776-2786.
148. Minegishi, N, Ohta, J, Suwabe, N, Nakauchi, H, Ishihara, H, Hayashi, N and Yamamoto, M. (1998) Alternative 
promoters regulate transcription of the mouse GATA-2 gene. J Biol Chem,  273, 3625-3634.
149. Minegishi, N, Ohta, J, Yamagiwa, H, Suzuki, N, Kawauchi, S, Zhou, Y, Takahashi, S, Hayashi, N, Engel, JD and 
Yamamoto, M. (1999) The mouse GATA-2 gene is expressed in the para-aortic splanchnopleura and aorta-gonads 
and mesonephros region. Blood,  93, 4196-4207.
150. Minegishi, N, Suzuki, N, Yokomizo, T, Pan, X, Fujimoto, T, Takahashi, S, Hara, T, Miyajima, A, Nishikawa, 
S and Yamamoto, M. (2003) Expression and domain-specific function of GATA-2 during differentiation of the 
hematopoietic precursor cells in midgestation mouse embryos. Blood,  102, 896-905.
151. Mitchell, PJ and Tjian, R. (1989) Transcriptional regulation in mammalian cells by sequence-specific DNA 
binding proteins. Science,  245, 371-378.
152. Molkentin, JD. (2000) The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed 
regulators of tissue-specific gene expression. J Biol Chem,  275, 38949-38952.
153. Moore, MA and Metcalf, D. (1970) Ontogeny of the haemopoietic system: yolk sac origin of in vivo and in vitro 
colony forming cells in the developing mouse embryo. Br J Haematol,  18, 279-296.
154. Mosmann, TR, Cherwinski, H, Bond, MW, Giedlin, MA and Coffman, RL. (1986) Two types of murine helper 
T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol,  136, 
2348-2357.
155. Motoyama, N, Wang, F, Roth, KA, Sawa, H, Nakayama, K, Negishi, I, Senju, S, Zhang, Q, Fujii, S and et al. 
(1995) Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science,  267, 
1506-1510.
156. Mouthon, MA, Bernard, O, Mitjavila, MT, Romeo, PH, Vainchenker, W and Mathieu-Mahul, D. (1993) Expression 
of tal-1 and GATA-binding proteins during human hematopoiesis. Blood,  81, 647-655.
157. Muller, AM, Medvinsky, A, Strouboulis, J, Grosveld, F and Dzierzak, E. (1994) Development of hematopoietic 
stem cell activity in the mouse embryo. Immunity,  1, 291-301.
158. Muller, S, Ledl, A and Schmidt, D. (2004) SUMO: a regulator of gene expression and genome integrity. Oncogene, 
23, 1998-2008.
159. Mundschau, G, Gurbuxani, S, Gamis, AS, Greene, ME, Arceci, RJ and Crispino, JD. (2003) Mutagenesis of 
GATA1 is an initiating event in Down syndrome leukemogenesis. Blood.
160. Nagai, T, Harigae, H, Ishihara, H, Motohashi, H, Minegishi, N, Tsuchiya, S, Hayashi, N, Gu, L, Andres, B, Engel, 
JD and et al. (1994) Transcription factor GATA-2 is expressed in erythroid, early myeloid, and CD34+ human 
leukemia-derived cell lines. Blood,  84, 1074-1084.
161. Nakamura, T, Kamogawa, Y, Bottomly, K and Flavell, RA. (1997) Polarization of IL-4- and IFN-gamma-
producing CD4+ T cells following activation of naive CD4+ T cells. J Immunol,  158, 1085-1094.
162. Nardelli, J, Thiesson, D, Fujiwara, Y, Tsai, FY and Orkin, SH. (1999) Expression and genetic interaction of 
transcription factors GATA-2 and GATA-3 during development of the mouse central nervous system. Dev Biol, 
210, 305-321.
163. Nawijn, MC, Dingjan, GM, Ferreira, R, Lambrecht, BN, Karis, A, Grosveld, F, Savelkoul, H and Hendriks, RW. 
(2001) Enforced expression of GATA-3 in transgenic mice inhibits Th1 differentiation and induces the formation 
of a T1/ST2-expressing Th2-committed T cell compartment in vivo. J Immunol,  167, 724-732.
164. Nawijn, MC, Ferreira, R, Dingjan, GM, Kahre, O, Drabek, D, Karis, A, Grosveld, F and Hendriks, RW. (2001) 
Enforced expression of GATA-3 during T cell development inhibits maturation of CD8 single-positive cells and 
induces thymic lymphoma in transgenic mice. J Immunol,  167, 715-723.
165. Nerlov, C and Graf, T. (1998) PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. 
Genes Dev,  12, 2403-2412.
166. Nerlov, C, Querfurth, E, Kulessa, H and Graf, T. (2000) GATA-1 interacts with the myeloid PU.1 transcription 
Introduction
49
factor and represses PU.1-dependent transcription. Blood,  95, 2543-2551.
167. Nishikawa, K, Kobayashi, M, Masumi, A, Lyons, SE, Weinstein, BM, Liu, PP and Yamamoto, M. (2003) Self-
association of Gata1 enhances transcriptional activity in vivo in zebra fish embryos. Mol Cell Biol,  23, 8295-
8305.
168. Nossal, GJ. (1994) Negative selection of lymphocytes. Cell,  76, 229-239.
169. Nuez, B, Michalovich, D, Bygrave, A, Ploemacher, R and Grosveld, F. (1995) Defective haematopoiesis in fetal 
liver resulting from inactivation of the EKLF gene. Nature,  375, 316-318.
170. O’Garra, A and Arai, N. (2000) The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell 
Biol,  10, 542-550.
171. Okuda, T, van Deursen, J, Hiebert, SW, Grosveld, G and Downing, JR. (1996) AML1, the target of multiple 
chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell,  84, 321-330.
172. Onodera, K, Takahashi, S, Nishimura, S, Ohta, J, Motohashi, H, Yomogida, K, Hayashi, N, Engel, JD and 
Yamamoto, M. (1997) GATA-1 transcription is controlled by distinct regulatory mechanisms during primitive and 
definitive erythropoiesis. Proc Natl Acad Sci U S A,  94, 4487-4492.
173. Onodera, K, Yomogida, K, Suwabe, N, Takahashi, S, Muraosa, Y, Hayashi, N, Ito, E, Gu, L, Rassoulzadegan, 
M, Engel, JD and Yamamoto, M. (1997) Conserved structure, regulatory elements, and transcriptional regulation 
from the GATA-1 gene testis promoter. J Biochem (Tokyo),  121, 251-263.
174. Orkin, SH. (1992) GATA-binding transcription factors in hematopoietic cells. Blood,  80, 575-581.
175. Orlic, D, Anderson, S, Biesecker, LG, Sorrentino, BP and Bodine, DM. (1995) Pluripotent hematopoietic stem 
cells contain high levels of mRNA for c-kit, GATA-2, p45 NF-E2, and c-myb and low levels or no mRNA for 
c-fms and the receptors for granulocyte colony-stimulating factor and interleukins 5 and 7. Proc Natl Acad Sci U 
S A,  92, 4601-4605.
176. Osada, H, Grutz, G, Axelson, H, Forster, A and Rabbitts, TH. (1995) Association of erythroid transcription factors: 
complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1. Proc Natl Acad Sci U S A,  92, 
9585-9589.
177. Osada, H, Grutz, GG, Axelson, H, Forster, A and Rabbitts, TH. (1997) LIM-only protein Lmo2 forms a protein 
complex with erythroid transcription factor GATA-1. Leukemia,  11 Suppl 3, 307-312.
178. Ouyang, W, Ranganath, SH, Weindel, K, Bhattacharya, D, Murphy, TL, Sha, WC and Murphy, KM. (1998) Inhibition 
of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity,  9, 745-755.
179. Pai, SY, Truitt, ML, Ting, CN, Leiden, JM, Glimcher, LH and Ho, IC. (2003) Critical roles for transcription factor 
GATA-3 in thymocyte development. Immunity,  19, 863-875.
180. Pai, SY, Truitt, ML and Ho, IC. (2004) GATA-3 deficiency abrogates the development and maintenance of T 
helper type 2 cells. Proc Natl Acad Sci U S A,  101, 1993-1998.
181. Palis, J, Robertson, S, Kennedy, M, Wall, C and Keller, G. (1999) Development of erythroid and myeloid 
progenitors in the yolk sac and embryo proper of the mouse. Development,  126, 5073-5084.
182. Palis, J and Yoder, MC. (2001) Yolk-sac hematopoiesis: the first blood cells of mouse and man. Exp Hematol,  29, 
927-936.
183. Pandolfi, PP, Roth, ME, Karis, A, Leonard, MW, Dzierzak, E, Grosveld, FG, Engel, JD and Lindenbaum, MH. 
(1995) Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver 
haematopoiesis. Nat Genet,  11, 40-44.
184. Partington, GA and Patient, RK. (1999) Phosphorylation of GATA-1 increases its DNA-binding affinity and is 
correlated with induction of human K562 erythroleukaemia cells. Nucleic Acids Res,  27, 1168-1175.
185. Perkins, AC, Sharpe, AH and Orkin, SH. (1995) Lethal beta-thalassaemia in mice lacking the erythroid CACCC-
transcription factor EKLF. Nature,  375, 318-322.
186. Perry, C and Soreq, H. (2002) Transcriptional regulation of erythropoiesis. Fine tuning of combinatorial multi-
domain elements. Eur J Biochem,  269, 3607-3618.
187. Persons, DA, Allay, JA, Allay, ER, Ashmun, RA, Orlic, D, Jane, SM, Cunningham, JM and Nienhuis, AW. (1999) 
Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. Blood,  93, 488-499.
188. Pevny, L, Simon, MC, Robertson, E, Klein, WH, Tsai, SF, D’Agati, V, Orkin, SH and Costantini, F. (1991) 
Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor 
GATA-1. Nature,  349, 257-260.
189. Pevny, L, Lin, CS, D’Agati, V, Simon, MC, Orkin, SH and Costantini, F. (1995) Development of hematopoietic 
cells lacking transcription factor GATA-1. Development,  121, 163-172.
190. Philipsen, S, Pruzina, S and Grosveld, F. (1993) The minimal requirements for activity in transgenic mice of 
hypersensitive site 3 of the beta globin locus control region. Embo J,  12, 1077-1085.
191. Philipsen, S and Suske, G. (1999) A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. 
Nucleic Acids Res,  27, 2991-3000.
192. Ponka, P. (1997) Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms 
in erythroid cells. Blood,  89, 1-25.
193. Porcher, C, Swat, W, Rockwell, K, Fujiwara, Y, Alt, FW and Orkin, SH. (1996) The T cell leukemia oncoprotein 
SCL/tal-1 is essential for development of all hematopoietic lineages. Cell,  86, 47-57.
Chapter 1 
50
194. Porritt, HE, Rumfelt, LL, Tabrizifard, S, Schmitt, TM, Zuniga-Pflucker, JC and Petrie, HT. (2004) Heterogeneity 
among DN1 prothymocytes reveals multiple progenitors with different capacities to generate T cell and non-T cell 
lineages. Immunity,  20, 735-745.
195. Prohaska, SS, Scherer, DC, Weissman, IL and Kondo, M. (2002) Developmental plasticity of lymphoid progenitors. 
Semin Immunol,  14, 377-384.
196. Ranganath, S, Ouyang, W, Bhattarcharya, D, Sha, WC, Grupe, A, Peltz, G and Murphy, KM. (1998) GATA-3-
dependent enhancer activity in IL-4 gene regulation. J Immunol,  161, 3822-3826.
197. Rekhtman, N, Radparvar, F, Evans, T and Skoultchi, AI. (1999) Direct interaction of hematopoietic transcription 
factors PU.1 and GATA-1: functional antagonism in erythroid cells. Genes Dev,  13, 1398-1411.
198. Rengarajan, J, Szabo, SJ and Glimcher, LH. (2000) Transcriptional regulation of Th1/Th2 polarization. Immunol 
Today,  21, 479-483.
199. Robb, L, Lyons, I, Li, R, Hartley, L, Kontgen, F, Harvey, RP, Metcalf, D and Begley, CG. (1995) Absence of yolk 
sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc Natl Acad Sci U S A,  92, 7075-
7079.
200. Roberts, SG. (2000) Mechanisms of action of transcription activation and repression domains. Cell Mol Life Sci, 
57, 1149-1160.
201. Rodriguez, P, Bonte, E, Krijgsveld, J, Kolodziej, K, Guyot, B, Heck, A, Vyas, P, de Boer, E, Grosveld, F and 
Strouboulis, J. (manuscript submitted for publication).
202. Romeo, PH, Prandini, MH, Joulin, V, Mignotte, V, Prenant, M, Vainchenker, W, Marguerie, G and Uzan, G. 
(1990) Megakaryocytic and erythrocytic lineages share specific transcription factors. Nature,  344, 447-449.
203. Rylski, M, Welch, JJ, Chen, YY, Letting, DL, Diehl, JA, Chodosh, LA, Blobel, GA and Weiss, MJ. (2003) GATA-
1-mediated proliferation arrest during erythroid maturation. Mol Cell Biol,  23, 5031-5042.
204. Sauvageau, G, Thorsteinsdottir, U, Eaves, CJ, Lawrence, HJ, Largman, C, Lansdorp, PM and Humphries, RK. 
(1995) Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive 
populations in vitro and in vivo. Genes Dev,  9, 1753-1765.
205. Scott, EW, Simon, MC, Anastasi, J and Singh, H. (1994) Requirement of transcription factor PU.1 in the 
development of multiple hematopoietic lineages. Science,  265, 1573-1577.
206. Seder, RA, Paul, WE, Davis, MM and Fazekas de St Groth, B. (1992) The presence of interleukin 4 during in vitro 
priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J 
Exp Med,  176, 1091-1098.
207. Seder, RA, Gazzinelli, R, Sher, A and Paul, WE. (1993) Interleukin 12 acts directly on CD4+ T cells to enhance 
priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad 
Sci U S A,  90, 10188-10192.
208. Shimizu, R, Takahashi, S, Ohneda, K, Engel, JD and Yamamoto, M. (2001) In vivo requirements for GATA-1 
functional domains during primitive and definitive erythropoiesis. Embo J,  20, 5250-5260.
209. Shirihai, OS, Gregory, T, Yu, C, Orkin, SH and Weiss, MJ. (2000) ABC-me: a novel mitochondrial transporter 
induced by GATA-1 during erythroid differentiation. Embo J,  19, 2492-2502.
210. Shivdasani, RA, Mayer, EL and Orkin, SH. (1995) Absence of blood formation in mice lacking the T-cell 
leukaemia oncoprotein tal-1/SCL. Nature,  373, 432-434.
211 Shivdasani, RA and Orkin, SH. (1996) The transcriptional control of hematopoiesis. Blood,  87, 4025-4039.
212. Shivdasani, RA, Fujiwara, Y, McDevitt, MA and Orkin, SH. (1997) A lineage-selective knockout establishes the 
critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. Embo J,  16, 
3965-3973.
213. Silva, M, Grillot, D, Benito, A, Richard, C, Nunez, G and Fernandez-Luna, JL. (1996) Erythropoietin can promote 
erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood,  88, 1576-1582.
214. Smith, VM, Lee, PP, Szychowski, S and Winoto, A. (1995) GATA-3 dominant negative mutant. Functional 
redundancy of the T cell receptor alpha and beta enhancers. J Biol Chem,  270, 1515-1520.
215. Stephenson, JR, Axelrad, AA, McLeod, DL and Shreeve, MM. (1971) Induction of colonies of hemoglobin-
synthesizing cells by erythropoietin in vitro. Proc Natl Acad Sci U S A,  68, 1542-1546.
216. Struhl, K. (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev,  12, 599-606.
217. Suciu-Foca, N, Manavalan, JS and Cortesini, R. (2003) Generation and function of antigen-specific suppressor 
and regulatory T cells. Transpl Immunol,  11, 235-244.
218. Szabo, SJ, Kim, ST, Costa, GL, Zhang, X, Fathman, CG and Glimcher, LH. (2000) A novel transcription factor, 
T-bet, directs Th1 lineage commitment. Cell,  100, 655-669.
219. Takahashi, S, Onodera, K, Motohashi, H, Suwabe, N, Hayashi, N, Yanai, N, Nabesima, Y and Yamamoto, M. 
(1997) Arrest in primitive erythroid cell development caused by promoter-specific disruption of the GATA-1 gene. 
J Biol Chem,  272, 12611-12615.
220. Takemoto, N, Kamogawa, Y, Jun Lee, H, Kurata, H, Arai, KI, O’Garra, A, Arai, N and Miyatake, S. (2000) 
Cutting edge: chromatin remodeling at the IL-4/IL-13 intergenic regulatory region for Th2-specific cytokine gene 
cluster. J Immunol,  165, 6687-6691.
221. Thomas, JO. (1984) The higher order structure of chromatin and histone H1. J Cell Sci Suppl,  1, 1-20.
Introduction
51
222. Ting, CN, Olson, MC, Barton, KP and Leiden, JM. (1996) Transcription factor GATA-3 is required for development 
of the T-cell lineage. Nature,  384, 474-478.
223. Tolhuis, B, Palstra, RJ, Splinter, E, Grosveld, F and de Laat, W. (2002) Looping and interaction between 
hypersensitive sites in the active beta-globin locus. Mol Cell,  10, 1453-1465.
224. Towatari, M, May, GE, Marais, R, Perkins, GR, Marshall, CJ, Cowley, S and Enver, T. (1995) Regulation of 
GATA-2 phosphorylation by mitogen-activated protein kinase and interleukin-3. J Biol Chem,  270, 4101-4107.
225. Towatari, M, Ciro, M, Ottolenghi, S, Tsuzuki, S and Enver, T. (2004) Involvement of mitogen-activated protein 
kinase in the cytokine-regulated phosphorylation of transcription factor GATA-1. Hematol J,  5, 262-272.
226. Tsai, FY, Keller, G, Kuo, FC, Weiss, M, Chen, J, Rosenblatt, M, Alt, FW and Orkin, SH. (1994) An early 
haematopoietic defect in mice lacking the transcription factor GATA-2. Nature,  371, 221-226.
227. Tsai, FY and Orkin, SH. (1997) Transcription factor GATA-2 is required for proliferation/survival of early 
hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. Blood, 
89, 3636-3643.
228. Tsai, SF, Martin, DI, Zon, LI, D’Andrea, AD, Wong, GG and Orkin, SH. (1989) Cloning of cDNA for the major 
DNA-binding protein of the erythroid lineage through expression in mammalian cells. Nature,  339, 446-451.
229. Tsai, SF, Strauss, E and Orkin, SH. (1991) Functional analysis and in vivo footprinting implicate the erythroid 
transcription factor GATA-1 as a positive regulator of its own promoter. Genes Dev,  5, 919-931.
230. Tsang, AP, Visvader, JE, Turner, CA, Fujiwara, Y, Yu, C, Weiss, MJ, Crossley, M and Orkin, SH. (1997) FOG, a 
multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic 
differentiation. Cell,  90, 109-119.
231. Tsang, AP, Fujiwara, Y, Hom, DB and Orkin, SH. (1998) Failure of megakaryopoiesis and arrested erythropoiesis 
in mice lacking the GATA-1 transcriptional cofactor FOG. Genes Dev,  12, 1176-1188.
232. Turpen, JB, Knudson, CM and Hoefen, PS. (1981) The early ontogeny of hematopoietic cells studied by grafting 
cytogenetically labeled tissue anlagen: localization of a prospective stem cell compartment. Dev Biol,  85, 99-112.
233. Valge-Archer, VE, Osada, H, Warren, AJ, Forster, A, Li, J, Baer, R and Rabbitts, TH. (1994) The LIM protein 
RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells. Proc Natl Acad 
Sci U S A,  91, 8617-8621.
234. an der Wees, J, van Looij, MA, de Ruiter, MM, Elias, H, van der Burg, H, Liem, SS, Kurek, D, Engel, JD, Karis, 
A, van Zanten, BG, de Zeeuw, CI, Grosveld, FG and van Doorninck, JH. (2004) Hearing loss following Gata3 
haploinsufficiency is caused by cochlear disorder. Neurobiol Dis,  16, 169-178.
235. Van Esch, H, Groenen, P, Nesbit, MA, Schuffenhauer, S, Lichtner, P, Vanderlinden, G, Harding, B, Beetz, R, 
Bilous, RW, Holdaway, I, Shaw, NJ, Fryns, JP, Van de Ven, W, Thakker, RV and Devriendt, K. (2000) GATA3 
haplo-insufficiency causes human HDR syndrome. Nature,  406, 419-422.
236. van Ewijk, W. (1991) T-cell differentiation is influenced by thymic microenvironments. Annu Rev Immunol,  9, 
591-615.
237. Vo, N and Goodman, RH. (2001) CREB-binding protein and p300 in transcriptional regulation. J Biol Chem,  276, 
13505-13508.
238. von Boehmer, H. (1994) Positive selection of lymphocytes. Cell,  76, 219-228.
239. Vyas, P, Ault, K, Jackson, CW, Orkin, SH and Shivdasani, RA. (1999) Consequences of GATA-1 deficiency in 
megakaryocytes and platelets. Blood,  93, 2867-2875.
240. Vyas, P, McDevitt, MA, Cantor, AB, Katz, SG, Fujiwara, Y and Orkin, SH. (1999) Different sequence requirements 
for expression in erythroid and megakaryocytic cells within a regulatory element upstream of the GATA-1 gene. 
Development,  126, 2799-2811.
241. Wadman, I, Li, J, Bash, RO, Forster, A, Osada, H, Rabbitts, TH and Baer, R. (1994) Specific in vivo association 
between the bHLH and LIM proteins implicated in human T cell leukemia. Embo J,  13, 4831-4839.
242. Wadman, IA, Osada, H, Grutz, GG, Agulnick, AD, Westphal, H, Forster, A and Rabbitts, TH. (1997) The LIM-
only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the 
TAL1, E47, GATA-1 and Ldb1/NLI proteins. Embo J,  16, 3145-3157.
243. Wall, L, deBoer, E and Grosveld, F. (1988) The human beta-globin gene 3’ enhancer contains multiple binding 
sites for an erythroid-specific protein. Genes Dev,  2, 1089-1100.
244. Warren, AJ, Colledge, WH, Carlton, MB, Evans, MJ, Smith, AJ and Rabbitts, TH. (1994) The oncogenic cysteine-
rich LIM domain protein rbtn2 is essential for erythroid development. Cell,  78, 45-57.
245. Wechsler, J, Greene, M, McDevitt, MA, Anastasi, J, Karp, JE, Le Beau, MM and Crispino, JD. (2002) Acquired 
mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet,  32, 148-152.
246. Weiss, MJ, Keller, G and Orkin, SH. (1994) Novel insights into erythroid development revealed through in vitro 
differentiation of GATA-1 embryonic stem cells. Genes Dev,  8, 1184-1197.
247. Weiss, MJ and Orkin, SH. (1995) Transcription factor GATA-1 permits survival and maturation of erythroid 
precursors by preventing apoptosis. Proc Natl Acad Sci U S A,  92, 9623-9627.
248. Weiss, MJ and Orkin, SH. (1995) GATA transcription factors: key regulators of hematopoiesis. Exp Hematol,  23, 
99-107.
249. Weiss, MJ, Yu, C and Orkin, SH. (1997) Erythroid-cell-specific properties of transcription factor GATA-1 revealed 
Chapter 1 
52
by phenotypic rescue of a gene-targeted cell line. Mol Cell Biol,  17, 1642-1651.
250. Whitmarsh, AJ and Davis, RJ. (2000) Regulation of transcription factor function by phosphorylation. Cell Mol 
Life Sci,  57, 1172-1183.
251. Whyatt, D, Lindeboom, F, Karis, A, Ferreira, R, Milot, E, Hendriks, R, de Bruijn, M, Langeveld, A, Gribnau, 
J, Grosveld, F and Philipsen, S. (2000) An intrinsic but cell-nonautonomous defect in GATA-1-overexpressing 
mouse erythroid cells. Nature,  406, 519-524.
252. Whyatt, D and Grosveld, F. (2002) Cell-nonautonomous function of the retinoblastoma tumour suppressor protein: 
new interpretations of old phenotypes. EMBO Rep,  3, 130-135.
253. Whyatt, DJ, deBoer, E and Grosveld, F. (1993) The two zinc finger-like domains of GATA-1 have different DNA 
binding specificities. Embo J,  12, 4993-5005.
254. Whyatt, DJ, Karis, A, Harkes, IC, Verkerk, A, Gillemans, N, Elefanty, AG, Vairo, G, Ploemacher, R, Grosveld, F 
and Philipsen, S. (1997) The level of the tissue-specific factor GATA-1 affects the cell-cycle machinery. Genes 
Funct,  1, 11-24.
255. Williams, BO, Schmitt, EM, Remington, L, Bronson, RT, Albert, DM, Weinberg, RA and Jacks, T. (1994) 
Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. 
Embo J,  13, 4251-4259.
256. Wong, PM, Chung, SW, Chui, DH and Eaves, CJ. (1986) Properties of the earliest clonogenic hemopoietic 
precursors to appear in the developing murine yolk sac. Proc Natl Acad Sci U S A,  83, 3851-3854.
257. Wu, L, de Bruin, A, Saavedra, HI, Starovic, M, Trimboli, A, Yang, Y, Opavska, J, Wilson, P, Thompson, JC, 
Ostrowski, MC, Rosol, TJ, Woollett, LA, Weinstein, M, Cross, JC, Robinson, ML and Leone, G. (2003) Extra-
embryonic function of Rb is essential for embryonic development and viability. Nature,  421, 942-947.
258. Xu, Y. (2003) Regulation of p53 responses by post-translational modifications. Cell Death Differ,  10, 400-403.
259. Yamagata, T, Mitani, K, Oda, H, Suzuki, T, Honda, H, Asai, T, Maki, K, Nakamoto, T and Hirai, H. (2000) Acetylation 
of GATA-3 affects T-cell survival and homing to secondary lymphoid organs. Embo J,  19, 4676-4687.
260. Yamamoto, M, Ko, LJ, Leonard, MW, Beug, H, Orkin, SH and Engel, JD. (1990) Activity and tissue-specific 
expression of the transcription factor NF-E1 multigene family. Genes Dev,  4, 1650-1662.
261. Yang, HY and Evans, T. (1992) Distinct roles for the two cGATA-1 finger domains. Mol Cell Biol,  12, 4562-4570.
262. Yomogida, K, Ohtani, H, Harigae, H, Ito, E, Nishimune, Y, Engel, JD and Yamamoto, M. (1994) Developmental 
stage- and spermatogenic cycle-specific expression of transcription factor GATA-1 in mouse Sertoli cells. 
Development,  120, 1759-1766.
263. Yu, C, Cantor, AB, Yang, H, Browne, C, Wells, RA, Fujiwara, Y and Orkin, SH. (2002) Targeted deletion of a 
high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. 
J Exp Med,  195, 1387-1395.
264. Zhang, DH, Cohn, L, Ray, P, Bottomly, K and Ray, A. (1997) Transcription factor GATA-3 is differentially 
expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol 
Chem,  272, 21597-21603.
265. Zhang, DH, Yang, L and Ray, A. (1998) Differential responsiveness of the IL-5 and IL-4 genes to transcription 
factor GATA-3. J Immunol,  161, 3817-3821.
266. Zhang, P, Behre, G, Pan, J, Iwama, A, Wara-Aswapati, N, Radomska, HS, Auron, PE, Tenen, DG and Sun, Z. 
(1999) Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc Natl Acad Sci U 
S A,  96, 8705-8710.
267. Zhang, P, Zhang, X, Iwama, A, Yu, C, Smith, KA, Mueller, BU, Narravula, S, Torbett, BE, Orkin, SH and Tenen, 
DG. (2000) PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. 
Blood,  96, 2641-2648.
268. Zheng, W and Flavell, RA. (1997) The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine 
gene expression in CD4 T cells. Cell,  89, 587-596.
269. Zhou, Y, Lim, KC, Onodera, K, Takahashi, S, Ohta, J, Minegishi, N, Tsai, FY, Orkin, SH, Yamamoto, M and 
Engel, JD. (1998) Rescue of the embryonic lethal hematopoietic defect reveals a critical role for GATA-2 in 
urogenital development. Embo J,  17, 6689-6700.
270. Zhu, J and Emerson, SG. (2002) Hematopoietic cytokines, transcription factors and lineage commitment. 
Oncogene,  21, 3295-3313.
271. Zon, LI, Tsai, SF, Burgess, S, Matsudaira, P, Bruns, GA and Orkin, SH. (1990) The major human erythroid DNA-
binding protein (GF-1): primary sequence and localization of the gene to the X chromosome. Proc Natl Acad Sci 
U S A,  87, 668-672.
272. Zon, LI, Mather, C, Burgess, S, Bolce, ME, Harland, RM and Orkin, SH. (1991) Expression of GATA-binding 
proteins during embryonic development in Xenopus laevis. Proc Natl Acad Sci U S A,  88, 10642-10646.
273. Zon, LI, Youssoufian, H, Mather, C, Lodish, HF and Orkin, SH. (1991) Activation of the erythropoietin receptor 
promoter by transcription factor GATA-1. Proc Natl Acad Sci U S A,  88, 10638-10641.
274. Zon, LI, Yamaguchi, Y, Yee, K, Albee, EA, Kimura, A, Bennett, JC, Orkin, SH and Ackerman, SJ. (1993) 
Expression of mRNA for the GATA-binding proteins in human eosinophils and basophils: potential role in gene 
transcription. Blood,  81, 3234-3241.
Chapter 2
An intrinsic but cell-nonautonomous defect in 
GATA-1-overexpressing mouse erythroid cells.
David Whyatt, Fokke Lindeboom, Alar Karis, Rita Ferreira, Eric Milot, 
Rudi Hendriks, Marella de Bruijn, An Langeveld, Joost Gribnau, Frank 
Grosveld and Sjaak Philipsen.
Nature (2000) 406: 519-524
Chapter 2
54
An intrinsic but cell-nonautonomous defect in GATA-overexpressing 
mouse erythroid cells.
David Whyatt*, Fokke Lindeboom, Alar Karis, Rita Ferreira, Eric Milot, Rudi Hendriks, 
Marella de Bruijn, An Langeveld, Joost Gribnau, Frank Grosveld and Sjaak Philipsen.
Erasmus University, Department of Cell Biology and Genetics, Medical Genetics Centre, PO Box 1738, 3000 
DR Rotterdam, The Netherlands; *Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 
1066 CX Amsterdam, The Netherlands
 
 GATA-1 is a tissue-specific transcription factor essential for the production of red 
blood cells19,25. Here we demonstrate that overexpression of GATA-1 in erythroid cells inhibits 
their differentiation, leading to a lethal anaemia. Using chromosome-X-inactivation of a GATA-
1 transgene and chimaeric animals, we show that this defect is intrinsic to erythroid cells , but 
nevertheless cell nonautonomous. Usually, cell nonautonomy is thought to reflect aberrant gene 
function in cells other than those that exhibit the phenotype20. On the basis of our data, we 
propose an alternative mechanism in which a signal originating from wild-type erythroid cells 
restores normal differentiation to GATA-1 overexpressing cells in vivo. The existence of such 
a signalling mechanism indicates that previous interpretations of cell-nonautonomous defects 
may be erroneous in some cases and may in fact assign gene function to incorrect cell types.
 GATA-1 expression is required at the relatively immature proerythroblast stage19,25, 
since GATA-1 null proerythroblasts undergo apoptosis26 and reduced GATA-1 levels inhibit 
proerythroblast differentiation23. However, the role of GATA-1 later in erythroid differentiation 
remains obscure. Murine erythroleukemia (MEL) cells overexpressing GATA-1 under the control 
of the erythroid-specific human β-globin locus control region linked to the β-globin promoter 
(construct PEV3-GATA-1) fail to activate the expression of differentiation markers in response to 
the chemical inducer dimethyl sulphoxide (DMSO) and do not undergo differentiation-associated 
proliferative arrest27. Embryonic stem (ES) cell clones overexpressing GATA-1 also generate 
erythroid colonies that are inhibited in terminal differentiation27. Furthermore, overexpression of 
an inducible GATA-1 fusion protein (GATA-1-LBD, containing the tamoxifen-inducible ligand-
binding domain of the oestrogen receptor) also inhibits erythroid differentiation (R.F. and D.W., 
unpublished data). These results may explain our failure to produce a transgenic line of mice by 
conventional microinjection of PEV3-GATA-1, since loss of erythroid differentiation would be 
lethal in vivo. 
 We therefore exploited the process of X-inactivation13, as X-linked GATA-1 
transgene should be transcriptionally active in 50% of female erythroid precursors. In males, 
X-inactivation does not occur and all erythroid cells should overexpress GATA-1. Mice can 
survive to term when 50% of erythroid precursors fail to differentiate normally, for example 
in females with one disrupted GATA-1 allele (which is X-linked); however, roughly 30% of 
GATA-1 null heterozygous females die from severe anaemia by15.5 days post coitus (dpc). In 
survivors, anaemia is transient and recovery is thought to be due to in vivo selection of normal 
progenitors10,24. 
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 DNA fluorecence-in-situ-hybridization (FISH) screening of male ES cells stably 
transfected with PEV3-GATA-1 showed localization of the transgene to the X chromosome 
in clone G4. The expected ratio in male to female progeny (38:34) was observed from 100% 
germline transmitting male chimeras generated from this clone, F1 females carrying the 
transgene and F1 males (except one) being non-transgenic. The phenotypically male transgenic 
animal contained two X chromosomes (one carrying the transgene) and one Y chromosome 
(data not shown). Chimeras generated from four other ES cell clones containing autosomal 
transgene integrations failed to give germline transmission.
 We mated transgenic females and examined their progeny. Transgenic females were 
indistinguishable from wild-type littermates. Male transgenics were anaemic from 12.5 dpc 
and dead by 14.5 dpc (Fig. 1a and 1b). Back-crossing GATA-1 overexpressing females to FVB 
males for eight generations resulted in no viable transgenic males (excluding the XXY male). 
At 13.5 dpc, the number of enucleated erythrocytes relative to nucleated erythrocytes is reduced 
more than three-fold in transgenic males compared to controls, demonstrating that definitive 
erythropoiesis is inhibited (Fig. 1c). The fetal liver of transgenic male embryos, the site of 
definitive erythropoiesis at 13.5 dpc, was normal in size and cell number and contained similar 
numbers of apoptotic cells (terminal deoxyribonucleotide transferase (TdT)-mediated dUTP 
nick end labelling(TUNEL) assay; data not shown) compared to controls; however, transgenic 
male fetal livers contain significantly more early basophilic erythroid precursors and fewer late 
benzidine-positive  cells (Fig. 1c),  confirming  that  erythropoiesis is  defective in fetal  liver. 
Unexpectedly, female transgenics display no alteration in the morphology of cells in the fetal 
liver and have normal numbers of enucleated erythrocytes at this stage (Fig. 1c). Expression of 
putative GATA-1 target genes such as α-globin is unchanged in female transgenics, as RNA-
FISH detection of α-globin nascent transcripts on 13.5 dpc fetal liver cells showed a normal 
number of cells transcribing α-globin (72% compared to 73% in controls). Furthermore, co-
staining showed that half of these cells were positive for transgene-derived GATA-1 transcripts 
(data not shown), suggesting that the transgene is sensitive to X-inactivation. 
 Consistent with this interpretation, western blot analysis gave a higher level of 
transgene-derived GATA-1 protein in male versus female transgenic embryos (Fig. 2a). RNA-
FISH using a GATA-1 probe demonstrates that at 12.5 dpc, 66% of transgenic male fetal liver 
cells were positive for transgene-derived GATA-1 nascent transcripts (appearing as a bright 
nuclear dot), while 32% of transgenic female cells were GATA-1 positive (Fig. 2b). This 
method did not detect endogenous GATA-1 transcripts. Co-staining for Xist RNA showed a 
single punctate signal in male fetal liver cells, corresponding to transcription from the Xist 
allele on the active X chromosome. Female cells also contained a larger area of accumulated 
Xist RNA on the inactive X chromosome (or Barr body)18,22. Apparent co-localisation of Barr 
body and GATA-1 signals occured in less than 5% of double positive cells (Figure 2b and data 
not shown), confirming that male transgenics express the transgene pancellularly and females 
heterocellularly in response to X-inactivation. Survival of transgenic mice was not dependent 
on being female per se, as a transgenic XXY male (where X-inactivation occurs13) was viable. 
One might argue that the observed phenotype arises from the X chromosomal integration event 
itself; however, overexpression of the tamoxifen-inducible GATA-1-LBD in mice inhibits 
erythroid differentiation independent of the integration site. GATA-1-LBD accumulated to 
lower levels than PEV3-GATA-1 derived protein and consequently induced a milder phenotype 
(15% reduction as compared to a 60% reduction in the proportion of differentiated erythroid 
cells in a CFU-E assay, data not shown).
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Figure 1 - GATA-1 overexpression in vivo. (a) Representative wild-type (wt) males and transgenics (tg) of either sex, 
11.5 dpc to 14.5 dpc, yolk sacs intact. (b) Genotype and phenotype of embryos and adults, excluding F1. Death was 
defined by lack of heartbeat, pallor was scored by anaemia. (c) Disaggregated 12.5 dpc fetal liver and 13.5 dpc blood. 
Indicated by key is morphology of differentiating erythroid precusors and erythrocytes. Arrowheads indicate erythroid 
precusors in male transgenic blood (<3% of all cells). Percentage of enucleated erythrocytes (>300 events/embryo), 
number (n) of independent embryos and standard deviations and ratio of enucleated to nucleated erythroid cells are 
shown below.
 To examine the relative contribution of GATA-1-overexpressing cells to the erythroid 
lineage,  we bred transgenic females with males containing a lacZ gene insertion in the X-
inactivation sensitive Bruton’s tyrosine kinase (BtklacZ) locus11. We found the same number of 
lacZ positive erythroid cells in the fetal livers of 13.5 dpc BtklacZ/+ and compound BtklacZ+/GATA-1 
transgenic females (Fig. 2c). Adult BtklacZ males or females express lacZ in 50% or 25% of large 
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erythroid precursors in the bone marrow respectively. Compound BtklacZ+/GATA-1 transgenic 
females also express lacZ in 25% of large erythroid precursors (Fig. 2d). Thus, there is a normal 
representation  of  cells with  an active lacZ  gene  in the erythroid compartment of GATA-1-
overexpressing females throughout development. We conclude there is no selection for or 
against GATA-1-overexpressing cells in females. As these females generate normal numbers 
of definitive erythrocytes, the GATA-1 overexpressing cells must be differentiating normally 
in vivo. To confirm that GATA-1 overexpressing cells contribute to the adult erythrocyte 
pool, chimaeric animals were generated with clone G4 cells (which are male and express 
the GATA-1 transgene pancellularly). These cells contributed up to 50% of the erythrocytes, 
as assayed by globin chain isoform analysis (Fig. 3a) and confirmed by glucose phosphate 
isomerase analysis (data not shown). These cells were morphologically normal (Fig. 3b). 
Furthermore, analysis of the blood of female transgenic mice showed no effect on other blood 
cell parameters, including red cell number, cell volume and haemoglobin content (data not 
shown).
Figure 2 - GATA-1 transgene is subject to X-inactivation. (a) Western blot of nuclear extracts from 13.5 dpc fetal 
livers, with anti-GATA-1 antibody N6. DMSO-induced control (PEV3) and GATA-1 overexpressing (PEV3-GATA-1) 
MEL cell samples are included. Position of myc-tagged transgene-derived GATA-1 (trans.GATA-1) and endogenous 
GATA-1 (endo.GATA-1) are indicated. Cyclin A2 used as loading control. (b) RNA-FISH on 12.5 dpc disaggregated 
fetal liver cells. Cells stained for GATA-1 (green) and Xist (red). Representative cells shown. Percentage of transgene-
derived GATA-1 positive cells, number of embryos and standard deviations indicated. (c) Percentage of erythroid cells 
and percentage of lacZ+ erythroid cells in 13.5 dpc fetal livers from female GATA-1 transgenic mice mated to BtklacZ 
males. Number of embryos and standard deviations are indicated. (d) Percentage of lacZ+ staining cells in haematopoietic 
lineages of six week old mice. Erythroid cells are arbritrarily divided into large and medium-sized based on forward 
scatter (FSC) value. Note the GATA-1 transgenic Btklacz/+ female £1 which express lacZ in a high number of erythroid 
precursors also expresses lacZ in a higher than expected number of cells in the B-cell and monocytic lineages. This 
reflects the normal variance of the binomial distribution of X-inactivation balance in early pluripotent precursors.
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 To determine which differentiation stage is affected in the transgenic males we carried 
out burst-forming unit-erythroid (BFU-E, reflecting early committed erythroid progenitors) 
and colony-forming unit-erythroid (CFU-E, reflecting a later stage in erythroid differentiation) 
assays.  The same number of colonies in BFU-E and CFU-E assays were formed from both 
wild-type and transgenic 12.5 dpc and 13.5 dpc fetal livers (data not shown). CFU-E colonies 
develop from single cells6 and do not require accessory cells to form21, so the effect of GATA-
1 overexpression on female transgenic precursors when no longer in close contact with non-
overexpressing cells could be addressed. In male transgenic CFU-E colonies, the production 
of small late differentiated erythroid cells is inhibited (Fig. 4a) and after 24 hours approximately 
40% of erythroid cells were dead, compared to 20% in wild-type cultures (Fig. 4b). Female 
transgenic CFU-E cultures had an intermediate phenotype (Figure 4a and 4b), identical to that 
found when wild-type and male transgenic cells were mixed before or after culture at a 1:1 ratio. 
This shows that female GATA-1 overexpressing erythroid precursors are intrinsically defective 
and behave identically to transgenic male erythroid precursors when removed from the fetal 
liver. 
Figure 3 - Cells overexpressing GATA-1 contribute to erythroid lineage in adult chimaeric mice. (a) Triton-acid-urea 
gel of lysed blood from C57bl6 (host-blastocyst, Hb single), 129OLA (ES cell strain, Hb diffuse) or clone G4 derived 
chimeras (G4ch#8, 11 and 14). Indicated are the positions of the alpha-type (α) and beta-type globin (β) chains. (b) 
Morphology of the blood derived from C57bl6, 129OLA and G4 chimera #8 mice.
 Gene function is “cell autonomous” when a cell displays a phenotype that corresponds 
to its genotype, regardless of the genotype of surrounding cells. Gene function is defined as “cell 
nonautonomous” when a cell exhibits a phenotype that does not correspond to its genotype2. In 
mosaics (that is. female transgenics and male chimeras), the phenotype of GATA-1 transgenic 
cells is wild-type. Therefore, the function of the GATA-1 transgene is cell nonautonomous. The 
conventional interpretation would be that GATA-1 overexpressing erythroid cells are normal 
and that the GATA-1 transgene causes a defect in a non-erythroid cell normally supporting 
erythropoiesis. If so, then all erythroid precursors in female transgenics would behave identically 
in vivo and in vitro; however, this is not the case (Fig. 4). Thus, the conventional interpretation 
of cell nonautonomy is incorrect. 
 Perhaps the mutant erythroid cells produce a negative factor inhibiting differentiation 
and this is diluted in mosaics. To be cell nonautonomous, however, expression of such a 
negative signalling factor would have to be the only defect in the GATA-1 overexpressing cells. 
Considering the biochemical effects of GATA-1 overexpression in erythroid cells5,8,27, this is 
unlikely. As GATA-1 overexpressing erythroid cells are intrinsically defective, they must be 
responding to a signal reversing these defects in mosaics. We propose wild-type cells produce 
α
β
C57bl6 129OLA G4ch#8
 An intrinsic but cell non-autonomous defect in GATA-1-overexpressing mouse erythroid cells
59
a positive factor activating the differentiation of GATA-1 overexpressing cells. We tentatively 
name this activity “red cell differentiation signal” or REDS. The cells producing REDS must 
be absent or reduced in transgenic males. Definitive erythropoiesis occurs in erythroblastic 
islands4. These contain a central macrophage surrounded by erythroid cells at all stages of 
maturation, with immature cells close to the macrophage and mature cells near the edge of the 
island3,4 (Fig. 5). The obvious candidate source of REDS is mature erythroid cells, as this is the 
only cell population clearly reduced in the transgenic males. Merely allowing wild-type fetal 
liver cells to contact GATA-1 overexpressing cells by mixing them in liquid culture does not 
restore differentiation to the latter (data not shown), indicating that disruption of the structure of 
the erythroblastic island also disrupts REDS activity. We suggest mature erythroid cells on the 
periphery of the island are the source of REDS. In mosaics, late erythroid cells overexpressing 
GATA-1 are juxtaposed with REDS-producing wild-type mature cells in the same erythroblastic 
island and/or the neighbouring island. This overcomes the defects induced by high GATA-1 
levels and allows the final stages of erythroid maturation to proceed. In male transgenic mice 
there is no such juxtaposition. Death ligands expressed by mature erythroid cells can induce the 
degradation of GATA-17. It is therefore possible that death ligands are a component of REDS. In 
supporting of this, death ligands partially reverse the effect of GATA-1 overexpression in vitro 
(data not shown). 
Figure 4 - GATA-1 overexpressing CFU-Es fail to differentiate and undergo apoptosis in vitro. (a) Representative 
histogram plots of FSC (indicating relative cell size) of viable erythroid cells from CFU-E assays performed on 
disaggregated fetal liver cells of 13.5 dpc embryos. Cells harvested before culture (day 0), after 24 hours (day 1) and 48 
hours (day 2) of culture. Shown is the curve obtained by mixing transgenic male and wild-type samples in a 1:1 ratio 
after different periods of culture. (b) Percentage of dead erythroid cells in same samples as a. Owing to a background of 
dead cells with a FSC of less than 327 (using our instrument settings), present in all CFU-E samples, cells with a FSC of 
less than 327 were excluded from this analysis.
 There is one precedent for a signalling mechanism similar to the one we propose. C. 
elegans larvae null for the IGF receptor homologue DAF-2 enter a state of diapause rather 
than develop into adulthood, however, DAF-2 null mosaic animals can become adult with all 
cells differentiating into adult tissues. Significantly, an adult phenotype is not associated with 
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an obligatory requirement for DAF-2 activity in a particular cell. Consequently, secondary 
signals operate to ensure that all cells adopt the same developmental fate2. Furthermore, our 
observations have important implications in interpreting other cell nonautonomous defects. For 
example, loss of the retinoblastoma protein (pRb) results in a cell nonautonomous inhibition of 
erythropoiesis. In accordance with the conventional interpretation of cell nonautonomy, it was 
concluded that pRb null erythroid cells are normal and that pRb function is required in stromal 
cells supporting erythropoiesis14,29. This conclusion may be incorrect, since transplantation 
studies suggest that pRb is required in erythroid cells12. This discrepancy remains unexplained.; 
however, one resolution may by that the effect of pRb loss in erythroid cells is reversed by a 
signal supplied by wild-type cells, similar to the one that restores the normal differentiation of 
erythroid cells overexpressing GATA-1.  
Figure 5 - A simplified model of the erythroblastic island. The position of the central macrophage and the arrangement 
of the erythroid precursors (as indicated by the key) within the macrophage’s cytoplasmic extensions are shown. The 
processes of  pyknosis, enucleation and phagocytosis of expelled pyknotic nuclei are represented. Arrows indicate the 
putative signal REDS, being produced by late differentiated erythroid cells.  Graph indicates  the proposed process of 
GATA-1 regulation late in the differentiation process.  
Methods
Plasmids, probes and primers 
 Plasmids PEV3-GATA-1 and PEV3 have been described9. Details of the cloning steps to 
produce the puromycin resistant version of PEV3-GATA-1 are available on request. Integration 
of PEV3-GATA-1 in ES cells and mice was screened by Southern blot using a 1kb internal 
probe corresponding to the 5’ end of the GATA-1 minigene. DNA-FISH and RNA-FISH was 
performed using a FITC-labelled 4.3 kb fragment spanning exon 2 to exon 6 of the GATA-1 
gene, a Texas-Red labelled 21 kb human beta-globin LCR probe and a Texeas-Red labelled 6.5 
kb fragment corresponding to the Xist RNA (a gift of N. Brockdorff). Embryos were sexed by 
PCR using primers specific for the Zfy gene16.
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Western blotting
  Nuclear extracts were prepared as  described1. Each sample (5µg) was subject to 
electrophoresis through a 10% SDS polyacrylamide gel, transferred onto nitrocellulose and 
probed with anti-GATA-1 antibody N6 (Santa Cruz) or anti-cyclin A2 antibody C-19 (Santa 
Cruz) and an appropriate secondary antibody before detection using chemiluminesence.
ES cells
  The puromycin resistant version of PEV3-GATA-1 was linearized with Pvu1 and 
electroporated into 129OLA-derived ES cells as previously described17 and individual clones 
selected in 1µg/ml puromycin.
Mice
  Chimeric mice were generated by injecting ES cell clones generated as above into 
C57bl6 blastocysts. Chimeras were then bred with wild-type FVB males and screened by coat 
colour for germ-line transmission. Transgenic females were then mated to FVB males or BtklacZ 
males and sacrificed during gestation or allowed to go to term.
Blood and fetal liver cell analysis
  Blood and/or disaggregated fetal livers were collected from embryos or adults and 
prepared on slides by cytocentrifugation. Slides were stained with neutral benzidine and a 
modified Giemsa-like stain. 
Haemaglobin analysis
  Globin chain representation in chimeric animals was analysed as described14.
DNA- and RNA-FISH
  DNA-FISH was done as described15. RNA-FISH was performed on disaggregated 
fetal liver cells as described28.
CFU-E assay
  CFU-E  assays were done as described30. Fetal livers were disaggregated into 
single cells by passage through a 100µm mesh and plated at a density of 3x105 cells per ml 
in methylcellulose containing 1U/ml Epo. Colonies were grown for times indicated and then 
collected and washed with PBS to remove residual methylcellulose before staining. 
FACS analysis
  Single cell suspensions of bone marrow, fetal livers and cultured cells were prepared 
as above, stained and analysed by FACS as described21, with  5x104 events taken per sample. 
We used the following antibodies and stains: R-PE-conjugated TER119 antibody (Pharmingen), 
7-aminoactinomycin-D (7AAD, Molecular Probes BV), fluoroscein-di-b-D-galactopyranoside 
(FDG, Molecular Probes BV), biotin-conjugated ER-MP20 antibody, cychrome-conjugated 
CD45R/B220 (Pharmingen) and Tricolor-streptavidin secondary antibody (Calatag Laboratories, 
CA). Cell populations were divided as follows: non-viable (7AAD+), erythroid (TER119+), large 
erythroid (TER119+/FSChigh), medium-sized erythroid (TER119+/FSCmedium), B-cell lineage 
(B220+/ER-MP20-/TER-), granulocytic (ER-MP20+/TER119-) and monocytic (ER-MP20high/
TER119-). 
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Expression profiling of GATA1-overexpressing erythroid cells.
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We have previously shown that GATA1 overexpression in erythroid cells inhibits 
terminal erythroid differentiation, both in vivo and in vitro. However, specific GATA1 functions 
in terminal erythroid differentiation remain unclear. We employed cDNA microarray technology 
to analyse the expression profile of GATA1-overexpressing erythroid cells in an attempt to 
identify putative new GATA1 target genes.We started by analysing the gene expression profile 
of GATA1-overexpressing cells in vivo, using the GATA1 overexpressing transgenic mouse 
model previously generated in our laboratory.  Transgenic female (TgF) embryos, expressing 
the transgene in approximately 50% of the erythroid cells, survive to adulthood but transgenic 
male (TgM) embryos, expressing the transgene in all the erythroid cells, die from anemia around 
embryonic day 13.5 (E13.5). Using E12.5 fetal livers from TgF, TgM and wild type (WT) embryos 
we identified 744 differentially expressed genes. Of these 18% were differentially expressed in 
both TgF and TgM. The remaining genes were differentially expressed in either TgF (26%) 
or TgM (56%). Differentially expressed genes were classified in agreement with their known 
role in particular physiological processes according to the Gene Ontology (GO) classification 
system. In a first analysis we identified particular physiological processes containing larger 
number of differentially expressed genes that correlate well with the known GATA1 functions 
in proliferation/differentiation, regulation of transcription and apoptosis. 
 Since variation is high between embryos we continued our analysis using and in vitro 
model system. GATA1-overexpressing (GATA1) and WT MEL cells were induced to differentiate 
and samples collected at day 0, 1,1.5, 2 and 3 of differentiation. With this approach 2704 genes 
were identified with statistically significant different levels of expression. These genes were 
also classified by gene ontology and interestingly the physiological processes containing the 
majority of the GO-classified genes were the same as in the in vivo analysis.  However, in the in 
vitro analysis more genes were identified that are known to be involved in cell cycle control. 
 Our data indicate that that GATA1 is involved in several important cellular processes. 
Furthermore, we show that the experimental approach used in this analysis, i.e., the combined 
analysis of in vivo and in vitro systems, is reliable and thus provide a powerful new tool in the 
further analysis of the regulatory functions of GATA1 in terminal erythroid differentiation. 
Introduction
  GATA1 is the founding and best-studied member of the GATA family of transcription 
factors. Like all GATA transcription factors (GATA1 to 6) GATA1 is characterized by the 
presence of two zinc finger motifs that mediate DNA binding to (T/A)GATA(A/G) consensus 
sequences. Initially identified as an erythroid-specific transcription factor23,  GATA1 is now 
known to be expressed and play crucial roles in the generation and terminal differentiation of 
megakaryocytes21, eosinophils28 and mast cells15. 
GATA1 function in the erythroid lineage has been extensively studied but its role in 
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terminal erythroid differentiation remains unclear. Gene targeting studies revealed that GATA1 
is essential for both primitive and definitive erythropoiesis17 since GATA1 null erythroid 
precursors fail to mature beyond the proerythroblast stage18 and die through apoptosis25. 
Consequently, GATA-1 null murine embryos die from severe anemia between embryonic day 
(E) 10.5 and E11.56.
We have shown previously that overexpression of GATA1 in erythroid cells inhibits 
terminal differentiation, both in vivo and in vitro26,27.  Mouse erythroleukemia  (MEL) cells 
overexpressing GATA1 under the control of the β-globin promoter and locus control region 
show defective differentiation in response to chemical induction by dimethyl sulphoxide 
(DMSO). These cells fail to undergo the proliferation arrest associated with differentiation, and 
to activate transcription of genes associated with late stages or erythroid differentiation, such 
as the β-globin and carbonic anhydrase form II genes27. A transgenic mouse line was generated 
in which GATA1 is overexpressed under the control of the β-globin promoter and locus control 
region, expressing the transgene at  later stages of erythroid differentiation. The transgene was 
integrated on the X-chromosome, and therefore subject to X-inactivation. In this way, females 
express the transgene in ~50% of the erythroid cells while the males, where X-inactivation 
does not occur, express the transgene in all erythroid cells.  Transgenic females (TgF) are able 
to survive to adulthood but transgenic males (TgM) die between E12.5 and E13.5 from lethal 
anemia26. We have shown that the defect in terminal erythroid differentiation is intrinsic to 
the overexpressing cells but it is cell-nonautonomous, since the overexpressing cells are able 
to mature to erythrocytes in the presence of wild-type cells. Embryos containing ~50% of 
the erythroid cells overexpressing GATA1 and the GATA1 gene inactivated in the remaining 
erythroid cells, showed a phenotype similar to the GATA1 overexpressing males. This confirms 
that terminal erythroid differentiation of GATA1 overexpressing cells is rescued by a homotypic 
signal from the wild–type erythroid cells present in the fetal liver9.
The consequences of GATA1 overexpression both in vivo and in vitro support the 
notion that GATA1 plays a crucial role in the transcriptional regulation of key genes involved 
in terminal erythroid differentiation. Many erythroid-specific genes possess GATA binding sites 
in their promoters suggesting that GATA1 may directly regulate transcription of a large number 
of these genes16. For example, GATA1 is responsible for the regulation of heme biosynthesis 
genes16,20, the erythropoietin and erythropoietin receptor genes3,12,29 as well as other hematopoietic 
transcription factors, such as GATA27,24, EKLF4 and TAL114.  GATA1 is also implicated in the 
prevention of apoptosis during differentiation since the pro-apoptic gene Bcl-
XL
 has also been 
identified as a direct GATA1 target gene8.  Furthermore, gene expression profiling studies 
performed during induced differentiation of the GATA1 null cell line G1E by reintroduction of 
GATA-1 identified a variety of potential direct and indirect GATA1 target genes. Among these 
genes are core cell cycle components, such as cyclin D2, Cdk 6 and cyclin kinase inhibitors 
p18 and p27, and genes involved in proliferation20. Abnormal expression of such genes can be 
a potential explanation for the defect in terminal erythroid differentiation observed in GATA1 
null and overexpressing cells. 
All the GATA1 target genes identified to date were based on comparisons of GATA1 
null versus GATA1 expressing cells. Some of the these genes may be involved in the phenotype 
observed in GATA1 overexpressing cells but it is reasonable to assume that new target genes can 
be identified by analysis of the expression profile of GATA1 overexpressing cells. Therefore, we 
set out to identify new GATA1 target genes by comparing the expression profiles of wild type 
and overexpressing GATA1 erythroid cells using cDNA microarray technology. Comparison 
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between cells from E12.5 fetal livers from TgF, that survive to adulthood, and TgM, that die by 
E13.5, allow us to distinguish between direct GATA1 target genes and genes which expression is 
altered by secondary effects. For confirmation of the results obtained in vivo, we also compared 
the expression profiles of wild-type (WT) and GATA1 overexpressing  (GATA1) MEL cells 
during DMSO-induced differentiation.
Results and Discussion
In vivo expression profiling of GATA1-overexpressing erythroid cells
 Transgenic mice overexpressing GATA1 were generated by blastocyst injection of 
embryonic stem (ES) cells in which a GATA1 transgene under the control of the β-globin 
promoter and LCR was targeted to the X-chromosome (Fig. 1 A)26. In TgM, possessing a single 
X-chromosome, all erythroid cells overexpress GATA1 while in TgF, in which one of the X-
chromosomes is randomly inactivated, approximately 50% of the erythroid cells express the 
transgene. Surprisingly, this leads to very distinct phenotypes in females and males. While the 
TgF are born normal, are fertile and possess normal life span, TgM die in utero by E13.5. 
Figure 1 - GATA1-overexpressing transgenic mice (A) Schematic representation of the construct used to generate 
GATA1 overexpressing ES cells and transgenic mice. (B) Experimental design of expression profiling analysis GATA1 
overexpressing mice. TgM-transgenic male; TgF-Transgenic female; WTM-wild-type male; WTF- wild-type female; 
Reference- pooled amplified RNA from WTM and WTF at a ratio 1:1.
 To investigate the consequences of GATA1 overexpression in erythroid cells we 
performed an expression profiling analysis of both TgF and TgM.  The fetal liver was the tissue 
of choice for these experiments since it is the main hematopoietic site during late embryonic 
development, composed of approximately 70% erythroid cells9. Fetal livers were collected at 
E12.5 to avoid secondary effects caused by the fact that transgenic males are dying by E13.5 and 
consequently cells are expected to express genes involved in hypoxia and apoptosis. To reduce 
the impact of variability between samples, transgenic and wild type littermates were used for 
the analysis. Total RNA from individual fetal livers collected from TgF, TgM and both wild-type 
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females (WTF) and males (WTM) was used for probe preparation. Poly-adenylated RNA from 
those samples was amplified by T7-mediated in vitro transcription, and 3µg of amplified RNA 
was used for probe preparation. Probes were labelled by direct incorporation of Cy3 or Cy5 
dyes by reverse transcription and hybridised to cDNA microarray containing approximately 
15000 murine cDNAs.  A reference design was used for this experiment, as described in Figure 
1B. Each individual sample was hybridised against a common reference sample composed of 
amplified RNA from WTF and WTM fetal livers RNA, pooled at a ratio 1:1. To avoid bias due 
to dye incorporation dye-reversed hybridisations were performed for each sample. 
 To identify the sex-independent differentially expressed genes in TgF and TgM, we 
performed independent one-way multivariante analysis of variance (ANOVA) between TgF and 
WT (WTF and WTM) and TgM and WT.  Genes with a p value lower or equal to 0.05 (p≤0.05) 
and with a fold change equal or higher than 1.5 in at least three hybridisations were considered 
to be significantly different. To further eliminate differentially expressed sex-dependent genes, 
the same analysis was performed between WTM and WTF and the significantly different 
genes were then removed from the list of TgF and TgM differentially expressed genes. With 
this approach, 330 and 550 differentially expressed genes were identified in TgF and TgM 
respectively.
 To confirm that the above results reflect significant rather than random changes in 
gene expression, we performed unsupervised hierarchical clustering of genes identified as 
significantly different (Fig. 2). 
Figure 2 - Non-supervised hierarchical cluster of differentially expressed genes (p≤0.05, fold difference of ±1.5 in at 
least 3 experiments) between TgF and WT and TgM and WT.
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WTF and WTM cluster together indicating that they are almost indistinguishable 
from each other upon removal of the sex-specific genes.  In contrast, TgMs and TgFs cluster 
separately from each other. TgMs cluster separately from all the remaining samples, indicating 
that they are the most dissimilar, in agreement with the observed phenotype. Three out of the 
4 TgFs cluster together and are more similar to the WTMs and WTFs that to the TgMs. The 
fourth TgF is more similar to the TgM. This correlates well with the observation that TgFs, 
due to the random nature of X-inactivation, show a more variable phenotype. Some TgF are 
indistinguishable from the WT littermates but others show a range of erythroid defects.
In order to reduce the complexity of the data set and confirm the clustering results, 
we employed a Principle Component Analysis (PCA) (Fig. 3). The PCA results are in good 
agreement with the clustering results. TgMs group together and are the most dissimilar from 
the WTs. Three of the TgFs group together and are more similar to the WTs than the TgMs. The 
fourth TgF is less similar to the WTs than the other three TgFs, and is more similar to the TgMs. 
Detailed analysis of GATA1 expression in the different samples shows that from all the TgFs, 
this one has the highest GATA1 expression (data not shown).
Figure 3 - Principal component analysis of differently expressed genes (p≤ 0.05, fold difference ±1.5 in at least 3 
experiments) between TgF and WT and TgM and WT.
To identify the genes regulated by GATA1 we compared the differentially expressed 
genes in TgFs and TgMs to each other (Fig. 4). From the total number of differentially expressed 
genes (744) identified in TgFs and TgMs, 18% (136 genes) of the genes were common to both 
groups (TgMF), while 26% (194 genes) and 56% (414 genes) were exclusively found in the 
TgF and TgM groups, respectively. Differentially expressed genes common to TgFs and TgMs 
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are likely to reflect the direct effect of GATA1 overexpression in the erythroid cells. The large 
number of differentially expressed genes in TgMs will be partially due to secondary effects 
of GATA1 overexpression. It will also reflect differences in the cell population since terminal 
erythroid differentiation of GATA1-overexpressing erythroid cells in males is blocked. This 
does not happen in the TgFs due to the presence of wild type cells which rescue the terminal 
differentiation of the GATA1-overexpressing cells26. The relatively small number of genes 
differentially expressed in the TgFs may reflect variation between the different females, since 
they show variable phenotypes due to the random nature of X-inactivation, or to the influence 
of the wild-type cells on the differentiation of the GATA1 overexpressing cells.
Figure 4 - Venn diagram representation of TgF and TgM biosets. Each circle represents the number of differently 
expressed genes (p≤0.05, fold difference of ±1.5 in at least 3 experiments) between TgF and WT  (TgF) and TgM and 
WT (TgM). The percentage of genes shared between differently expressed genes ( TgM TGF) is indicated.
To further validate the data obtained several differentially expressed genes were 
selected for further analysis by real-time quantitative (RQ)-PCR. These genes were chosen 
on the basis of their significance, fold change and/or their status as putative GATA1 target 
genes. This analysis was performed on non-amplified RNA samples to discard possible bias 
due to RNA amplification. TFE3 (Transcription Factor binding to immunoglobulin heavy chain 
Enhancer 3) and RUFY1 (Run and Fyve domain containing 1) transcripts are two of the most 
significant differentially expressed genes identified in this analysis. They have low p-values and 
are upregulated over 2-fold in TgFs and up to 7-fold TgMs. Furthermore these genes are found 
to be upregulated in 21 and 16 hybridisations, respectively, out of a total of 24 experiments. RQ-
PCR analysis using primers specific for TFE3 and RUFY1 confirmed the expression profiles 
observed in the microarray experiments (Fig 5A). Both TFE3 and RUFY1 are overexpressed in 
TgFs (~ 2.5 fold) and TgMs (~ 6 fold). TFRC (Transferrin receptor) expression was moderately 
but significantly downregulated in TgMs (~3 fold) and 1.5 to 3-fold downregulation was seen in 
some TgFs, although not statistically significant. Samples analysed by RQ-PCR show a decrease 
in TCFR expression in both TgMs and TgFs indicating that the degree of TCFR downregulation 
varies between TgFs (Fig 5B). This suggests that TCFR is a direct target of GATA1 since GATA1 
expression levels also varies between females due to the random nature of X-inactivation.
TgFM TgM
26% 18% 56%
TgF
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GATA binding sites are present in the LCR and promoter regions of the α-globin and 
β-globin gene clusters10,19 but only a small reduction of the expression level of α-globin (HBA1) 
and β-major (HBB-B1) genes was observed in in vitro differentiated GATA1 null cells24. A 
reduction in the HBA1 expression was detected in TgMs and at lesser extent in TgFs, with 
a borderline significance (p value ranging from 0.04 to 0.02).  RQ-PCR analysis confirmed 
that HBA1 is reduced about 2-fold in TgMs but no significant reduction was detected in TgFs 
(Fig. 5B). No significant reduction in HBB-B1 was detected in TgFs and TgMs, probably due 
to the fact that HBB-B1 is present in only a few spots on the microarray. Analysis of HBB-B1 
expression by RQ-PCR revealed that HBB-B1 is expressed at lower level (~2 fold) in TgMs 
(Fig. 5B). Dowregulation of HB1A and HBB-B1 expression was confirmed by quantitative 
S1 protection assay  (Fig 5C). Using this more sensitive assay, a small reduction in expression 
levels of HB1A and HBB-B1 was also detected in TgFs.
Figure 5 - Validation of microarray data by RQ-PCR and S1protection assay. (A) RQ-PCR analysis of TFE3 and 
RUFY1 expression in WT, TgF and TgM. (B) RQ-PCR analysis of HBA1, HBB-B1 and TFRC expression in WT, TgF 
and TgM. (C) S1 protection  analysis of HBA1 and HBB-B1 expression in WT, TgF and TgM. (D) Analysis of the 
expression of genes involved in  heme byosinthesis by RQ-PCR analysis. 
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Since GATA binding sites are present in regulatory sequences of genes involved in 
heme biosynthesis, we analysed the expression pattern of the genes involved in this pathway 
in more detail. Some of these genes, namely ALAS2, UROD, PPOX and FECH, are among 
the 15000 cDNA spotted on the microarrays used for this analysis. ALAS2 and UROD are 
downregulated in the TgMs while FECH is downregulated in both TgFs and TgMs. PPOx is also 
downregulated but at levels below the threshold of significance. RQ-PCR analysis confirmed 
that ALAS2 is slightly downregulated in the TgMs but not in the TgFs once more reflecting the 
large variability among TgFs. Other genes, such as UROD, CPOX, PPOX and FECH are also 
downregulated in TgMs by RQ-PCR. The effect on the biosynthesis of heme, however mild, 
may be either a consequence of the fact that GATA1 cells are unable to normally differentiate or 
a possible cause for their inability to differentiate.
 The RQ-PCR and S1 analysis performed on a number of selected genes validates the 
results obtain with microarray analysis and discards the possibility of bias introduced by the 
amplification of the original RNA samples. 
Gene ontology classification and network analysis of in vivo differentially expressed 
genes
The interpretation of high throughput biological data is difficult due to the large 
amounts of data generated. In order to facilitate the understanding of the biological relevance of 
the data, functional categories, describing the full repertoire of biological processes according 
to the publicly available Gene Ontology (GO) classification system (www.geneontology.org), 
were assigned to the genes in each bioset  (TgM, TgF and TgMF), beginning at the level of 
“Physiological Processes” (GO:0007582). To visualize these functional groups of significant 
genes we used a tool based on Star Tree™ visualization technology, in order to represent the 
data set within the tree-like structure of the GO classification system (see Figure 6A-B or “in 
vivo” and “star tree visualization” at  http://michael.bioinformatix.nl/GATA1/). 
In an attempt to identify ‘over-represented’ GO-classified biological processes we 
compared the number of pertinent genes in a given biological process to the total number of 
the relevant genes printed on the NIH 15K cDNA microarray for a particular biological process 
(Fisher exact test, P≤0.05, False detection rate (FDR) ≤0.1) using the publicly accessible 
software Ease 11. Such analysis did not reveal any significantly over-represented processes, 
which suggests either that GATA1 is involved in a wide variety of functions or that the cDNA 
microarray platform is not the best platform to be used for this analysis. 
However, comparison between the numbers of significantly expressed genes assigned 
to each GO-classified biological process may suggest a role for GATA1 in those processes. 
From the total number of differentially expressed genes identified (744) only 28% (208 genes) 
were assigned to physiological processes by GO-classification. The processes containing the 
largest numbers of genes were “cell growth and maintenance” (GO:0008151; 39%) followed by 
“protein metabolism” (GO:0019538; 28%), “Nucleic acid metabolism” (GO:0006139, 23%), 
“regulation of transcription” (GO:0045449; 19%) and “biosynthesis” (GO: 0009058; 16%). This 
distribution of genes assigned to physiological processes correlates well with known GATA1 
functions in cell proliferation/differentiation, apoptosis, transcription activation/repression, and 
heme biosynthesis.  Within the “cell growth and maintenance” process, the majority of the genes 
(60%, 24% of the total GO-classified genes) are categorized under “transport” (GO:0006810). 
More detailed analysis of the genes in this category reveals that the majority of these genes are 
differentially expressed exclusively in TgMs and therefore may not be direct GATA1 target 
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genes. Interestingly, many of these genes are either erythroid-specific, such as HBA1, which is 
dowregulated in the TgMs and in some TgFs, and/or with known functions in erythroid cells, 
such as TFRC (transferrin receptor), important for the heme biosynthesis.
Figure 6 - Graphical representation of the interactive visualizations. (A) Analysis of GO-classified data using the 
StarTree View, allowing the three-dimensional representation of the full repertoire of biological processes within GO 
classification system. (B) Selection of any node from (A) allows interactive querying of expression profiles of the 
individual genes. (C) Visualization of significant genes classified according to gene networks in which they are most 
likely to participate based on known molecular interactions. 
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To further elucidate the structure and meaning of these expression patterns we annotated 
the genes whose products function in common pathways or “networks” as defined by the 
commercially available Ingenuity database (www.ingenuity.com). Each network was annotated 
by listing its statistical significance and the top functions associated with combinations of genes 
in that network (see Fig.  6C or  “in vivo” and “pathway analysis” at  http://michael.bioinformatix.
nl/GATA1/). The most significant network (based on the network significance score) contained 
genes involved in the transformation, adhesion, proliferation and apoptosis of cells. The majority 
of genes within this network as similar or opposite expression pattern from GATA1, i.e. either 
are upregulated or downregulated in TgMs and, to a lesser extent, in TgFs. At least one of the 
genes in these network, BNIP3 has been implicated in apoptotic response induced by hypoxia 
suggesting that its upregulation may be a consequence of the phenotype rather that a direct effect 
of GATA1 overexpression13. Not surprisingly the network containing GATA1 is implicated in 
transcription, cell cycle progression, growth and differentiation, processes in which GATA1 is 
known to be involved. This network contains other genes, such as IGF1 (Insulin-Like Growth 
Factor 1) and IGFBP3 (IGF1 binding protein 3), which are important in fetal and adult growth 
and also in cancer. Other significant network contained genes involved in G1 progression, DNA 
damage and chromosome condensation. We have shown before that GATA1 overexpression in 
MEL cells prevents their arrest in G1 phase of the cell cycle 27. Furthermore, deregulation of the 
process of chromosomal condensation may be one of the reasons why GATA1-overexpressing 
cells to fail to enucleate.
In vitro expression profiling of GATA1 overexpressing erythroid cells
Since embryos display some developmental variation, and the phenotype of TgF is also 
variable depending on X-inactivation, we decided to compare the expression profiles of WT 
and GATA1-oerexpressing MEL cells. MEL cells are transformed mouse erythroblasts that 
can be induced to differentiate with DMSO, thereby providing a synchronized system to study 
erythroid differentiation.
 MEL cells were stably transfected with the same construct used for the generation of 
transgenic mice, expressing GATA1 under the control of β-globin promoter and Locus Control 
Region (GATA1) or vector alone (WT) as described27 (Fig. 1A).  Three independent GATA1 
and two WT MEL cell populations were induced to differentiate with DMSO and samples 
were collected at day 0, 1, 1.5, 2 and 3 of differentiation. RNA isolated from GATA1 and WT 
populations at the different time points was amplified by T7-mediated in vitro transcription and 
used for probe preparation. Probes were labelled by direct incorporation of Cy3 or Cy5 dyes 
by reverse transcription and hybridised to cDNA microarray containing approximately 15000 
murine genes.  
A “time-vehicle control” approach was employed to eliminate potential variation 
between samples through time due to technical variations (Fig. 7A). Probes from each time 
of differentiation of the GATA1 populations were hybridised using the corresponding time of 
differentiation of the WT populations as the reference.  Hybridisations were also performed 
between the two WT populations. To avoid bias due to dye incorporation dye-reversed 
hybridisations were performed for each sample. 
Differentially expressed genes between WT and GATA1 MEL cell populations were 
identified by one-way multivariate analysis of variance (ANOVA). This analysis was performed 
for all the different days of differentiation and 2704 genes were identified as significantly 
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different (p≤0.05 and with a fold change ≥1.5 in at least 1 experiment). These significantly 
different genes were subjected to unsupervised hierarchical clustering analysis, revealing a 
good correlation between the time of differentiation and the different replicates (Fig. 8). WT 
cells, of all days of differentiation, cluster together with GATA1 cells at day 0 of differentiation 
indicating that they are very similar. The different GATA1 replicates cluster according to the 
day of differentiation: Day 1 and day 1.5 cluster separately but day 2 and day 3 cluster together. 
Since we compared RNA samples of corresponding differentiation times, GATA1-independent 
differences occurring during MEL cell differentiation are in principle taken out of the analysis. 
The clustering between WT controls and the different GATA1 populations at day 0, when the 
transgene is not expressed or expressed at very low levels, shows that the expression profiles of 
these cells are very similar. The observation that GATA1 replicates at day 1, day1.5 and day2-3 
cluster separately indicates that GATA1 expression interferes dynamically with the expression 
profile of the cells during the first two days of differentiation, reaching a plateau by day 2-3. 
This correlates well with the expression pattern of the GATA1 transgene (Fig. 7B).
Figure 7 - GATA1-overexpressing MEL cells (A) Experimental design of expression profiling analysis GATA1 
overexpressing MEL cells. (B) Western blot analysis of nuclear extracts from WT and GATA1 MEL cells throughout 
DMSO induced differentiation.
Gene ontology classification and network analysis of in vitro differentially expressed 
genes
Functional categories were assigned to the differentially expressed genes according 
to the publicly available Gene Ontology (GO) classification system (www.geneontology.org) 
and visualized using Star Tree™ (see “in vitro” and “star tree visualization” at  http://michael.
bioinformatix.nl/GATA1/). 
We compared the numbers of significantly expressed genes assigned to each GO-
classified biological process. From the total number of differently expressed genes identified 
(2704) only 33.4% (903 genes) were assigned to physiological process by GO-classification. 
The processes containing the largest numbers of genes were “cell growth and maintenance” 
(GO:0008151; 45%) followed by “protein metabolism” (GO:0019538; 29%), “Nucleic acid 
metabolism” (GO:0006139; 29%), “regulation of transcription” (GO:0045449; 15%) and 
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“biosynthesis” (GO:0009058; 15%). The increased numbers of genes assigned to processes 
correlate well not only with known GATA1 functions but also with the physiological process 
identified in the in vivo analysis.  Within the “cell growth and maintenance” process, the majority 
of the genes are categorized under “transport” (GO:0006810; 47.3%, 21% of the total GO-
classified genes), “cell cycle” (GO:0007049; 29.7%, 13.3% of the total GO-classified genes) 
and “cell organization and biogenesis” (GO:0016043; 28%, 12.5% of the total GO-classified 
genes). The number of differently expressed genes associated with cell cycle control is increased 
in the in vitro data when compared with the in vivo results. This may reflect the fact that DMSO-
induced MEL cell differentiation is a synchronized process involving G1 arrest, while in the 
fetal liver the population of cells is mixed, potentially masking GATA1-dependent alterations to 
the cell cycle machinery. 
Figure 8 - Non-supervised hierarchical cluster of differentially expressed genes (p≤0.05, fold difference of ±1.5) 
between WT and GATA1 MEL cells throughout DMSO induced differentiation.
GO-classified differentially expressed genes between GATA1 and WT MEL cell 
populations were organized into “networks” as defined by the commercially available Ingenuity 
database (www.ingenuity.com). Each network was further annotated by listing its statistical 
significance and the top functions associated with combinations of genes in that network 
(see “in vivo” and “pathway analysis” at  http://michael.bioinformatix.nl/GATA1/). The most 
significant network (based on the network significance score) contained genes involved in cell 
survival, proliferation, G1 progression. GATA1 itself is part of this network, which also includes 
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for example CCND2 (Cyclin D2) and CCND3 (Cyclin D3), which expression at is altered in 
MEL cells overexpressing GATA1 (data not shown). Other networks are implicated in cell 
cycle control, differentiation/proliferation, chromosome condensation, DNA modification (in 
particular DNA unwinding and methylation), transcription and transport.  Under the category of 
transport we find important erythroid genes like α and β-like globins (HBA1 HBE1 and HBB-
B2) among other erythroid-specific genes. One of the genes included in this category is ABCme 
(ABCB10) a known GATA1 target gene. 
Conclusion
 The data presented above, demonstrates that GATA1 is involved in several important 
cellular processes. The biological processes discussed above were selected on the bases of the 
percentage of differentially expressed genes under a particular gene ontology category but they 
correlate well with known GATA1 functions. This validates the quality of the data and data 
analysis and indicates that this data provide a good platform for future analysis of the regulatory 
functions of GATA1 in terminal erythroid differentiation. 
Materials and Methods
Mice
 Timed pregnancies were set with GATA1 overexpressing females 26 and FVB males. 
Fetal livers were isolated from E12.5 embryos. The embryos were genotyped by Southern blot 
using probes specific for GATA1 and for the Y-specific YMT gene. 
Cells
 C88 MEL cells were stably transfected with a construct expressing GATA1 under the 
control of the β-globin promoter and Locus Control Region (GATA1) or vector alone (WT) as 
described27.  Three and two independent populations of GATA1 and WT MEL cell populations, 
respectively , were used in this study. These populations were expanded in DMEM medium 
containing 10% serum and antibiotics. Differentiation was induced by addition of 2% (v/v) 
DMSO for 3 days. Samples were collected at day 0, 1, 1.5, 2 and 3 of differentiation.
RNA isolation
Total RNA was isolated from WT and GATA1 overexpressing fetal livers and MEL cells 
using Tri-reagent (Sigma. RNA quantity and quality were assessed by spectrophotometry and by 
direct visualization of the RNA on 1% agarose gels containing formamide. Only samples with 
an OD 260nm/280nm ratio equal or superior to 1.8 and with a ratio of 2 between the 28S and 
18S ribosomal RNA bands were used for probe preparation.
RNA amplification
A constant amount of total RNA (4µg) was used for amplification by T7 mediated in 
vitro transcription. In brief, double stranded cDNA was prepared by standard procedures using 
a T7dT primer (5’-GGC CAG TGA ATT GTA ATA GCA CTC ACT ATA GGG AGG CGG 
TTT TTT TTT TTT TTT TTT TTT TTT-3’2), in vitro transcribed using T7 MEGAscript Kit 
(Ambion) and purified using the RNeasy Kit (Qiagen)
Amplified RNA quantity and quality were assessed by spectrophotometry and by direct 
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visualization of the RNA on 1% agarose gels containing formamide. Samples with an OD 
260nm/280nm ratio equal or superior to 1.8 and showing no signs of degradation were used for 
further processing.
cDNA labelling, hybridization and data extraction
Amplified RNA was labelled and hybridised to 15K cDNA microarrays, obtained from 
the Netherlands Cancer Institute (NKI), using protocols adapted from the National Institute 
of Aging (NIA, Bethesda, Maryland). In brief, cDNA was synthesized from 3µg amplified 
RNA by reverse transcription in the presence of Cy3-UTP or Cy5-UTP (Amersham). Cy3 
and Cy5 labelled probes were purified using the QIAquick PCR purification Kit (Qiagen) and 
concentrated via Microcon YM-30 columns (Millipore). Purified probes from two samples 
were pooled and hybridised to cDNA microarrays in 25% formamide, 5X SCC, 0.01% SDS 
(containing poly d(A), yeast transfer RNA and COT-1 DNA), overnight at 42oC. Upon washing, 
hybridised microarrays were scanned using a laser confocal scanner (Scanarray Express HT, 
Perkin Elmer Inc, USA). Data was extracted with the Imagene software package version 5.0 
(Biodiscovery Inc, CA, USA).
To account for possible dye-dependent bias, all amplified RNA samples were reversed 
labelled and reversed-dye hybridisations performed. Self-self hybridisations were also performed 
and any deviation from a ratio of 1 (centred to 0 for 2log ratio data) was assigned to either 
dye effect or residual error. Dye-reversed hybridisations were considered technical replicates 
allowing gene-specific dye effects to be averaged out during clustering while excluding dye-
dependent variances during the ANOVA analysis. In order to assure a balanced design, the same 
number of dye-reversed replicates was used for all samples.
Data processing and analysis
Data within each experiment (microarray) were normalized, per sub-array, using the 
Lowess normalization method. Data from dye-reversed hybridizations was combined by means 
of a weighted average. Normalization between experiments (between microarrays), from 
combined and non-combined dye-reversed data was obtained via the Z-score transformation. 
One-way-analysis-of-variance (ANOVA) was employed to extract the statistically 
significant changes in mRNA expression levels. To account for the inherent variability as well 
as to compensate for the fact that dye bias is often not consistent, we performed this analysis on 
independent (non-averaged) microarray hybridizations. A p-value (P≤0.05) and fold change (+/-
1.5 fold change) criterion were set to alleviate the effect of significance errors while minimizing 
loss of significant information. Due to the expected high variation between in vivo (fetal liver) 
samples, statistically significant genes that had a fold change of +/- 1.5 in less than 3 (non–
combined) experiments were removed from the analysis. 
 Non-supervised agglomerative hierarchical clustering, principal component analysis 
(PCA) and self-organizing maps (SOM) were performed on the statistically significant genes 
identified by ANOVA.
Z-score transformation, analysis of variance (ANOVA), hierarchical clustering, principal 
component analysis (PCA) and self-organizing maps (SOM) were performed by the Spotfire 
Decision Site software package 7.2 version 10.0 (Spotfire Inc., MA, USA). 
Real time quantitative PCR 
Four µg of total RNA was used for the reverse transcription reaction with oligo(dT) 
Chapter 3
80
(18mer) and random hexamers. Real-time quantitative (RQ)±PCR was performed in triplicate 
reactions on a Bio Rad iCycler machine, using the Eurogentec (Seraing,Belgium) SYBR green 
kit.  Primers sets used: TFE3 (s 5’-acagaaggaacagcaacgc-3’; as 5’-aactcgtggttagggagagca-
3’), RUFY1 (s 5’-ggttgaaaga tgacgaggcaa-3’; as 5’-acacacacgcactggctta-3’), TFRC (s 5’- 
cgttgttgaggcagaccttg-3’; as 5’-accctgatgactgagatggc-3’), HBA1 (s 5’-tttccagggcttcagctcc-3’; as 
5’-tgattctga cagactcaggaag-3’), HBB-B1 (s 5’-atgccaaagtgaaggcccat-3’; as 5’-cccagcacaatcacgatc 
at-3’), ALAS (s 5’-cacctatgcttaaggagcca-3’; as 5’-cagaagcacacaggaaagca-3’), ALAD (s 5’-
ctttgatctcaggactgctg-3’; as 5’-aacagctgcggtgcaaagta-3’), HMBS ( s 5’-tacttctggcttccaagtgc-3’; 
as 5’-caaggtgaggcatatcttcc-3’), UROD (s 5’-atccctgtgccttgtatgca-3’; as 5’-aggttggcaattgagcgttg-
3’), CPOX (s 5’-caatttgaagccagtccgtg-3’; as 5’-ctggactagaactccctttg-3’), PPOX (s 5’-
attccagcttcagagctcag-3’; as 5’-tactgcagattcaccacagc-3’), FECH ( s 5’-accagtgaccacattgagac-
3’; as 5’-ggccttggagaacaatggat) and Cyclophiline  ( s 5’-tcaccatttccgactgtggac-3’; as 5’-
acaggacattgcgagcagatg). Expression levels of cyclophiline were used for normalization.  
Quantitative S1 protection assay
Quantitative S1 protection assay was performed on total RNA from fetal liver of E12.5 
WT, TgF and TgM embryos has described5,22. Quantitation of the protected fragments was 
performed using the ImageQuant 5.2 software (Molecular Dynamics).
Gene Ontology classification and network analysis 
All significant genes were subjected to GO classification  (http://www.geneontology.org). 
Significant over-representation of GO-classified biological processes was assessed by comparing 
the number of pertinent genes in a given biological process to the total number of the relevant 
genes printed on the NIH 15K cDNA microarray for that biological process (Fisher exact test, 
P≤0.05, False detection rate (FDR) ≤0.1) using the publicly accessible software Ease 11. 
Network data was generated through the use of Ingenuity Pathways Analysis. A detailed 
description of Ingenuity Pathways Analysis can be found at www.ingenuity.com.
Western blot
 Total nuclear protein from MEL cells was extracted as previously described1. Protein 
concentration in the nuclear extracts was determined using the bicinchoninic acid protein assay 
(Pierce, Rockford, IL). For Western blotting analysis, 10 µg of total nuclear protein was loaded 
per lane and separated on 10% SDS-PAGE gels under reducing conditions and transferred to 
polyvinylidene difluoride membrane (Immobilon-P; Millipore, Bedford, MA). Blots were 
probed with rat anti-GATA1 mAb (N6) purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA) and HRP-conjugated goat anti-rat Ig (Dako, Glostrup, Denmark). Peroxidase activity was 
visualized by ECL using standard procedures.
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Rescue of GATA1 null mice by GATA transgenes requires the correct 
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We have previously demonstrated that hematopoietic GATA proteins (GATA1, GATA2 
and GATA3), when expressed under the control of GATA1 regulatory sequences (HRD), are 
able to rescue the lethal phenotype of the GATA1.05 knockdown mutation. Here we show that 
the same HRD-GATA transgenes are able to rescue the GATA1 null phenotype, thus eliminating 
the possibility that the remaining 5% of endogenous GATA1 expression in the GATA1.05 
knockdown is required for the rescue by the HRD-driven GATA factors.
 However, the same hematopoietic GATA proteins are unable to rescue the lethal GATA1 
null phenotype when expressed under control of the β-globin promoter and locus control region 
(βLCR). The temporal expression of the βLCR driven GATA factor transgenes is distinct from 
that of the HRD driven transgene and the endogenous GATA1 gene. We show that the HRD 
driven transgenes and the endogenous GATA1 gene are upregulated during erythropoiesis but 
their expression levels out at the later stages of terminal erythroid differentiation. In contrast, 
βLCR transgene driven expression keeps rising during terminal differentiation. These results 
demonstrate that the correct spatio-temporal expression pattern of GATA factor, rather than the 
actual GATA factor expressed, is decisive for the appropriate execution of terminal erythroid 
differentiation program,. 
 Introduction
The GATA family of transcription factors is composed of 6 members (GATA1 to 6). 
These transcription factors are characterized by the presence of two zinc finger protein domains 
that mediate DNA binding to (T/A)GATA(A/G) consensus sequences15. The zinc finger motifs 
are highly homologous between the different GATA proteins, but very little amino acid sequence 
homology is found outside these domains.  Within the GATA family, GATA1, GATA2 and 
GATA3 constitute a subfamily since all three are expressed in hematopoietic cells39.
  GATA1 is the founding member of the GATA family. Within the hematopoietic system, 
GATA1 is expressed in erythrocytes16, megakaryocytes19, eosinophils43 and mast cells19. Gene 
targeting studies have shown that GATA1 is required for normal erythroid differentiation. 
Loss of GATA1 activity results in a developmental arrest at the proerythroblast stage, causing 
these cells to undergo apoptosis40. Consequently, GATA1 null mouse embryos die from severe 
anemia between day 10.5 and 11.5 of gestation (E10.5-E11.5)10,27. Paradoxically, overexpression 
of GATA1 in the erythroid lineage also causes a lethal anemia. GATA1 overexpressing 
embryos die around E12.5 and E13.5 owing to the failure of erythroid precursors to undergo 
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terminal differentiation41. This suggests that GATA1 activity is dynamically regulated during 
erythropoiesis.
The hematopoietic expression pattern of GATA2 overlaps substantially with that of 
GATA1. GATA2 is expressed in multilineage progenitors, mast cells and megakaryocytes16,21. 
The main hematopoietic expression site of GATA3 is in the T-cell lineage11. In addition, 
expression in multilineage progenitors has been inferred from the knockout phenotype26
  These overlapping expression patterns suggest that these transcription factors may have 
redundant functions. However, gene knockout studies demonstrated that a given GATA protein 
does not compensate for the absence of another member of the GATA family. For instance, it 
has been shown that in vitro differentiation of GATA1 null embryonic stem (ES) cells results in 
a 50-fold increase of GATA2 mRNA in erythroid cells. However, these cells are still arrested 
in differentiation and eventually die by apoptosis40. In contrast to these results, several studies 
have shown that other GATA proteins can rescue the GATA1 null phenotype at least partially, 
when expressed under the control of GATA1 regulatory sequences. In vitro differentiation of 
GATA1 null ES cells was restored when GATA3 and GATA4 were expressed under the control 
of GATA1 promoter3. The knock-in of GATA3 cDNA into the GATA1 locus partially rescued 
the GATA1 KO mice phenotype36. The GATA3 knock-in mice were still embryonic lethal but 
they could survive up to E13.5 and presented an increased survival of erythroid precursor cells. 
In addition, we have shown that GATA2 and GATA3 transgenes under the control of GATA1 
regulatory sequences can rescue the embryonic lethality of a GATA1 knockdown mutation33. 
Mice carrying this mutation express ~5% of the wild-type GATA1 levels and die at E12.5. 
The rescued mice survived into adulthood, although they were anemic and presented abnormal 
erythroid cells in peripheral blood. This suggests that the GATA1 protein performs functions in 
adult erythropoiesis that cannot be performed by the GATA2 and GATA3 proteins. Employing 
the GATA1 knockdown mutant leaves open the possibility that the remaining endogenous 
GATA1 contributes to the rescue phenotype. To address this question, we have now performed 
the rescue experiment in mice carrying a complete GATA1 null mutation.
  The previous studies indicate that other GATA proteins are able to compensate for the 
absence of GATA1 when expressed under the control of GATA1 regulatory sequences. This 
raises the possibility that the spatio-temporal control of GATA activity is the most important 
parameter during erythroid differentiation, rather than the actual GATA factor expressed.
In the present study, we have tested this hypothesis by comparing the potential of GATA1, 
GATA2 and GATA3 transgenes to rescue the GATA1 null phenotype when expressed under the 
control of different regulatory sequences. We expressed these transgenes under the control of 
either the hematopoietic regulatory domain (HRD) of the GATA1 gene23,33, or under the control 
of the β-globin promoter and Locus Control Region (β-LCR). The β-LCR is most highly active 
in late erythroid cells, as it recapitulates the expression pattern of β-like globin genes6. Thus, we 
have used the rescue of a GATA1 null mutation by HRD and β-LCR transgenes to demonstrate 
the importance of timing of GATA factor expression levels during erythroid development. 
Results
Generation and characterization of transgenic mice
 We have demonstrated previously that transgenic mice expressing GATA1, GATA2 
and GATA3 under the control of GATA1 regulatory sequences are able to rescue erythropoiesis 
in GATA1.05 knockdown mice33. In order to ascertain the importance of the spatio-temporal 
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control of GATA1 expression during erythropoiesis we set out to check the potential of the same 
genes to rescue the GATA1 null phenotype when expressed under the control of the β-globin 
promoter and Locus Control Region (β-LCR).  The β-LCR drives erythroid-specific expression 
of transgenes, recapitulating the expression pattern of β-like globin genes6 and it has been used 
previously to rescue the lethal phenotype of the erythroid-specific transcription factor EKLF34.
 GATA1, GATA2 and GATA3 cDNAs were cloned in an β-LCR expression vector22. To 
facilitate the identification of the transgenic proteins all cDNA were tagged. A Myc-peptide tag 
was introduced at the start of the GATA1 open reading frame, while two and three HA-peptide 
tags were introduces at the GATA2 and GATA3 translation start site, respectively (Figure 1A). 
These constructs were used to generate transgenic mice. Several transgenic lines were obtained 
containing variable numbers of copies of the transgenes:  Three β-LCR-GATA1 lines (A to C), 
containing one to two copies of the transgene; two β-LCR-GATA2 lines containing low (A) 
and high (B) copy numbers and three β-LCR-GATA3 lines of which one contained 2 copies 
(A) and the remaining (B and C) contained more than 7 copies (data not shown). The fact that 
no high copy number β-LCR-GATA1 were obtained from more than 50 founders analysed may 
be the result of embryonic lethality caused by overexpression of GATA1 in erythroid cells41. 
Heterozygous animals from all transgenic lines were born at Mendelian ratios and appeared 
normal. 
 The expression levels of the different GATA proteins in the different β-LCR transgenic 
lines were assessed by Western blot. The fetal liver is the main hematopoietic organ during 
late embryonic development where definitive erythroid cells are produced. Since by E12.5 it is 
mainly composed of erythroid progenitors (approximately 70% of all cells) we used the fetal 
liver as the source of erythroid cells to determine the expression levels of the transgenic GATA 
proteins. Western blot analysis of fetal liver cells from β-LCR-GATA1 transgenic lines revealed 
a variety of expression levels  (Fig. 1B), but the expression of the transgenic protein was always 
lower than the endogenous GATA-1 protein. The low expression level of the β-LCR -GATA1 
protein provides an explanation for the fact that these animals are viable, since overexpression 
of GATA1 blocks terminal erythroid differentiation and causes embryonic lethality due to 
anemia41. The β-LCR-GATA2 and β-LCR-GATA3 transgenic lines also express the GATA 
factors at different levels (data not shown); a direct comparison to the endogenous GATA1 
levels is not possible in this case.
To check whether embryonic erythropoiesis is affected in the different β-LCR transgenic 
lines, E12.5 fetal livers were collected and the presence of erythroid precursors was assessed by 
flow cytrometric analysis using the erythroid marker TER119. TER119 starts to be expressed 
at the proerythroblast stage and is used as a marker for the erythroid lineage14. No significant 
difference in the percentage of TER119 positive cells was detected between wild-type and β-
LCR transgenic fetal livers from all different transgenic lines (Fig. 1C). The differentiation 
potential of the erythroid precursors in these fetal livers was assessed in suspension cultures, 
an in vitro erythroid differentiation assay13. In this assay, fetal liver cells are cultured for two 
days in medium containing erythropoietin (Epo), insulin and hemin in small drops hanging from 
the lid of the culture dish. Terminal differentiation, assessed by enucleation, after two days of 
culture was determined by the cell size of the TER119 positive cells (FSClow). No significant 
difference was observed in the percentage of enucleated cells at Day 2 between wild-type and 
β-LCR-GATA1 and β-LCR-GATA3 transgenic mice lines (Fig. 1D). In contrast, a small but 
significant reduction (p<0.001) in the percentage of enucleated cells is observed between wild-
type and β-LCR-GATA2 transgenic mice with the highest expression of the transgene. This 
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result is in agreement with previously published data showing that ectopic expression of GATA2 
in erythroid precursors arrests erythroid differentiation4. 
Figure 1 - Generation and characterization of β-LCR transgenic mice. (A) Schematic representation of the constructs 
used for the generation of HRD and β-LCR transgenic mice. (B) Western blot on E12.5 fetal liver cells from different 
β-LCR-GATA1 transgenic lines showing different expression levels of the GATA1 transgene. (C) Graph showing the 
percentage of TER119+ erythroid cells in E12.5 fetal livers from wild-type and β-LCR transgenic lines, determined by 
flow cytrometic analysis. Dead cells (7AAD+) were excluded from the analysis. (D) Flow cytrometric analysis of the 
percentage of enucleated (FCSlow TER119+) erythroid cells in wild-type and β-LCR transgenic E12.5 fetal liver cells, 
after two days in suspension cultures. Cells were stained with the erythroid-specific surface marker TER119 and dead 
cells were excluded by staining with 7AAD. Enucleation was determined by cell size (FCSlow). * Significant difference 
(p<0.01) between βLCR-GATA2 and WT. 
Comparison between HRD and βLCR driven transgene expression 
 To compare the expression profile of the transgenes under the control of the two 
distinct regulatory elements (Fig 1A), E12.5 fetal livers of HRD-GATA2 and β-LCR-GATA2 
transgenic embryos were isolated and erythroblasts purified. These erythroblasts were expanded 
in liquid cultures containing dexamethasone (Dex), Epo and stem cell factor (SCF), for 3-4 
days. Erythroblasts were then allowed to terminally differentiate by removing the Dex and SCF, 
increasing the Epo concentration and adding transferrin7,38. Samples were collected at several 
time points during erythroid differentiation until the stage prior to enucleation (Fig. 2A). As 
shown in Fig. 2B, no significant difference in the course of differentiation of cells different 
genotypes was observed during sampling. A reduction in enucleated cells was observed in β-
LCR-GATA2 culture when compared with wild-type at later time points, in agreement with the 
results obtained from the suspension cultures.  Nuclear extracts were prepared for Western blot 
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analysis of the expression of endogenous GATA1 and the GATA2 transgenes (Fig. 2C). The 
expression of nucleophosmin, a nucleolar phosphoprotein found at high levels in the nucleolus9, 
was used to normalize for the amount of protein loaded.
The endogenous GATA1 protein is detected before induction of differentiation and 
increases during differentiation but its expression declines at the later stages of differentiation. 
The increase of the GATA-1 levels is mainly due to the increase of phosphorylated GATA-1 
(Fig. 2C and data not shown). Like the endogenous GATA1 gene, the HRD-driven GATA2 
transgene is expressed in undifferentiated erythroblasts and its expression increases moderately 
during differentiation. Contrary to endogenous GATA1 expression, a decline in expression at 
later stages of differentiation is not observed; this may be explained by differences in protein 
turnover between GATA1 and GATA2. The GATA2 transgene under the control of the β-LCR 
shows a very distinct temporal expression pattern from the endogenous GATA1. The transgenic 
protein is expressed at low levels in erythroblasts, greatly upregulated during differentiation, 
still increasing at the latest time point analysed here.
We conclude that HRD-driven expression mimics the endogenous GATA1 expression 
profile during terminal erythroid differentiation, while β-LCR-driven expression results in a 
very distinct pattern with increased expression during terminal differentiation.
Figure 2 - HRD and β-LCR driven transgenes have distinct expression patterns during terminal erythroid differentiation. 
(A) Changes in cellular diameter during 48 hours in differentiation medium of a representative erythroblast culture. (B) 
Comparison between HRD-GATA2, βLCR-GATA2 and WT erythroblast cultures during differentiation. Reduction of 
cell diameter indicates progression in differentiation. (C) Western blot comparing the expression pattern of the GATA2 
protein under the control of HRD and β-LCR. Top panel shows the expression of the GATA2 protein and the endogenous 
GATA1 protein and the bottom panel shows the staining of the same blot with an antibody against nucleophosmin, 
used as a loading control.  (D) Graphic representation of the expression levels of the transgenic GATA2 proteins and 
endogenous GATA1 expression shown in Fig. 2B after normalization for nucleophosmin expression. 
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Rescue of GATA1 null mice by HRD and βLCR GATA1 transgenic mice
 GATA1 KO mice were generated by breeding GATA1 conditional KO mice18 with Zp3-
Cre transgenic mice expressing Cre recombinase at early stages of embryogenesis. As expected10, 
GATA1 KO male embryos, containing only one GATA1 allele at the X-chromosome (KO:Y), 
died between E10.5-E11.5 due to severe anemia while GATA1 KO females, heterozygous for the 
KO GATA1 allele (KO:X), showed transient anemia with most of them surviving to adulthood10 
(data not shown).  
To confirm that the HRD-GATA1 transgene is able rescue the GATA1 null mutation, 
GATA1 KO females were mated with transgenic males from a high expressing HRD-GATA1 
transgenic line. Seven GATA1 KO rescued males (HRD-G1/KO:Y) were identified out of a 
total of 41 newborn pups.  All rescued mice developed normally, were fertile and showed no 
signs of anemia or thrombocytopenia (Table1). This demonstrates that GATA1 transgenes, 
when expressed under the control of the HRD, fully rescue the GATA1 null phenotype in the 
erythroid and megakaryocytic lineages. This also proves that the presence of the remaining 5% 
of endogenous GATA1 in GATA1.05 mice is not required for the rescue by the GATA1-HRD 
construct23,33. 
To verify to what extent βLCR-GATA1 transgenes are able to rescue the GATA1 null 
mutation, GATA1 KO females were mated with βLCR-GATA1 transgenic mice with different 
expression levels of the GATA1 transgene (Fig. 1B).  In contrast to HRD-GATA1, no newborn 
βLCR-G1/KO:Y were obtained from these breedings (Table 2).
Table 1 - Peripheral blood indices from GATA1 KO rescued by the HRD-GATA1 transgene.
Table 2 - Genotype of progeny from GATA1 KO females and βLCR-GATA1 transgenic males.
Considering that GATA1 overexpression is embryonic lethal41 we checked when the 
βLCR -G1/KO:Y embryos die during development. Progeny from intercrosses between GATA1 
KO females and βLCR-GATA1 transgenic mice was analysed at different stages of embryonic 
development. Live βLCR-G1/KO:Y embryos were observed up to E15.5 from crosses between 
GATA1 KO females and males from two βLCR-GATA1 transgenic lines expressing the transgene 
at different levels (Fig. 1B and Table 2). No significant differences were observed with the two 
*Dead
90
Chapter 4
βLCR-GATA1 transgenic lines analysed. At E12.5 βLCR-G1/KO:Y embryos showed normal 
morphology and were indistinguishable from the KO:X and βLCR -G1/KO:X, which survive 
to adulthood (Fig. 3A, upper panel). Also, no difference was observed between the embryonic 
blood of E12.5 βLCR-G1/KO:Y embryos and littermates, indicating that primitive erythropoiesis 
has been fully rescued by the expression of the βLCR-GATA1 transgenes (data not shown). In 
contrast, KO:X and βLCR-G1/KO:Y embryos have smaller and pale livers when compared 
with wild-type littermates, suggesting a defect in  definitive erythropoiesis. βLCR-G1/KO:X 
embryos have a larger and less pale liver in comparison with KO:X embryos not expressing the 
transgene (Fig. 3A, lower panel). 
By E15.5, βLCR-G1/KO:Y embryos are very pale, as well as a βLCR-G1/KO:X 
littermate, expressing the transgene (Fig. 3B, upper panel). Analysis of the embryonic blood reveals 
that βLCR-G1/KO:Y embryos have increased numbers of nucleated erythrocytes in circulation, 
comparable to the βLCR-G1/KO:X littermate (Fig. 3B, lower panel). The phenotype of this 
βLCR-G1/KO:X  may be due to the random nature of X-chromosome inactivation. GATA1 KO 
females show variable phenotypes depending of the number of cell with a inactivated wild-type 
X-chromosome. It is apparent from the analysis of mutants expressing GATA1 at different levels 
that there is a threshold level of GATA1 necessary for normal definitive erythropoiesis20,32.
Analysis of E12.5 fetal liver cells by flow cytometry, using the erythroid marker 
TER119, showed a reduction in the percentage of TER119+ cells of ~50% in the KO:X and 
~85% in the βLCR -G1/KO:Y by E12.5 (Fig. 3C). βLCR -G1/KO:X heterozygous for the 
βLCR-GATA1 transgene, do not show a significant increase in the percentage of TER119+ 
cells. The differentiation potential of the fetal liver progenitors was analysed in vitro using the 
suspension culture system as described above. The percentage of enucleated erythrocytes in 
wild-type, KO:X and βLCR-G1/KO:X was not significantly different after two days in culture. 
However, the percentage of enucleated erythrocytes was severely impaired in βLCR -G1/KO:
Y (Fig. 3C). This suggests that in the KO:X have a reduction of TER119+ cells, correlated with 
the percentage of cells expressing GATA1, but the GATA1-expressing cells have competitive 
advantage over the GATA1 null cells compensating for the inability of GATA1 null cells to 
terminally differentiate. 
The reduction in the percentage of TER119+ cells in the KO:X and βLCR -G1/KO:
Y raises the question of the identity of the TER119- cells in the liver. To address this question 
we analysed the expression of TER119 and CD71 (transferrin receptor) in cells from E15.5 
fetal livers, before (Day 0) and after (Day 2) in vitro differentiation in suspension cultures. 
CD71 expression is high in early erythroid precursors that do not express TER119 yet, but its 
expression is gradually downregulated during terminal erythroid differentiation, where TER119 
is expressed30. As shown in Figure 3D, in wild-type cells at Day 0 the majority of the cells in 
the liver express both CD71 and TER119 but at Day 2 the number of cells expressing only 
TER119 is increased, demonstrating that these cells are at a more differentiated stage. In βLCR-
G1/KO:Y cells at Day 0, the number of CD71+TER119+ cells is decreased but the percentage of 
CD71+ cells is increased indicating that these cells are early erythroid precursors, most likely 
CFU-e. We can therefore conclude that GATA1 null cells are arrested at a developmental stage 
prior to the proerythroblast stage, the stage at which TER119 starts to be expressed. After two 
days in suspension cultures, some of the CD71+TER119+ cells become TER119+, indicating 
that they were able to progress in differentiation. However, the number of CD71+TER119+ and 
CD71+ positive cells are increased, indicating an arrest in differentiation of the early erythroid 
precursors.
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Taken together, these results show that the βLCR-GATA1 transgenes can rescue 
primitive erythropoiesis but are unable to rescue the definitive erythopoiesis. βLCR-G1/KO:Y 
survive up to E15.5 due to the presence of primitive erythrocytes in circulation but these cells 
are no longer present at later embryonic stages leading to embryonic lethality. The inability 
of the βLCR -GATA1 transgene to rescue definitive erythropoiesis can either be due to the 
reduced expression level of the transgene at the stage where GATA1 null erythroid progenitors 
are blocked in differentiation or to the high expression level of the βLCR -GATA1 transgene at 
latter stages of erythroid differentiation. These findings underscore the importance of the correct 
spatio-temporal expression of GATA1 during erythroid differentiation.
Figure 3 - Phenotype of β-LCR-GATA1 rescued GATA1 KO males. (A) The β-LCR-GATA1 transgene can rescue 
GATA1 KO embryos until E12.5. Top panel shows E12.5 embryos from different genotypes and the bottom panel shows 
the fetal livers isolated from these embryos. (B) The β-LCR-GATA1 transgene can rescue GATA1 KO embryos until 
E15.5. Top panel shows E15.5 embryos from different genotypes. Bottom panel shows erythroid cells from blood of 
embryos of different genotypes (C) Graph showing the percentage of TER119+ erythroid cells in E12.5 fetal livers from 
βLCR-G1/KO:Y and littermates, determined by flow cytometric analysis. Dead cells (7AAD+) were excluded from the 
analysis. (D) Graph showing the percentage of enucleated erythroid cells (TER119+ FSClow) in E12.5 fetal livers from 
βLCR-G1/KO:Y and littermates, determined by flow cytometric analysis. Dead cells (7AAD+) were excluded from the 
analysis. (E) Graphs showing the percentage of cells expressing CD71 and TER119 in E12.5 fetal liver from βLCR-G1/
KO:Y and littermates before (Day 0) and after (Day 2) in vitro differentiation in suspension cultures.
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Rescue of GATA1 null mice by HRD and βLCR GATA2 and GATA3 transgenic 
mice
To test the potential of non-erythroid GATA transcription factors to rescue the GATA1 
null phenotype, we analysed the offspring from crosses between GATA1 KO females and 
HRD- and βLCR- driven GATA2 and GATA3 transgenic males. Breeding between GATA1 KO 
females and a high copy number HRD-GATA3 transgenic lines gave rise to progeny containing 
HRD-G3/KO:Y, indicating that the HRD- driven transgenes are able to rescue the GATA-1 
null phenotype, extending previous observations on the rescue of the GATA1.05 knockdown 
phenotype23,33.  In contrast, no βLCR/KO:Y was obtained when GATA1KO females were 
crossed with males from 2 βLCR-GATA-2 and 3 βLCR-GATA3 transgenic lines (Table 3).
Next, we investigated the rescue potential of the βLCR-GATA2 and βLCR-GATA3 
transgenic lines during embryonic development. Timed pregnancies were set up between GATA1 
KO females and males from the different βLCR-GATA2 and βLCR-GATA3 transgenics, and 
embryos were collected at E12.5, E15.5 and E18.5.
Table 3 - Genotype of progeny from GATA1 KO females and βLCR-GATA2 and  βLCR-GATA3 transgenic males.
A direct correlation was observed between the rescue potential of the GATA2 transgene 
and the expression level of the protein. βLCR–G2/KO:Y embryos were present at both 
E12.5 and E15.5 in litters from crosses between GATA1 KO animals and the  βLCR-GATA2 
transgenic line with highest transgene expression, Line A (Table3). At E12.5, βLCR-G2/KO:
Y embryos were indistinguishable from  KO:X embryos but could be distinguished  from their 
wild-type littermates by the presence of a relatively pale fetal liver (Fig. A, left panel). By 
E15.5 βLCR-G2/KO:Y were easily distinguishable from their littermates due to their overall 
paleness (Fig. 4, right panel).  No βLCR-2/KO:Y embryos were detected at E18.5. In progeny 
from crosses between GATA1 KO and the lower expressing βLCR-GATA-2 transgenic line, 
line B, βLCR-2/KO:Y embryos were only detected at E12.5 and these embryos showed severe 
growth retardation or were already dead (Table2). No alive βLCR-G3/KO:Y embryos were 
detected at E12.5 among the progeny of crosses  between GATA1 KO females and the different 
βLCR-GATA3 transgenic lines (Table 3). A live βLCR–G3/KO:Y embryo was identified in an 
E11.5 litter, but this embryo showed severe growth retardation, reinforcing the idea that βLCR-
GATA3 is unable to rescue, even partially, the GATA1 null phenotype.
More detailed analysis of the βLCR-G2/KO:Y indicated that, although these animals 
are alive, fetal erythropoiesis is impaired. Analysis of the number of TER119+ cells present in 
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the fetal livers at E12.5 showed that βLCR-GATA2 expression in the βLCR-G2/KO:X does not 
have a significant effect on the numbers of TER119 positive cells. Like in KO:X a reduction of 
about 50% in the percentage of TER119+  cells is observed in βLCR-G2/KO:X. The defect in the 
TER119+ cells is even more pronounced, reaching over 80%, in the βLCR-G2/KO:Y (Fig. 4C). 
The differentiation capacity of the fetal liver erythroid progenitors was assessed in suspension 
cultures. After 2 days in culture the expected reduction in differentiated erythroid cells was 
observed in βLCR-GATA2 transgenics. Once again a normal percentage of differentiated KO:
X cells was observed after two days in culture but this percentage was reduced in the βLCR-
G2/KO:X female, reflecting again the negative effect of GATA2 overexpression in erythroid 
differentiation. The percentage of enucleated erythroid cells was severely reduced in the βLCR-
2/KO:Y cells. Analysis of the fetal blood at E15.5 revealed the presence of large numbers of 
nucleated erythroid cells in circulation. The number of nucleated cells is increased in KO:X 
and βLCR-G2/KO:X but it is extremely elevated in βLCR-G2/KO:Y (Fig 4D). This shows that 
primitive erythropoiesis was rescued, allowing the male embryos to survive until midgestation. 
However, they develop a fatal anemia when they become dependent on definitive fetal liver 
erythropoiesis.
Figure 4 - Phenotype of β-LCR-GATA2 rescued GATA1 KO males. (A) The β-LCR-GATA2 transgene can rescue 
GATA1 KO embryos until E12.5. Left panel shows E12.5 embryos and right panel shows E15.5 embryos with the 
indicated genotypes. (B) Cytospins from embryonic blood of E15.5 embryos. (C) Graph showing the percentage of 
TER119+ erythroid cells in E12.5 fetal livers from βLCR-G2/KO:Y and littermates, determined by flow cytometric 
analysis. (D) Graph showing the percentage of enucleated erythroid cells (TER119+ FSClow) in E12.5 fetal livers from 
βLCR-G2/KO:Y and littermates, determined by flow cytometric analysis. Dead cells (7AAD+) were excluded from the 
analysis.  
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Discussion
The results presented in this paper clearly demonstrate that the proper spatio-temporal 
expression of GATA transcription factors is crucial for normal erythroid differentiation. When 
hematopoietic GATA transcription factors are expressed under the control of GATA1 regulatory 
sequences (HRD), mimicking the endogenous GATA1 expression, a full rescue of the GATA1 
null phenotype is achieved. In contrast, when these factors are expressed under the control 
the β-globin promoter and locus control region (β-LCR), which is expressed later in erythroid 
development and remains high at the later stages of terminal erythroid differentiation, the 
lethality of the GATA1 null phenotype is not rescued.
HRD but not βLCR transgene expression mimics the endogenous GATA1 expression 
pattern
 To compare the expression profile of the HRD and β-LCR driven GATA transgenes 
during erythroid differentiation we isolated primary erythroblasts from E12.5 fetal livers of 
transgenic embryos and analysed the expression profile of the transgenic proteins during 
in vitro differentiation. The culture method used allows us to maintain and expand the 
erythroblast population by inhibiting erythroid differentiation with the glucocorticoid hormone 
dexamethasone37. After 3 to 4 days a pure erythroblast culture is obtained that can then be 
induced to differentiate by removal of dexamethasone and addition of growth factors required 
for erythoid differentiation7,38. This culture system provides us with a controlled way of 
analysing the cellular changes that occur during terminal erythroid differentiation in settings 
closely resembling the in vivo situation.
 To minimize the interference of enucleation in the quantification of the expression 
levels of the proteins, we collected samples at different time points prior to enucleation. In 
this way, the changes observed in protein levels in the latest stages of differentiation cannot be 
attributed to the loss of the nucleus.
 Analysis of the expression of endogenous GATA1 protein during GATA1 terminal 
erythroid differentiation clearly demonstrates that GATA1 is expressed at the erythroblast stage, 
prior to induction of  differentiation. Its levels increase during the first 24 hours after induction of 
differentiation, but declines afterwards. The reduction in GATA1 levels during the latest stages 
of erythroid differentiation has been inferred previously in different experimental settings12,31. 
Interestingly, the increase in GATA1 levels coincides with the increase in phosphorylated 
GATA1. GATA1 is phosphorylated at seven serine residues5 and it has recently been reported 
that GATA1 phosphorylation is regulated through a MAP kinase pathway35 suggesting that 
GATA1 phosphorylation may alter or regulate  GATA1 function during erythroid differentiation, 
in response to receptor-mediated signaling.
 Comparison of the expression profiles from HRD-GATA2 and β-LCR-GATA2 
transgenes shows that the two transgenes have very distinct expression patterns. HRD-GATA2 
expression is observed already prior to induction of differentiation while β-LCR-GATA2 only 
can be detected 12 hours after induction of differentiation, in agreement with the expression 
of β-globin. Both HRD and β-LCR-GATA2 expression levels increase during erythroid 
differentiation but while HRD-GATA2 shows only a moderate increase, β-LCR-GATA2 shows 
a very sharp increase in the levels of the protein and expression keeps rising even during the 
latest stages of differentiation. Contrary to what was expected, a decrease in the levels of HRD-
GATA2 during the later stage of differentiation was not observed. This may reflect differences 
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in the turnover time of GATA1 and GATA2 proteins.
βLCR-driven transgenes are unable to rescue the lethal GATA1 null 
phenotype
 Analysis of the progeny from GATA1 KO females with transgenic mice revealed, 
as expected, that HRD-driven transgenes were able to fully rescue GATA1 KO males from 
embryonic lethality. These animals were normal and did not show any signs of anemia or 
thrombocytopenia. 
Despite the observation that β-LCR-GATA1 and β-LCR-GATA2 transgenes were capable 
of rescuing GATA1 KO males from lethality up to E15.5, no rescued GATA1 KO male (β-LCR/
KO:Y) was born. Analysis of the blood from β-LCR/KO:Y embryos at E15.5 showed increased 
numbers of nucleated erythroid cells in  circulation, suggesting that these animal are alive due 
to the presence of primitive erythrocytes in the blood stream. The death of these embryos during 
the later stages of development can be attributed to the disappearance of the primitive erythroid 
cells, which normally occurs by E1625. Rescue of primitive, but not definitive, erythropoiesis 
has been observed in studies with different GATA1 mutants suggesting that the requirements for 
lineage-specific transcription factors are not so strict during primitive erythropoiesis24,29.
 When compared to wild-type littermates, GATA1 KO females (KO:X and β-LCR/KO:
X) show approximately 50% reduction in TER119+ cells in the fetal liver. This suggests that 
GATA1 KO cells, which in the females comprise ~50% of the cells due to X-chromosome 
inactivation, are arrested in differentiation at a stage prior to the expression of TER119. This 
reduction is more pronounced in the males, reaching 85-90%. A more detailed analysis, using 
the TER119 and CD71 cell markers, revealed that the percentage of TER119+ CD71- cells, 
representing the later stages of erythroid differentiation, is clearly reduced in βLCR/KO:Y. This 
reduction is compensated by an increase in the percentage of CD71+ cells and, at a lesser extent, 
of CD71-TER119- cells. This is in agreement with the report from Suzuki and colleagues31  in 
which they demonstrate that GATA1 is expressed at very low levels in BFU-Es (CD71-cells) but 
starts to be expressed at higher levels in CFU-Es (CD71+cells) and thereafter (CD71+TER119+). 
This reinforces the idea that GATA1 KO erythroid cells are arrested at a stage prior to the 
expression of TER119, most likely at the CFU-E- to proerythroblast stage, in agreement with 
previous reports28,40.
 Analysis of the differentiation potential of the fetal liver cells of βLCR/KO:Y and 
βLCR/KO:X showed that after 2 days of differentiation the percentage of enucleated cells in 
KO:X and βLCR-G1/KO:X is similar to the wild type cells while in KO males only about 
10-15% of the cells enucleate. This suggests that, in the females, cells expressing GATA1 
have a competitive advantage over the GATA1 KO cells and are able to compensate for the 
differentiation deficiency of those cells. In βLCR/KO:Y cells expressing GATA1 are absent and 
cells expressing β-LCR-driven transgenes are not able to compensate for the loss of endogenous 
GATA1 due to the differences in the spatio-temporal expression pattern of the transgene.
The βLCR-GATA2 rescue potential is dependent on the expression level of the 
transgene, since only the βLCR-GATA2 transgenic line with the highest GATA2 expression 
rescued primitive erythropoiesis. Interestingly, after two days of differentiation in suspension 
culture, βLCR-GATA2:KO:X erythroid cells show a reduced percentage of enucleated cells 
compared with KO:X, not expressing the transgene. This is due the inhibitory effect of GATA2 
in erythroid differentiation4. The same reduction is observed in βLCR-GATA2 expressing cells, 
when compared with wild-type cells.
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βLCR-GATA3 fails to rescue both primitive and definitive erythropoiesis in GATA1 
KO males since no βLCR-G3/KO:Y was found alive at E12.5. This lower rescue potential of 
GATA3 is consistent with previous observations. A knock in of GATA3 cDNA into the GATA1 
locus only rescued embryos until E13.536, suggesting a defect in both primitive and definitive 
eythropoiesis. Furthermore, HRD-GATA3 was able to rescue the GATA1.05 knockdown mutant 
from embryonic lethality, but newborn mice were anemic and died earlier than wild-type 
and and GATA1.05 mutants rescued with HRD-GATA1 and HRD-GATA2 transgenes33. The 
difference in rescue potential may be due to differences at protein level between the GATA1 and 
GATA3 proteins42. The inability of βLCR-GATA3 to rescue primitive erythropoiesis may also 
be associated with the fact that endogenous GATA3 is never expressed in the erythroid lineage 
and abnormal high expression of this transcription factor may by harmful for these cells or 
interfere with the endogenous activity of other transcription factors.
 
 Thus, we concluded that GATA1 is dynamically regulated during terminal erythroid 
differentiation (Fig. 5). It must be expressed at high levels in earlier progenitors but its expression 
must be downregulated in late progenitors for terminal erythroid differentiation to occur. 
Deregulation of GATA1 expression, either by reducing expression levels in early 
progenitors or by overexpressing it in late progenitors, leads to embryonic lethality. This 
emphasises that the appropriate expression pattern of the hematopoietic GATA factors is an 
important determinant of their biological function. 
Figure 5 - Model for GATA1 and GATA2 expression during erythroid differentiation.GATA2 is expressed in early 
erythroid progenitors but its expression is downregulated when GATA1 starts to be expressed. GATA1 is expressed at 
high levels in early erythroid precursosr but it is downregulated in late erythroid precursors.
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Materials and Methods
Generation and genotyping of mice
GATA1 null mice were generated by breeding mice harbouring a floxed GATA1 allele18 
with transgenic mice expressing Cre under the control of the zona pellucida 3 (Zp3) gene 
promoter17.  For detection of the GATA1 recombined allele, genomic DNA was analysed by 
PCR using primers for the GATA1 gene (5’G1: 5’-CGCCGAGCTGTGTGTAGTAA-3’ and 
3’G1: 5’-TTCCTGTTTCTCCTCCTCCG-3’) located 5’ and 3’ of the first loxP site respectively 
and a primer located in the GFP gene (GFP: 5’-GGTGCTCAGGTAGTGGTTG-3’). GATA1 
primers generate a 1.4kb product correspondent to the floxed GATA1 locus while 5’G1 and GFP 
produce a 2.8kb product correspondent to the recombined GATA1 locus.
Myc-tagged GATA1, 2xHA-tagged GATA2 and 3xHA-tagged GATA3 cDNAs were 
cloned in the PEV3 vector, containing human β-globin promoter and Locus Control Region22,8. 
β-LCR transgenic mice were generated by microinjection of PEV3-GATA1, PEV3-GATA2 
and PEV3-GATA3 constructs in fertilized eggs.  The genotype of these mice was assayed 
either by Southern blot using specific probes for the cDNAs or by PCR using primers specific 
for human β-globin sequences (βIVS2-s: CAGTGTGGAAGTCTCAGGATCC; βIVS2-as 
GAATGGTGCAAAGAGGCATGA), present in the vector.
HRD transgenic mice were generated and genotyped as described33.
Histological staining
Fetal blood, fetal liver cell suspensions or cultured erythroblasts were spun onto glass 
slides and air-dried. Slides were stained with 1% O-dianisidine (Sigma) in methanol and 
Differential Quick Red and Blue staining as described 2.
Erythroid suspention cultures
 Fetal livers, dissected from E12.5 mouse embryos, were disrupted and cells were grown 
in suspension13. In brief, fetal liver cells were seeded in Dulbecco’s Modified Eagle’s Medium 
(DMEM) 20% fetal calf serum (FCS), 200 µM hemin chloride (Sigma), 2 u/ml erythropoietin 
(Epo; Eprex, Janssen-Cilag), 5µg/ml Insulin and 100µM β-mercaptoethanol (Sigma), at a 
density of 2.5x106 cells/ml. Cells were grown for 2 days in 20µl drops (containing 5x105 cells) 
hanging from the lid of the culture dish. 
Primary mouse erythroblast cultures
Primary erythroblasts, obtained from fetal livers of E12.5 transgenic mice, were 
maintained in serum-free medium (StemPro-34TM; Life Technologies) supplemented with 0.5 u/
ml human recombinant Epo  (Epo; Eprex, Janssen-Cilag), 100 ng/ml murine recombinant stem 
cell factor (SCF; R&D Systems), and 10-6 M dexamethasone (Dex; Sigma) as described 7,38. 
Erythroblast cultures were expanded, keeping cell densities at 1x106 cells/ml, by daily addition 
of medium with fresh growth factors. 
Terminal differentiation was triggered by washing the erythroblast in proliferation 
medium in PBS and reseeding them at 1 to 2x106 cells/ml in serum-free medium, supplemented 
with 5 u/ml Epo and 1mg/ml iron-saturated human transferrin (Sigma). Cell numbers and size 
distributions were determined using an electronic cell counter (CASY-1, Schärfe-System, 
Reutlingen, Germany) and differentiation was assessed by the size reduction of the cells.
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FACS analysis 
 After 2 days in suspension culture, cells were collected and incubated with PE-conjugated 
anti-mouse TER119 (BD Pharmingen), CD71 (BD Pharmnigen) and 7-aminoactinomycin-
D (7AAD; Molecular Probes). Fifty thousand cells were analysed by FACS and dead cells 
(7AAD+) were removed from the analysis. Enucleation of erythroid cells was evaluated by the 
expression of TER119 (TER119+) and reduction of cell size (FSClow).
Western blot 
 Total nuclear protein from fetal liver cells or cultures erythroblast was extracted as 
previously described 1. Protein concentration in the nuclear extracts was determined using the 
bicinchoninic acid protein assay (Pierce, Rockford, IL). For Western blotting analysis, 20 to 50 
µg of total nuclear protein was loaded per lane and separated on 10% SDS-PAGE gels under 
reducing conditions and transferred to polyvinylidene difluoride membrane (Immobilon-P; 
Millipore, Bedford, MA). Blots were probed with rat anti-GATA1 mAb (N6) and polyclonal 
rabbit anti-GATA2 (H-116) purchased from Santa Cruz Biotechnology (Santa Cruz, CA) or 
mouse monoclonal against B23 nucleophosmin (a kind gift by Pui K. Chan,  Baylor College of 
Medicine, Houston, TX). Second-step reagents were HRP-conjugated goat anti-rat Ig and goat 
anti-rabbit Ig (Dako, Glostrup, Denmark). Peroxidase activity was visualized by ECL using 
standard procedures.
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The zinc-finger transcription factor GATA-3 is of critical importance for early T 
cell development and commitment of Th2 cells. To study the role of GATA-3 in early T cell 
development, we analyzed and modified GATA-3 expression in vivo. In mice carrying a targeted 
insertion of a lacZ reporter on one allele, we found that GATA-3 transcription in CD4+CD8+ 
double positive thymocytes correlated with the onset of positive selection events, i.e., TCRαβ 
upregulation and CD69 expression. LacZ expression remained high (~80 % of cells) during 
maturation of CD4 single positive (SP) cells in the thymus, but in developing CD8 SP cells 
the fraction of lacZ-expressing cells decreased to <20%. We modified this pattern by enforced 
GATA-3 expression driven by the CD2 locus control region, which provides transcription of 
GATA-3 throughout T cell development. In two independent CD2-GATA3-transgenic lines, 
~50% of the mice developed thymic lymphoblastoid tumors that were CD4+CD8+/low and mostly 
CD3+. In tumor-free CD2-GATA3-transgenic mice the total numbers of CD8 SP cells in the 
thymus were within normal ranges, but their maturation was hampered, as indicated by increased 
apoptosis of CD8 SP cells and a selective deficiency of mature CD69lowHSAlow CD8 SP cells. 
In the spleen and lymph nodes, the numbers of CD8+ T cells were significantly reduced. These 
findings indicate that GATA-3 supports development of the CD4 lineage and inhibits maturation 
of CD8 SP cells in the thymus.
Introduction
In the thymus early CD4-CD8- double negative (DN) precursors develop into mature 
CD4 or CD8 single positive (SP) T cells following a tightly regulated program of cellular diffe
rentiation15,39,53,57. The DN population is generally subdivided into four distinct developmental 
stages, defined by differential expression of the surface makers IL-2Rα chain CD25 and 
phagocyte glycoprotein 1 CD4419. Precursor T cells rearrange their TCRβ genes during the 
CD25+CD44- DN stage, and only those cells that produce a functional TCRβ protein proceed 
via a proliferative phase to the CD25-CD44- DN stage15,27,37. These cells rapidly up-regulate 
CD4 and CD8, and start to rearrange their TCRα genes. After successful TCRα rearrangement, 
TCRαβ-bearing immature cells are selected for MHC recognition during the process of positive 
selection 21,28,41. Concomitantly, developing T cells will undergo lineage commitment to ensure 
the correlation of the TCR specificity for MHC class I with the CD8 lineage and for MHC class 
II with the CD4 lineage29,39,64. In addition, potential self-reactive T lymphocytes are eliminated 
by selection against self-recognition within the MHC context51. 
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T cell development is regulated by a large number of transcription factors9,30. One of the 
transcription factors critically involved in T cell development is GATA-3, which was originally 
identified in the T cell lineage as a protein that binds to the TCRα gene enhancer26. GATA-3 is a 
member of a family of transcription factors that bind a GATA-consensus motif through a highly 
conserved C
4
 zinc-finger binding domain67. Mice with a targeted deletion of GATA-3 display 
massive internal bleeding and central nervous defects and die between embryonic day 11 and 
12 due to noradrenaline deficiency35,47. GATA-3-/- fetuses that were pharmacological rescued 
by feeding catechol intermediates to pregnant females displayed severe thymic hypoplasia at 
fetal day 16.535. GATA-3 expression is abundant in the developing central nervous system, 
adrenal gland and kidney. Within the hematopoietic system GATA-3 expression is confined to T 
lymphocytes4,18,24,44,47. In mature T helper cells, GATA-3 has been shown to be essential for Th2 
differentiation14,70,71, and has been implicated in the regulation of locus accessibility of the IL-4, 
IL-5 and IL-13 genes by chromatin remodeling2,3,46. 
The GATA-3 gene is expressed in common lymphoid progenitors and in the earliest 
CD25-CD44+ DN progenitors in day 12 fetal thymus4,22. Antisense GATA-3 oligonucleotides 
inhibited T cell development from fetal liver precursors in fetal thymic organ cultures, 
indicating the critical importance of GATA-3 for early T cell development22. Moreover, RAG-
2-/- complementation experiments in vivo demonstrated that the development of GATA-3-/- 
embryonic stem (ES) cell-derived T cell precursors is arrested at or before the DN stage62. In 
such GATA-3-/-/RAG-2-/- chimeric mice, the GATA-3-deficient ES cells contributed significantly 
to nonhaematopoietic tissues and to the erythroid, myeloid and B cell lineages. In chimeric mice 
generated by injection of GATA-3-deficient lacZ-expressing ES cells in wild-type blastocysts, 
we previously showed that GATA-3-/- ES cells did not contribute to the T cell lineage, not even 
to the earliest subset of CD25-CD44+ DN thymic progenitors24. 
Because GATA-3-/- cells display a block before the earliest T cell progenitor, few data 
are available on the role of GATA-3 during T cell development in the thymus. Using mice 
with an insertion of a lacZ reporter in the GATA-3 gene on one allele (GATA-3+/nlslacZ), we 
examined the proportion of GATA-3-expressing cells as a function of T cell development24. We 
found significant GATA-3 expression at the earliest DN stage in the thymus. The two waves 
of TCRβ and TCRα gene recombination were associated with low proportions of lacZ+ cells. 
The stage of rapidly proliferating CD44-CD25- DN cells, which insulates these two periods 
of TCR rearrangement, was characterized by a large proportion of lacZ-expressing cells. The 
proportion of lacZ+ cells increased again as double positive (DP) cells progressed into CD4 or 
CD8 SP cells. The presence of significant proportions of lacZ+ cells within the CD8 SP T cell 
subpopulation in the thymus was in strong contrast with the almost complete absence of lacZ 
expression in mature CD8+ T cells in the periphery24. 
The differential regulation of GATA-3 gene expression in the CD4 versus the CD8 
lineage prompted us to investigate its expression during positive selection and CD4/CD8 lineage 
commitment in the thymus in more detail. We analyzed the GATA-3+/nlslacZ mice, using additional 
markers for the maturation stages of DP and SP cells, including CD3, TCRαβ, heat stable 
antigen (HSA), CD62 L-selectin (CD62L) and particularly CD69, which is typically induced by 
TCR signaling and therefore marks cells that are in the process of positive selection7,17,49,61,68. In 
addition, we investigated the functional role of GATA-3 during T cell development in vivo by 
the generation of transgenic mice with enforced GATA-3 expression driven by the human CD2 
locus control region (LCR), which provides expression of the GATA-3 transgene throughout T 
cell development20. 
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Results 
GATA-3 expression is strongly induced during positive selection of developing T 
cells
We have previously quantified the GATA-3 expression profile during T cell development 
in vivo, by placing a lacZ reporter gene, containing a nuclear localization signal, under direct 
GATA-3 transcriptional control. In these GATA-3+/nlslacZ mice GATA-3 directed lacZ expression 
was analyzed by flow cytometry using fluorescein-di-β-D-galacto-pyranoside (FDG) as a β-
galactosidase substrate, and differential expression of GATA-3 in DP (~16% lacZ+ cells), CD4 
SP (~84%) and CD8 SP (~33%) cells was found24. Since it has been shown that double positive 
T cells differentiate into mature single positive T cells via a series of phenotypically distinct 
subpopulations, reflecting the multistage process of positive selection and CD4/CD8 lineage 
commitment29,39,64, we investigated GATA-3 gene expression in these subpopulations in more 
detail.
Upon MHC/TCRαβ interaction in DP cells, the surface expression of the CD69 marker 
is upregulated7,49,61,68, followed by a down-regulation of the CD4/CD8 co-receptor surface 
expression39. Therefore, we analyzed lacZ activity in conjunction with surface expression of 
CD4, CD8 and CD69 (Fig. 1). The majority of DP cells (~85%) did not express CD69 on the 
cell surface, and in this CD69- DP population lacZ was expressed in ~19 % of cells. By contrast, 
within the CD69+ DP subpopulation, lacZ was expressed in ~54% of the cells. After subsequent 
downregulation of co-receptor expression and transition into the CD4lowCD8low subpopulation, 
~80% of the CD69+ cells expressed lacZ (Fig. 1). The CD4lowCD8low cells have been shown to 
subsequently enhance CD4 expression39, thereby developing into the CD4+CD8low subset, which 
still contains precursors for both CD4 and CD8 single positive T cells31,39,40,60. LacZ expression 
was present in ~86% of these CD4+CD8low CD69+ cells (Fig. 1). In addition, we found that 
in the DP, CD4lowCD8low and CD4+CD8low subpopulations, lacZ expression correlated with the 
expression levels of TCRαβ or CD3 on the cell surface (Shown for TCRαβ in Fig.1A). These 
results indicated that the induction of GATA-3 transcription coincides with CD3 and TCRαβ 
upregulation and CD69 expression in DP cells. 
GATA-3 gene expression is downregulated after commitment to the CD8 lineage
Bipotential CD4+CD8low CD69+ T cells differentiate into either CD4 or CD8 SP cells 
by shutting down expression of the reciprocal coreceptor gene31,39,40,60. Final maturation of 
SP thymocytes is accompanied by downregulation of CD69 and HSA on the cell surface and 
induction of high-level expression of CD62L and CD445,8,17. 
As shown in Fig. 1, lacZ expression was present in ~87% of the cells committed to 
the CD4 lineage (CD4+CD8-CD69+TCRαβhigh cells) and in ~78% of the more mature CD4+ 
cells with a CD69-HSAlow surface profile. By contrast, during the maturation of CD8 lineage 
cells, ~40% of the CD69+HSA+ and only ~16% of the mature CD69-HSAlow CD8+TCRαβhigh 
cells expressed lacZ. Likewise, lacZ expression was found to be significantly downregulated 
in mature CD44+ and CD62L+ CD8+ cells (data not shown). The intensities of the fluorescence 
signals show that the lacZ expression levels per cell increased slightly during the maturation 
process of CD4 SP cells, whereas CD8 SP cells displayed lower and more heterogeneous lacZ 
expression levels (Fig. 1A). 
When the T cells leave the thymus, the proportions of GATA-3+ cells decrease to ~20% 
of the CD4+ and to <1% of the CD8+ T cell populations in the spleen and lymph nodes24. For the 
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CD4+ lineage cells in the spleen, we did not observe a clear correlation between GATA-3 and the 
expression of the HSA, CD69, CD44, CD62L or CD25 surface markers, which are instrumental 
to specify subpopulations of naive, activated or memory T cells13,59.
As summarized in Fig. 1B, the proportions of GATA-3 expressing cells were low 
in CD3-TCRαβ-CD69- DP cells (~19%), and increased at the onset of positive selection 
events, characterized by upregulation of CD3 and TCRαβ surface expression and induction 
of CD69. The proportions increased to ~86% at the stage of the last uncommitted subset 
of CD4+CD8lowCD69+cells, and remained high for the most mature thymic CD69-CD4+ 
subpopulation. By contrast, commitment to the CD8 lineage was associated with downregulation 
of GATA-3 expression, resulting in <20% GATA-3+ cells within the mature population of CD69-
CD8+ cells. 
Figure 1 - Analysis of lacZ expression in thymocytes from GATA-3+/nlslacZ mice by four-color flow cytometry. 
(A)Thymus cell suspensions were loaded with the b-galactosidase substrate FDG and subsequently stained with anti-CD4, 
anti-CD8, in combination with anti-CD69, anti-TCRab or anti-HSA antibodies. Cells were analyzed for the expression 
of CD4 and CD8, the indicated subpopulations A-E were gated, and analyzed for lacZ expression and the fourth surface 
marker (CD69, TCRab or HSA). The numbers indicate the percentage of lacZ expressing cells in the subpopulations 
analyzed. All samples are lymphocyte gated by forward and sideward scatter. (B) Overview of the proportions of lacZ 
expressing cells in the indicated thymocyte subpopulations in GATA-3+/nlslacZ mice. The numbers are mean values + SD 
(n=3). The background percentages of b-galactosidase positive cells, as determined in wild-type control mice, was <1% 
in all subpopulations. 
GATA-3 gene expression is down-regulated after commitment to
the CD8 lineage
Bipotential CD4�CD8lowCD69� T cells differentiate into either
CD4 or CD8 SP cells by shutting down expression of the recip-
rocal coreceptor gene (2, 44–46). Final maturation of SP thymo-
cytes is accompanied by down-regulation of CD69 and HSA on
the cell surface and induction of high-level expression of CD62L
and CD44 (36, 47, 48).
As shown in Fig. 1, lacZ expression was present in �87% of the
cells committed to the CD4 lineage (CD4�CD8�CD69�TCR��high
cells) and in �78% of the more mature CD4� cells with a
CD69�HSAlow surface profile. By contrast, during the maturation of
CD8 lineage cells,�40% of the CD69�HSA� and only�16% of the
mature CD69�HSAlow CD8�TCR��high cells expressed lacZ. Like-
wise, lacZ expression was found to be significantly down-regulated in
mature CD44� and CD62L�CD8� cells (data not shown). The in-
tensities of the fluorescence signals show that the lacZ expression
levels per cell increased slightly during the maturation process of CD4
SP cells, whereas CD8 SP cells displayed lower and more heteroge-
neous lacZ expression levels (Fig. 1A).
When the T cells leave the thymus, the proportions of
GATA-3� cells decrease to�20% of the CD4� and to�1% of the
CD8� T cell populations in the spleen and lymph nodes (22). For
the CD4� lineage cells in the spleen, we did not observe a clear
correlation between GATA-3 and the expression of the HSA,
CD69, CD44, CD62L, or CD25 surface markers, which are instru-
mental to specify subpopulations of naive, activated, or memory T
cells (49, 50).
As summarized in Fig. 1B, the proportions of GATA-3-express-
ing cells were low in CD3�TCR���CD69� DP cells (�19%) and
increased at the onset of positive selection events characterized by
up-regulation of CD3 and TCR�� surface expression and induc-
tion of CD69. The proportions increased to �86% at the stage of
the last uncommitted subset of CD4�CD8lowCD69�cells and re-
mained high for the most mature thymic CD69�CD4� subpopu-
lation. By contrast, commitment to the CD8 lineage was associated
with down-regulation of GATA-3 expression, resulting in �20%
GATA-3� cells within the mature population of CD69�CD8�
cells.
Transgenic expression of GATA-3 driven by the human CD2
LCR
To modify GATA-3 expression in vivo, transgenic mice were gen-
erated in which the murine GATA-3 gene, 5� tagged with three HA
epitopes, was expressed under the control of the human CD2 LCR
(38). Two independent CD2-GATA3-transgenic lines, TgA and
TgB, were established that appeared to contain comparable num-
bers of transgene copies (data not shown). No differences were
found between the two lines in any of the performed analyses. The
offspring did not manifest developmental defects or any increased
susceptibilities to infectious disease or malignancies for over 9 mo
of age, with the exception of the observed thymic lymphomas dis-
cuss d below.
Expression of the CD2-GATA3 transgene was analyzed in var-
ious lymphoid tissues by comparing transgenic and nontransgenic
littermates. Western blotting experiments were performed on nu-
clear protein extracts from 2- to 3-mo-old mice using a mouse
mAb specific for GATA-3 and a polyclonal Ab specific for the HA
tag. The endogenous GATA-3 gene encodes a �47-kDa protein
that was detected in nuclear extracts from thymus and spleen of
wild-type as well as CD2-GATA3-transgenic mice (Fig. 2A). The
anti-GATA-3 Ab also detected a slightly larger �51-kDa band in
the thymus samples from mice of both transgenic lines. Compar-
ison of the intensities of the �47- and �51-kDa GATA-3-specific
bands in these nuclear protein extracts from thymus samples
showed that the expression level of the 3XHA-GATA-3 transgene-
encoded protein was similar to that of the endogenous GATA-3
protein. In contrast, in the spleen samples, the �51-kDa GATA-
3-specific band was very weak or absent (Fig. 2A). The �51-kDa
band in the thymus extracts of transgenic mice was also recognized
by Ab against the HA tag, but the expression levels of transgene-
encoded GATA-3 protein in the spleen and lymph node extracts
were very low and often almost undetectable by Western blotting
analyses (Fig. 2B).
To further investigate differential expression of GATA-3 in the
individual stages of T cell development, intracellular flow cytom-
etry experiments were performed using the mouse monoclonal an-
tiserum specific for GATA-3. Although this technique is limited by
a background signal of the GATA-3 Ab, it allows a comparison of
GATA-3 expression levels in nontransgenic and CD2-GATA3-
transgenic mice in separate T cell subpopulations. In the wild-type
FIGURE 1. Analysis of lacZ expression in thymocytes from GATA-3�/nlslacZ
mice by four-color flow cytometry. A, Thymus cell suspensions were
loaded with the �-galactosidase substrate FDG and subsequently stained
with anti-CD4 and anti-CD8 in combination with ti-CD69, anti-TCR��,
or a ti-HSA A s. Cells were analyzed for the expression of CD4 and CD8,
the indicated subpopulations A–E were gated and analyzed for lacZ ex-
pression and the fourth surface marker (CD69, TCR��, or HSA). The
numbers indicate the percentage of lacZ-expressing cells in the subpopu-
lations analyzed. All samples are lymphocyte gated by FSC and side scat-
ter. B, Overview f the prop rtions of lacZ- xpressing cells in the indicated
thymocyte subpopulations in GATA-3�/nlslacZ mice. The numbers are mean
values � SD (n � 3). The background percentages of �-galactosidase-
positive cells, as determined in wild-type control mice, was �1% in all
subpopulations.
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GATA-3 gene expression is down-regulated after commitment to
the CD8 lineage
Bipotential CD4�CD8lowCD69� T cells differentiate into either
CD4 or CD8 SP cells by shutting down expression of the recip-
rocal coreceptor gene (2, 44–46). Final maturation of SP thymo-
cytes is accompanied by down-regulation of CD69 and HSA on
the cell surface and induction of high-level expression of CD62L
and CD44 (36, 47, 48).
As shown in Fig. 1, lacZ expression was present in �87% of the
cells committed to the CD4 lineage (CD4�CD8�CD69�TCR��high
cells) and in �78% of the more mature CD4� cells with a
CD69�HSAlow surface profile. By contrast, during the maturation of
CD8 lineage cells,�40% of the CD69 HSA� and only�16% of the
mature CD69�HSAlow CD8�TCR��high cells expressed lacZ. Like-
wise, lacZ expression was found to be significantly down-regulated in
mature CD44� and CD62L�CD8� cells (data not shown). The in-
tensities of the fluorescence signals show that the lacZ expression
levels per cell increased slightly during the maturation process of CD4
SP cells, whereas CD8 SP cells displayed lower and more heteroge-
neous lacZ expression levels (Fig. 1A).
When the T cells leave the thymus, the proportions of
GATA-3� cells decr ase to�20% of the CD4� and t �1% of the
CD8� T cell populations in the spleen nd lymph nodes (22). For
the CD4� lineage cells in the spleen, we did not observe a clear
correlation between GATA-3 and the expression of the HSA,
CD69, CD44, CD62L, or CD25 surface markers, which are instru-
mental to specify subpopulations of naive, activated, or memory T
cells (49, 50).
As summarized in Fig. 1B, the proportions of GATA-3-express-
ing cells were low in CD3�TCR���CD69� DP cells (�19%) and
increased at the onset of positive selection events characterized by
up-regulation of CD3 and TCR�� surface expression and induc-
tion of CD69. The proportions increased to �86% at the stage of
the last uncommitted subset of CD4�CD8lowCD69�cells and re-
mained high for the most mature thymic CD69�CD4� subpopu-
lation. By contrast, commitment to the CD8 lineage was associated
with down-regulation of GATA-3 expression, resulting in �20%
GATA-3� cells within the mature population of CD69�CD8�
cells.
Transgenic expression of GATA-3 driven by the human CD2
LCR
To modify GATA-3 expression in vivo, transgenic mice were gen-
erated in which the murine GATA-3 gene, 5� tagged with three HA
epitopes, was expressed under the control of the human CD2 LCR
(38). Two independent CD2-GATA3-transgenic lines, TgA and
TgB, were established that appeared to contain co parable num-
bers of transgene copies (data not shown). No differences were
found between the two lines in any of the performed analyses. The
offspring did not manifest developmental d fects or an increased
susceptibilities to infectious disease or malignancies for over 9 mo
of ag , with the exception of the observed thymic lymphomas dis-
cussed bel w.
Expression of the CD2-GATA3 transg e was analyzed in var-
ious lymphoid tissues by comparing transgenic and nontransgenic
littermates. Western blotting experiments were performed on nu-
clear protein extracts from 2- to 3-mo-old mice using a mouse
mAb specific for GATA-3 and a polyclonal Ab specific for the HA
tag. The endogenous GATA-3 gene encodes a �47-kDa protein
that was detected in nuclear extracts from thymus and spleen of
wild-type as well as CD2-GATA3-transgenic mice (Fig. 2A). The
anti-GATA-3 Ab also detected a slightly larger �51-kDa band in
the thymus samples from mice of both transgenic lines. Compar-
ison of the intensities of the �47- and �51-kDa GATA-3-specific
bands in these nuclear protein extracts from thymus samples
showed that the expression level of the 3XHA-GATA-3 transgene-
encoded protein was similar to that of the endogenous GATA-3
protein. In contrast, in the spleen samples, the �51-kDa GATA-
3-specific band was very weak or absent (Fig. 2A). The �51-kDa
band in the thymus extracts of transgenic mice was also recognized
by Ab against the HA tag, but the expression levels of transgene-
encoded GATA-3 protein in the spleen and lymph node extracts
were very low and often almost undetectable by Western blotting
analyses (Fig. 2B).
To further investigate differential expression of GATA-3 in the
individual stages of T cell development, intracellular flow cytom-
etry experiments were performed using the mouse monoclonal an-
tiserum specific for GATA-3. Although this technique is limited by
a background signal of the GATA-3 Ab, it allows a comparison of
GATA-3 expression levels in nontransgenic and CD2-GATA3-
transgenic mice in separate T cell subpopulations. In the wild-type
FIGURE 1. Analysis of lacZ expression in thymocytes from GATA-3�/nlslacZ
mice by four-color flow cytometry. A, Thymus cell suspensions were
loaded with the �-galactosidase substrate FDG and subsequently stained
with anti-CD4 and anti-CD8 in combination with anti-CD69, anti-TCR��,
or anti-HSA Abs. Cells were analyzed for the expression of CD4 and CD8,
the indicated subpopulations A–E were gated and analyzed for lacZ ex-
pression and the fourth surface marker (CD69, TCR��, or HSA). The
numbers indicate the percentage of lacZ-expressing cells in the subpopu-
lations analyzed. All samples are lymphocyte gated by FSC and side scat-
ter. B, Overview of the proportions of lacZ-expressin cells in the indicated
thymocyte subpopulations in GATA-3�/nlslacZ mice. The numbers are mean
values � SD (n � 3). The background percentages of �-galactosidase-
positive cells, as determined in wild-type control mice, was �1% in all
subpopulations.
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Transgenic expression of GATA-3 driven by the human CD2 LCR
To modify GATA-3 expression in vivo, transgenic mice were generated in which 
the murine GATA-3 gene, 5’ tagged with 3 HA epitopes, was expressed under the control of 
the human CD2 LCR72. Two independent CD2-GATA3 transgenic lines, tgA and tgB, were 
established that appeared to contain comparable numbers of transgene copies (data not shown). 
No differences were found between the two lines in any of the performed analyses. The offspring 
did not manifest developmental defects or any increased susceptibilities to infectious disease or 
malignancies for over 9 months of age, with the exception of the observed thymic lymphomas 
discussed below. 
Expression of the CD2-GATA3 transgene was analyzed in various lymphoid tissues 
by comparing transgenic and non-transgenic littermates. Western blotting experiments were 
performed on nuclear protein extracts from 2-3 month-old mice, using a mouse mAb specific 
for GATA-3 and a polyclonal antibody specific for the HA-tag. The endogenous GATA-3 gene 
encodes a ~47 kD protein that was detected in nuclear extracts from thymus and spleen of 
wild-type as well as CD2-GATA3 transgenic mice (Fig. 2A). The anti-GATA-3 antibody also 
detected a slightly larger ~51 kD band in the thymus samples from mice of both transgenic lines. 
Comparison of the intensities of the ~47 and ~51 kD GATA-3 specific bands in these nuclear 
protein extracts from thymus samples, showed that the expression level of the 3HA-GATA-3 
transgene encoded protein was similar to that of the endogenous GATA-3 protein. In contrast, in 
the spleen samples the ~51 kD GATA-3 specific band was very weak or absent (Fig. 2A). The 
~51kD band in the thymus extracts of transgenic mice was also recognized by antibody against 
the HA-tag, but the expression levels of transgene encoded GATA-3 protein in the spleen and 
lymph node extracts were very low and often almost undetectable by Western blotting analyses 
(Fig. 2B).
To further investigate differential expression of GATA-3 in the individual stages of T 
cell development, intracellular flow cytometry experiments were performed, using the mouse 
monoclonal antiserum specific for GATA-3. Although this technique is limited by a background 
signal of the GATA-3 antibody, it allows a comparison of GATA-3 expression levels in non-
transgenic and CD2-GATA3 transgenic mice in separate T cell subpopulations. In the wild-
type animals, the GATA-3 levels were low in DP cells, increased during positive selection in 
CD4lowCD8low cells, and were high in CD4 SP cells (Fig. 2C), consistent with our findings in 
the GATA-3+/nlslacZ mice (Fig. 1). Expression of the CD2-GATA3 transgene was determined by 
comparison of the mean fluorescence intensities of intracellular GATA-3 staining in histogram 
overlays of transgenic and non-transgenic mice, revealing substantial GATA-3 overexpression in 
most thymocyte subpopulations (Fig. 2C). GATA-3 protein levels were uniformly higher in DP, 
CD4lowCD8low, CD4+CD8low and CD4 SP thymic subpopulations from CD2-GATA3 transgenic 
mice, as compared to wild-type mice. By contrast, for the CD8 SP cells in the thymus and 
the CD4+ or CD8+ T cells in the spleen, GATA-3 levels in the CD2-GATA3 transgenic were 
close to those observed in wild-type littermates. Therefore, these findings confirm the very 
low expression levels of the transgene encoded GATA-3 protein in peripheral T cells that were 
observed in the Western blotting experiments. As CD2 surface expression in the individual 
T cell subpopulations in thymus and spleen was comparable (data not shown), the observed 
modulated GATA-3 protein expression profile in the transgenic mice does not appear to reflect 
the activity of the CD2 LCR.   (Fig. 2B).
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Figure 2 - Expression of GATA-3 in lymphoid organs of wild-type and CD2-GATA3 transgenic mice.(A) Western 
blotting analyses of GATA-3 protein expression in total nuclear protein extracts from thymus and spleen from wild-type 
(wt) and CD2-GATA3 transgenic mouse lines (tgA and tgB), as detected by anti-GATA-3 antibodies (~47 kD band: 
endogenous GATA-3; ~51kD band: transgenic GATA-3).(B) Western blotting analyses of GATA-3 protein expression 
in nuclear extracts from the indicated tissues from wild-type and CD2-GATA3 tgA mice. GATA-3 is detected by anti-
GATA3 antibodies (upper half) or anti-HA antibodies (lower half). In the α-HA blot, thymus and spleen cell extracts from 
both non-transgenic and CD2-GATA3 transgenic mice displayed two weak background bands, just above the ~51 kD 
HA-GATA-3 band. (C) Cell suspensions were stained for surface CD3, CD4, and CD8 expression, and subsequently for 
intracellular GATA-3 protein. The indicated T cell subpopulations were gated and analyzed for GATA-3 expression. The 
results are displayed as histograms of CD2-GATA3 transgenic mice (bold lines), together with those of non-transgenic 
control mice (thin lines). CD4-CD8- populations were gated on CD3- cells. CD4loCD8lo cells and CD4+CD8lo were gated 
on CD3+ cells. The numbers indicate the mean fluorescence intensities in nontransgenic (normal type) and CD2-GATA3 
transgenic mice (bold type). Data shown are representative of 6 mice examined within each group.
Collectively, these data show that the presence of the CD2-GATA3 transgene resulted in 
a modification the expression pattern of GATA-3 during T cell development, without extreme 
overexpression of GATA-3 protein in any of the thymic subpopulations. Especially in the DP 
population, which normally show little GATA-3 expression, the presence of the CD2-GATA3 
transgene strongly increased the GATA-3 protein levels. 
CD2-GATA3 transgenic mice have decreased CD8+ T cell numbers in the periphery 
To analyze the effect of the CD2-GATA3 transgene on T cell development, we examined 
the T cell populations in thymus, spleen and mesenteric lymph nodes from 2-3 month-old CD2-
GATA3 transgenic mice and non-transgenic littermates by flow cytometry (Fig. 3). In the CD2-
GATA3 mice the sizes of the main thymocyte subpopulations, the DN, DP and SP cells, were 
within the normal ranges, indicating that the enforced GATA-3 expression did not dramatically 
impede thymocyte development (Fig. 3). Moreover, thymus cellularity was not significantly 
different between transgenic mice (99 + 34 x 106, n= 21) and non-transgenic littermates (103 
+ 37 x 106, n= 14). No significant differences were detected between CD2-GATA3 transgenic 
mice and normal littermates within the DN subpopulations as defined by differential CD44 and 
animals, the GATA-3 levels were low in DP cells, increased dur-
ing positive selection in CD4lowCD8low cells, and were high in
CD4 SP cells (Fig. 2C), consistent with our findings in the GATA-
3�/nlslacZ mice (Fig. 1). Expression of the CD2-GATA3 transgene
was determined by comparison of the mean fluorescence intensi-
ties of intracellular GATA-3 staining in histogram overlays of
transgenic and nontransgenic mice, revealing substantial GATA-3
overexpression in most thymocyte subpopulations (Fig. 2C).
GATA-3 protein levels were uniformly higher in DP,
CD4lowCD8low, CD4�CD8low, and CD4 SP thymic subpopula-
tions from CD2-GATA3-transgenic mice as compared with wild-
type mice. By contrast, for the CD8 SP cells in the thymus and the
CD4� or CD8� T cells in the spleen, GATA-3 levels in the CD2-
GATA3-transgenic mice were close to those observed in wild-type
littermates. Therefore, these findings confirm the very low expres-
sion levels of the transgene-encoded GATA-3 protein in peripheral
T cells that were observed in the Western blotting experiments.
Since CD2 surface expression in the individual T cell subpopulations
in thymus and spleen was comparable (data not shown), the observed
modulated GATA-3 protein expression profile in the transgenic mice
does not appear to reflect the activity of the CD2 LCR.
Collectively, these data show that the presence of the CD2-
GATA3 transgene resulted in a modification of the expression pat-
tern of GATA-3 during T cell development, without extreme over-
expression of GATA-3 protein in any of the thymic
subpopulations. Especially in the DP population, which normally
show little GATA-3 expression, the presence of the CD2-GATA3
transgene strongly increased the GATA-3 protein levels.
CD2-GATA3-transg nic mic have decreased CD8� T cell
numbers in the p riphery
To analyze the effect of the CD2-GATA3 transgene on T cell de-
velopment, we examined the T cell populations in thymus, spleen,
and mesenteric lymph nodes from 2- to 3-mo-old CD2-GATA3-
transgenic mice and nontransgenic littermates by flow cytometry
(Fig. 3). In the CD2-GATA3 mice, the sizes of the main thymocyte
subpopulations, the DN, DP, and SP cells, were within the normal
ranges, indicating that the enforced GATA-3 expression did not
dramatically impede thymocyte development (Fig. 3). Moreover,
thymus cellularity was not significantly different between trans-
genic mice (99� 34� 106, n� 21) and nontransgenic littermates
(103 � 37 � 106, n � 14). No significant differences were de-
tected betwee CD2-GATA3-transgenic mice and normal litter-
mates within the DN subpopulations as defined by differential
CD44 a d CD25 expression (data not shown). In contrast, the
CD2-GATA3-transgenic mice had fewer CD8� T cells (�50% of
control) in spleen and lymph nodes (shown for spleen in Fig. 3).
The residual transgenic CD8� T cells present exhibited a more
heterogeneous CD8 expression and higher CD3 expression on the
cell surface. The numbers of CD4� T cells in the periphery were
comparable between the two groups of mice.
Taken together, these results indicated that enforced expression
of GATA-3 did not result in detectable adverse effects on CD4� T
cell development in 2- to 3-mo-old CD2-GATA3-transgenic mice.
FIGURE 2. Expression of GATA-3 in lymphoid organs of wild-type
and CD2-GATA3-transge ic mice. A, Western blotting analyses of
GATA-3 pr tein expressi in total nuclear protein extracts from thy us
and spleen from wild-type (wt) and CD2-GATA3-transgenic mouse lines
(tgA and tgB) as detected by anti-GATA-3 Abs (�47-kDa band, endoge-
nous (endo.) GATA-3; �51-kDa band, transgenic (trans.) GATA-3). B,
Western blotting analyses of GATA-3 protein expression in nuclear ex-
tracts from the indicated tissues from wild-type and CD2-GATA3 tgA mice.
GATA-3 is detected by anti-GATA3 Abs (upper half) or anti-HA Abs
(lower half). In the anti-HA blot, thymus and spleen cell extracts from both
nontransgenic and CD2-GATA3 transgenic mice displayed two weak back-
ground bands, just above the �51-kDa HA-GATA-3 band. C, Cell sus-
pensions were stained for surface CD3, CD4, and CD8 expression, and
subsequently for intracellular GATA-3 protein. The indicated T cell sub-
populations were gated and analyzed for GATA-3 expression. The results
are displayed as histograms of CD2-GATA3-transgenic mice (bold lines)
along with those of nontransgenic control mice (thin lines). CD4�CD8�
populations were gated on CD3� cells. CD4lowCD8low cells and
CD4�CD8low were gated on CD3� cells. The numbers indicate the mean
fluorescence intensities in nontransgenic (normal type) and CD2-GATA3-
transgenic mice (bold type). Data shown are representative of six mice
examined within each group.
FIGURE 3. Phenotype of CD2-GATA3-transgenic mice. T cell devel-
opment in the presence of the CD2-GATA3 transgene results in reduced
numbers of peripheral CD8� cells. Flow cytometric analyses of the thymus
and spleen of 2-mo-old wild-type and CD2-GATA3 mice. Single-cell sus-
pensions were stained with anti-CD3, anti-CD4, and anti-CD8 Abs. Results
are displayed as dot plots of lymphocyte gate cells; percentages of total
cells within the indicated quadrants are given. Data shown are representa-
tive of �20 mice examined within each group.
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animals, the GATA 3 levels w re low in DP c lls, increased dur-
ing positive s lection in CD4lowCD8low cell , and w re high in
CD4 SP cells (Fig. 2C), consistent with our findings in the GATA-
3�/ lslacZ mice (Fig. 1). Expression of the CD2-GATA3 transgene
was determined by omparison of the mean fluorescence intensi-
ties of intracellular GATA-3 staining i histogram overlays of
transgenic and nontransgenic mice, revealing substantial GATA-3
ov rexpression in most thymocyte subpopulations (Fig. 2C).
GATA-3 protein levels were uniformly higher in DP,
CD4lowCD8low, CD4�CD8low, and CD4 SP thymic subpopula-
tions from CD2-GATA3-transgenic mice as compared with wild-
type mice. By contrast, for the CD8 SP cells in the thymus and the
CD4� or CD8� T cells in the spleen, GATA-3 levels in the CD2-
GATA3-transgenic mice were close to those observed in wild-type
littermates. Therefore, these findings confirm the very low expres-
sion levels of the transgene-encoded GATA-3 protein in peripheral
T cells that were observed in the Western blotting experiments.
Since CD2 surface expression in the individual T cell subpopulations
in thymus and spleen was comparable (data not shown), the observed
modulated GATA-3 protein expression profile in the transgenic mice
does not appear to reflect the activity of the CD2 LCR.
Collectively, these data show that the presence of the CD2-
GATA3 transgene resulted in a modification of the expression pat-
tern of GATA-3 during T cell development, without extreme over-
expression of GATA-3 protein in any of the thymic
subpopulations. Especially in the DP population, which normally
show little GATA-3 expression, the presence of the CD2-GATA3
transgene strongly increased the GATA-3 protein levels.
CD2-GATA3-transgenic mice have decreased CD8� T cell
numbers in the periphery
To analyze the effect of the CD2-GATA3 transgene on T cell de-
velopment, we examined the T cell populations in thymus, spleen,
and mesenteric lymph nodes from 2- to 3-mo-old CD2-GATA3-
transgenic mice and nontransgenic littermates by flow cytometry
(Fig. 3). In the CD2-GATA3 mice, the sizes of the main thymocyte
subpopulations, the DN, DP, and SP cells, were within the normal
ranges, indicating that the enforced GATA-3 expression did not
dramatically impede thymocyte development (Fig. 3). Moreover,
thymus cellularity was not significantly different between trans-
genic mice (99� 34� 106, n� 21) and nontransgenic littermates
(103 � 37 � 106, n � 14). No significant differences were de-
tected between CD2-GATA3-transgenic mice and normal litter-
mates within the DN subpopulations as defined by differential
CD44 and CD25 expression (data not shown). In contrast, the
CD2-GATA3-transgenic mice had fewer CD8� T cells (�50% of
control) in spleen and lymph nodes (shown for spleen in Fig. 3).
The residual transgenic CD8� T cells present exhibited a more
heterogeneous CD8 expression and higher CD3 expression on the
cell surface. The numbers of CD4� T cells in the periphery were
comparable between the two groups of mice.
Taken together, these results indicated that enforced expression
of GATA-3 did not result in detectable adverse effects on CD4� T
cell development in 2- to 3-mo-old CD2-GATA3-transgenic mice.
FIGURE 2. Expression of GATA-3 in lymphoid organs of wild-type
and CD2-GATA3-transgenic mice. A, Western blotting analyses of
GATA-3 protein expression in total nuclear rotein extracts from thymus
and spleen from wild-type (wt) and CD2-GATA3-transgenic mouse lines
(tgA and tgB) as detected by anti-GATA-3 Abs (�47-kDa band, endoge-
nous (endo.) GATA-3; �51-kDa band, transgenic (trans.) GATA-3). B,
Western blotting analyses of GATA-3 protein expression in nuclear ex-
tracts from the indicated tissues from wild-type and CD2-GATA3 tgA mice.
GATA-3 is detected by anti-GATA3 Abs (upper half) or anti-HA Abs
(lower half). In the anti-HA blot, thymus and spleen cell extracts from both
nontransgenic and CD2-GATA3 transgenic mice displayed two weak back-
ground bands, just above the �51-kDa HA-GATA-3 band. C, Cell sus-
pensions were stained for surface CD3, CD4, and CD8 expression, and
subsequently for intracellular GATA-3 protein. The indicated T cell sub-
populations were gated and analyzed for GATA-3 expression. The results
are displayed as histograms of CD2-GATA3-transgenic mice (bold lines)
along with those of nontransgenic control mice (thin lines). CD4�CD8�
populations were gated on CD3� cells. CD4lowCD8low cells and
CD4�CD8low were gated on CD3� cells. The numbers indicate the mean
fluorescence intensities in nontransgenic (normal type) and CD2-GATA3-
transgenic mice (bold type). Data shown are representative of six mic
examined within each group.
FIGURE 3. Phenotype of CD2-GATA3-transgenic mice. T cell devel-
opment in the presence of the CD2-GATA3 transgene results in reduced
numbers of peripheral CD8� cells. Flow cytometric analyses of the thymus
and spleen of 2-mo-old wild-type and CD2-GATA3 mice. Single-cell sus-
pensions were stained with anti-CD3, anti-CD4, and anti-CD8 Abs. Results
are displayed as dot plots of lymphocyte gate cells; percentages of total
cells within the indicated quadrants are given. Data shown are representa-
tive of �20 mice examined within each group.
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CD25 expression (data not shown). In contrast, the CD2-GATA3 transgenic mice had fewer 
CD8+ T cells (~50% of control) in spleen and lymph nodes (Shown for spleen in Fig. 3). The 
residual transgenic CD8+ T cells present exhibited a more heterogeneous CD8 expression and 
higher CD3 expression on the cell surface. The numbers of CD4+ T cells in the periphery were 
comparable between the two groups of mice.  
Taken together, these results indicated that enforced expression of GATA-3 did not 
result in detectable adverse effects on CD4+ T cell development in 2-3 month-old CD2-GATA3 
transgenic mice. In contrast, mature CD8 SP cells manifested decreased survival, either within 
the thymus or shortly after leaving the thymus.
Figure 3 - Phenotype of CD2-GATA3 transgenic mice. T cell development in the presence of the CD2-GATA3 
transgene results in reduced numbers of peripheral CD8+ cells. Flow cytometric analyses of the thymus and spleen 
of 2-month-old wild-type and CD2-GATA3 mice. Single-cell suspensions were stained with anti-CD3, anti-CD4 and 
anti-CD8 antibodies. Results are displayed as dot plots of lymphocyte gate cells; percentages of total cells within the 
indicated quadrants are given. Data shown are representative of over 20 mice examined within each group. 
CD2-GATA3 transgenic mice develop thymic lymphomas
When the CD2-GATA3 transgenic mice were followed up to 9 months of age, ~50% (26 
out of 51) developed thymic lymphomas (Fig. 4A). Typically, these lymphomas were noticed as 
mice displayed respiratory distress at the age of 6-8 months, but in three cases such animals were 
observed at ~3 months of age. Tumor frequencies in the two independent transgenic lines were 
similar, while tumors were not seen in non-transgenic littermates. Several animals with a thymic 
lymphoma exhibited enlargement of spleen or lymph nodes. Lymphoma cells were found to be 
present in the spleen, liver, lymph nodes, and kidney, indicating that the thymic lymphomas 
metastasized to the periphery. This was confirmed by the presence of identical clonal TCRβ 
rearrangement patterns in Southern blotting analyses, using probes specific for Jβ1 or Jβ2 gene 
segments (Fig. 4B). In a fraction of the tumors analyzed, we observed Jβ2 restriction fragment 
patterns that would be consistent with biclonality (see Fig 4B, TL5). Often particular restriction 
fragments were lost in metastases, suggesting ongoing TCRβ  rearrangement or deletion (see 
Fig. 4B, compare thymus and lymph node of TL2). 
When tumor cell samples from thymus, spleen, or lymph node were analyzed for the 
expression of GATA-3 in western blotting experiments, high levels of transgenic HA-tagged 
animals, the GATA-3 levels were low in DP cells, increased dur-
ing positive selection in CD4lowCD8low cells, and were high in
CD4 SP cells (Fig. 2C), consistent with our findings in the GATA-
3�/nlslacZ mice (Fig. 1). Expression of the CD2-GATA3 transgene
was determined by comparison of the mean fluorescence intensi-
ties of intracellular GATA-3 staining in histogram overlays of
transgenic and nontransgenic mice, revealing substantial GATA-3
overexpression in most thymocyte subpopulations (Fig. 2C).
GATA-3 protein levels were uniformly higher in DP,
CD4lowCD8low, CD4�CD8low, and CD4 SP thymic subpopula-
tions from CD2-GATA3-transgenic mice as compared with wild-
type mice. By contrast, for the CD8 SP cells in the thymus and the
CD4� or CD8� T cells in the spleen, GATA-3 levels in the CD2-
GATA3-transgenic mice were close to those observed in wild-type
littermates. Therefore, these findings confirm the very low expres-
sion levels of the transgene-encoded GATA-3 protein in peripheral
T cells that were observed in the Western blotting experiments.
Since CD2 surface expression in the individual T cell subpopulations
in thymus and spleen was comparable (data not shown), the observed
modulated GATA-3 protein expression profile in the transgenic mice
does not appear to reflect the activity of the CD2 LCR.
Collectively, these data show that the presence of the CD2-
GATA3 transgene resulted in a modification of the expression pat-
tern of GATA-3 during T cell development, without extreme over-
expression of GATA-3 protein in any of the thymic
subpopulations. Especially in the DP population, which normally
show little GATA-3 expression, the presence of the CD2-GATA3
transgene strongly increased the GATA-3 protein levels.
CD2-GATA3-transgenic mice have decreased CD8� T cell
numbers in the periphery
To analyze the effect of the CD2-GATA3 transgene on T cell de-
velopment, we examined the T cell populations in thymus, spleen,
and mesenteric lymph nodes from 2- to 3-mo-old CD2-GATA3-
transgenic mice and nontransgenic littermates by flow cytometry
(Fig. 3). In the CD2-GATA3 mice, the sizes of the main thymocyte
subpopulations, the DN, DP, and SP cells, were within the normal
ranges, indicating that the enforced GATA-3 expression did not
dramatically impede thymocyte development (Fig. 3). Moreover,
thymus cellularity was not significantly different between trans-
genic mice (99� 34� 106, n� 21) and nontransgenic littermates
(103 � 37 � 106, n � 14). No significant differences were de-
tected between CD2-GATA3-transgenic mice and normal litter-
mates within the DN subpopulations as defined by differential
CD44 and CD25 expression (data not shown). In contrast, the
CD2-GATA3-transgenic mice had fewer CD8� T cells (�50% of
control) in spleen and lymph nodes (shown for spleen in Fig. 3).
The residual transgenic CD8� T cells present exhibited a more
heterogeneous CD8 expression and higher CD3 expression on the
cell surface. The numbers of CD4� T cells in he p riphery were
comparable b tween the two groups of mice.
Taken ogether, these results indicated that enforced expression
f GATA-3 did not result in d tec able adverse effects on CD4� T
cell de lopment in 2- to 3-mo-old CD2-GATA3-transgenic mice.
FIGURE 2. Expression of GATA-3 in lymphoid organs of wild-type
and CD2-GATA3-transgenic mice. A, Western blotting analyses of
GATA-3 protein expression in total nuclear protein extracts from thymus
and spleen from wild-type (wt) and CD2-GATA3-transgenic mouse lines
(tgA and tgB) as detected by anti-GATA-3 Abs (�47-kDa band, endoge-
nous (endo.) GATA-3; �51-kDa band, transgenic (trans.) GATA-3). B,
Western blotting analyses of GATA-3 protein expression in nuclear ex-
tracts from the indicated tissues from wild-type and CD2-GATA3 tgA mice.
GATA-3 is detected by anti-GATA3 Abs (upper half) or anti-HA Abs
(lower half). In the anti-HA blot, thymus and spleen cell extracts from both
nontransgenic and CD2-GATA3 transgenic mice displayed two weak b ck-
ground bands, just above the �51-kDa HA-GATA-3 band. C, Cell sus-
pensions were stained for surface CD3, CD4, and CD8 expression, and
subsequently for intracellular GATA-3 protein. The indicated T cell sub-
populations were gated and analyzed for GATA-3 expression. The results
are displayed as histograms of CD2-GATA3-transgenic mice (bold lines)
along with those of nontransgenic control mice (thin lines). CD4�CD8�
populations were gated on CD3� cells. CD4lowCD8low cells and
CD4�CD8low were gated on CD3� cells. The numbers indicate the mean
fluorescence intensities in nontransgenic (normal type) and CD2-GATA3-
transgenic mice (bold type). Data shown are representative of six mice
examined within each group.
FIGURE 3. Phenotype of CD2-GATA3-transgenic mice. T cell devel-
opment in the presence of the CD2-GATA3 transgene results in reduced
numbers of peripheral CD8� cells. Flow cytometric analyses of the thymus
and spleen of 2-mo-old wild-type and CD2-GATA3 mice. Single-cell sus-
pension w re tain with anti-CD3, anti-CD4, and anti-CD8 Abs. Results
are displayed as dot plots of lymphocyte gate cells; percentages of total
cells within the indicated quadrants are given. Data shown are representa-
tive of �20 mice examined within each group.
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GATA-3 were observed, often accompanied by high endogenous GATA-3 expression (Fig. 4C). 
The ratio between transgenic and endogenous GATA-3 varied, not only between individual 
tumors, but also between different metastases of a single tumor (see Fig. 4C, compare mesenteric 
lymph node and spleen of TL 9). 
Flow cytometric analyses demonstrated that the thymic lymphomas consisted of CD4+ 
lymphoblasts with variable levels of CD8 coexpression. Fig. 5A shows four examples of thymic 
lymphomas (CD4+CD8+/low cells), with different metastases in lymph nodes and spleen, showing 
the variability of surface CD4 and CD8 expression on the malignant cells. Immunohistochemical 
examination of thymic tumor tissue sections confirmed that the tumors mainly consisted of 
CD4+CD8+ lymphoblasts. Most of the tumors contained areas that had lost expression of CD8, 
and sometimes also CD4. A network of MHC class II negative fibroblasts supported these 
lymphoblasts, while characteristic structures of epithelial cells expressing cortical or medullar 
cell markers were absent (data not shown). 
Figure 4 - Characteristics of thymic lymphomas in CD2-GATA3 transgenic mice. (A) Survival of wild-type mice (gray 
line, n=42) and CD2-GATA3 transgenic mice (black line, n=51), followed for 38 weeks in a Kapplan-Meyer curve as 
fraction of the total numbers of mice. (B) Southern blotting analysis of TCRβ rearrangements in various lymphoblastoid 
tumor samples. EcoRI digests were hybridized to a TCR Jβ2 probe. T= thymus; S= spleen; L= lymph node. An asterisk 
indicates the position of the germ-line 2.4 kb EcoRI fragment; on the left the positions of  λ X BsteII restriction fragments 
are indicated in kb. (C) Western blotting analyses of GATA-3 protein expression in total nuclear extracts from the 
indicated tumor tissues, as detected by anti-GATA-3 antibodies. Trans.= ~51 kD transgenic GATA-3; endo.=  ~47 kD 
endogenous GATA-3; T= thymus; S= spleen; M= mesenteric lymph node; L= axillary lymph node. 
Among CD2-GATA3 transgenic mice that did not exhibit outward signs of illness, nor 
manifested a macroscopically visible thymic tumor at ~3 months of age, we found evidence 
for early stages of tumor development in 6 out of 32 cases (~ 19%). In flow cytometric 
analyses of thymus cell suspensions the CD4+CD8+/low subsets contained atypical fractions of 
CD3+ lymphoblastoid cells with high FSC characteristics, suggestive of tumor growth. In the 
example shown in Fig. 5BC, the lymphoblastoid cells had a CD3+ CD4+CD8lo phenotype and 
expressed high levels of GATA-3 protein, as determined by intracellular flow cytometry. In 
In contrast, mature CD8 SP cells manifested decreased survival,
either within the thymus or shortly after leaving the thymus.
CD2-GATA3-transgenic mice develop thymic lymphomas
When the CD2-GATA3-transgenic mice were followed up to 9 mo
of age, �50% (26 of 51) developed thymic lymphomas (Fig. 4A).
Typically, these lymphomas were noticed as mice displayed re-
spiratory distress at the age of 6–8 mo, but in three cases such
animals were observed at �3 mo of age. Tumor frequencies in the
two independent transgenic lines were similar, whereas tumors
were not seen in nontransgenic littermates. Several animals with a
thymic lymphoma exhibited enlargement of spleen or lymph
nodes. Lymphoma cells were found to be present in the spleen,
liver, lymph nodes, and kidney, indicating that the thymic lym-
phomas metastasized to the p riphery. This was confirmed by the
presence of identic l clonal TCR� r arrangement patter s n
Southern blotting an lyses using prob s pecific for J�1 or J�2 gene
segments (Fig. 4B). In a fraction of the tumors analyzed, we ob-
served J�2 restriction fragment patterns that would be consistent
with biclonality (see Fig. 4B, TL5). Often particular restriction
fragments were lost in metastases, suggesting ongoing TCR� re-
arrangement or deletion (see Fig. 4B, compare thymus and lymph
node of TL2).
When tumor cell samples from thymus, spleen, or lymph node
were analyzed for the expression of GATA-3 in Western blotting
experiments, high levels of transgenic HA-tagged GATA-3 were
observed, often accompanied by high endogenous GATA-3 ex-
pression (Fig. 4C). The ratio between transgenic and endogenous
GATA-3 varied, not only between individual tumors but also be-
tween different metastases of a single tumor (see Fig. 4C, compare
mesenteric lymph node and spleen of TL 9).
Flow cytometric analyses demonstrated that the thymic lympho-
mas consisted of CD4� lymphoblasts with variable levels of CD8
coexpression. Fig. 5A illustrates four examples of thymic lympho-
mas (CD4�CD8�/low cells), with different metastases in lymph
n des and spleen, showing the variability of surface CD4 and CD8
expression on th malignant cells. Immunohistochemical exami-
ation of thymic tumor tissue sections confirmed that the tumors
mainly consisted of CD4�CD8� lymphoblasts. Most of the tumors
contained areas that had lost expression of CD8 and sometimes
FIGURE 4. Characteristics of thymic lymphomas in CD2-GATA3-
transgenic mice. A, Survival of wild-type mice (gray line, n � 42) and
CD2-GATA3-transgenic mice (black line, n � 51), followed for 38 wk in
a Kaplan-Meier curve as fraction of the total numbers of mice. B, Southern
blotting analysis of TCR� rearrangements in various lymphoblastoid tumor
samples. EcoRI digests were hybridized to a TCR J�2 probe. T, Thymus;
S, spleen; L, lymph node. �, Position of the germline 2.4-kb EcoRI frag-
ment; on the left the positions of � X BsteII restriction fragments are
indicated in kb. C, Western blotting analyses of GATA-3 protein expres-
sion in total nuclear extracts from the indicated tumor tissues as detected by
anti-GATA-3 Abs. trans., �51-kDa transgenic GATA-3; endo., �47-kDa
endogenous GATA-3; T, thymus; S, spleen; M, mesenteric lymph node; L,
axillary lymph node.
FIGURE 5. Su face profile of lymphoblastoid tumor cells in CD2-GATA3-
transgenic mice. A, Fl w cytometric analyses of four different CD4�CD8�/low
hymic ymphoma pri ary tumor samples as well as metastases present in
lymph node and spleen. B, Identification of an atypical GATA-
3highCD3�CD4�CD8low lymphoblastoid cell population in the thymus of a
CD2-GATA3-transgenic mouse, indicative for a thymic lymphoma (TL7).
Nontransgenic and tumor-free CD2-GATA3-transgenic mice are shown as
controls. Results are displayed as dot plots for CD4 and CD8. The given
percentages of the gated CD4�CD8low populations are of all thymocytes. C,
Analysis of FSC, CD3, and intracellular GATA-3 expression in the gated
CD4�CD8low thymocyte subpopulation shown in B. The results are displayed
as histograms of the CD2-GATA3-transgenic TL7 mouse (bold lines) along
with those of a nontransgenic (dashed lines) and a tumor-free CD2-GATA3-
transgenic mouse (thin lines). Cell suspensions were stained for CD3, CD4,
and CD8 and subsequently for intracellular GATA-3. All samples are lym-
phocyte/lymphoblast gated by FSC and side scatter.
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pression (Fig. 4C). The ratio between transgenic and endogenous
GATA-3 varied, not only between individual tumors but also be-
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mesenteric lymph node and spleen of TL 9).
Flow cytometric analyses demonstrated that the thymic lympho-
mas consisted of CD4� lymphoblasts with variable levels of CD8
coexpression. Fig. 5A illustrates four examples of thymic lympho-
mas (CD4�CD8�/low cells), with different metastases in lymph
nodes and spleen, showing the variability of surface CD4 and CD8
expression on the malignant cells. Immunohistochemical exami-
n tion of thymic tumor tissue sections confirmed that the tumors
mainly consisted of CD4�CD8� lymphoblasts. Most of the tumors
contained areas that had lost expression of CD8 and sometimes
FIGURE 4. Characteristics of thymic lymphomas in CD2-GATA3-
transgenic mice. A, Survival of wild-type mice (gray line, n � 42) and
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FIGURE 5. Surface profile of lymphoblastoid tumor cells in CD2-GATA3-
transgenic mice. A, Flow cytometric analyses of four different CD4�CD8�/low
thymic lymphoma primary tumor samples as well as metastases present in
lymph node and spleen. B, Identification of an atypical GATA-
3highCD3�CD4�CD8low lymphoblastoid cell population in the thymus of a
CD2-GATA3-transgenic mouse, indicative for a thymic lymphoma (TL7).
Nontransgenic and tumor-free CD2-GATA3-transgenic mice are shown as
controls. Results are displayed as dot plots for CD4 and CD8. The given
percentages of the gated CD4�CD8low populations are of all thymocytes. C,
Analysis of FSC, CD3, and intracellular GATA-3 expression in the gated
CD4�CD8low thymocyte subpopulation shown in B. The results are displayed
as histograms of the CD2-GATA3-transgenic TL7 mouse (bold lines) along
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and CD8 nd subsequ tly for intracellular GATA-3. All samples are lym-
phocyte/lymphoblast gated by FSC and side scatter.
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ment; on the left the positions of � X BsteII restriction fragments are
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sion in total nuclear extracts from the indicated tumor tissues as detected by
anti-GATA-3 Abs. trans., �51-kDa transgenic GATA-3; endo., �47-kDa
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FIGURE 5. Surface profile of lymphoblastoid tumor cells in CD2-GATA3-
transgenic mice. A, Flow cytometric analyses of four different CD4�CD8�/low
thymic lymphoma primary tumor samples as well as metastases present in
lymph node and spleen. B, Identification of an atypical GATA-
3highCD3�CD4�CD8low lymphoblastoid cell population in the thymus of a
CD2-GATA3-transgenic mouse, indicative for a thymic lymphoma (TL7).
Nontransgenic and tumor-free CD2-GATA3-transgenic mice are shown as
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these lymphoblastoid cells, CD69 expression was variable (data not shown).
These findings indicate that dysregulation of GATA-3 expression results in the formation 
of lymphoblastoid tumors at a specific stage of thymic development, i.e. the CD4+CD8+/low 
thymocyte subpopulation. 
Figure 5 - Surface profile of lymphblastoid tumor cells in CD2-GATA3 transgenic mice.(A)Flow cytometric analyses 
of four different CD4+CD8+/lo thymic lymphoma primary tumor samples, as well as metastases present in lymph node 
and spleen. (B)Identification of an atypical GATA-3hiCD3+CD4+CD8lo lymphoblastoid cell population in the thymus of 
a CD2-GATA3 transgenic mouse, indicative for a thymic lymphoma (TL7). Non-transgenic and tumor-free CD2-GATA3 
transgenic mice are shown as controls. Results are displayed as dot plots for CD4 and CD8. The given percentages of 
the gated CD4+CD8lo populations are of all thymocytes. (C) Analysis of forward scatter (FSC), CD3 and intracellular 
GATA-3 expression in the gated CD4+CD8lo thymocyte subpopulation shown in panel B. The results are displayed as 
histograms of the CD2-GATA3 transgenic TL7 mouse (bold lines), together with those of a non-transgenic (dashed lines) 
and a tumor-free CD2-GATA3 transgenic mouse (thin lines). Cell suspensions were stained for CD3, CD4, and CD8, 
and subsequently for intracellular GATA-3. All samples are lymphocyte/lymphoblast gated by forward and sideward 
scatter.
GATA-3 enhances TCRαβ upregulation during positive selection 
 As we observed a correlation between GATA-3 expression and TCRαβ or CD3 surface 
levels in GATA-3+/nlslacZ mice, we investigated these parameters in the thymocyte subpopulations 
of the CD2-GATA3 mice (Fig. 6A). The expression of CD69 in the DP, CD4lowCD8low and 
CD4+CD8low subpopulations was similar in CD2-GATA3 and wild-type mice. In contrast, the 
proportions of TCRαβhigh or CD3high cells were significantly increased in CD2-GATA3 mice, 
particularly in CD69+CD4loCD8lo subpopulation (Shown for TCRαβ expression in Fig. 6A). 
In the more mature fractions of CD4lowCD8+ and SP cells, the expression levels of CD3 and 
TCRαβ were similar in transgenic animals and wild-type littermates. 
 We noticed that in the CD2-GATA3 transgenic mice, the cells within the DP 
subpopulations had increased average forward scatter values, closer to those of normal SP cells 
(Fig. 6B). The increased size of CD2-GATA3 transgenic DP cells did not reflect an enhanced 
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animals were observed at �3 mo of age. Tumor frequencies in the
two independent transgenic lines were similar, whereas tumors
were not seen in nontransgenic littermates. Several animals with a
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nodes. Lymphoma cells were found to be present in the spleen,
liver, lymph nodes, and kidney, indicating that the thymic lym-
phomas metastasized to the periphery. This was confirmed by the
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Southern blotting analyses using probes specific for J�1 or J�2 gene
segments (Fig. 4B). In a fraction of the tumors analyzed, we ob-
served J�2 restriction fragment patterns that would be consistent
with biclonality (see Fig. 4B, TL5). Often particular restriction
fragments were lost in metastases, suggesting ongoing TCR� re-
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observed, often accompanied by high endogenous GATA-3 ex-
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coexpression. Fig. 5A illustrates four examples of thymic lympho-
mas (CD4�CD8�/low cells), with different metastases in lymph
nodes and spleen, showing the variability of surface CD4 and CD8
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nation of thymic tumor tissue sections confirmed that the tumors
mainly consisted of CD4�CD8� lymphoblasts. Most of the tumors
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sion in total nuclear extracts from the indicated tumor tissues as detected by
anti-GATA-3 Abs. trans., �51-kDa transgenic GATA-3; endo., �47-kDa
endogenous GATA-3; T, thymus; S, spleen; M, mesenteric lymph node; L,
axillary lymph node.
FIGURE 5. Surface profile of lymphoblastoid tumor cells in CD2-GATA3-
transgenic mice. A, Flow cytometric analyses of four different CD4�CD8�/low
thymic lymphoma primary tumor samples as well as metastases present in
lymph node and spleen. B, Identification of an atypical GATA-
3highCD3�CD4�CD8low lymphoblastoid cell population in the thymus of a
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activation status of these cells, as we failed to detect activated cells with high Th2 cytokine 
production14 in immunohistochemical analyses of the thymuses of CD2-GATA3 mice. We also 
did not find evidence for a direct effect of transgenic GATA-3 on the cell cycle in DP cells, as 
flow cytometric analyses, using anti-CD4, anti-CD8 and To-Pro3, did not reveal differences 
in the cell cycle between CD2-GATA3 transgenic animals and their wild-type littermates (data 
not shown). The development of CD3/TCRαβlow DP into CD3/TCRαβhigh SP cells is normally 
accompanied by an increase in the average cell size. Therefore, the findings of the small increase 
in DP cell size and the slightly accelerated upregulation of surface TCRαβ and CD3 expression 
in CD2-GATA3 transgenic mice suggest that enforced GATA-3 expression may influence the 
kinetics of positive selection. 
Figure 6 - The CD2-GATA3 transgene enhances TCRαβ upregulation during positive selection. (A) Cell suspensions 
were stained for CD4, CD8 and CD69 expression, together with either CD3 or  TCRαβ  The indicated T cell subpopulations 
(see also Fig. 1A) were gated and analyzed for TCRαβ expression. The results are displayed as histograms of CD2-
GATA3 transgenic mice (bold lines), together with those of non-transgenic control mice (thin lines). The percentages 
shown are the fractions of the CD69+CD4loD8lo cells that are in the indicated TCRαβhi gate in wild-type mice (below 
marker) and CD2-GATA3 transgenic mice (above marker, bold type). (B) The effect of the CD2-GATA3 transgene on 
the cell sizes of the DP thymocyte subpopulation. Cell suspensions were stained for CD4 and CD8. DP cells were gated 
and analyzed for FSC; the results are displayed as histogram overlays of a CD2-GATA3 transgenic (bold line) and non-
transgenic control (thin line) mouse. 
GATA-3 inhibits maturation of CD8 single positive T cells
As the reduction of peripheral CD8+ T cell numbers in the CD2-GATA3 transgenic mice 
suggested increased cell death or hampered maturation of CD8 SP cells in the thymus, we 
analyzed the thymic CD8 SP compartment in more detail and specifically evaluated the final 
maturation steps of CD8 SP cells. 
To analyze the extent of apoptosis in the SP subpopulations, we determined the fraction 
of cells that were annexin V-positive in CD2-GATA3 transgenic mice and their non-transgenic 
littermates. In addition, we performed TUNEL assays in conjunction with surface CD4/CD8 
staining. Using these techniques, we found that the thymuses of CD2-GATA3 transgenic mice 
contained higher numbers of apoptotic cells, not only in the CD8 SP, but to some extent also in 
the CD4 SP subpopulations (Fig. 7AB). 
also CD4. A network of MHC class II-negative fibroblasts sup-
ported these lymphoblasts, whereas characteristic structures of ep-
ithelial cells expressing cortical or medullar cell markers were ab-
sent (data not shown).
Among CD2-GATA3-transgenic mice that did not exhibit out-
ward signs of illness nor manifested a macroscopically visible thy-
mic tumor at �3 mo of age, we found evidence for early stages of
tumor development in 6 of 32 cases (�19%). In flow cytometric
analyses of thymus cell suspensions, the CD4�CD8�/low subsets
contained atypical fractions of CD3� lymphoblastoid cells with
high forward scatter (FSC) characteristics suggestive of tumor
growth. In the example shown in Fig. 5, B and C, the lymphoblas-
toid cells had a CD3�CD4�CD8low phenotype and expressed high
levels of GATA-3 protein, as determined by intracellular flow cy-
tometry. In these lymphoblastoid cells, CD69 expression was vari-
able (data not shown).
These findings indicate that dysregulation of GATA-3 expres-
sion results in the formation of lymphoblastoid tumors at a specific
stage of thymic development, i.e., the CD4�CD8�/low thymocyte
subpopulation.
GATA-3 enhances TCR�� up-regulation during positive
selection
As we observed a correlation between GATA-3 expression and
TCR�� or CD3 surface levels in GATA-3�/nlslacZ mice, we inves-
tigated these parameters in the thymocyte subpopulations of the
CD2-GATA3 mice (Fig. 6A). The expression of CD69 in the DP,
CD4lowCD8low, and CD4�CD8low subpopulations was similar in
CD2-GATA3 and wild-type mice. In contrast, the proportions of
TCR��high or CD3high cells were significantly increased in CD2-
GATA3 mice, particularly in the CD69�CD4lowCD8low subpopu-
lation (shown for TCR�� expression in Fig. 6A). In the more ma-
ture fractions of CD4lowCD8� and SP cells, the expression levels
of CD3 and TCR�� were similar in transgenic animals and wild-
type littermates.
We noticed that in the CD2-GATA3-transgenic mice, the cells
within the DP subpopulations had increased average FSC values
closer to those of normal SP cells (Fig. 6B). The increased size of
CD2-GATA3-transgenic DP cells did not reflect an enhanced ac-
tivation status of these cells, as we failed to detect activated cells
with high Th2 cytokine production (26) in immunohistochemical
analyses of the thymi of CD2-GATA3 mice. We also did not find
evidence for a direct effect of transgenic GATA-3 on the cell cycle
in DP cells, as flow cytometric analyses, using anti-CD4, anti-
CD8, and To-Pro3, did not reveal differences in the cell cycle
between CD2-GATA3-transgenic animals and their wild-type lit-
termates (data not shown). The development of CD3/TCR��low
DP into CD3/TCR��high SP cells is normally accompanied by an
increase in the average cell size. Therefore, the findings of the
small increase in DP cell size and the slightly accelerated up-reg-
ulation of surface TCR�� and CD3 expression in CD2-GATA3-
transgenic mice suggest that enforced GATA-3 expression may
influence the kinetics of positive selection.
GATA-3 inhibits maturation of CD8 SP T cells
As the reduction of peripheral CD8� T cell numbers in the CD2-
GATA3 transgenic mice suggested increased cell death or ham-
pered maturation of CD8 SP cells in the thymus, we analyzed the
thymic CD8 SP compartment in more detail and specifically eval-
uated the final maturation steps of CD8 SP cells.
To analyze the extent of apoptosis in the SP subpopulations, we
determined the fraction of cells that were annexin V-positive in
CD2-GATA3-transgenic mice and their nontransgenic littermates.
In addition, we performed TUNEL assays in conjunction with sur-
face CD4/CD8 staining. Using these techniques, we found that the
thymi of CD2-GATA3-transgenic mice contained higher numbers
of apoptotic cells, not only in the CD8 SP but to some extent also
in the CD4 SP subpopulations (Fig. 7, A and B).
It has been reported that final maturation of SP T cells is ac-
companied by a down-regulation of CD69 and HSA expression
(36, 48). The enforced GATA-3 expression appeared to inhibit the
final maturation of CD8� cells, as a selective deficiency of
CD69lowHSAlow cells was observed, when CD2-GATA3-trans-
genic and wild-type littermates were compared (Fig. 7C). For
CD4� cells, the enforced GATA-3 expression only mildly affected
the final thymic maturation steps. In addition, in the CD2-GATA3-
transgenic mice an increase in the surface expression of CD44, a
marker for activated or memory T cells, was observed both in the
CD4 and the CD8 SP population (Fig. 7C). This phenomenon was
also seen in the mature CD4� and CD8� T cells in the spleen (see
accompanying paper). Finally, the expression of L-selectin
(CD62L), a marker which is expressed at high levels on naive T
cells and which is essential for homing to peripheral lymphoid
organs (51), was comparable in transgenic and nontransgenic an-
imals. Therefore, the decrease in peripheral CD8� T cell numbers
in CD2-GATA3-transgenic mice cannot be explained by a reduced
capacity of the mature CD8 SP T cells to leave the thymus.
In summary, we observed a substantial increase of apoptotic
CD8 SP cells and a decrease of mature CD69lowHSAlow cells in
the thymic CD8 SP subpopulation, as well as reduced numbers of
CD8� T cells in the peripheral organs. These findings indicate that
enforced GATA-3 expression resulted in a partial differentiation
arrest of CD8� cells associated with significant cell death in the
thymus.
Discussion
In this report, we have used two different mouse models to study
the role of GATA-3 in early T cell development in vivo. We eval-
uated GATA-3-directed lacZ expression in GATA-3�/nlslacZ mice
FIGURE 6. The CD2-GATA3 transgene enhances TCR�� up-regula-
tion during positive selection. A, Cell suspensions were stained for CD4,
CD8, and CD69 expression along with either CD3 or TCR��. The indi-
cated T cell subpopulations (see also Fig. 1A) were gated and analyzed for
TCR�� expression. The results are displayed as histograms of CD2-
GATA3-transgenic mice (bold lines) along with those of nontransgenic
control mice (thin lines). The percentages shown are the fractions of the
CD69�CD4lowD8low cells that are in the i dicat d TCR��high g te in wild-
type mice (below marker) and CD2-GATA3-transgenic mice (above
marker, bold type). B, The effect of the CD2-GATA3 transgene on the cell
sizes of the DP thymocyte subpopulation. Cell suspensions were stained for
CD4 and CD8. DP cells were gated and analyzed for FSC; the results are
displayed as histogram overlays of a CD2-GATA3-transgenic (bold line)
and nontransgenic control (thin line) mouse.
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 t has been reported that final maturation of single positive T cells is accompanied by a 
downregulation of CD69 and HSA expression5,17. The enforced GATA-3 expression appeared to 
inhibit the final maturation of CD8+ cells, as a selective deficiency of CD69low HSAlow cells was 
observed, when CD2-GATA3 transgenic and wild-type littermates were compared (Fig. 7C). For 
CD4+ cells the enforced GATA-3 expression only mildly affected the final thymic maturation 
steps. In addition, in the CD2-GATA3 transgenic mice an increase in the surface expression of 
CD44, a marker for activated or memory T cells, was observed both in the CD4 and the CD8 SP 
population (Fig. 7C). This phenomenon was also seen in the mature CD4+ and CD8+ T cells in 
the spleen (see accompanying paper). Finally, the expression of L-selectin (CD62L), a marker 
which is expressed at high levels on naive T cells and which is essential for homing to peripheral 
lymphoid organs58, was comparable in transgenic and non-transgenic animals. Therefore, the 
decrease in peripheral CD8+ T cell numbers in CD2-GATA3 transgenic mice cannot be explained 
by a reduced capacity of the mature CD8 SP T cells to leave the thymus.
Figure 7 - Enforced expression of GATA-3 induces apoptosis and inhibits the maturation of CD69loHSAlo CD8 SP 
cells in the thymus. Thymus cell suspensions were stained for CD4, CD8 and Annexin V (A) or TUNEL (B). Thymocytes 
were analyzed for the expression for CD4 and CD8, the indicated SP subpopulations were gated and analyzed for FSC 
and Annexin V or TUNEL. The numbers indicate the percentage of Annexin V-positive (A) or TUNEL-positive (B) cells 
in the subpopulations analyzed. (C) In four-color flow cytometry experiments, thymus cell suspensions were stained for 
CD4 and CD8 expression, together with anti-HSA and anti-CD69 or with anti-CD62L and anti-CD44. The CD4 and CD8 
SP T cells were gated and analyzed for the expression of the indicated markers. The results are displayed as histograms of 
CD2-GATA3 transgenic mice (bold lines), together with those of non-transgenic control mice (thin lines).
 In summary, we observed a substantial increase of apoptotic CD8 SP cells and a 
decrease of mature CD69lowHSAlow cells in the thymic CD8 SP subpopulation, as well as reduced 
numbers of CD8+ T cells in the peripheral organs. These findings indicate that enforced GATA-3 
expression resulted in a partial differentiation arrest of CD8+ cells, associated with significant 
cell death in the thymus.
and examined the effects of enforced GATA-3 expression through-
out T cell development in CD2-GATA3-transgenic mice in which
GATA-3 transcription is driven by the CD2 LCR.
Our findings implicate GATA-3 as a participant in the commit-
ment process to the CD4 vs the CD8 lineage. First, we found that
commitment to the CD8 T cell lineage coincided with down-reg-
ulation of GATA-3 expression. The most mature subpopulation of
uncommitted thymocytes, the CD4�CD8low subset, contained
high numbers of GATA-3-expressing cells. During the maturation
of CD8� cells in the thymus, GATA-3 expression was gradually
lost. By contrast, GATA-3 expression remained high during differ-
entiation of CD4� cells in the thymus. Second, enforced GATA-3
expression inhibited the maturation of CD8� cells. The CD8 SP
fraction in the thymus contained increased numbers of apoptotic
cells and exhibited a selective deficiency of mature CD69lowHSAlow
cells. In the spleen and lymph nodes, the numbers of CD8� T cells
were significantly reduced.
Enforced expression of GATA-3 did not appear to directly in-
fluence the CD4 vs CD8 lineage cell fate decision, as in the CD2-
GATA3 mice the percentages of CD4 and CD8 SP cells in the
thymus were in the normal ranges. Although the molecular mech-
anisms underlying the developmental choice between CD4 and
CD8 T cell fates are not known, they are thought to depend on
differences in signal strengths of the MHC class I-CD8 and MHC
class II-CD4 interactions. The influence of signaling molecules on
lineage commitment is supported by the finding of differentiation
toward the CD4 lineage in a gain-of-function extracellular signal-
related kinase 2 mutant and in Csk- or C-Cbl-deficient mice (52–
54). Activated Notch transmembrane receptor or Bcl-2 overexpres-
sion was shown to promote differentiation to the CD8 lineage,
probably by rescue from apoptosis and development along the
CD8 lineage of cells that have a very low-affinity MHC interac-
tion, which would normally die by neglect (55–57).
Our data point at a role for GATA-3 in the maturation of the
cells once commitment has occurred. There is a progressive de-
cline of GATA-3 expression during CD8 lineage maturation, and
the enforced GATA-3 expression impaired cell survival in the most
mature CD8 lineage cells. Furthermore, peripheral CD8� T cells
from CD2-GATA3-transgenic mice manifested functional defects
in IL-2 and IFN-� production (see accompanying paper). In this
context, there is a striking parallel with Th1/Th2 differentiation,
where GATA-3 is expressed in naive peripheral T cells, followed
by a substantial increase during Th2 development and a gradual
down-regulation during Th1 development (24, 25). The Th2 phe-
notype is initiated by IL-4 signaling, and by the action of GATA-3
becomes stable over time and independent of extrinsic factors,
such as IL-4 (27, 29, 58). Retroviral tagging of naive progenitors
with GATA-3 provided direct evidence for instructive differenti-
ation, rather than selective outgrowth of committed Th1 or Th2
cells (26). It was further shown that GATA-3 generates stability of
Th2 commitment by chromatin remodeling of Th2-specific cyto-
kine loci, associated with a positive autoactivation pathway, which
is a recognized mechanism contributing to cell fate determination
(29). Concomitantly, GATA-3 inhibits Th1 development by re-
pressing IL-12R� expression and, as a result, IL-12 induced IFN-�
production (59). Assuming a parallel role for GATA-3 in CD4/
CD8 and Th1/Th2 development, we propose that GATA-3 is in-
volved in the stabilization of the distinct gene expression profiles
in committed CD4 cells, whereas for the full maturation of CD8 T
cells, GATA-3 expression needs to be down-regulated. Alterna-
tively, GATA-3 may affect lineage commitment indirectly by in-
ducing higher TCR�� expression levels (Fig. 6A), thereby increas-
ing the intensity of the signal delivered to DP cells, which has been
shown to skew development toward the CD4 lineage (60, 61). A
mechanism by which the influence of enforced expression of
GATA-3 on CD4/CD8 commitment is directly related to the pres-
ence of GATA-3 recognition sites in the CD8� promoter (62) can
also not be excluded. In that case, GATA-3 would have to directly
repress CD8 expression in mature cytotoxic T cells.
It is at present not clear why in CD2-GATA3 mice the levels of
transgene-encoded GATA-3 protein are down-regulated in CD8
SP cells and peripheral T cells. GATA-3 levels may be subject to
posttranslational regulation, as indicated by the presence of
caspase-mediated degradation of the closely related transcription
factor GATA-1 in immature erythroid cells (63). However, such a
mechanism should apply to both endogenous and transgene-en-
coded GATA-3. Therefore, the presence of the HA tag would then
affect posttranscriptional regulation.
Additional experiments will be needed to identify the critical
target genes for GATA-3 in early T cell development. Intriguingly,
GATA recognition sequences are present in the Notch4 promoter
region (64). If Notch genes would be regulated by GATA-3, this
could explain the parallels that exist between the in vivo function
of GATA-3 and Notch. Both genes are essential for the develop-
ment of the first stage of T cell development and not for any other
hemopoietic lineage (22, 31, 65). Apart from the accelerated
FIGURE 7. Enforced expression of GATA-3 in-
duces apoptosis and inhibits the maturation of
CD69lowHSAlow CD8 SP cells in the thymus. Thy-
mus cell suspensions were stained for CD4, CD8,
and annexin V (A) or TUNEL (B). Thymocytes were
analyzed for the expression for CD4 and CD8; the
indicated SP subpopulations were gated and ana-
lyzed for FSC and annexin V or TUNEL. The num-
bers indicate the percentage of annexin V-positive
(A) or TUNEL-positive (B) cells in the subpopula-
tions analyzed. C, In four-color flow cytometry ex-
periments, thymus cell suspensions were stained for
CD4 and CD8 expression along with anti-HSA and
anti-CD69 or with anti-CD62L and anti-CD44. The
CD4 and CD8 SP T cells were gated and analyzed
for the expression of the indicated markers. The re-
sults are displayed as histograms of CD2-GATA3-
transgenic mice (bold lines) along with those of non-
transgenic control mice (thin lines).
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Discussion
In this report we have used two different mouse models to study the role of GATA-3 
in early T cell development in vivo. We evaluated GATA-3 directed lacZ expression in GATA-
3+/nlslacZ mice, and examined the effects of enforced GATA-3 expression throughout T cell 
development in CD2-GATA3 transgenic mice, in which GATA-3 transcription is driven by the 
CD2 LCR. 
Our findings implicate GATA-3 as a participant in the commitment process to the CD4 
versus the CD8 lineage. First, we found that commitment to the CD8 T cell lineage coincided 
with downregulation of GATA-3 expression. The most mature subpopulation of uncommitted 
thymocytes, the CD4+CD8lo subset, contained high numbers of GATA-3 expressing cells. During 
the maturation of CD8+ cells in the thymus, GATA-3 expression was gradually lost. By contrast, 
GATA-3 expression remained high during differentiation of CD4+ cells in the thymus. Second, 
enforced GATA-3 expression inhibited the maturation of CD8+ cells. The CD8 SP fraction in the 
thymus contained increased numbers of apoptotic cells and exhibited a selective deficiency of 
mature CD69lowHSAlow cells. In the spleen and lymph nodes the numbers of CD8+ T cells were 
significantly reduced. 
Enforced expression of GATA-3 did not appear to directly influence the CD4 versus 
CD8 lineage cell fate decision, as in the CD2-GATA3 mice the percentages of CD4 and CD8 SP 
cells in the thymus were in the normal ranges. Although the molecular mechanisms underlying 
the developmental choice between CD4 and CD8 T cell fates are not known, they are thought 
to depend on differences in signal strengths of the MHC class I-CD8 and MHC class II-CD4 
interactions. The influence of signaling molecules on lineage commitment is supported by the 
finding of differentiation towards the CD4 lineage in a gain-of-function extracellular signal-
related kinase (Erk)-2 mutant, and in Csk or C-Cbl deficient mice42,54,56. Activated Notch 
transmembrane receptor or Bcl-2 overexpression were shown to promote differentiation to the 
CD8 lineage, probably by rescue from apoptosis and development along the CD8 lineage of cells 
that have a very low affinity MHC-interaction, which would normally die by neglect11,38,52.
Our data point at a role for GATA-3 in the maturation of the cells once commitment has 
occurred. There is a progressive decline of GATA-3 expression during CD8 lineage maturation, 
and the enforced GATA-3 expression impaired cell survival in the most mature CD8 lineage 
cells. Furthermore, peripheral CD8+ T cells from CD2-GATA3 Tg mice manifested functional 
defects in IL-2 and IFNγ production (See accompanying paper). In this context, there is a 
striking parallel with Th1/Th2 differentiation, where GATA-3 is expressed in naive peripheral T 
cells, followed by a substantial increase during Th2 development and a gradual downregulation 
during Th1 development70,71. The Th2 phenotype is initiated by IL-4 signaling, and by the action 
of GATA-3 becomes stable over time and independent of extrinsic factors, such as IL-41,2,46. 
Retroviral tagging of naive progenitors with GATA-3 provided direct evidence for instructive 
differentiation, rather than selective outgrowth of committed Th1 or Th2 cells14. It was further 
shown that GATA-3 generates stability of Th2 commitment by chromatin remodeling of Th2-
specific cytokine loci, associated with a positive autoactivation pathway, which is a recognized 
mechanism contributing to cell fate determination46. Concomitantly, GATA-3 inhibits 
Th1 development by repressing IL-12Rα expression and, as a result, IL-12 induced IFNγ 
production45. Assuming a parallel role for GATA-3 in CD4/CD8 and Th1/Th2 development, 
we propose that GATA-3 is involved in the stabilization of the distinct gene expression profiles 
in committed CD4 cells, while for the full maturation of CD8 T cells, GATA-3 expression 
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needs to be downregulated. Alternatively, GATA-3 may affect lineage commitment indirectly 
by inducing higher TCRαβ expression levels (Fig. 6A), thereby increasing the intensity of 
the signal delivered to DP cells, which has been shown to skew development toward the CD4 
lineage25,69. A mechanism by which the influence of enforced expression of GATA-3 on CD4/
CD8 commitment is directly related to the presence of GATA-3 recognition sites in the CD8α 
promoter32 can also not be excluded. In that case GATA-3 would have to directly repress CD8 
expression in mature cytotoxic T cells. 
It is at present not clear why in CD2-GATA3 mice the levels of transgene encoded 
GATA-3 protein are downregulated in CD8 SP cells and peripheral T cells. GATA-3 levels 
may be subject to posttranslational regulation, as indicated by the presence of caspase-mediated 
degradation of the closely related transcription factor GATA-1 in immature erythroid cells10. 
However, such mechanism should apply to both endogenous and transgene-encoded GATA-3. 
Therefore, the presence of the HA-tag would then affect posttranscriptional regulation. 
Further experiments will be needed to identify the critical target genes for GATA-3 in 
early T cell development. Intriguingly, GATA recognition sequences are present in the Notch4 
promoter region33. If Notch genes would be regulated by GATA-3, this could explain the parallels 
that exist between the in vivo function of GATA-3 and Notch. Both genes are essential for the 
development of the first stage of T cell development, and not for any other haematopoietic 
lineage24,50,62. Apart from the accelerated TCRαβ upregulation in developing CD69+ thymocytes 
that progress from the DP to the CD4+CD8lo stage, we did not see any effects on the surface 
expression of presumed GATA-3 target loci, such as TCRα, β  , and δ or CD8α. 
Our previous finding of low GATA-3 expression during the two waves of TCR gene 
rearrangement, separated by a stage of high GATA-3 expression, suggested a role of GATA-
3 in the regulation of proliferation events associated with the essential coupling of V(D)J 
recombination activity to cell cycle24. However, the absence of any detectable effects of the 
CD2-GATA3 transgene on the cell cycle would argue against such an essential role for GATA-3. 
Nevertheless, all thymic lymphomas in the CD2-GATA3 mice characterized so far appeared to 
have originated at the DP stage, in which all TCRα locus gene rearrangements occur. Therefore, 
it remains possible that - in the presence of high levels of GATA-3 - oncogenic events, such 
as translocations, are mediated by aberrant use of the V(D)J recombination machinery, as has 
been found in V(D)J-recombination driven thymic lymphoma in mice deficient for the ataxia 
telangiectasia gene34.
Alternatively, the oncogenic potential of GATA-3 could be related to the ability of 
GATA-3 to form a complex with the TAL-1 and LMO transcription factors, which are implicated 
in a large fraction of human T-cell acute lymphoblastic leukemias43. Normally TAL-1 and LMO 
are not expressed in the T cell lineage, but expression is induced by translocation events. It was 
recently shown that forced expression of GATA-3 in vitro potentiated the induction by the TAL-
1 and LMO transcription factors of retinaldehyde dehydrogenase 2, which inhibits apoptosis of 
T cells by generating retinoic acid43. 
Thirdly, enforced GATA-3 expression probably leads to increased basal transcription 
of the RAD50 gene, which is involved in chromosomal double-stranded break repair. Because 
of the localization of the RAD50 gene within the IL-4/IL-5/IL-13 Th2 cytokine gene cluster, an 
increase of basal RAD50 transcription is observed in Th2 cells2. It is possible that in the CD2-
GATA3 transgenic T cells the increase might be more extreme, thereby resulting in destabilization 
of the MRE11-RAD50-NBS1 protein complex, which is essential for chromosome stability48. 
Finally, a more general mechanism might be responsible for the oncogenic effect 
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of GATA-3, as GATA factors have a key role in the regulation of development toward cell 
division and differentiation via the cell cycle machinery65. Recently several other GATA family 
factors have been implicated in various human tumors, e.g. GATA-2 in acute promyelocytic 
leukemia, acute myeloid leukemia and myelodysplastic syndrome, and GATA-4 in esophageal 
adenocarcinomas and malignancies of the gonads36,63,66. Further characterization of the tumor 
cells should identify the possible involvement of any of these oncogenic pathways in the origin 
of the thymic lymphomas in the CD2-GATA3 mice.
In conclusion, this study adds to our knowledge of the function of GATA-3 in early T cell 
development, as we have established a correlation between GATA-3 expression and maturation 
towards the CD4 versus the CD8 lineage. We propose that in early T cell development, expression 
of GATA-3 is essential for the maintenance of CD4 cell lineage fate commitment, but inhibits 
CD8 differentiation. Inferred from the recent findings that GATA-3 acts a key regulator of Th2 
development by stabilizing patterns of gene expression, it is attractive to hypothesize that in 
early T cell development GATA-3 would stabilize, by chromatin remodeling, the unique gene 
expression profiles that are characteristic for the CD4 lineage. 
Materials and Methods
Mice
The GATA-3+/nlslacZ mice in which one GATA-3 allele was replaced by a lacZ reporter have 
been described previously24. For the generation of the CD2-GATA3 construct, the translation 
initiation site was mutated (ATG to GTG) in a murine GATA-3 cDNA clone and 3 HA epitope 
tags were added together with a new ATG and Kozak’s consensus sequence. Subsequently, the 
~ 2 kb mGATA-3 was cloned into a human CD2 mini-gene Bluescript SK vector, with ~5 kb of 
CD2 5’promoter sequence and ~ 5.5 kb 3’ CD2 flanking sequences72. The latter contained the 
3’ untranslated sequence and poly(A) addition site of the CD2 gene, as well as the LCR, which 
was shown to confer T-cell specific, copy-dependent, integration site independent expression 
in transgenic mice20.  A 13.2-kb linear fragment was injected into pronuclei of FVB X FVB 
fertilized oocytes at a concentration of ~2 ng/µl. Founder mice were identified by genomic 
Southern blotting and crossed onto an FVB background. To determine the genotype of the 
subsequent generations, tail DNA was analyzed by Southern blotting of either EcoRI /XbaI 
double digests hybridized to a 2 kb HindIII CD2 LCR probe16, or EcoRI digests hybridized to a 
800 kb partial GATA-3 cDNA probe44.
Western blotting analyses
Total nuclear protein extracts were prepared according to Andrews et al.6. Protein 
concentration in the nuclear extracts was determined using BCA protein assay (Pierce, 
Rockford, IL). For Western blotting analysis, 50 µg of total nuclear protein was loaded per lane 
and separated on 10% SDS-PAGE gels under reducing conditions and transferred to PVDF 
membrane (Immobilon-P, Millipore, Bedford, MA). Blots were blocked with 2% BSA in PBS 
pH 7.0, 0.05% Tween 20 and incubated with first- and second step reagents in 2% non-fat dry 
milk in PBS pH 7.0, 0.05% Tween 20. The mouse anti-GATA-3 mAb HG 3-31 and the polyclonal 
rabbit-anti-HA antibody Y11 were from SantaCruz Biotechnology (Santa Cruz, CA). Second-
step reagents were horseradish peroxidase-conjugated goat-anti-mouse Ig and swine-anti-rabbit 
Ig from DAKO (Glostrup, Denmark). Peroxidase activity was visualized by enhanced chemi-
luminescence, using standard procedures. 
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Flow cytometric analyses
The preparation of single-cell suspensions, determination of β-galactosidase activity 
using fluorescein-di-β-D-galactopyranoside (FDG), mAb incubations and three or four 
color cytometry have been described previously23. The following mAb were purchased from 
Pharmingen: FITC-conjugated anti-CD3ε and anti-TCRαβ, PE-conjugated anti-CD4 (L3T4), 
anti-CD24/heat stable antigen (HSA), anti-CD25 (clone 3C7), anti-CD62L and anti-CD69, 
CyChrome-conjugated anti-CD4, anti-CD8 and anti-CD44, biotinylated anti-CD4 and anti-
CD8, APC-labeled anti-CD3ε and anti-CD4. Secondary antibodies used were PE-, TriColor, or 
APC-conjugated streptavidin (Caltag Laboratories, Burlingame, CA). FDG and To-Pro3 were 
from Molecular Probes Europe BV (Leiden, The Netherlands). FITC-labeled Annexin V was 
from Nexins Research BV, Hoeven, The Netherlands.
For intracellular detection of GATA-3 protein, cells were fixed and permeabilized 
using paraformaldehyde and saponin, as described12 and subsequently incubated with the Hg-
3-31 anti-GATA-3 MoAb (Santa Cruz, Dan Diego, CA) and FITC-labeled anti-mouse IgG1 
(Pharmingen) as a second step.
Simultaneous two-color staining of membrane CD4 and CD8, combined with a TUNEL 
(TdT-mediated dUTP-biotin nick end labeling) technique to quantify apoptosis was performed, 
using fluorescein in situ cell death detection (Roche Molecular Biochemicals, Mannheim, 
Germany), as described55.
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The transcription factor GATA-3 is essential for early T cell development and 
differentiation of naive CD4+ T cells into Th2 effector cells. To study the function of GATA-3 
during T cell mediated immune responses in vivo, we investigated CD2-GATA3 transgenic mice, 
in which GATA-3 expression is driven by the CD2 locus control region. Both in the CD4+ and 
the CD8+ T cell population the proportion of cells exhibiting a CD44hiCD45RBloCD62Llo 
antigen-experienced phenotype was increased. In CD2-GATA3 transgenic mice, large fractions 
of peripheral CD4+ T cells expressed the IL-1 receptor family member T1/ST2, indicative of 
advanced Th2 commitment. Upon in vitro T cell stimulation, the ability to produce interleukin-2 
(IL-2) and interferon-γ (IFNγ) was decreased. Moreover, CD4+ T cells manifested rapid secretion 
of the Th2 cytokines IL-4, IL-5 and IL-10, reminiscent of Th2 memory cells. In contrast to wild-
type CD4+ cells, which lost GATA-3 expression when cultured under Th1-polarizing conditions, 
CD2-GATA3 transgenic CD4+ cells maintained expression of GATA-3 protein. Under Th1 
conditions, cellular proliferation of CD2-GATA3 transgenic CD4+ cells was severely hampered, 
IFNγ production was decreased and Th2 cytokine production was increased. Enforced GATA-3 
expression inhibited Th1-mediated in vivo responses, such as antigen-specific IgG2a production 
or a delayed type hypersensitivity response to KLH. Collectively, these observations indicate 
that enforced GATA-3 expression selectively inhibits Th1 differentiation and induces Th2 
differentiation. The increased functional capacity to secrete Th2 cytokines, together with the 
increased expression of surface markers for antigen-experienced Th2 committed cells, would 
argue for a role of GATA-3 in Th2 memory formation. 
Introduction
The CD4+ T helper (Th) lymphocytes develop into two functionally distinct subsets 
that can be distinguished on the basis of their cytokine production profile32,38. Th1 cells are 
characterized by the production of interferon-γ (IFNγ) and tumor necrosis factor β (TNFβ), 
whereas Th2 cells typically produce interleukin-4 (IL-4), IL-5, IL-10 and IL-13. Each subset 
mediates distinct effector functions in vivo. Th1 cells are predominantly involved in immune 
responses against intracellular pathogens, and are associated with autoimmune disease. Th2 
cells are of importance in the defense against extracellular pathogens, and are implicated in 
atopy and allergic diseases1,34,41.
Both Th1 and Th2 cells are derived from a common naive precursor1,3,34. Signaling 
pathways initiated by cytokines play a dominant role in driving the differentiation of 
GATA-3 inhibitsTh1 responses in vivo
123
activated naive CD4+ T cells into either effector phenotype4,38. For instance, IL-12 induces 
the differentiation of naive Th cells to the Th1 effector phenotype19,29,30,43, by activation of the 
transcription factor Stat421,48,52. On the other hand, Th2 differentiation is mediated by Stat6 
activation through IL-4 receptor engagement18,22,24,42,44,47,50. In response to chronic antigenic 
stimulation in vivo, progressive polarization of the cytokine responses ultimately leads to the 
commitment of T helper cells to mutually exclusive Th phenotypes, which are thought to be 
maintained independently of extrinsic factors20,33.
Stat6 induces the expression of the transcription factors GATA-3 and c-Maf23, which have 
been shown to be selectively expressed in a Th2-specific fashion17,56,59. Using Stat6-deficient cells 
it has been shown that, although IL-4 and Stat6 signaling may initially direct Th2 development, 
GATA-3 and c-Maf are capable of inducing the development of stabile Th2 commitment, 
independent of Stat636. In vitro differentiation into Th1 cells induces chromatin remodeling of 
the IFNγ locus and, conversely, the differentiation into Th2 cells induces remodeling of the IL-
4/IL-5/IL-13 locus2,51. Recently, GATA-3 has been shown to play an instructive role in directing 
Th2 differentiation10. 
During early T cell development, GATA-3 gene expression is required for the 
development of the earliest T cell progenitors14,16,53. GATA-3 levels are low during the two 
phases of TCR gene rearrangement, but are high in the fraction of rapidly proliferating cells 
that insulates these two periods of TCR rearrangement16. GATA-3 expression remains high 
in CD4+ thymocytes, but progressively declines in CD8+ thymocytes (see accompanying 
paper). GATA-3 is detected in naive CD4+ T cells and expression levels increase substantially 
during Th2 differentiation56,59. GATA-3 expression has been shown to be indispensable for Th2 
development, and is downregulated in response to IL-12-mediated Stat4 activation35,59. GATA-
3 strongly transactivates the IL-5 promoter, but appears to have only limited effects on IL-4 
gene transcription40,57,59. Retroviral introduction of GATA-3 during in vitro Th1 differentiation 
of naive CD4+ T cells, resulted in an inhibition of IFNγ production, independently of IL-411,35, 
and a downregulation of IL-12Rβ235, which normally accompanies Th-2 differentiation49. 
 The manipulation of Stat6 and GATA-3 expression in Th1 and Th2 polarization 
cultures of wild-type or specific cytokine-deficient cells in vitro have added significantly to 
our understanding of the molecular basis of Th1/Th2 differentiation. However, limited data are 
available on the role of GATA-3 during immune responses in animal models, partly because 
the embryonic lethality of GATA-3 deficiency in mice precluded in vivo studies37. Analysis 
of transgenic mice with T cell-specific expression of a dominant-negative mutant of GATA-3 
indicated that inhibition of GATA-3 activity reduced the key features of asthma, including Th2 
cytokine levels, eosinophilia and IgE production58.
To study the function of GATA-3 during T cell differentiation, we generated transgenic 
mice in which the expression of GATA-3 is under the control of the human CD2 locus control 
region (see accompanying paper). In these mice, the enforced GATA-3 expression induced the 
development of thymic lymphomas of CD4+CD8+/lo T cells and inhibited the maturation of CD8 
single positive (SP) cells in the thymus. Within the CD8 SP population in the thymus apoptosis 
was increased and the fraction of mature CD69loHSAlo cells was significantly reduced. The 
numbers of peripheral CD8+ T cells were ~50% of normal. These observations supported a role 
for GATA-3 in the regulation of CD4/CD8 lineage commitment (see accompanying paper). 
To investigate how the enforced expression of GATA-3 affected T helper cell 
differentiation, we analyzed T cell-mediated immune responses in vivo in CD2-GATA3 transgenic 
mice. The observations of a selective deficiency of antigen-specific IgG2a production and 
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severely reduced delayed-type hypersensitivity responses in these mice showed that enforced 
GATA-3 expression inhibited the differentiation of Th1 cells in vivo. Furthermore, the expression 
of surface markers specific for antigen-experienced Th2 cells, together with the increased 
functional capacity to secrete the Th2 cytokines, indicated that transgenic GATA-3 expression 
induced Th2 commitment and pointed at a role for GATA-3 in Th2 memory formation.
 Results 
Increased expression of antigen-experienced T cell surface markers in CD2-GATA3 
transgenic mice
In two independent CD2-GATA-3 transgenic lines expression of HA-tagged GATA-3 
was under the control of the CD2 locus control region. Due to the presence of this transgene, 
GATA-3 expression was significantly enhanced in the thymus, especially in the DP fraction. In 
these mice, the expression of transgenic GATA-3 in peripheral lymphoid organs was low (see 
accompanying paper). In the experiments described below, we did not detect any differences 
between the two independent lines, TgA and TgB.
To determine the effect of enforced GATA-3 expression on the development of the 
peripheral T cell compartments, we investigated the sizes of the CD4+ and CD8+ populations 
in CD2-GATA3 transgenic mice and their non-transgenic littermates at different ages (Fig. 1A). 
In spleen and mesenteric lymph nodes, the numbers of CD4+ T cells in CD2-GATA3 mice were 
either increased (3 weeks of age) or within normal ranges (12 weeks of age). In contrast, the 
CD8+ T cell populations were consistently reduced in number, to ~50% of normal, irrespective 
of the age analyzed (Fig. 1A). Despite the observed increased apoptosis in the fraction of mature 
single positive cells in the thymus (see accompanying paper), the CD2-GATA3 transgenic mice 
were not found to be lymphopenic at any of the ages analyzed.
As GATA-3 is involved in the stabilization of the Th2 phenotype and the maintenance 
of Th2 cytokine expression, which are important features of T helper memory, we wanted to 
assess whether the enforced expression of GATA-3 had an effect on the development of memory 
T cells. Antigen activation induces the expression of CD44 and decreases CD45RB and L-
selectin (CD62L) expression on the cell surface of T cells. As this profile of cell surface marker 
expression is maintained, even after cells have reverted to a quiescent state, it can be used to 
define antigen-experienced T cells8. As shown in Fig. 1BC, in CD2-GATA3 transgenic mice 
both the CD4+ and the CD8+ T cell populations contained increased proportions of CD44hi, 
CD45RBlo and CD62Llo cells. This was found both in spleen and in lymph nodes, and pointed 
to the presence of elevated numbers of either recently activated or antigen-experienced T cells8. 
The expression levels of CD69 and IL-2Rα (CD25), which are markers of recently activated 
T cells28, were low in CD2-GATA3 mice and non-transgenic littermates (Shown for CD25 in 
Fig.1AB), arguing against the presence of major fractions of recently activated T cells in CD2-
GATA3 mice. It has been shown that the proportions of T cells with an antigen-experienced 
phenotype increases with age, probably as a result of progressive antigen experience9,46. When 
we compared CD44 and CD62L expression at two different ages, 3 months and 7 months, we 
indeed found that the conversion to the CD44hiCD62Llo antigen-experienced T cell phenotype 
increased with age, both in CD2-GATA3 transgenic mice and in control mice (shown for CD62L 
in Fig. 1C). 
Taken together, these results indicated that in the CD2-GATA3 mice both the CD4+ and 
the CD8+ T cell population contained increased proportions of cells with an antigen-experienced 
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phenotype.
Figure 1 - Enforced GATA-3 expression is associated with increased numbers of T cells with a memory surface 
phenotype.(A) Single-cell suspensions from spleen and mesenteric lymph nodes from 3-week old and 12 week-old CD2-
GATA3 transgenic mice and non-transgenic littermates were analyzed for CD4 and CD8 expression. Surface CD4/CD8 
profiles are shown as dot plots, in which the percentages of total lymphocytes within the indicated CD4+ and CD8+ 
gates are given. (B) Single-cell suspensions from spleen and mesenteric lymph nodes from 12 week-old CD2-GATA3 
transgenic mice and non-transgenic littermates were stained for CD4 and CD8, together with CD44, CD45RB or CD25. 
Total CD4+ and CD8+ T cell populations were analyzed for the indicated markers. Results are displayed as histograms 
of CD2-GATA3 transgenic mice (bold lines) and those of non-transgenic littermates (thin lines). The percentages of 
activated/antigen-experienced cells  (CD44high, CD45RBlow or CD25+) are indicated above the marker line in bold (CD2-
GATA3 transgenic mice) and below the marker line (non-transgenic littermates). Data shown are representative of at least 
6 mice examined in each group. (C) The numbers of activated/antigen-experienced (CD62Llow) cells in CD2-GATA3 
transgenic and control mice at two different ages, 12 weeks and 30 weeks. The percentages are indicated as in panel B. 
Enforced expression of GATA-3 results in increased numbers of T1/ST2 positive 
CD4+ T cells in the periphery
The IL-1R family member T1/ST2 is preferentially expressed on the surface of murine 
Th2 cells5,25,54,55. It was recently shown that CD4+ cells become T1/ST2 positive after repeated 
antigenic stimulation under Th2-polarizing conditions and that Th2 cytokine production 
precedes T1/ST2 expression31. Therefore, T1/ST2 expression appears to be a late event in Th2 
commitment. 
To investigate whether CD4+ T cells in CD2-GATA3 mice exhibited preferential Th2 
polarization and advanced Th2 commitment in vivo we evaluated surface expression of T1/ST2 
(Fig. 2). In non-transgenic controls we found T1/ST2 expression on 5.1% + 1.3 and 1.1% + 
GATA-3 expression was significantly enhanced in the thymus, es-
pecially in the DP fraction. In these mice, the expression of trans-
genic GATA-3 in peripheral lymphoid organs was low (see ac-
companying paper). In the experiments described below, we did
not detect any differences between the two independent lines TgA
and TgB.
To determine the effect of enforced GATA-3 expression on the
development of the peripheral T cell compartments, we investi-
gated the sizes of the CD4� and CD8� populations in CD2-
GATA3-transgenic mice and their nontransgenic littermates at dif-
ferent ages (Fig. 1A). In spleen and mesenteric lymph nodes, the
numbers of CD4� T cells in CD2-GATA3 mice were either in-
creased (3 wk of age) or within normal ranges (12 wk of age). In
contrast, the CD8� T cell populations were consistently reduced in
number, to�50% of normal, irrespective of the age analyzed (Fig.
1A). Despite the observed increased apoptosis in the fraction of
mature SP cells in the thymus (see accompanying paper), the CD2-
GATA3-transgenic mice were not found to be lymphopenic at any
of the ages analyzed.
Because GATA-3 is involved in the stabilization of the Th2
phenotype and the maintenance of Th2 cytokine expression, which
are important features of Th memory, we wanted to assess whether
the enforced expression of GATA-3 had an effect on the develop-
ment of memory T cells. Ag activation induces the expression of
CD44 and decreases CD45RB and L-selectin (CD62L) expression
on the cell surface of T cells. As this profile of cell surface marker
expression is maintained, even after cells have reverted to a qui-
escent state, it can be used to define Ag-experienced T cells (48).
As shown in Fig. 1, B and C, in CD2-GATA3-transgenic mice both
the CD4� and the CD8� T cell populations contained increased
proportions of CD44high, CD45RBlow, and CD62Llow cells. This
was found both in spleen and in lymph nodes, and pointed to the
presence of elevated numbers of either recently activated or Ag-
experienced T cells (48). The expression levels of CD69 and IL-
2R� (CD25), which are markers of recently activated T cells (49),
were low in CD2-GATA3 mice and nontransgenic littermates
(shown for CD25 in Fig. 1, A and B), arguing against the presence
of major fractions of recently activated T cells in CD2-GATA3
mice. It has been shown that the proportions of T cells with an
Ag-experienced phenotype increases with age, probably as a result
of progressive Ag experience (50, 51). When we compared CD44
and CD62L expression at two different ages, 3 and 7 mo, we in-
deed found that the conversion to the CD44highCD62Llow Ag-ex-
perienced T cell phenotype increased with age, both in CD2-
GATA3-transgenic mice and in control mice (shown for CD62L in
Fig. 1C).
Taken together, these results indicated that in the CD2-GATA3
mice both the CD4� and the CD8� T cell population contained
increased proportions of cells with an Ag-experienced phenotype.
Enforced expression of GATA-3 results in increased numbers of
T1/ST2-positive CD4� T cells in the periphery
The IL-1R family member T1/ST2 is preferentially expressed on
the surface of murine Th2 cells (43, 52–54). It was recently shown
that CD4� cells become T1/ST2 positive after repeated antigenic
stimulation under Th2-polarizing conditions and that Th2 cytokine
production precedes T1/ST2 expression (55). Therefore, T1/ST2
expression appears to be a late event in Th2 commitment.
To investigate whether CD4� T cells in CD2-GATA3 mice ex-
hibited preferential Th2 polarization and advanced Th2 commit-
ment in vivo, we evaluated surface expression of T1/ST2 (Fig. 2).
In nontransgenic controls, we found T1/ST2 expression on 5.1%�
FIGURE 1. Enforced GATA-3 expression is associated with increased numbers of T cells with a memory surface phenotype. A, Single-cell suspensions
from spleen and mesenteric lymph nodes from 3- and 12-wk-old CD2-GATA3-transgenic mice and nontransgenic littermates were analyzed for CD4 and
CD8 expression. Surface CD4/CD8 profiles are shown as dot plots in which the percentages of total lymphocytes within the indicated CD4� and CD8�
gates are given. B, Single-cell suspensions from spleen and mesenteric lymph nodes from 12-wk-old CD2-GATA3-transgenic mice and nontransgenic
littermates were stained for CD4 and CD8, along with CD44, CD45RB, or CD25. Total CD4� and CD8� T cell populations were analyzed for the indicated
markers. Results are displayed as histograms of CD2-GATA3-t ansgenic mice (bold lines) and those of nontransg nic ittermates (thin lines). The per-
centages of activated/Ag-experienced cells (CD44high, CD45RBlow, or CD25�) are indicated above the marker line in bold (CD2-GATA3-transgenic mice)
and below the marker line (nontransgenic littermates). Data shown are representative of at least six mice examined in each group. C, The numbers of
activated/Ag-experienced (CD62Llow) cells in CD2-GATA3-transgenic and control mice at two different ages, 12 and 30 wk. The percentages are indicated
as in B.
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0.1 (n=5) of CD4+ T cells in spleen and mesenteric lymph nodes, respectively. In four-color 
labelings with CD4, CD8, CD44 and T1/ST2, it was shown that in non-transgenic mice T1/ST2 
expression was largely confined to the CD44hi fraction of activated/memory CD4+ T cells 
(Fig. 2). 
 The CD2-GATA3 transgenic animals showed a significant increase in the proportions of 
T1/ST2+ cells: 31% + 1 and 23% + 2 (n=3) in spleen and mesenteric lymph nodes, respectively. 
This increase could not be attributed solely to the increased proportion of CD4+ T cells with 
a CD44hi activated/memory phenotype, as T1/ST2 was also found to be expressed on naive 
CD4+ T cells with a CD44lo surface profile (Fig. 2). 
Figure 2 - Aberrant T1/ST2 surface expression in CD2-GATA3 transgenic mice.Single-cell suspensions from spleen 
(A) and mesenteric lymph nodes (B) from 2-3 month-old CD2-GATA3 transgenic mice and non-transgenic littermates 
were stained for CD4, CD8, CD44 and T1/ST2. CD4+ and CD8+ T cells were gated and analyzed for CD44 and T1/ST2 
expression. Data are displayed as dot plots, and the percentages of gated cells within the indicated T1/ST2+ quadrants 
are shown.
When we analyzed T1/ST2 expression in the thymic subpopulations, we found induction 
of T1/ST2 on a small fraction of the CD4 single positive cells in CD2-GATA3 transgenic mice: 
6.0% + 1.0 (n=3), compared with 0.4% + 0.05 in non-transgenic mice (n=5). In contrast, T1/
ST2 expression was not significantly induced on CD8 SP thymocytes (<0.5%). Consistent 
with the reported absence of T1/ST2 on the surface of CD8+ cells25,55, we found very low 
numbers of T1/ST2 positive cells in non-transgenic mice.  However, some T1/ST2 expression 
was observed on CD8+ T cells in spleen (3.0% + 0.8) and lymph node (1.7% + 0.6) from CD2-
GATA3 transgenic mice (Fig. 2).
 In summary, these data indicate that enforced expression of GATA-3 resulted in 
1.3 nd 1.1% � 0.1 (n � 5) of CD4� T cell in spleen and mes-
enteric lymph nodes, respectively. In four-c lor labelings with
CD4, CD8, CD44, and T1/ST2, it was shown that in nontransgenic
mice T1/ST2 expression was largely confined to the CD44high
fraction of activated/memory CD4� T cells (Fig. 2).
The CD2-GATA3-transgenic animals showed a significant in-
crease in the proportions of T1/ST2� cells: 31% � 1 and 23% �
2 (n� 3) in spleen and mesenteric lymph nodes, respectively. This
increase could not be attributed solely to the increased proportion
of CD4� T cells with a CD44high activated/memory phenotype,
since T1/ST2 was also found to be expressed on naive CD4� T
cells with a CD44low surface profile (Fig. 2).
When we analyzed T1/ST2 expression in the thymic subpopu-
lations, we found induction of T1/ST2 on a small fraction of the
CD4 SP cells in CD2-GATA3-transgenic mice: 6.0%� 1.0 (n� 3)
compared with 0.4% � 0.05 in nontransgenic mice (n � 5). In
contrast, T1/ST2 expression was not significantly induced on CD8
SP thymocytes (�0.5%). Consistent with the reported absence of
T1/ST2 on the surface of CD8� cells (43, 52), we found very low
numbers of T1/ST2-positive cells in nontransgenic mice. How-
ever, some T1/ST2 expression was observed on CD8� T cells in
spleen (3.0% � 0.8) and lymph node (1.7% � 0.6) from CD2-
GATA3-transgenic mice (Fig. 2).
In summary, these data indicate that enforced expression of
GATA-3 resulted in significantly increased numbers of peripheral
CD4� T cells with an advanced Th2-committed T1/ST2� pheno-
type, not only in the CD44high activated/memory T cell compart-
ment but also in CD44low naive T cells.
Increased ability to secrete Th2 cytokines in CD2-GATA3-
transgenic T cells
As one hallmark of a memory cell population is the ability to
secrete a wider diversity of cytokines (48), we investigated the
ability of peripheral T cells to synthesize various cytokines. After
polyclonal in vitro stimulation of mesenteric lymph node cells,
significant differences in the cytokine production profiles between
wild-type and CD2-GATA3-transgenic mice were observed. When
intracellular cytokine expression was analyzed by flow cytometry,
CD2-GATA3-transgenic CD4� and CD8� T cells manifested de-
creased expression of IL-2 and IFN-� (Fig. 3A). In addition, the
FIGURE 2. Aberrant T1/ST2 surface expression in CD2-GATA3-trans-
genic mice. Single-cell suspensions from spleen (A) and mesenteric lymph
nodes (B) from 2–3-mo-old CD2-GATA3-transgenic mice and nontrans-
genic littermates were stained for CD4, CD8, CD44, and T1/ST2. CD4�
and CD8� T cells were gated and analyzed for CD44 and T1/ST2 expres-
sion. Data are displayed as dot plots, and the percentages of gated cells
within the indicated T1/ST2� quadrants are shown.
FIGURE 3. Peripheral T cells from CD2-GATA3-transgenic mice pro-
duce Th2 cytokines upon activation. A, Decreased synthesis of IL-2 and
IFN-� in CD2-GATA3-transgenic T cells. Mesenteric lymph node T cells
were stimulated with anti-CD3� for 40 h, and intracellular IL-2 and IFN-�
were determined by flow cytometry, in conjunction with membrane ex-
pression of CD4 and CD8. Results are displayed as histograms of CD2-
GATA3-transgenic mice (bold lines) and those of nontransgenic littermates
(thin lines). The percentages of cytokine-positive cells are indicated below
the marker line in bold (CD2-GATA3-transgenic mice) and above the
marker line (nontransgenic littermates). B, Th2 cytokine profiles of CD2-
GATA3-transgenic and control T cells. Mesenteric lymph node T cells were
stimulated with anti-CD3� for either 40 or 60 h as indicated.�, Wild-type
mice; f, CD2-GATA3-transgenic mice. The levels of the indicated cyto-
kines were measured in the culture supernatants by ELISA. C, Prolifera-
tion, determined by [3H]thymidine incorporation, in response to anti-CD3�
stimulation of purified CD4� T cells. Data are given as mean values� SD.
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significantly increased numbers of peripheral CD4+ T cells with an advanced Th2 committed 
T1/ST2+ phenotype, not only in the CD44hi activated/memory T cell compartment, but also in 
CD44lo naive T cells. 
Increased ability to secrete Th2 cytokines in CD2-GATA3 transgenic T cells 
As one hallmark of a memory cell population is the ability to secrete a wider diversity 
of cytokines8, we investigated the ability of peripheral T cells to synthesize various cytokines. 
After polyclonal in vitro stimulation of mesenteric lymph node cells, significant differences 
in the cytokine production profiles between wild-type and CD2-GATA3 transgenic mice were 
observed. When intracellular cytokine expression was analyzed by flow cytometry, CD2-GATA3 
transgenic CD4+ and CD8+ T cells manifested decreased expression of IL-2 and IFNγ (Fig. 
3A). In addition, the production of the Th2 cytokines IL-4, IL-5 and IL-10 was increased in 
CD2-GATA3 transgenic T cells after 40 and 60 hours of culture (Fig. 3B).
 The effect of enforced GATA-3 expression on T cell proliferation was studied in in vitro 
stimulations of purified CD4+ T cells. When 28thymidine incorporation was assessed at day 1 
or day 2,  the CD2-GATA3 transgenic T cells manifested significantly reduced proliferation, as 
compared to non-transgenic T cells (Fig. 3C). 
Collectively, the CD2-GATA3 transgenic T cells were characterized by an increased 
production of Th2 cytokines and reduced production of IL-2 and IFNγ upon stimulation, 
suggesting the presence of an increased memeory compartment within the peripheral T cell 
population in vivo.
Expression of GATA-3 in CD2-GATA3 transgenic T cell cultures under Th1 polarizing 
conditions 
Next, we performed in vitro Th1/Th2 polarization culture experiments on purified 
CD4+ T cells from spleen and lymph nodes to investigate whether the differentiation potential 
into T effector phenotypes was altered in the CD2-GATA3 mice. In these experiments, cells 
were stimulated with anti-CD3ε mAbs, either under “default” conditions (without additional 
cytokines or antibodies), Th1 polarizing conditions (in the presence of IL-12 and anti-IL-4 
mAbs) or under Th2 polarizing conditions (in the presence of IL-4 and anti-IFNγ mAbs) for 4 
days. Subsequently, the cells were washed and restimulated with anti-CD3ε mAbs for 3 days, 
without additional antibodies or cytokines.  
First, we evaluated the GATA-3 expression in lymph node derived T cell cultures by 
Western blotting and intracellular flow cytometric analyses, using a mouse monoclonal antiserum 
specific for GATA-3 (Fig. 4AB). In non-transgenic and CD2-GATA3 transgenic CD4+ T cell 
cultures, GATA-3 protein was abundantly expressed both under default and Th2 polarizing 
conditions. GATA-3 protein could not be detected in non-transgenic Th1 cultures (Fig. 4A). In 
contrast, GATA-3 was expressed in CD2-GATA3 transgenic Th1 cultures, although the levels of 
expression were lower than in the corresponding Th2 or default cultures (Fig. 4A). The GATA-3 
protein present had the apparent molecular weight of endogenous GATA-3, and no transgene 
encoded GATA-3 bands could be detected, using antibodies specific for the HA tag present in 
the transgenic GATA-3 protein. 
Intracellular GATA-3 protein flow cytometric assays allowed a comparison of mean 
fluorescence intensity values in histogram overlays. Although these analyses are limited by 
a background signal of the GATA-3 antibody, they showed that GATA-3 protein levels were 
higher in the cultures of CD2-GATA3 transgenic mice, when compared to those of the non-
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transgenic littermates, irrespective of the culture conditions (Shown for Th1 and Th2 conditions 
in Fig. 4B). 
Therefore, we conclude that due to the presence of the CD2-GATA3 transgene, GATA-
3 protein expression is maintained in CD4+ T cells that are cultured under Th1-polarizing 
conditions. 
Figure 3 - Peripheral T cells from CD2-GATA3 transgenic mice produce Th2 cytokines upon activation. (A) Decreased 
synthesis of IL-2 and IFNγ in CD2-GATA3 transgenic T cells. Mesenteric lymph node T cells were stimulated with anti-
CD3ε for 40 hours, and intracellular IL-2 and IFNγ  was determined by flow cytometry, in conjunction with membrane 
expression of CD4 and CD8. Results are displayed as histograms of CD2-GATA3 transgenic mice (bold lines) and those 
of non-transgenic littermates (thin lines). The percentages of cytokine-positive cells are indicated below the marker 
line in bold (CD2-GATA3 transgenic mice) and above the marker line (non-transgenic littermates).(B) Th2 cytokine 
profiles of CD2-GATA3 transgenic and control T cells. Mesenteric lymph node T cells were stimulated with anti-CD3ε 
for either 40 or 60 hours, as indicated. Open bars: wild-type mice; closed bars: CD2-GATA3 transgenic mice. The 
levels of the indicated cytokines were measured in the culture supernatants by ELISA. (C) Proliferation, determined by 
[3H]thymidine incorporation, in response to anti-CD3ε stimulation of purified CD4+ T cells. Data are given as mean 
values +  standard deviation 
The Th1/Th2 differentiation potential of CD2-GATA3 transgenic T cells in vitro
Cytokine production was evaluated in the Th1/Th2 polarized CD4+ T cell cultures from 
lymph nodes or spleen. CD2-GATA3 transgenic CD4+ T cells produced normal amounts of IL-
4, but higher levels of IL-5 and IL-10 in the default or Th2-polarized cultures, when compared 
to non-transgenic CD4+ T cells (Fig. 4C). In addition, when CD2-GATA3 transgenic CD4+ 
T cells were cultured under Th1 polarizing conditions, they produced significantly increased 
amounts of IL-4, IL-5 and IL-10. Irrespective of the culture conditions, the production of IFNγ 
was significantly reduced in the CD2-GATA3 transgenic CD4+ T cells, when compared to those 
from non-transgenic littermates (Fig. 4C).
1.3 and 1.1% � 0.1 (n � 5) of CD4� T cells in spleen and mes-
enteric lymph nodes, respectively. In four-color labelings with
CD4, CD8, CD44, and T1/ST2, it was shown that in nontransgenic
mice T1/ST2 expression was largely confined to the CD44high
fraction of activated/memory CD4� T cells (Fig. 2).
The CD2-GATA3-transgenic animals showed a significant in-
crease in the proportions of T1/ST2� cells: 31% � 1 and 23% �
2 (n� 3) in spleen and mesenteric lymph nodes, respectively. This
increase could not be attributed solely to the increased proportion
of CD4� T cells with a CD44high activated/memory phenotype,
since T1/ST2 was also found to be expressed on naive CD4� T
cells with a CD44low surface profile (Fig. 2).
When we analyzed T1/ST2 expression in the thymic subpopu-
lations, we found induction of T1/ST2 on a small fraction of the
CD4 SP cells in CD2-GATA3-transgenic mice: 6.0%� 1.0 (n� 3)
compared with 0.4% � 0.05 in nontransgenic mice (n � 5). In
contrast, T1/ST2 expression was not significantly induced on CD8
SP thymocytes (�0.5%). Consistent with the reported absence of
T1/ST2 on the surface of CD8� cells (43, 52), we found very low
numbers of T1/ST2-positive cells in nontransgenic mice. How-
ever, some T1/ST2 expression was observed on CD8� T cells in
spleen (3.0% � 0.8) and lymph node (1.7% � 0.6) from CD2-
GATA3-transgenic mice (Fig. 2).
In summary, these data indicate that enforced expression of
GATA-3 resulted in significantly increased numbers of peripheral
CD4� T cells with an advanced Th2-committed T1/ST2� pheno-
type, not only in the CD44high activated/memory T cell compart-
ment but also in CD44low naive T cells.
Increased ability to secrete Th2 cytokines in CD2-GATA3-
transgenic T cells
As one hallmark of a memory cell population is the ability to
secrete a wider diversity of cytokine (48), we investigated the
ability of peripheral T cells to synthesize various cytokines. After
polyclonal in vitro stimulation of mesenteric lymph node cells,
significant differences in the cytokine production profiles between
wild-type and CD2-GATA3-transgenic mice were observed. When
intracellular cytokine expression was analyzed by flow cytometry,
CD2-GATA3-transgenic CD4� and CD8� T cells manifested de-
creased expression of IL-2 and IFN-� (Fig. 3A). In addition, the
FIGURE 2. Aberrant T1/ST2 surface expression in CD2-GATA3-trans-
genic mice. Single-cell suspensions from spleen (A) and mesenteric lymph
nodes (B) from 2–3-mo-old CD2-GATA3-transgenic mice and nontrans-
genic littermates were stained for CD4, CD8, CD44, and T1/ST2. CD4�
and CD8� T cells were gated and analyzed for CD44 and T1/ST2 expres-
sion. Data are displayed as dot plots, and the percentages of gated cells
within the indicated T1/ST2� quadrants are shown.
FIGURE 3. Peripheral T cells from CD2-GATA3-transgenic mice pro-
duce Th2 cytokines upon ctivation. A, Decreased synthesis of IL-2 and
IFN-� in CD2-GATA3-transgenic T cells. Mesenteric lymph node T cells
were stimulated with anti-CD3� for 40 h, and intracellular IL-2 and IFN-�
were determined by flow cytometry, in conjunction with membrane ex-
pression of CD4 and CD8. Results are displayed as histograms of CD2-
GATA3-transgenic mice (bold lines) and those of nontransgenic littermates
(thin lines). The percentages of cytokine-positive cells are indicated below
the marker line in bold (CD2-GATA3-transgenic mice) and above the
marker line (nontransgenic littermates). B, Th2 cytokine profiles of CD2-
GATA3-transgenic and control T cells. Mesenteric lymph node T cells were
stimulated with anti-CD3� for either 40 or 60 h as indicated.�, Wild-type
mice; f, CD2-GATA3-transgenic mice. The levels of the indicated cyto-
kines were measured in the culture supernatants by ELISA. C, Prolifera-
tion, determined by [3H]thymidine incorporation, in response to anti-CD3�
stimulation of purified CD4� T cells. Data are given as mean values� SD.
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1.3 and 1.1% � 0.1 (n � 5) of CD4� T cells in spleen and mes-
enteric lymph nodes, respectively. In four-color labelings with
CD4, CD8, CD44, and T1/ST2, it was shown that in nontransgenic
mice T1/ST2 expression was largely confined to the CD44high
fraction of activated/memory CD4� T cells (Fig. 2).
The CD2-GATA3-transgenic animals showed a significant in-
crease in the proportions of T1/ST2� cells: 31% � 1 and 23% �
2 (n� 3) in spleen and mesenteric lymph nodes, respectively. This
increase could not be attributed solely to the increased proportion
of CD4� T cells with a CD44high activated/memory phenotype,
since T1/ST2 was also found to be expressed on naive CD4� T
cells with a CD44low surface profile (Fig. 2).
When we analyzed T1/ST2 expression in the thymic subpopu-
lations, we found induction of T1/ST2 on a small fraction of the
CD4 SP cells in CD2-GATA3-transgenic mice: 6.0%� 1.0 (n� 3)
compared with 0.4% � 0.05 in nontransgenic mice (n � 5). In
contrast, T1/ST2 expression was not significantly induced on CD8
SP thymocytes (�0.5%). Consistent with the reported absence of
T1/ST2 on the surface of CD8� cells (43, 52), we found very low
numbers of T1/ST2-positive cells in nontransgenic mice. How-
ever, some T1/ST2 expression was observed on CD8� T cells in
spleen (3.0% � 0.8) and lymph node (1.7% � 0.6) from CD2-
GATA3-transgenic mice (Fig. 2).
In summary, these data indicate that enforced expression of
GATA-3 resulted in significantly increased numbers of peripheral
CD4� T cells with an advanced Th2-committed T1/ST2� pheno-
type, not only in the CD44high activated/memory T cell compart-
ment but also in CD44low naive T cells.
Increased ability to secrete Th2 cytokines in CD2-GATA3-
transgenic T cells
As one hallmark of a memory cell population is the ability to
secrete a wider diversity of cytokines (48), we investigated the
ability of peripheral T cells to synthesize various cytokines. After
polyclonal in vitro stimulation of mesenteric lymph node cells,
significant differences in the cytokine production profiles betw en
wild-type and CD2-GATA3-transgenic mice were observed. When
intracellular cytokine expression was analyzed by flow cytometry,
CD2-GATA3-transgenic CD4� and CD8� T cells manifested de-
creased expression of IL-2 and IFN-� (Fig. 3A). I addition, the
FIGURE 2. Aberrant T1/ST2 surface expression in CD2-GATA3-trans-
genic mice. Single-cell suspensions from spleen (A) and mesenteric lymph
nodes (B) from 2–3-mo-old CD2-GATA3-transgenic mice and nontrans-
genic littermates were stained for CD4, CD8, CD44, and T1/ST2. CD4�
and CD8� T cells were gated and analyzed for CD44 and T1/ST2 expres-
sion. Data are displayed as dot plots, and the percentages of gated cells
within the indicated T1/ST2� quadrants are shown.
FIGURE 3. P ripheral T cells from CD2-GATA3-transgenic mice pro-
duce Th2 cytokines upon activation. A, Decrea ed synthesis of IL-2 and
IFN-� in CD2-GATA3-transgenic T cells. Mesenteric lymph node T cells
were stimulated with anti-CD3� for 40 h, and intracellular IL-2 and IFN-�
were determined by flow cytometry, in conjunction with membrane ex-
pression of CD4 and CD8. Results are displayed as histograms of CD2-
GATA3-transgenic mice (bold lines) and those of nontransgenic littermates
(thin lines). The percentages of cytokine-positive cells are indicated below
the marker line in bold (CD2-GATA3-transgenic mice) and above the
marker line (nontransgenic littermates). B, Th2 cytokine profiles of CD2-
GATA3-transgenic and control T cells. Mesenteric lymph node T cells were
stimulated with anti-CD3� for either 40 or 60 h as indicated.�, Wild-type
mice; f, CD2-GATA3-transgenic mice. The levels of the indicated cyto-
kines were measured in the culture supernatants by ELISA. C, Prolifera-
tion, determined by [3H]thymidine incorporation, in response to anti-CD3�
stimulation of purified CD4� T cells. Data are given as mean values� SD.
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1.3 and 1.1% � 0.1 (n � 5) of CD4� T cells in spleen and m -
enteric lymph nodes, respectively. In four-color labelings with
CD4, CD8, CD44, and T1/ST2, it was shown that in nontransgenic
mice T1/ST2 expression was largely confined to the CD44high
fraction of activated/memory CD4� T cells (Fig. 2).
The CD2-GATA3-transgenic animals showed a significant in-
crease in the proportions of T1/ST2� cells: 31% � 1 and 23% �
2 (n� 3) in spleen and mesenteric lymph nodes, respectively. This
increase could not be attributed solely to the increased proportion
of CD4� T cells with a CD44high activated/memory phenotype,
since T1/ST2 was also found to be expressed on naive CD4� T
cells with a CD44low surface profile (Fig. 2).
When we analyzed T1/ST2 expression in the thymic subpopu-
lations, we found induction of T1/ST2 on a small fraction of the
CD4 SP cells in CD2-GATA3-transgenic mice: 6.0%� 1.0 (n� 3)
compared with 0.4% � 0.05 in nontransgenic mice (n � 5). In
contrast, T1/ST2 expression was not significantly induced on CD8
SP thymocytes (�0.5%). Consistent with the reported absence of
T1/ST2 on the surface of CD8� cells (43, 52), we found very low
numbers of T1/ST2-positive cells in nontransgenic mice. How-
ever, some T1/ST2 expression was observed on CD8� T cells in
spleen (3.0% � 0.8) and lymph node (1.7% � 0.6) from CD2-
GATA3-transgenic mice (Fig. 2).
In summary, these data indicate that enforced expression of
GATA-3 resulted in significantly increased numbers of peripheral
CD4� T cells with an advanced Th2-committed T1/ST2� pheno-
type, not only in the CD44high activated/memory T cell compart-
ment but also in CD44low naive T cells.
Incr ased ability to secrete Th2 cytokines in CD2-GATA3-
transgenic T cells
As one hallmark of a memory cell population is the ability to
secrete a wider diversity of cytokines (48), we investigated the
ability of peripheral T cells to synthesize various cytokines. After
polyclonal in vitro stimulation of mesenteric lymph node cells,
significant differences in the cytokine production profiles between
wild-type and CD2-GATA3-transgenic mice were observed. When
intracellular cytokine expression was analyzed by flow cytometry,
CD2-GATA3-transgenic CD4� and CD8� T cells manifested de-
creased expression of IL-2 and IFN-� (Fig. 3A). In addition, the
FIGURE 2. Aberrant T1/ST2 surface expression in CD2-GATA3-trans-
genic mice. Single-cell suspensions from spleen (A) and mesenteric lymph
nodes (B) from 2–3-mo-old CD2-GATA3-transgenic mice and nontrans-
genic littermates were stained for CD4, CD8, CD44, and T1/ST2. CD4�
and CD8� T cells were gated and analyzed for CD44 and T1/ST2 expres-
sion. Data are displayed as dot plots, and the percentages of gated cells
within the indicated T1/ST2� quadrants are shown.
FIGURE 3. Peripheral T cells from CD2-GATA3-transgenic mice pro-
duce Th2 cytokines upon activation. A, Decreased synthesis of IL-2 and
IFN-� in CD2-GATA3-transgenic T cells. Mesenteric lymph node T cells
ere stimulated with anti-CD3� for 40 h, and intracellular IL-2 and IFN-�
were d termined by flow cytometry, in co jun tion with membrane ex-
pr sion of CD4 and CD8. Results are displayed a histograms of CD2-
GATA3-transgenic mice (bold lines) and those of nontransgenic littermates
(thin lines). The percentages of cytokine-positive cells are indicated below
the marker line in bold (CD2-GATA3-transgenic mice) and above the
marker lin (nontransgenic littermates). B, Th2 cytokine profi e of CD2-
GATA3-transgenic and control T cells. Mesenteric lymph node T cells were
stimulated with anti-CD3� for either 40 or 60 h as indicated.�, Wild-type
mice; f, CD2-GATA3-transgenic mice. The levels of the indicated cyto-
kines were measured in the culture supernatants by ELISA. C, Prolifera-
tion, determined by [3H]thymidine incorporation, in response to anti-CD3�
stimula ion of purified CD4� T cells. Data are given as me n values� SD.
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Figure 4 -The effect of enforced GATA-3 expression in CD4+ T cell cultures under Th1 and Th2 polarizing conditions. 
(A) Western blotting analysis, showing the expression of GATA-3 in purified CD4+ T cells from the indicated non-
transgenic (wt) and CD2-GATA3 (tgA and tgB) mice, cultured for 7 days under default (D), Th1 and Th2 polarizing 
conditions. (B) Expression of GATA-3 in CD2-GATA3 transgenic (bold lines) and non-transgenic (thin lines) purified 
CD4+ T cells that were activated under Th1 or Th2 conditions as indicated. Cell suspensions were stained for surface 
CD4 and CD8 and subsequently for intracellular GATA-3 protein. Flow cytometry results are displayed as histograms 
of CD4+CD8- cells. (C) Cytokine production in supernatants of 7-day cultures of purified CD4+ T cells under default, 
Th1 and Th2 conditions, as indicated (Open bars: wild-type mice; closed bars: CD2-GATA3 transgenic mice). (D) Cell 
viability after 7 days of culture under Th1- or Th2-priming conditions of purified CD4+ T cells of the indicated mice. 
Cell suspensions were stained for surface CD4 and CD8 and propidium iodide (PI). Results are displayed as histograms 
of CD4+CD8- cells. The percentages of viable (PI-) cells are indicated. (E) Proliferation, determined by [3H]thymidine 
incorporation, in response to stimulation with anti-CD3ε of purified CD4+ cells, under Th1 and Th2 conditions. Data 
are given as mean values + SD (Open bars: wild-type mice; closed bars: CD2-GATA3 transgenic mice). Data are 
representative of five repeat experiments.
The reduced IFNγ production by CD2-GATA3 transgenic CD4+ T cells cultured under 
Th-1 polarizing conditions could either result from an inhibitory effect of GATA-3 on the 
differentiation of naïve cells into Th1 cells, or by an inhibition of the amount of IFNγ produced 
by differentiated Th1 effector cells. To distinguish between these possibilities, we assessed 
cell viability and proliferation in the T cell cultures. When analyzed by flow cytometry using 
propidium iodide, CD4+ T cells from CD2-GATA3 transgenic mice showed increased cell death 
under Th1 culture conditions at day 7, as compared with non-transgenic littermates (Fig. 4D). 
When [3H]thymidine incorporation was assessed at day 7, we observed a specific inhibitory 
production of the Th2 cytokines IL-4, IL-5, and IL-10 was in-
creased in CD2-GATA3-transgenic T cells after 40 and 60 h of
culture (Fig. 3B).
The effect of enforced GATA-3 expression on T cell proliferation
was studied in in vitro stimulations of purified CD4� T cells. When
[3H]thymidine incorporation was assessed at day 1 or day 2, the CD2-
GATA3-transgenic T cells manifested significantly reduced prolifera-
tion, as compared with nontransgenic T cells (Fig. 3C).
Collectively, the CD2-GATA3-transgenic T cells were charac-
terized by an increased production of Th2 cytokines and reduced
production of IL-2 and IFN-� upon stimulation, suggesting the
presence of an increased memory compartment within the periph-
eral T cell population in vivo.
Expression of GATA-3 in CD2-GATA3-transgenic T cell
cultures under Th1-polarizing conditions
Next, we performed in vitro Th1/Th2 polarization culture experi-
ments on purified CD4� T cells from spleen and lymph nodes to
investigate whether the differentiation potential into T effector phe-
notypes was altered in the CD2-GATA3 mice. In these experi-
ments, cells were stimulated with anti-CD3� mAbs, either under
“default” conditions (without additional cytokines or Abs), Th1-
polarizing conditions (in the presence of IL-12 and anti-IL-4
mAbs), or under Th2-polarizing conditions (in the presence of IL-4
and anti-IFN-� mAbs) for 4 days. Subsequently, the cells were
washed and restimulated with anti-CD3� mAbs for 3 days, without
additional Abs or cytokines.
First, we evaluated the GATA-3 expression in lymph node-de-
rived T cell cultures by Western blotting and intracellular flow
cytometric analyses using a mouse monoclonal antiserum specific
for GATA-3 (Fig. 4, A and B). In nontransgenic and CD2-GATA3-
transgenic CD4� T cell cultures, GATA-3 protein was abundantly
expressed both under default and Th2-polarizing conditions.
GATA-3 protein could not be detected in nontransgenic Th1 cul-
tures (Fig. 4A). In contrast, GATA-3 was expressed in CD2-
GATA3-transgenic Th1 cultures, although the levels of expression
were lower than in the corresponding Th2 or default cultures (Fig.
4A). The GATA-3 protein present had the apparent molecular mass
of endogenous GATA-3, and no transgene encoded GATA-3
bands could be detected using Abs specific for the HA tag present
in the transgenic GATA-3 protein.
Intracellular GATA-3 protein flow cytometric assays allowed a
comparison of mean fluorescence intensity values in histogram
overlays. Although these analyses are limited by a background
signal of the GATA-3 Ab, they showed that GATA-3 protein lev-
els were higher in the cultures of CD2-GATA3-transgenic mice
when compared with those of the nontransgenic littermates, irre-
spective of the culture conditions (shown for Th1 and Th2 condi-
tions in Fig. 4B).
FIGURE 4. The effect of enforced GATA-3 expression in CD4� T cell cultures under Th1-and Th2-polarizing conditions. A,Western blotting analysis showing
the expression of GATA-3 in purified CD4� T cells from the indicated nontransgenic (wt) and CD2-GATA3 (tgA and tgB) mice cultured for 7 days under default
(D), Th1-, and Th2-polarizing conditions. B, Expression of GATA-3 in CD2-GATA3-transgenic (bold lines)- and nontransgenic (thin lines)- purified CD4� T cells
that were activated under Th1 or Th2 conditions as indicated. Cell suspensions were stained for surface CD4 and CD8 and subsequently for int acellular GATA-3
protein. Flow cytometry results are displayed as histograms of CD4�CD8� cells. C, Cytokine production in supernatants of 7-day cultures of purified CD4� T
cells under default, Th1, and Th2 conditions as indicated.�, Wild-type mice;f, CD2-GATA3-transgenic mice. D, Cell viability after 7 days of culture under Th1-
or Th2-priming conditions of purified CD4� T cells of the indicated mice. Cell suspensions were stained for surface CD4 and CD8 and propidium iodide (PI).
Results are displayed as histogram of CD4�CD8� cells. The percentages of viable (PI�) cells are indicat d. E, P oliferation, eterm ned by [3H]thymidine
incorporation, in response to stimulation with anti-CD3� of purified CD4� cells under Th1 and Th2 conditions. Data are given as mean values� SD.�, Wild-type
mice; f, CD2-GATA3-transgenic mice. Data are representative of five repeat experiments.
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effect of enforced GATA-3 expression on cell proliferation in Th1 cultures (Fig. 4E). By contrast, 
the presence of the CD2-GATA3 transgene enhanced viability and proliferation of CD4+ T cells 
in the Th2 cultures (Fig. 4DE). 
Collectively, these observations demonstrate that although the presence of the CD2-
GATA3 transgene inhibited the proliferation of Th cells under Th1 polarizing conditions, 
considerable production of Th2 cytokines was still present. Furthermore, the enforced GATA-3 
expression significantly supported proliferation and differentiation of Th2 effector cells in a Th2 
environment. 
GATA-3 expressing lymphoblastoid tumors express Th2 cytokines
The coordinate expression of IL4, IL5 and IL-13 is thought to be under the direct control 
of GATA-3, as GATA-3 specifically interacts with an intergenic DNAse I hypersensitivity site in 
Th2 cytokine locus that contains the IL-4/IL-5/IL-13 gene cluster51. However, the mechanism 
by which GATA-3 would regulate IL-10 expression is unknown. The rapid production of IL-10 
after anti-CD3 stimulation in vitro (Fig. 3C) would suggest that GATA-3 is directly involved 
in the regulation of IL-10 gene expression. To further address this question, we examined 
lymphoblastoid tumor samples from CD2-GATA3 transgenic mice. At the age of 9 months, 
~50% of these mice developed thymic lymphomas that were CD4+CD8+/lo and expressed high 
levels of GATA-3 (see accompanying paper). Immunohistochemical analyses of thymic tumor 
tissues showed that most of the tumors contained areas where the lymphoblastoid cells had lost 
expression of CD8, and sometimes also CD4 (data not shown). Particularly in such areas very 
high expression of the Th2 cytokines IL-4, IL-5 or IL-10 was found (Fig. 5ABC). Moreover, 
when tumor cells were cultured in the presence of anti-CD3ε an extremely high production of 
Th2 cytokines, including IL-10, was observed (An example is shown in Fig. 5D). Proliferative 
responses were determined by [3H]thymidine incorporation and showed that CD2-GATA3 
transgenic mice had enhanced in vitro recall responses (Fig. 6C). 
Figure 5 - Cytokine production by thymic lymphoblastoid tumor cells. Immunohistochemical analysis of three 
thymic lymphoblastoid tumor tissue samples from CD2-GATA3 transgenic mice, showing areas with cells that produce 
high levels of (A) IL-4, (B) IL-5 and (C) IL-10. (D) Cytokine production in the supernatant of a 40-hour culture of 
lymphoblastoid tumor cells in the presence of anti-CD3ε. (Closed bars: CD2-GATA3 transgenic lymph node cells from a 
tumor-free mouse; hatched bars: lymphoblastoid tumor cells from a lymph node).   
In conclusion, the observed suppression of TNP-specific IgG2a production indicated 
that transgenic GATA-3 expression is sufficient to inhibit IFNγ-mediated antigen-specific 
class switching. In the CD2-GATA3 transgenic mice the Th2-dependent induction of IgE was 
enhanced, while increased class switching to IgG1 was only 
 These findings show that high expression of GATA-3 in lymphoblastoid tumor cells 
is associated with high level production of Th2 cytokine production, suggesting that like the 
Therefore, we conclude that due to the presence of the CD2-
GATA3 transgene, GATA-3 protein expression is maintained in
CD4� T cells that are cultured under Th1-polarizing conditions.
The Th1/Th2 differentiation potential of CD2-GATA3-transgenic
T cells in vitro
Cytokine production was evaluated in the Th1/Th2-polarized
CD4� T cell cultures from lymph nodes or spleen. CD2-GATA3-
transgenic CD4� T cells produced normal amounts of IL-4, but
higher levels of IL-5 and IL-10 in the default or Th2-polarized
cultures when compared with nontransgenic CD4� T cells (Fig.
4C). In addition, when CD2-GATA3-transgenic CD4� T cells were
cultured under Th1-polarizing conditions, they produced signifi-
cantly increased amounts of IL-4, IL-5, and IL-10. Irrespective of
the culture conditions, the production of IFN-� was significantly
reduced in the CD2-GATA3-transgenic CD4� T cells when com-
pared with those from nontransgenic littermates (Fig. 4C).
The reduced IFN-� production by CD2-GATA3-transgenic
CD4� T cells cultured under Th1-polarizing conditions could ei-
ther result from an inhibitory effect of GATA-3 on the differenti-
ation of naive cells into Th1 cells, or by an inhibition of the amount
of IFN-� produced by differentiated Th1 effector cells. To distin-
guish between these possibilities, we assessed cell viability and
proliferation in the T cell cultures. When analyzed by flow cytom-
etry using propidium iodide, CD4� T cells from CD2-GATA3-
transgenic mice showed increased cell death under Th1 culture
conditions at day 7, as compared with nontransgenic littermates
(Fig. 4D). When [3H]thymidine incorporation was assessed at day
7, we observed a specific inhibitory effect of enforced GATA-3
expression on cell proliferation in Th1 cultures (Fig. 4E). By con-
trast, the presence of the CD2-GATA3 transgene enhanced viability
and proliferation of CD4� T cells in the Th2 cultures (Fig. 4, D
and E).
Collectively, these observations demonstrate that although the
presence of the CD2-GATA3 transgene inhibited the proliferation
of Th cells under Th1-polarizing conditions, considerable produc-
tion of Th2 cytokines was still present. Furthermore, the enforced
GATA-3 expression significantly supported proliferation and dif-
ferentiation of Th2 effector cells in a Th2 environment.
GATA-3-expressing lymphoblastoid tumors express Th2
cytokines
The coordinate expression of IL-4, IL-5. and IL-13 is thought to be
under the direct control of GATA-3, as GATA-3 specifically in-
teracts with an intergenic DNase I hypersensitivity site in the Th2
cytokine locus that contains the IL-4/IL-5/IL-13 gene cluster (30).
However, the mechanism by which GATA-3 would regulate IL-10
expression is unknown. The rapid production of IL-10 after anti-
CD3 stimulation in vitro (Fig. 3C) would suggest that GATA-3 is
directly involved in the regulation of IL-10 gene expression. To
further address this question, we examined lymphoblastoid tumor
samples from CD2-GATA3-transgenic mice. At the age of 9 mo,
�50% of these mice developed thymic lymphomas that were
CD4�CD8�/low and expressed high levels of GATA-3 (see ac-
companying paper). Immunohistochemical analyses of thymic tu-
mor tissues showed that most of the tumors contained areas where
the lymphoblastoid cells had lost expression of CD8 and some-
times also CD4 (data not shown). Particularly in such areas, very
high expression of the Th2 cytokines IL-4, IL-5, or IL-10 was
found (Fig. 5, A–C). Moreover, when tumor cells were cultured in
the presence of anti-CD3�, an extremely high production of Th2
cytokines, including IL-10, was observed (an example is shown in
Fig. 5D).
These findings show that high expression of GATA-3 in lym-
phoblastoid tumor cells is associated with high level production of
Th2 cytokine production, suggesting that like the IL4/IL-5/IL-13
locus, also the IL-10 gene may be a direct target of GATA-3.
Enforced GATA-3 expression inhibits switching to IgG2a in an
Ag-specific immune response
Serum levels of individual Ig isotypes are generally dependent on
the Th1/Th2 balance. IL-4 primes mouse B lymphocytes for
switching to IgG1 and IgE, while IgG2a responses are induced by
IFN-� (56). When total serum Ig levels were determined in 2–3-
mo-old CD2-GATA3-transgenic mice and nontransgenic litter-
mates by ELISA, a selective increase in IgG1 was found in the
CD2-GATA3-transgenic animals (Fig. 6A). The levels of all other
isotypes, including IgE, were similar in the two groups of mice
(Fig. 6, A and C, IgE preimmune values).
To analyze Ig class switching in a T cell-dependent response in
vivo, mice were immunized i.p. with 10 �g TNP-KLH, which was
precipitated on alum. After 2 mo a booster dose of 100 �g TNP-
KLH in PBS was given. CD2-GATA3-transgenic mice showed a
significantly decreased secondary TNP response for the IFN�-de-
pendent isotype IgG2a on day 7 after the booster injection, as
measured in a TNP-specific ELISA (Fig. 6B). The TNP-specific
levels of the other Ig isotypes elicited in this response were com-
parable between transgenic animals and wild-type littermates
(shown for IgG1 in Fig. 6B). Also the primary IgG2a response to
TNP-KLH in vivo was specifically decreased in the CD2-GATA3-
transgenic animals (to �15% of normal), as determined in the
serum at day 7 and 14 after an i.p. immunization with 100 �g
TNP-KLH precipitated on alum (data not shown). The Th2-depen-
dent induction of heavy chain class switch to IgE was determined
at day 11 after i.p. injection of 10 �g TNP-KLH precipitated on
alum. CD2-GATA3-transgenic mice manifested elevated total se-
rum IgE levels in this response (Fig. 6C).
Next, we directly tested the ability of CD2-GATA3-transgenic T
cells to respond to Ag after a previous i.p. immunization with
TNP-KLH. CD4� T cells were purified from spleens of immu-
nized CD2-GATA3-transgenic mice and control littermates 4 wk
FIGURE 5. Cytokine production by thymic lymphoblastoid tumor cells.
Immunohistochemical analysis of three thymic lymphoblastoid tumor tis-
sue samples from CD2-GATA3-transgenic mice showing areas with cells
that produce high levels of IL-4 (A), IL-5 (B), and IL-10 (C). D, Cytokine
production in the supernatant of a 40-h culture of lymphoblastoid tumor
cells in the presence of anti-CD3�. f, CD2-GATA3-transgenic lymph node
cells from a tumor-free mouse; o, lymphoblastoid tumor cells from a
lymph node.
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Therefore, we conclude that due to the presence of the CD2-
GATA3 transgene, GATA-3 protein expression is maintained in
CD4� T cells that are cultured under Th1-polarizing conditions.
The Th1/Th2 differentiation potential of CD2-GATA3-transgenic
T cells in vitro
Cytokine production was evaluated in the Th1/Th2-polarized
CD4� T cell cultures from lymph nodes or spleen. CD2-GATA3-
transgenic CD4� T cells produced normal amounts of IL-4, but
higher levels of IL-5 and IL-10 in the default or Th2-polarized
cultures when compared with nontransgenic CD4� T cells (Fig.
4C). In addition, when CD2-GATA3-transgenic CD4� T cells were
cultured under Th1-polarizing conditions, they produced signifi-
cantly increased amounts of IL-4, IL-5, and IL-10. Irrespective of
the culture conditions, the production of IFN-� was significantly
reduced in the CD2-GATA3-transgenic CD4� T cells when com-
pared with those from nontransgenic littermates (Fig. 4C).
The reduced IFN-� production by CD2-GATA3-transgenic
CD4� T cells cultured under Th1-polarizing conditions could ei-
ther result from an inhibitory effect of GATA-3 on the differenti-
ation of naive cells into Th1 cells, or by an inhibition of the amount
of IFN-� produced by differentiated Th1 effector cells. To distin-
guish between these possibilities, we asses ed cell via ility and
proliferation in the T cell cultures. When analyzed flow cytom-
etry using propidiu iodide, CD4� T cells from CD2-GATA3-
transgenic mice showed increased cell death under Th1 culture
conditions at day 7, as compared with nontransgenic littermates
(Fig. 4D). When [3H]thymidine incorporation was assessed at day
7, we observed a specific inhibitory effect of enforced GATA-3
expression on cell proliferation in Th1 cultures (Fig. 4E). By con-
trast, the presence of the CD2-GATA3 transgene enhanced viability
and proliferation of CD4� T cells in the Th2 cultures (Fig. 4, D
and E).
Collectively, these observatio s demonstrate that although the
presence of the CD2-GATA3 transgene inhibited the proliferation
of Th cells under Th1-polarizing conditions, considerable produc-
tion of Th2 cytokines was still present. Furthermore, the enforced
GATA-3 expression significantly supported proliferation and dif-
ferentiation of Th2 effector cells in a Th2 environment.
GATA-3-expressing lymphoblast id tumors express Th2
cytokines
The coordinate expression of IL-4, IL-5. and IL-13 is thought to be
under the direct control of GATA-3, as GATA-3 specifically in-
teracts with an intergenic DNase I hypersensitivity site in the Th2
cytokine locus that contains the IL-4/IL-5/IL-13 gene cluster (30).
However, the mechanism by which GATA-3 would regulate IL-10
expression is unknown. The rapid production of IL-10 after anti-
CD3 stimulation in vitro (Fig. 3C) would suggest that GATA-3 is
directly involved in the regulation of IL-10 gene expression. To
further address this question, we examined lymphoblastoid tumor
samples from CD2-GATA3-transgenic mice. At the age of 9 mo,
�50% of these mice developed thymic lymphomas that were
CD4�CD8�/low and expressed high levels of GATA-3 (see ac-
companying paper). Immunohistochemical analyses of thymic tu-
mor tissues showed that most of the tumors contained areas where
the lymphoblastoid cells had lost expression of CD8 and some-
times also CD4 (data not shown). Particularly in such areas, very
high expression of the Th2 cytokines IL-4, IL-5, or IL-10 was
found (Fig. 5, A–C). Moreover, when tumor cells were cultured in
the presence of anti-CD3�, an extremely high production of Th2
cytokines, including IL-10, was observed (an example is shown in
Fig. 5D).
These findings show that high expression of GATA-3 in lym-
phoblastoid tumor cells is associated with h gh level production of
Th2 cytokin production, sugge tin that like the IL4/IL-5/IL-13
lo us, also the IL-10 gene may be a direct target of GATA-3.
Enforced GATA-3 expression inhibits switching to IgG2a in an
Ag-specific immune response
Serum levels of individual Ig isotypes are generally dependent on
the Th1/Th2 balance. IL-4 primes mouse B lymphocytes for
switching to IgG1 and IgE, while IgG2a responses are induced by
IFN-� (56). When total serum Ig levels were determined in 2–3-
mo-old CD2-GATA3-transgenic mice and nontransgenic litter-
mates by ELISA, a selective increase in IgG1 was found in the
CD2-GATA3-transgenic animals (Fig. 6A). The levels of all other
isotypes, including IgE, were similar in the two groups of mice
(Fig. 6, A and C, IgE preimmune values).
To analyze Ig class switching in a T cell-dependent response in
vivo, mice were immunized i.p. with 10 �g TNP-KLH, which was
precipitated on alum. After 2 mo a booster dose of 100 �g TNP-
KLH in PBS was given. CD2-GATA3-transgenic mice showed a
significantly decreased secondary TNP response for the IFN�-de-
pendent isotype IgG2a on day 7 after the booster injection, as
measured in a TNP-specific ELISA (Fig. 6B). The TNP-specific
levels of the other Ig isotypes elicited in this response were com-
parable between transgenic animals and wild-type littermates
(shown for IgG1 in Fig. 6B). Also the primary IgG2a response to
TNP-KLH in vivo was specifically decreased in the CD2-GATA3-
transgenic animals (to �15% of normal), as determined in the
serum at day 7 and 14 after an i.p. immunization with 100 �g
TNP-KLH precipitated on alum (data not shown). The Th2-depen-
dent induction of heavy chain class switch to IgE was determined
at day 11 after i.p. injection of 10 �g TNP-KLH precipitated on
alum. CD2-GATA3-transgenic mice manifested elevated total se-
rum IgE levels in this response (Fig. 6C).
Next, we directly tested the ability of CD2-GATA3-transgenic T
cells to respond to Ag after a previous i.p. immunization with
TNP-KLH. CD4� T cells were purified from spleens of immu-
nized CD2-GATA3-transgenic mice and control littermates 4 wk
FIGURE 5. Cytokine production by thymic lymphoblastoid tumor cells.
Immunohistochemical analysis of three thymic lymphoblastoid tumor tis-
sue samples from CD2-GATA3-transgenic mice showing areas with cells
that produce high levels of IL-4 (A), IL-5 (B), and IL-10 (C). D, Cytokine
producti n in the supernatant of a 40-h culture of lymphoblastoid tumor
cells in the presence of anti-CD3�. f, CD2-GATA3-transgenic lymph node
cells from a tumor-free mouse; o, lymphoblastoid tumor cells from a
lymph node.
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IL4/IL-5/IL-13 locus, also the IL-10 gene may be a direct target of GATA-3.
Enforced GATA-3 expression inhibits switching to IgG2a in an antigen-specific 
immune response
Serum levels of individual Ig isotypes are generally dependent on the Th1/Th2 balance. 
IL-4 primes mouse B-lymphocytes for switching to IgG1 and IgE, while IgG2a responses are 
induced by IFNγ45. When total serum Ig levels were determined in 2-3 month-old CD2-GATA3 
transgenic mice and non-transgenic littermates by ELISA, a selective increase in IgG1 was found 
in the CD2-GATA3 transgenic animals (Fig. 6A). The levels of all other isotypes, including IgE, 
were similar in the two groups of mice (Fig. 6A and Fig. 6C IgE pre-immune values). 
Figure 6 - Expression of the CD2-GATA3 transgene affects Ig class switching in vivo.  (A) Serum concentrations 
of Ig isotypes in unimmunized 2-3-month-old mice (open symbols: non-transgenic mice, n=15, closed symbols: CD2-
GATA3 transgenic mice, n=12). Data are shown as mean values + standard errors. (B) For T cell dependent responses, 
serum concentrations of TNP-specific IgG1 and IgG2a were determined by ELISA, before (day 0) and after (day 7) 
i.p. booster injection of TNP-KLH in PBS (open bars: non-transgenic mice, n= 6, closed bars: CD2-GATA-2 transgenic 
mice, n=6). (C) Total serum IgE levels in unimmunized animals (pre) and 11 days after i.p. injection of TNP-KLH on 
alum. (D) In vitro recall response of splenic T cells, 4 weeks after i.p. TNP-KLH immunization. Data shown are mean 
values for 4 wild-type mice (open squares), and 2 mice of each independent transgenic CD2-GATA3 line TgA and TgB 
(closed symbols). 
To analyze Ig class switching in a T cell-dependent response in vivo, mice were 
immunized i.p. with 10 µg TNP-KLH, which was precipitated on alum. After two months a 
after i.p. injection with TNP-KLH precipitated on alum and stim-
ulated in vitro using wild-type irradiated APCs, which had been
preincubated with KLH for 4 h. Proliferative responses were de-
termined by [3H]thymidine incorporation and showed that CD2-
GATA3-transgenic mice had enhanced in vitro recall responses
(Fig. 6C).
In conclusion, the observed suppression of TNP-specific IgG2a
production indicated that transgenic GATA-3 expression is suffi-
cient to inhibit IFN-�-mediated Ag-specific class switching. In the
CD2-GATA3-transgenic mice, the Th2-dependent induction of IgE
was enhanced, whereas increased class switching to IgG1 was only
observed in the total serum levels. In addition, CD2-GATA3-trans-
genic CD4� T cells were shown to have an elevated in vitro recall
response.
Enforced GATA-3 expression diminishes the DTH response to
KLH
To directly test whether enforced GATA-3 expression suppresses
Th1-dependent immune responses in vivo, we assayed DTH re-
sponses to the protein Ag KLH. Two-month-old mice were primed
by i.p. injection of 100 �g KLH and challenged on day 6 by in-
jection of 25 �l PBS alone and 25 �l PBS containing 150 �g KLH
in the left and right hind footpad, respectively. Twenty-four hours
after the injections, footpad thickness was measured and the dif-
ference between the two footpads was calculated (Fig. 7). The
KLH-induced footpad swelling was significantly reduced in CD2-
GATA3-transgenic animals, as compared with the wild-type litter-
mates. This reduction of footpad swelling did not reflect delayed
kinetics of the DTH response, since also at 48 h after the injections
footpad swellings were still essentially absent in the
CD2-GATA3-transgenic mice.
These observations demonstrate that GATA-3 expression has a
severe inhibitory effect on the Th1-mediated DTH response
in vivo.
Discussion
Previous studies using Th1 and Th2 polarization cultures of wild-
type and specific cytokine-deficient cells in vitro have identified
GATA-3 as a master switch in Th2 development (26–28, 30, 31,
35, 38). GATA-3 does not only induce the expression of Th2-
specific cytokines, but also acts as a repressor of Th1 differentia-
tion. Intr duction f GATA-3 by retroviral infection into naive T
cells strongly i hibited IFN-� production, independently of IL-4
expression (35, 38).
To analyze the function of GATA-3 in an in vivo system, we
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expression when cultured under Th1-polarizing conditions, CD2-
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nous GATA-3 protein. The finding by Ouyang et al. (28) that
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genic GATA-3 enhance the expression of endogenous GATA-3.
This could explain our observation of increased GATA-3 protein
levels in T cell cultures, while transgenic GATA-3 could not be
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alum. D, In vitro recall response of splenic T cells 4 wk after i.p. TNP-KLH
immunization. Data shown are mean values for four wild-type mice (�)
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FIGURE 7. Diminished DTH responses in CD2-GATA3-transgenic
mice. Ratios of footpad swelling of KLH-injected over PBS-injected foot-
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mates. This reduction of footpad swelling did not reflect delayed
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footpad swellings were still essentially absent in the
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These observations demonstrate that GATA-3 expression has a
severe inhibitory effect on the Th1-mediated DTH response
in vivo.
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booster dose of 100 µg of TNP-KLH in PBS was given. CD2-GATA3 transgenic mice showed a 
significantly decreased secondary TNP-response for the INFγ-dependent isotype IgG2a on day 
7 after the booster injection, as measured in a TNP-specific ELISA (Fig. 6B). The TNP-specific 
levels of the other Ig isotypes elicited in this response were comparable between transgenic 
animals and wildtype littermates (shown for IgG1 in Fig. 6B). Also the primary IgG2a response 
to TNP-KLH in vivo was specifically decreased in the CD2-GATA3 transgenic animals (to 
~15% of normal), as determined in the serum at day 7 and 14 after an i.p. immunozation with 
100 µg TNP-KLH precipitated on alum (data not shown). The Th2-dependent induction of 
heavy chain class switch to IgE was determined at day 11 after i.p. injection of 10 µg TNP-KLH 
precipitated on alum. CD2-GATA3 transgenic mice manifested elevated total serum IgE levels 
in this response (Fig. 6C). 
Next, we directly tested the ability of CD2-GATA3 transgenic T cells to respond to 
antigen after a previous i.p. immunization with TNP-KLH. CD4+ T cells were purified from 
spleens of immunized CD2-GATA3 transgenic mice and control littermates 4 weeks after i.p. 
injection with TNP-KLH precipitated on alum and stimulated in vitro using wild-type irradiated 
APCs, which had been pre-incubated with KLH for 4 hours. observed in the total serum levels. 
In addition, CD2-GATA3 transgenic CD4+ T cells were shown to have an elevated in vitro recall 
response.
Enforced GATA-3 expression diminishes delayed type hypersensitivity response to 
KLH 
To directly test whether enforced GATA-3 expression suppresses Th1-dependent 
immune responses in vivo, we assayed delayed type hypersensitivity (DTH) responses to the 
protein antigen KLH. Two-month-old mice were primed by i.p. injection of 100 µg KLH, and 
challenged on day 6 by injection of 25 µl PBS alone and 25 µl PBS containing 150 µg KLH 
in the left and right hind footpad, respectively. Twenty-four hours after the injections, footpad 
thickness was measured and the difference between the two footpads was calculated (Fig. 
7). The KLH-induced footpad swelling was significantly reduced in CD2-GATA3 transgenic 
animals, as compared to the wild type littermates. This reduction of footpad swelling did not 
reflect delayed kinetics of the DTH response, as also at 48 hours after the injections footpad 
swellings were still essentially absent in the CD2-GATA3 transgenic mice. 
These observations demonstrate that GATA-3 expression has a severe inhibitory effect 
on the Th1-mediated DTH response in vivo. 
Discussion
Prior studies using Th1 and Th2 polarization cultures of wild-type and specific cytokine-
deficient cells in vitro have identified GATA-3 as a master switch in Th2 development10,11,35,36,
51,56,59. GATA-3 does not only induce the expression of Th2-specific cytokines, but also acts as 
a repressor of Th1 differentiation. Introduction of GATA-3 by retroviral infection into naive T 
cells strongly inhibited IFNγ production, independently of IL-4 expression11,35. 
 To analyze the function of GATA-3 in an in vivo system, we investigated transgenic 
mice that expressed GATA-3 under the control of the CD2 LCR. In these mice, the expression 
of transgenic GATA-3 in the peripheral T cells of the spleen or lymph nodes was very low 
(see accompanying paper). However, in contrast to wild-type CD4+ cells, which lost GATA-3 
expression when cultured under Th1-polarizing conditions, CD2-GATA3 transgenic CD4+ cells 
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maintained expression of endogenous GATA-3 protein. The finding by Ouyang et al.36 that 
GATA-3 may, either directly or indirectly, activate its own expression, could be a mechanism 
by which low amounts of transgenic GATA-3 enhance the expression of endogenous GATA-
3. This could explain our observation of increased GATA-3 protein levels in T cell cultures, 
while transgenic GATA-3 could not be detected in Western blotting analyses using antibodies to 
GATA-3 or the HA-tag (Fig. 4AB). 
Figure 7 -  Diminished DTH responses in CD2-GATA3 transgenic mice. Ratios of footpad swelling of KLH-injected 
over PBS-injected footpads, in non-transgenic mice (open symbols, n=9) and CD2-GATA3 transgenic mice (closed 
symbols, n=6) 24 hours after the injections.
 Our analyses of the CD2-GATA3 transgenic mice support the findings that GATA-3 
expression inhibits Th1 development. The enforced GATA-3 expression inhibited Th1-mediated 
responses in vivo, including antigen-specific IgG2a production and DTH responses to protein 
antigen. In our Th1/Th2 polarization cultures, enforced GATA-3 expression under Th1-inducing 
culture conditions resulted in a reduction of cell survival, proliferation and IFNγ production. 
The additional findings of increased T1/ST2-expression in CD4+ T cells and elevated total IgG1 
serum levels suggest that the presence of the CD2-GATA3 gene drives T cells preferentially 
towards differentiation along the Th2 pathway. Therefore, we conclude that GATA-3 plays a 
dual role in vivo in the differentiation of naive T helper cells into Th2 cells, as it both represses 
Th1 differentiation and induced Th2 differentiation. 
Various lines of evidence indicate that the enforced expression of GATA-3 may 
enhance Th2 memory cell formation. First, In CD2-GATA3 transgenic mice, the peripheral T 
cell compartment contained a high proportion of cells with an antigen-experienced cell surface 
profile, defined as CD44highCD45RBlowCD62Llow and negative for CD25 and CD69. The ratio 
of naive versus memory-phenotype cells decreased with age, as normally seen in wild-type 
mice. The possibility that peripheral T cells obtained the antigen-experienced surface phenotype 
because of a homeostatic proliferation mechanism13 in the CD2-GATA3 transgenic mice is 
unlikely, as these mice were not lymphopenic at any of the ages analyzed. Second, In CD2-
GATA3 transgenic mice the expression of the Th2-specific T1/ST2 marker within the CD44hi 
memory Th cell population in spleen and lymph nodes was increased by a factor ~6 and ~20, 
respectively. T1/ST2 marker expression is associated with advanced Th2 commitment, as it 
was shown to be expressed only after repeated antigenic stimulation under Th2-polarizing 
after i.p. injection with TNP-KLH precipitated on alum and stim-
ulated in vitro using wild-type irradiated APCs, which had been
preincubated with KLH for 4 h. Proliferative responses were de-
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GATA3-transgenic mice had enhanced in vitro recall responses
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production indicated that transgenic GATA-3 expression is suffi-
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jection of 25 �l PBS alone and 25 �l PBS containing 150 �g KLH
in the left and right hind footpad, respectively. Twenty-four hours
after the injections, footpad thickness was measured and the dif-
ference between the two footpads was calculated (Fig. 7). The
KLH-induced footpad swelling was significantly reduced in CD2-
GATA3-transgenic animals, as compared with the wild-type litter-
mates. This reduction of footpad swelling did not reflect delayed
kinetics of the DTH response, since also at 48 h after the injections
footpad swellings were still essentially absent in the
CD2-GATA3-transgenic mice.
These observations demonstrate that GATA-3 expression has a
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in vivo.
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nous GATA-3 protein. The finding by Ouyang et al. (28) that
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pression could be a mechanism by which low amounts of trans-
genic GATA-3 enhance the expression of endogenous GATA-3.
This could explain our observation of increased GATA-3 protein
levels in T cell cultures, while transgenic GATA-3 could not be
detected in Western blotting analyses using Abs to GATA-3 or the
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conditions in vitro, with delayed kinetics compared with the kinetics of Th2 cytokines31. Third, 
CD2-GATA3 transgenic T cells were rapidly induced to synthesize IL-4, IL-5 and IL-10 in vitro, 
whereas production of IL-2 was low, which is typical for memory Th2 cells8. Fourth, T cells 
from CD2-GATA3 mice exhibited an increased recall response to TNP-KLH antigen in vitro. 
Finally, the selective increase of the total levels of the IL-4 dependent isotype IgG1 in the serum 
would also be consistent with increased Th2 memory formation.
It is presently not clear how GATA-3 would affect Th2 memory formation. GATA-3 
may regulate the cell fate decision of activated CD4+ T cells, by reducing activation-induced 
cell death, in favor of Th2 memory cell formation. Alternatively, GATA-3 may facilitate the 
differentiation process of dividing effector T cells that are already committed to the memory 
cell fate. A third possibility is that GATA-3 would act as a survival factor for Th2 memory cells. 
This is not very likely, because survival alone does not appear to be sufficient for memory cell 
formation, as was shown by the absence of increased memory formation in Bcl-2 transgenic 
mice39. Further experiments are required to define GATA-3 targets that are involved in Th2 
memory cell formation. 
One of the molecules involved in Th2 memory development may be T1/ST2, as 
it is normally specifically expressed in the Th2 lineage within the compartment of CD44hi 
activated/memory T cells (Fig. 2). As cross-linking of T1/ST2 enhanced proliferaton of Th2 
cells that were stimulated with sub-optimal concentrations of anti-CD3 mAb31, it is possible 
that the increased proliferation and cell survival of CD2-GATA3 transgenic CD4+ T cells in the 
in vitro Th2 polarization cultures originates from increased T1/ST2 expression. The increased 
expression of T1/ST2 in CD2-GATA3 transgenic mice would argue for a direct regulation of 
T1/ST2 transcription in T cells by GATA-3. The identification of three GATA elements in the 
minimal GATA-responsive T1/ST2 promoter in mast cells12 would support this hypothesis of 
a direct regulation of T1/ST2 expression by GATA-3, independent of Th2-specific cytokines. 
Therefore, we hypothesize that GATA-3 is not only essential for instructive differentiation of 
naive Th cells into committed Th2 cells10,35,36,56,59, but can also affect proliferation and survival 
of GATA-3 expressing CD4+ T cells through the induction of T1/ST2. 
In conclusion, this study shows that enforced expression of GATA-3 inhibits Th1 
function and induces Th2 commitment in vivo. Moreover, the increased expression of T1/ST2, 
the enhanced production of Th2 cytokines in response to T cell activation, and the elevated serum 
levels of IgG1 in CD2-GATA3 transgenic mice argue for a role of GATA-3 in the formation of 
Th2 memory.
Material and Methods
Mice 
The CD2-GATA3 mice are described in the accompanying paper and were crossed on a 
uniform FVB background. To determine the genotype of the mice, tail DNA was analyzed by 
Southern blotting, as described in the accompanying paper. 
Flow cytometric analyses
The preparation of single-cell suspensions, mAb incubations and three- or four-color 
cytometry have been described previously15. The following mAb were purchased from Pharmingen 
(San Diego, CA): FITC-conjugated anti-CD3ε, PE-conjugated anti-CD4 (L3T4), anti-CD24/
heat stable antigen (HSA), anti-CD25 (clone 3C7), anti-CD62L and anti-CD69, CyChrome-
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conjugated anti-CD4 (L3T4), anti-CD8 and anti-CD44, biotinylated anti-CD4 (L3T4), and anti-
CD8, APC-labeled anti-CD3ε and anti-CD4. Anti-CD45RB (MB23G2) was a purified mAb 
conjugated to biotin, according to standard procedures. Secondary antibodies used were PE-, 
TriColor-, or APC-conjugated streptavidin (Caltag Laboratories, Burlingame, CA). The Th2-
selective surface marker T1/ST2 (3E10, rat IgG1, kindly provided by A.J. Coyle, Cambridge, 
MA) was detected by secondary goat-anti-rat IgG-PE (Jackson Immunoresearch)25.
For intracellular detection of GATA-3 protein, cells were fixed and permeabilized 
using paraformaldehyde and saponin, as described27 and subsequently incubated with the Hg-
3-31 anti-GATA-3 MoAb (Santa Cruz, Dan Diego, CA) and FITC-labeled anti-mouse IgG1 
(Pharmingen) as a second step. For three-color analysis, 0.5-1 x 105 events were scored using 
a FACScan analyzer (Becton Dickinson, Sunnyvale, CA). For four-color analysis, 105 - 2x106 
events were scored using a FACS Calibur dual laser instrument (Becton Dickinson). 
For intracellular detection of cytokines, cells were stimulated for 40 hours in the 
presence of mAb to CD28 (37.51; 5 µg/ml) in 96-well plates (106 cells/well) pre-coated with 
mAb to CD3ε (145 2C11; 10 µg/ml in PBS). Subsequently, cells were stimulated by adding PMA 
(50 ng/ml; Sigma) and calcium-ionophore (500 ng/ml; Sigma) for 5 hours. For the last three 
hours of the culture, BrefeldinA (10 µg/ml; Sigma) was added to the cells. Finally, cells were 
harvested and stained with CyChrome-labeled mAb to CD4 or CD8 (Pharmingen). Cells were 
fixed using 2% paraformaldehyde and stored up to 3 days at 4º C. Intracellular cytokine staining 
was performed using PE-labeled mAb to IL-2, IL-4 and IL-10 (Pharmingen) and APC-labeled 
mAb to IL-2, IL-5 and IFNγ (Pharmingen) according to the manufacturer’s instructions.
Serum Ig detection and in vivo immunizations 
Total serum Ig levels were determined by subclass-specific sandwich ELISA, as 
described previously7. Immunizations were done i.p. with 100 µg TNP-KLH precipitated on 
alum. Serum levels of TNP-specific Ig subclasses were determined by ELISA, using TNP-
specific standards (IgG1, IgG2a and IgG2b) or TNP-specific reference serum samples (IgM and 
IgG3), as described26.
Purification of CD4+ T cells and in vitro cultures 
Single cell suspensions from spleen were incubated with biotinylated mAb to CD8 
(YTS-169), CD11b/Mac-1 (M1/70), CD40 (FGK-45.5), B220 (RA3-6B2) and IgM (M41), 
followed by streptavidin-conjugated microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany). Using a Vario-MACS magnetic-activated cell sorter, CD4+ T cells were purified 
according to the manufacturer’s instruction to purity >95%. The CD4+ T cells were cultured for 
up to 5 days in the presence of IL-2 (50 U/ml) on 96 well plates pre-coated with 10 µg/ml anti-
CD3 (145 2C11) mAb. 
Purified CD4+ T cells were polarized into Th-1 and Th-2 effector cells in a total volume 
of 200 µl for 4 days in the presence of 5 µg/ml anti-CD28 (37.51) and 50 IU/ml IL-2 on 96-well 
plates, which were pre-coated with 10 µg/ml anti-CD3ε (145 2C11)16. Th1-polarizing cultures 
included 5 ng/ml rIL-12 (R&D Systems, Minneapolis, MN) and 10 µg/ml neutralizing mAbs 
to IL-4 (11B11). Th2 polarized cells were cultured in the presence of 10-50 ng/ml rIL-4 and 10 
µg/ml neutralizing mAbs to IFNγ (XMG1.2). After 4 days of culture, the cells were thoroughly 
washed and transferred to new anti-CD3 coated 96-well plates, and cultured in the presence of 
IL-2, without addition of further cytokines or neutralizing antibodies. 
To measure DNA synthesis during T cell cultures, cells were pulsed with [3H]thymidine 
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for ~16 hours, harvested and counted using standard methods. Cytokine levels in culture 
supernatants were determined by ELISA using the Opteia kit for IL-4, IL-5, IL-10 and IFN-γ 
(Pharmingen) according to the manufacturer’s instructions. Expression of GATA-3 protein was 
evaluated using a Western blotting procedure, as described in the accompanying paper.
DTH responses
DTH responses were performed essentially as described by Cua et al.6.  In short, mice 
were immunized i.p. with 100 µg KLH in 250 µl PBS and on day 6 they were challenged with 
150 µg of KLH in 25 µl PBS in the left hind footpad. The right hind footpad was in injected with 
a vehicle control (25 µl PBS). Responses were quantified 24 and 48 hours after the challenge, 
by measuring the difference in footpad thickness between the KLH- and the PBS-injected 
footpads.
Immunohistochemistry 
Tissue samples were embedded in OCT compound and frozen 5µm cryostat sections 
were acetone fixed and single labelings were performed using standard procedures7. The 
monoclonal antibodies biotinylated anti-IL-4 (11B11) and alkaline phosphatase-conjugated anti-
IL-5 (TRFK5) were purified hybridoma supernatants and conjuagated according to standard 
procedures. Biotinylated anti-IL-10 (SXC1) was purchased from Pharmingen. 
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Discussion
Understanding how hematopoietic stem cells (HSC) can give rise to the variety of cells 
composing the hematopoietic system has been the goal of many researchers over the years. 
Despite great progress over the last decades many tantalizing questions remain to be answered.
Hematopoiesis occurs by a succession of lineage-commitment steps associated with a 
restriction of differentiation potential and the establishment of lineage-specific expression profiles. 
The establishment of such expression profiles relies on lineage-specific transcription factors to 
regulate the expression of particular genes. Therefore, a strict regulation of the expression and 
function of such transcription factors is essential to ensure the differentiation into the different 
hematopoietic lineages. A variety of lineage-specific transcription factors have been identified 
which are crucial for different lineage-commitment steps during hematopoiesis5,6,25,30. 
In this thesis we focus on the importance of transcription regulation for the specific 
function(s) of the hematopoietic GATA transcription factors.  To test the importance of accurate 
spatio-temporal expression of the GATA transcription factors we used transgenic mouse models 
where the different GATA factors are expressed under the control of heterologous promoters, 
thus leading to an expression pattern that differs from that of the endogenous gene.  From the 
analysis of the phenotypes of these transgenic mice and the ability of some of these transgenes 
to rescue the absence of the endogenous gene, we can conclude that tight dynamic regulation of 
GATA transcription factors is essential for their normal function in hematopoiesis.
GATA1 and GATA2 are dynamically regulated during erythropoiesis
 GATA1 and GATA2 are expressed in both primitive and definitive erythroid cells and are 
essential for normal erythropoiesis. GATA1 null primitive and definitive erythroid progenitors 
fail to progress in differentiation beyond the proerythroblast26,27. Consequently, GATA1 null 
mice die from anemia between embryonic day (E) 10.5 and E11.5 due to the impaired primitive 
erythropoiesis13. Mutations in GATA1 regulatory sequences leading to a reduced expression 
of the GATA1 gene revealed a direct correlation between the amount of protein produced and 
the severity of the phenotype. GATA1.05 mice, expressing approximately 5% of endogenous 
GATA1 protein die around E12.5 due to impaired primitive erythropoiesis32. However, about 
10% of the GATA1 low mice, expressing about 20% of the endogenous GATA1 protein are born 
alive and a small number survive to adulthood18. These mice are anemic at birth but eventually 
recover and show a normal life span. GATA2 null mice also die from anemia around E10.5 
due to impaired production of primitive erythroid cells. In fact, GATA2 is a key regulator of 
proliferation and differentiation of stem cell/multipotential precursors. Thus, GATA2 null cells 
fail to contribute to any hematopoietic lineage36.
 Both GATA1 and GATA2 expression must be tightly regulated for normal erythropoiesis 
to occur. Deregulation of either of these transcription factors has serious consequences for the 
development of erythroid cells (Fig.1). 
We show in Chapter 240 that erythroid-specific GATA1 overexpression leads to a failure 
of  terminal erythroid differentiation and subsequent  embryonic death between E12.5 and E13.5 
due to severe anemia. This, together with the known phenotypes of knockout and knockdown 
mutations in the GATA1 gene, suggested that GATA1 levels must be high at the early stages of 
erythroid differentiation but must decline in the later stages in order for terminal differentiation 
to occur. This model is reinforced by the data presented in Chapter 4 where we show that 
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GATA1 transgenes, under the control of a heterologous promoter (β-LCR), are unable to rescue 
definitive erythropoieisis in GATA1 null mice, whereas the same transgene under the control of 
GATA1 regulatory sequences is able to do so. Detailed analysis of endogenous and transgene 
encoded GATA1 during terminal erythroid differentiation revealed that indeed these GATA1 
transgenes are expressed in a very distinct way. In contrast with endogenous GATA1, β-LCR 
GATA1 transgenes are expressed in later erythroid progenitors and their expression remains 
high, preventing normal terminal differentiation.
Figure 1 - Model of GATA1 and GATA2 expression during erythroid differentiation.
In agreement with previously published data4, we also show in Chapter 4 that GATA2 
overexpression in erythroid cells leads to a defect in terminal erythroid differentiation. 
Overexpression of GATA2 in late erythroid progenitors leads to a blockage in terminal erythroid 
differentiation, and the severity of this differentiation block correlates with the expression level 
of the transgene. These results support a model in which GATA2 downregulation in erythroid 
precursors correlates with GATA1 upregulation in the same progenitors Is there a reference 
for this model21. This suggests a cross-regulation between GATA1 and GATA2 where GATA2 
activates transcription of the GATA1 gene and the GATA1 protein represses the expression of 
GATA2 allowing erythroid differentiation to proceed. This hypothesis is supported by several 
data including the upregulation of GATA2 expression in GATA1 null cells38 and the observed 
repression of GATA2 trancription during GATA1-dependent differentiation of G1E GATA1 null 
erythroid precursors29. A recent report15 provides evidence that GATA1 can specifically bind 
regulatory sequences of the GATA2 gene, displacing GATA2 bound to the same sequences. 
Moreover, Rodriguez and colleagues28 have recently shown that the repressive complex GATA1/
Fog1/MeCP1 binds to GATA2 regulatory sequences in vivo
Interestingly, GATA2 transgenes expressed under the control of GATA1 regulatory 
sequences, but not under its own or other heterologous promoter, can rescue the GATA1 null 
phenotype33 (Chapter 4) indicating that  expression of one and the same transcription factor 
can have different outcomes depending on when and at what level it is expressed. This idea 
is reinforced by the fact that GATA3 is also able to rescue the GATA1 null phenotype when 
expressed under the control of GATA1 regulatory sequences but not of the β-globin LCR 
(Chapter 4).
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In an attempt to understand why GATA1 overexpression in late erythroid precursors 
impairs terminal erythroid differentiation we performed gene expression profiling of the GATA1 
overexpressing erythoid cells (Chapter 3). Differentially expressed genes were identified, 
using both in vivo (fetal livers from transgenic mice) and in vitro (MEL cells) systems, and 
classified in agreement with their known role in particular physiological processes. The 
majority of these genes are involved in biological processes such as regulation of transcription, 
proliferation, differentiation, apoptosis and cell cycle control. All these processes are known 
to be affected by GATA1. The data obtained with this analysis proved to be reliable and a 
good model system for more detailed analysis in the regulatory functions of GATA1 during 
terminal erythroid differentiation. Similar strategies should also be helpful to understand how 
GATA1 and GATA2 factors are regulated during erythropoiesis. Cultured primary fetal liver 
erythroblasts can provide a good model system for such analysis. Primary fetal liver cells can be 
grown in the presence of glucocorticoid hormones, allowing for the expansion of erythroblasts. 
Induction of terminal differentiation of these erythroblasts can be achieved through removal of 
the glucocorticoid hormones and addition of appropriate growth factors12,37.  This culture system 
provides an opportunity to collect samples over time, enabling us to analyse the expression 
profile of GATA1 and GATA2 and its downstream target genes, throughout terminal erythroid 
differentiation. Furthermore, this culture system allows us to use knockout or transgenic mice as 
the source of erythroblasts. Expression profiling of GATA1 null erythroid cells expressing other 
GATA transgenes, either under the control of endogenous or heterologous promoters, can also 
prove to be valuable to understand the functional overlap between these factors and the impact 
of correct spatio-temporal expression of such genes in terminal erythroid differentiation.
GATA3 is dynamically regulated during T-cell development
 GATA3 has a more restricted expression pattern than GATA1 and GATA2 in the 
hematopoietic system since it is exclusively expressed in T-cells42. Like GATA1 and GATA2, 
GATA3 is dynamically regulated during cellular differentiation (Figure 2). A variety of 
reports have demonstrated that GATA3 is required at distinct stages of T-cell differentiation 
and deregulation of its expression levels has severe consequences for the progression of 
differentiation.
 The first suggestion that GATA3 is necessary at different stages of T-cell development 
came from a detailed analysis of GATA3 expression during T-cell development in the thymus17. 
This report shows that GATA3 is expressed at low levels during the CD4 CD8 double negative 
(DN) stage but is upregulated during TCRβ rearrangement. GATA3 expression is maintained in 
CD4+ T-cells but its expression is gradually downregulated in CD8+ T-cells. The requirement of 
GATA3 in the DN stage of thymic T-cell development, in particular for TCRβ expression and 
β-selection, was later demonstrated22. Later in thymic T-cell differentiation, GATA3 is again 
required for the generation of CD4+ T-cells22. We show in Chapter 520 that deregulation (i.e. 
overexpression) of GATA3 at this stage inhibits the maturation of CD8 + T-cells and induces 
thymic lymphomas. 
GATA3 is also implicated in the lineage selection of CD4+ T-cells upon activation in 
the peripheral lymphoid organs. GATA3 is selectively expressed in the Th2 subset of activated 
CD4+ T-cells43,44 and is essential for the maintenance of the Th2 phenotype23.  We also show in 
Chapter 619 that GATA3 downregulation in the Th1 lineage is critical for the differentiation of 
naïve CD4+ T-cells.
143
Discussion
Figure 2 - Model of GATA3 expression during T-cell differentiation.
In the last few years a new GATA3 conditional knockout has been generated that 
allows deletion of the GATA3 gene at precise stages of T-cell differentiation22. The use of 
such conditional knockout models, together with transgenic mouse models in which GATA3 
is expressed under the control of heterologous promoters, provide new opportunities to deepen 
our insight in the importance of spatio-temporal expression of the GATA3 gene. Expression 
profiling of lymphocytes from such models will be a valuable tool in our quest to understand 
the functional role of GATA3 in T-cell lineage commitment.
Regulation of GATA transcription factors activity
 The activity of lineage specific transcription factors, like any other protein, can be 
regulated in multiple ways. Regulation at the transcriptional level is one way to ensure that 
these transcription factors have a correct spatio-temporal expression pattern. The importance 
of correct spatio-temporal expression is underscored by a number of experiments presented 
in this thesis. Both absence and overexpression of GATA1 in erythroid precursors, impairs 
terminal erythroid differentiation and leads to fatal anemia. Furthermore, forced expression of 
GATA3 throughout T-cell differentiation induces T-cell lymphomas and inhibits differentiation 
of specific T-cell lineages, such as CD8+ and Th1. In addition to transcriptional control, gene 
expression can be regulated at several other levels.  
Increasing evidence is accumulating for the importance of post-translational 
modifications as a mean of controlling transcription factor function. Despite the fact that the 
in vivo functions of many of these post-translational modifications are still unclear, increasing 
numbers of such modifications are being identified in a growing number of tissue specific 
transcription factors.
GATA1, GATA2 and GATA3 can be acetylated in vivo and acetylation appears to be 
crucial for their normal function2,16,31. However, how acetylation affects GATA factor function is 
still not clear.  GATA1 acetylation seems to stimulate its transcriptional activity2,3, increase its 
DNA-binding activity, at least in the avian system3, and has also been implicated in its targeting 
for degradation through ubiquitination (J. Boyes, personal communication). Acetylation of 
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GATA2 results in increased DNA-binding affinity and transcriptional activity through synergy 
with p300, the acetyltransferase involved in the acetylation. Acetylation of GATA3 does not 
affect its DNA-binding activity but its acetylation level directly correlates with transcriptional 
activity41. Other transcription factors, such has EKLF, p53, and E2F1, have been reported to be 
acetylated and acetylation is in many cases associated with increased DNA binding activity, 
increased transcriptional activation potential, protein stability and/or alterations in interactions 
with co-factors (reviewed  by Bannister and Miska1).
The hematopoietic GATA factors can also be phosphorylated7,10,34 but, again, the 
implication of phosphorylation in the function of these transcription factors is unclear.  It is 
possible that phosphorylation modulates the activity of such transcription factors by interfering 
with DNA binding, transactivation potential and interaction with co-factors, but reports are 
scarce and sometimes contradictory10,24,34,35. Phosphorylation of GATA transcription factors 
seems to be regulated by cytokine-mediated signalling through the MAPK pathway 34,35. 
Phosphorylation was also implicated in nuclear-cytoplasmic transport and protein degradation 
of other transcriptions factors (reviewed by Whitmarsh and Davis39).
SUMO is a ubiquitin-like polypeptide that can be conjugated to lysine residues of 
proteins14. Several transcription factors, such as the glucocorticoid receptor, P53, and SP3, are 
known to be SUMOylated. SUMOylation seems to influence transcription factor function in 
several ways, including cellular localization, reduction of transcriptional activation potential and 
prevention of protein degradation (through competition with ubiquitin for the lysine residues). 
Recent reports show that both GATA1 and GATA2 can be SUMOylated8,9 but the function of 
this modification remains to be identified.
Another important player in transcription factor regulation is the interaction with co-
factors and/or regulatory complexes. A variety of proteins have been identified as interaction 
partners of the GATA transcription factors and include other transcription factors, non-
DNA binding co-factors, chromatin-remodelling factors, and proteins involved in cell cycle 
regulation. 
GATA1 is known to interact with a diverse range of proteins. GATA1 interacting proteins 
include the co-factor FOG1, several transcription factors (including EKLF, SP1, LMO2, Pu.1), 
the tumor suppressor protein RB, and the acetyltransferases CBP and P300. The interaction with 
each of these proteins was identified individually and the experimental procedures are laborious 
and overall reveal only a small amount of information. Recently a new one-step purification 
technique for isolation of protein complexes was developed in our laboratory. This technique 
consists in tagging the protein of interest with a small biotinylated tag followed by purification of 
the tagged protein and its interacting partners using streptavidin-coated beads. Purified proteins 
are then identified by mass spectrometry. Using this method several new and already known 
GATA1 interacting proteins were identified28.  Interestingly, some of these proteins seem to be 
part of well-characterised complexes involved in transcription activation or repression. Using 
the same system it will be interesting to isolate complexes with, for example, GATA mutants 
for particular post-translational modifications. Comparing complexes identified with wild type 
and mutated GATA proteins may reveal specific functions of a particular posttranscriptional 
modification in the context of a GATA factor in specific cell lineages.
Assuming that GATA proteins show different post-translational modifications and/or can 
interact with distinct protein complexes in different progenitor cells it would be of considerable 
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interest to identify such modifications/complexes throughout differentiation. For example, in 
Chapter 4 we show that GATA1 becomes phosphorylated12 hours after the induction of terminal 
erythroid differentiation suggesting an alteration in its function. Functional analysis of transgenic 
mice models where GATA transcription factors are unable to be post-translationally modified 
by, for example, phosphorylation, acetylation or SUMOylation, may prove to be a very efficient 
method of unraveling the specific functions of such modifications. Furthermore, the simple 
purification system mention above can be employed not only in cell lines, but also in transgenic 
mice11.
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Summary
 The hematopoietic system is composed of a variety of cells, whose activity is essential 
for the normal functioning of an organism. Erythrocytes, or red blood cells, transport oxygen 
and carbon dioxide throughout the body, platelets are essential for coagulation and white blood 
cells (lymphocytes, granulocytes and macrophages) are responsible for the protection of the 
organism against pathogens. All these different cells originate from a single cell type, the 
hematopoietic stem cell (HSC), through a process denominated hematopoiesis. 
To understand how the HSC can originate so many different cell type has been the aim 
of many scientists over the years. Advances in molecular biology tools allowed the gathering of 
vast amounts of information about the hematopoietic system and the process of hematopoiesis. 
However, many questions remain without answers.
The HSC gives rise to the different hematopoetic cell lineages via a series of steps. HSCs 
are rare cells that have the capacity to duplicate themselves (self-renewal) as well as to give rise 
to all the different hematopoietic cell types (pluripotency). The descendants of the HSC are still 
able to give rise to all hematopoietic lineages but they lose the ability to self-renew. These cells 
will further differentiate into other cells that can give rise to an increasingly restricted number 
of hematopoietic lineages until they reach a stage were they can only differentiate into a single 
lineage. Such process is called lineage-commitment and its accuracy is essential for the normal 
function of the hematopoietic system.
How this lineage commitment occurs is as yet not clear. It is known that it is dependent 
on environmental cues as well as, at least partially, on stochastic events. The identity of each cell 
is dependent on their particular gene expression profile. Each cell expresses certain genes that are 
responsible for its specific characteristics. Transcription factors, proteins able to bind DNA and 
regulate the transcription of particular genes, are essential for the production of such expression 
profiles. There are two broad types of transcription factor: general transcription factors, which 
are present in every cell, and lineage-specific transcription factors, present only in particular 
cell lineages. Lineage-specific transcription factors are the main proteins responsible for the 
expression of genes in specific cell lineages, and are therefore responsible for their unique gene 
expression profiles. A variety of transcription factors has been identified which are crucial for 
the different lineage-commitment steps during hematopoiesis.
To generate the appropriate gene expression profiles, the function of these transcription 
factors must be tightly regulated. Expression of particular genes in the inappropriate cell lineage 
or at the wrong time may have severe consequences. Transcription factors functions, like any 
other protein, can be regulated at transcriptional level, controlling the expression of the protein, 
or after the protein is produced by modulating its activity. 
This thesis is focused on the importance of the transcription regulation of the 
GATA hematopoietic transcription factors. Three of the six members of the GATA family of 
transcription factors are expressed in the hematopoietic system. GATA1 is expressed in the 
erythroid, megakaryocytic, eosinophil and mast cell lineages. GATA2 in expressed in early 
multilineage precursors and in the erythroid and mast cell lineages while GATA3 is expressed 
exclusively in T-lymphocytes. 
In the studies presented in this thesis transgenic mice, were used where the expression 
of these genes is altered, to analyse the importance of the correct spatio-temporal regulation 
of these genes for the differentiation of the hematopoietic lineages were they are expressed. In 
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Chapter 2 we show that overexpression of GATA1 in erythroid cells impairs terminal erythroid 
differentiation leading to anemia, resulting in embryonic death. Detailed analysis of the gene 
expression profile of GATA1-overexpressing erythroid cells, presented in Chapter 3, reveals 
that GATA1 overexpression interferes with important physiological processes. To demonstrate 
the importance of timing of GATA factor expression during erythroid development, we used the 
rescue of a GATA1 null mutation by GATA1, GATA2 and GATA3 transgenes under the control 
of different promoters in Chapter 4. GATA1, GATA2 and GATA3 expressed under the control 
of GATA1 regulatory sequences, therefore mimicking the endogenous GATA1 expression, 
are able to rescue the GATA1 null phenotype. However, when placed under the control of β-
globin regulatory sequences, resulting in expression at high levels in late stages of erythroid 
differentiation, the GATA transgenes fail to rescue the GATA1 null phenotype. Chapters 5 and 
6 show the consequences of GATA3 overexpression throughout T-cell differentiation. GATA3 
overexpression in transgenic mice inhibits the maturation of specific subsets of T-cells, and 
induces thymic lymphomas.
Taken together, the studies presented in this thesis demonstrate that hematopoietic GATA 
transcripton factors are dynamically regulated during hematopoiesis. They also emphasize the 
importance of a correct spatio-temporal expression of these GATA transcription factors for their 
function in the different hematopoietic lineages.
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Samenvatting
 Bloed bestaat uit een aantal verschillende celtypes, die nodig zijn voor het optimale 
functioneren van een organisme. Erytrocyten of rode bloedcellen, transporteren zuurstof 
en kooldioxide door het lichaam; bloedplaatjes zijn essentieel voor de bloedstolling, en de 
witte bloedcellen (lymfocyten, granulocyten en macrofagen) zijn verantwoordelijk voor de 
bescherming van het organisme tegen ziektekiemen. Al deze verschillende celtypen komen voort 
uit dezelfde voorlopercel, de hematopoietische stamcel (HSC), in een proces dat hematopoiese 
genoemd wordt.
 Vele wetenschappers hebben de afgelopen jaren experimenten gedaan om te leren 
hoe de HSC in staat is om al die verschillende cellen te produceren. De ontwikkelingen in 
de moleculaire biologie hebben het mogelijk gemaakt om enorme hoeveelheden informatie te 
verkrijgen over het hematopoietische systeem en het proces van hematopoiese. Toch blijven er 
nog vele vragen over voor verder onderzoek.
 De HSC produceert de verschillende hematopoietische celtypen in een aantal stappen. 
De HSC is een weinig voorkomende cel, die zichzelf kan vermenigvuldigen (zelf-vernieuwing) 
maar ook alle celtypen in het hematopoietische systeem kan maken. De HSC is een “alleskunner”, 
een eigenschap die “pluripotentie” wordt genoemd. Het vermogen om zelfvernieuwing te 
ondergaan is de eerste eigenschap die verloren gaat als de HSC hematopoietische cellen gaat 
produceren. Deze eerste afstammelingen kunnen nog wel alle celtypen in het bloed maken. Na 
verdere celdelingen zullen deze cellen zich in toenemende mate specialiseren, om uiteindelijk 
een stadium te bereiken waarin ze nog maar één celtype kunnen maken. Deze toewijding aan 
één bepaald celtype wordt “lineage commitment” genoemd.
 Hoe lineage commitment in z’n werk gaat is nog niet duidelijk. Het is bekend dat 
het afhankelijk is van omgevingsfactoren, en ook op z’n minst gedeeltelijk van toeval. De 
identiteit van iedere cel wordt bepaald door de genen die actief zijn, het genexpressieprofiel. 
Transcriptiefactoren, eiwitten die aan DNA binden en de expressie van genen beïnvloeden, spelen 
een sleutelrol in de productie van genexpressieprofielen. Er zijn grofweg twee verschillende 
types transcriptiefactoren: algemene transcriptiefactoren die in elke cel aanwezig zijn en 
celtype-specifieke transcriptiefactoren die alleen in bepaalde celtypes voorkomen. Celtype-
specifieke transcriptiefactoren zijn met name verantwoordelijk voor het produceren van de 
genexpressieprofielen die karakteristiek zijn voor een bepaald soort cel. Er is een groot aantal 
transcriptiefactoren bekend die cruciaal zijn voor het nemen van lineage commitment stappen 
in het hematopoietische systeem.
 De activiteit van dergelijke transcriptiefactoren is onderworpen aan diverse controle 
mechanismen. Dit is nodig omdat de expressie van bepaalde genen in verkeerde celtypes 
drastische gevolgen kan hebben. Het falen van deze controle mechanismen kan bijvoorbeeld 
leiden tot het ontstaan van kanker. De activiteit van transcriptiefactoren kan gecontroleerd 
worden door de hoeveelheid ervan te regelen op expressie-niveau en door het moduleren van de 
factoren. In dit proefschrift heb ik mij geconcentreerd op transcriptiefactoren die tot de GATA 
factor familie behoren. Drie van de zes GATA factor familieleden komen tot expressie in het 
hematopoietische systeem. GATA1 komt tot expressie in de erytroïde cellen (rode bloedcellen), 
megakaryocyten (bloedplaatjes), eosinofielen en mest cellen (types witte bloedcellen). GATA2 
komt voor in vroege voorlopercellen, mogelijk zelfs in de HSC, erytroïde en mest cellen. 
GATA3 komt uitsluitend voor in T-lymphocyten. De factoren hebben heel belangrijke functies 
150
in de cellen waar ze tot expressie komen.
 Voor de studies beschreven in dit proefschrift heb ik gebruik gemaakt van transgene 
muizen waarin de expressie van deze transcriptiefactoren veranderd is, zodat het belang van 
het juiste expressiepatroon in een bepaald celtype en gedurende de ontwikkeling van de cellen 
bestudeerd kan worden. In Hoofdstuk 2 beschrijf ik dat overexpressie van GATA1 in erytroïde 
cellen de laatste stappen in de ontwikkeling van deze cellen blokkeert, wat resulteert in een 
dodelijke bloedarmoede. De gedetailleerde analyse van de genexpressieprofielen in deze cellen, 
beschreven in Hoofdstuk 3, onthult dat overexpressie van GATA1 leidt tot de verstoring van 
belangrijke fysiologische processen in de cel. Om het belang van de juiste hoeveelheid GATA 
factor op de juiste tijd en plaats gedurende de ontwikkeling van rode bloedcellen aan te tonen, 
heb ik onderzocht in hoeverre GATA1, GATA2 en GATA3 transgenen de afwezigheid van 
GATA1 kunnen compenseren. (Hoofdstuk 4). Hierbij heb ik gebruik gemaakt van transgenen 
die gecontroleerd worden door GATA1 regulerende elementen, waardoor het bona fide 
expressiepatroon van GATA1 wordt gereproduceerd. Met dit construct kan de afwezigheid 
van GATA1 door zowel GATA1, GATA2 als GATA3 vrijwel geheel gecompenseerd worden. 
Daarnaast heb ik transgenen gebruikt met β-globine regulerende elementen. Deze transgenen 
komen later tijdens de erytroïde ontwikkeling hoog tot expressie. Hiermee kan de afwezigheid 
van GATA1 niet gecompenseerd worden. In Hoofdstuk 5 en 6 beschrijf ik de consequenties van 
GATA3 overexpressie in de ontwikkeling van T-lymfocyten. Dit resulteert in remming van de 
rijping van specifieke types T-lymfocyten, en induceert lymfomen in de zwezerik, het orgaan 
waar T-lymfocyten geproduceerd worden.
 Het werk beschreven in dit proefschrift demonstreert dat de activiteit van de 
hematopoietische GATA transcriptiefactoren zeer dynamisch gereguleerd wordt tijdens de 
hematopoiese. De resultaten benadrukken dat expressie op de juiste tijd en plaats van het grootste 
belang zijn voor het correct uitvoeren van de functies van deze GATA transcriptiefactoren in de 
verschillende hematopoietische celtypes.
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Sumário
O sistema hematopoiético é composto por diferentes tipos de células cujas funções são 
cruciais para o funcionamento normal do organismo. Os eritrócitos, ou glóbulos vermelhos, 
transportam oxigénio e dióxido de carbono atravs do organismo, enquanto que as plaquetas são 
responsáveis pela coagulação do sangue e os glóbulos brancos (leucócitos) são responsáveis 
pela protecção do organismo contra patogenios. Surpreendentemente, todas estas células são 
originadas a partir de um único tipo de célula, a  célula estaminal hematopoiética (CEH), por 
um processo denomimado hematopoiese.
 Desde há muito que cientistas tentam compreender como é que uma única célula pode 
dar origem a tão grande variedade de células. Recentemente, avanços tecnológicos ao nível 
da biologia molecular tem permitido a recolha de uma grande quantidade de dados acerca do 
funcionamento do sistema hematopoiético e da hematopoiese. No entanto, muitas perguntas 
continuam sem resposta. 
 As CEH dão origem às diferentes células hematopoiéticas  através de  um processo 
hierárquico que envolve uma sucessão de passos bem definidos.  CEHs são células extremamente 
raras, caracterizadas pela  capacidade de duplicação (autoregeneração) e de diferenciação em 
todas as linhagens hematopoiéticas (pluripotência). As células directamente descendentes da 
CEH mantêm a pluripotência mas perdem a abilidade de autorenovação. Durante o processo de 
diferenciação estas células perdem progressivamente as suas características de pluripotência, 
ficando cada vez mais restritas a uma única linhagem celular. A precisão com que este processo 
decorre tem consequências drásticas no funcionamento normal do sistema hematopoiético.
O processo gradual de diferenciação da CEH em todas as linhagens hematopoiéticas tem 
como base alterações ao nível do perfil de expressão génica, definido como o conjunto de genes 
expressos em cada célula. A expressão destes genes é regulada por proteínas, denominadas 
factores de transcrição, capazes de interagir com o DNA e activar ou reprimir a expressão de 
certos genes. Cada célula  produz um conjunto específico de factores de transcrição. Alguns 
destes factores estão presentes em todos os tipos celulares enquanto que outros são expressos 
apenas em certas linhagens celular. Em conjunto estes factores são responsáveis pelo perfile 
de expressão génica de cada célula. Até ao momento, foram identificados vários factores de 
transcrição cujas funções são cruciais para o processo da hematopoiese.
Os factores de transcrição regulam a expressão génica mas, por sua vez, tem também de 
ser regulados. Tal como qualquer proteína, o seu funcionamento pode ser regulado de diversas 
formas. Esta tese foca-se na regulação destes factores ao nível da transcrição. Três dos seis 
factores de transcrição que fazem parte da família GATA, são expressos em células do sistema 
hematopoiético. GATA1 é expresso em eritrócitos, megacariócitos, eosinófilos e mastócitos. 
GATA2 é expresso em percursores hematopoiéticos enquanto que GATA3 é expresso apenas 
em linfócitos T.
Nos estudos apresentados nesta tese foram utilizados ratos transgénicos, onde a 
expressão destes factores foi geneticamente alterada, de forma a  analisar a importância da 
regulação espaço-temporal destes factores de transcrição na diferenciaçãoo de várias linhagens 
hematopoiéticas. Nos capítulos 2 e 3 demonstra-se que a sobrexpressão de GATA1 provoca uma 
interrupção na differenciação de eritrócitos e estes animais morrem durante a gestação devido 
a anemia. Pelos resultados apresentados no capítulo 4 conclui-se que a correcta espressão 
espaço-temporal é mais importante do que o factor de transcrição expresso (GATA1, GATA2 
ou GATA3). Finalmente nos capítulos 5 e 6 demonstra-se que a sobrexpressão de GATA3 em 
152
linfócitos T também tem consequências na maturação destas células e causa o desenvolvimento 
de linfomas.
Em conjunto, os resultados apresentados nesta tese demonstram que a expressão espaço-
temporal dos factores de transcrição hematopoiéticos pertencentes a família GATA é essencial 
para a sua função em várias linhagens hematopoiéticas.
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List of abbreviations
AGM   Aorta-Gonad-mesonephros
APC   Antigen presenting cell
BFU-e   Burst forming unit erythroid
CD   Cluster of differentiation
cDNA   Complementary  deoxyribonucleic acid
CFU-e   Colony forming unit erythroid
CLP   Common lymphoid precursor
CMP   Common myeloid precursor
CMLP   common myeloid lymphoid progenitor
Dex   Dexamethasone
DN   Double negative (CD4-CD8-)
DNA   Deoxyribonucleic acid
DP   Double positive (CD4+CD8+)
E   Embryonic day
Epo   Erythropoietin 
ES cells   Embryonic stem cells
FACS   Fluorescence-activated cell sorter
GMP   Granulocyte/macrophage precursor
HRD   Hematopoietic regulatory domain
HS   Hipersensitive site
HSC   Hematopoietic stem cell
IL   Interleukin
kb   Kilo base
kD   Kilo Dalton
KO   Knockout
LCR   Locus control region
MEL   Mouse erythroleukemia
MBP   Myeloid/B-cell precursor
MEP   Myeloid/erythroid precursor
MLP   Multilineage precursor
MTP   Myeloid/T-cell precursor
mRNA   Messenger ribonucleic acid
PCR   Polymerase chain reaction
SCF   Stem cell factor (also called  Kit ligand or steel factor)
SP   Single positive (CD4+ CD8- or CD4-CD8+)
TCR   T-cell receptor
TER119   Erythroid cell marker
TFRC   Transferrin receptor or CD71
Th1   T-helper cell type 1
Th2   T-helper cell type 2
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